0001558370-24-01505410-Q SOLIGENIX, INC. 20241108202411081606031606031606031606031606 0 0001558370-24-015054 10-Q 53 20240930 20241108 20241108 SOLIGENIX, INC. 0000812796 2834 411505029 DE 1231 10-Q 34 001-14778 241440529 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 DOR BIOPHARMA INC 20020329 ENDOREX CORP 19960916 IMMUNOTHERAPEUTICS INC 19920703 10-Q 1 sngx-20240930x10q.htm 10-Q
0.782.563.8410.0522039296488601376568429773000081279 6--12-312024Q3false22953046487610.06250.06250.06250.06250.06250.06250000812796sngx:NewWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-07-090000812796sngx:NewWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2024-07-090000812796sngx:NewWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2024-07-090000812796sngx:NewWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2024-07-090000812796sngx:WarrantModificationAndNewWarrantsMember2024-07-090000812796us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2024-09-300000812796us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2023-12-310000812796us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2023-09-300000812796us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2022-12-310000812796us-gaap:CommonStockMembersngx:AtMarketIssuanceSalesMember2024-07-012024-09-300000812796us-gaap:CommonStockMembersngx:PublicOfferingMember2024-04-222024-04-220000812796sngx:AssetPurchaseAgreementMember2020-03-012020-03-3100008127962024-06-052024-06-050000812796us-gaap:RetainedEarningsMember2024-09-300000812796us-gaap:AdditionalPaidInCapitalMember2024-09-300000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000812796us-gaap:RetainedEarningsMember2024-06-300000812796us-gaap:AdditionalPaidInCapitalMember2024-06-300000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000812796us-gaap:RetainedEarningsMember2023-12-310000812796us-gaap:AdditionalPaidInCapitalMember2023-12-310000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000812796us-gaap:RetainedEarningsMember2023-09-300000812796us-gaap:AdditionalPaidInCapitalMember2023-09-300000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000812796us-gaap:RetainedEarningsMember2023-06-300000812796us-gaap:AdditionalPaidInCapitalMember2023-06-300000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000812796us-gaap:RetainedEarningsMember2022-12-310000812796us-gaap:AdditionalPaidInCapitalMember2022-12-310000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000812796us-gaap:CommonStockMember2024-09-300000812796us-gaap:CommonStockMember2024-06-300000812796us-gaap:CommonStockMember2023-12-310000812796us-gaap:CommonStockMember2023-09-300000812796us-gaap:CommonStockMember2023-06-300000812796us-gaap:CommonStockMember2022-12-310000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2024-04-150000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2024-01-0300008127962024-04-220000812796us-gaap:GrantMember2024-01-012024-09-300000812796us-gaap:GrantMember2023-07-012023-09-300000812796us-gaap:GrantMember2023-01-012023-09-300000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2024-04-152024-04-150000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2024-01-032024-01-030000812796sngx:ExistingWarrantsMember2024-07-092024-07-090000812796sngx:AssetPurchaseAgreementMember2014-09-012014-09-300000812796sngx:AtMarketIssuanceSalesAgreementMember2024-01-012024-09-300000812796sngx:AtMarketIssuanceSalesAgreementMember2023-01-012023-09-300000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000812796us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000812796us-gaap:RetainedEarningsMember2024-07-012024-09-300000812796us-gaap:RetainedEarningsMember2024-01-012024-09-300000812796us-gaap:RetainedEarningsMember2023-07-012023-09-300000812796us-gaap:RetainedEarningsMember2023-01-012023-09-300000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2023-04-300000812796sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember2023-04-012023-04-300000812796srt:MaximumMemberus-gaap:ConvertibleDebtMember2020-12-310000812796us-gaap:ConvertibleDebtMember2020-12-310000812796sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheTwoMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2024-10-310000812796sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheOneMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2024-10-310000812796sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheTwoMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2024-10-080000812796sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheOneMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2024-10-080000812796us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember2024-07-012024-09-300000812796us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember2024-07-012024-09-300000812796us-gaap:CorporateNonSegmentMember2024-07-012024-09-300000812796us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember2024-01-012024-09-300000812796us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember2024-01-012024-09-300000812796us-gaap:CorporateNonSegmentMember2024-01-012024-09-300000812796us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember2023-07-012023-09-300000812796us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember2023-07-012023-09-300000812796us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000812796us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember2023-01-012023-09-300000812796us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember2023-01-012023-09-300000812796us-gaap:CorporateNonSegmentMember2023-01-012023-09-300000812796sngx:ThirdTrancheMemberus-gaap:ConvertibleDebtMember2020-12-310000812796sngx:SecondTrancheMemberus-gaap:ConvertibleDebtMember2020-12-310000812796sngx:FirstTrancheMemberus-gaap:ConvertibleDebtMember2020-12-310000812796us-gaap:ConvertibleDebtMember2024-09-300000812796us-gaap:ConvertibleDebtMember2023-12-310000812796us-gaap:ResearchAndDevelopmentArrangementMember2024-09-300000812796us-gaap:LeaseAgreementsMember2024-09-300000812796sngx:PreFundedWarrantsMembersngx:PublicOfferingMember2024-04-220000812796sngx:PreFundedWarrantMembersngx:PublicOfferingMember2024-04-220000812796sngx:CommonWarrantsMembersngx:PublicOfferingMember2024-04-220000812796sngx:NewWarrantsMemberus-gaap:CommonStockMember2024-07-230000812796sngx:NewWarrantsMemberus-gaap:CommonStockMember2024-07-110000812796sngx:NewWarrantsMemberus-gaap:CommonStockMember2024-07-100000812796sngx:ExistingWarrantsMemberus-gaap:CommonStockMember2024-07-100000812796sngx:ExistingWarrantsMember2024-07-090000812796sngx:ExistingWarrantsMember2024-07-080000812796sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-06-250000812796sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-06-200000812796sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-06-140000812796sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-06-110000812796us-gaap:CommonStockMembersngx:PublicOfferingMember2024-04-220000812796sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-04-220000812796sngx:PublicOfferingMember2024-04-2200008127962023-09-3000008127962022-12-310000812796us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember2024-09-300000812796us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember2024-09-300000812796us-gaap:CorporateNonSegmentMember2024-09-300000812796us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember2023-12-310000812796us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember2023-12-310000812796us-gaap:CorporateNonSegmentMember2023-12-310000812796srt:MaximumMemberus-gaap:ScenarioPlanMembersngx:AssetPurchaseAgreementMember2024-01-012024-09-300000812796us-gaap:WarrantMember2024-01-012024-09-300000812796us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000812796us-gaap:ConvertibleDebtSecuritiesMember2024-01-012024-09-300000812796us-gaap:WarrantMember2023-01-012023-09-300000812796us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000812796us-gaap:ConvertibleDebtSecuritiesMember2023-01-012023-09-300000812796us-gaap:AdditionalPaidInCapitalMembersngx:AtMarketIssuanceSalesMember2024-07-012024-09-300000812796sngx:AtMarketIssuanceSalesMember2024-07-012024-09-300000812796sngx:PublicOfferingMember2024-04-222024-04-220000812796us-gaap:AdditionalPaidInCapitalMembersngx:AtMarketIssuanceSalesMember2024-01-012024-09-300000812796sngx:AtMarketIssuanceSalesMember2024-01-012024-09-300000812796us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-3000008127962024-09-3000008127962023-12-310000812796us-gaap:SubsequentEventMembersngx:AtMarketIssuanceSalesMember2024-10-012024-11-010000812796us-gaap:CommonStockMembersngx:AtMarketIssuanceSalesMember2024-01-012024-09-300000812796sngx:NewWarrantsMember2024-07-092024-07-090000812796us-gaap:CommonStockMember2024-01-012024-09-300000812796us-gaap:AdditionalPaidInCapitalMembersngx:AtMarketIssuanceSalesMember2023-01-012023-09-300000812796sngx:AtMarketIssuanceSalesMember2023-01-012023-09-300000812796sngx:NewWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000812796sngx:ExistingWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000812796sngx:NewWarrantsMember2024-07-012024-09-300000812796sngx:ExistingWarrantsMember2024-07-012024-09-300000812796sngx:PreFundedWarrantMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300000812796sngx:NewWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300000812796sngx:ExistingWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300000812796sngx:PreFundedWarrantMember2024-01-012024-09-300000812796sngx:NewWarrantsMember2024-01-012024-09-300000812796sngx:ExistingWarrantsMember2024-01-012024-09-300000812796sngx:PreFundedWarrantMemberus-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000812796us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000812796us-gaap:CommonStockMembersngx:AtMarketIssuanceSalesMember2023-01-012023-09-300000812796sngx:NewWarrantsMemberus-gaap:CommonStockMember2024-07-232024-07-230000812796sngx:NewWarrantsMemberus-gaap:CommonStockMember2024-07-112024-07-110000812796sngx:NewWarrantsMemberus-gaap:CommonStockMember2024-07-102024-07-100000812796sngx:ExistingWarrantsMemberus-gaap:CommonStockMember2024-07-102024-07-100000812796sngx:NewWarrantsMemberus-gaap:CommonStockMember2024-07-012024-09-300000812796sngx:ExistingWarrantsMemberus-gaap:CommonStockMember2024-07-012024-09-300000812796sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-06-252024-06-250000812796sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-06-202024-06-200000812796sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-06-142024-06-140000812796sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-06-112024-06-110000812796sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember2024-04-222024-04-220000812796sngx:PreFundedWarrantMemberus-gaap:CommonStockMember2024-01-012024-09-300000812796sngx:NewWarrantsMemberus-gaap:CommonStockMember2024-01-012024-09-300000812796sngx:ExistingWarrantsMemberus-gaap:CommonStockMember2024-01-012024-09-300000812796sngx:PreFundedWarrantMemberus-gaap:CommonStockMember2023-07-012023-09-300000812796us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember2023-01-012023-09-300000812796us-gaap:CommonStockMember2023-01-012023-09-300000812796us-gaap:AdditionalPaidInCapitalMembersngx:PublicOfferingMember2024-01-012024-09-300000812796sngx:PublicOfferingMember2024-01-012024-09-300000812796us-gaap:AdditionalPaidInCapitalMembersngx:PublicOfferingMember2023-01-012023-09-300000812796sngx:PublicOfferingMember2023-01-012023-09-300000812796us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMembersngx:PublicOfferingMember2024-01-012024-09-300000812796us-gaap:CommonStockMembersngx:PublicOfferingMember2024-01-012024-09-300000812796us-gaap:CommonStockMembersngx:PublicOfferingMember2023-01-012023-09-300000812796us-gaap:OneTimeTerminationBenefitsMember2024-01-012024-09-300000812796srt:DirectorMember2024-01-012024-09-300000812796sngx:AtMarketIssuanceSalesMember2024-08-012024-08-310000812796sngx:AtMarketIssuanceSalesMember2024-08-310000812796sngx:AssetPurchaseAgreementMember2024-01-012024-09-300000812796sngx:ForPeriodFromNovember2024Member2022-06-2100008127962022-06-21000812796sngx:HybryteMember2024-01-012024-09-300000812796sngx:NationalInstitutesOfHealthMember2024-09-300000812796us-gaap:ConvertibleDebtMember2024-07-012024-09-300000812796us-gaap:ConvertibleDebtMember2024-01-012024-09-3000008127962023-07-012023-09-3000008127962023-01-012023-09-300000812796us-gaap:ConvertibleDebtMemberus-gaap:CommonStockMember2024-01-012024-09-300000812796sngx:PontifaxMedisonFinanceMembersngx:NumberOfFirstEquityInstrumentsCommonStockIssuableUponConversionMemberus-gaap:ConvertibleDebtMember2023-04-012023-04-300000812796us-gaap:ConvertibleDebtMember2020-12-012020-12-310000812796sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheOneMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2024-10-082024-10-080000812796sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheOneMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember2024-10-012024-10-310000812796us-gaap:SubsequentEventMembersngx:AtMarketIssuanceSalesMember2024-11-010000812796sngx:AssetPurchaseAgreementMember2020-03-3100008127962024-07-092024-07-090000812796us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000812796us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-3000008127962024-07-012024-09-3000008127962024-11-0100008127962024-01-012024-09-30xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharessngx:segmentsngx:YTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORMÂ 10-Qâ˜’QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934For the Quarterly Period Ended September 30, 2024orâ˜TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____ to _____Commission File No.Â 001-14778SOLIGENIX,Â INC.(Exact name of registrant as specified in its charter)â€‹â€‹â€‹â€‹DELAWAREÂ Â 41-1505029(State or other jurisdiction ofâ€‹(I.R.S. Employerincorporation or organization)â€‹Identification Number)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹29 EMMONS DRIVE, SUITEÂ B-10 PRINCETON, NJÂ Â 08540(Address of principal executive offices)â€‹(Zip Code)â€‹(609) 538-8200(Registrantâ€™s telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act:â€‹â€‹â€‹â€‹â€‹â€‹Title of each classÂ Â Trading Symbol(s)Â Â Name of each exchange on which registeredCommon Stock, par value $.001 per shareâ€‹SNGXâ€‹The Nasdaq Capital Marketâ€‹Indicate by check whether the registrant (1)Â filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Yes â˜’ No â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act.â€‹â€‹â€‹â€‹Large accelerated filerâ˜Accelerated filerâ˜Non-accelerated filerâ˜Smaller reporting companyâ˜’â€‹â€‹Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). Yes â˜ No â˜’As of November 1, 2024, 2,509,499 shares of the registrantâ€™s common stock (par value, $.001 per share) were outstanding.â€‹â€‹â€‹â€‹ Table of ContentsSOLIGENIX,Â INC. â€‹Indexâ€‹â€‹Â Â Â Â DescriptionÂ Â Â Â Pageâ€‹â€‹â€‹â€‹â€‹PartÂ Iâ€‹FINANCIAL INFORMATIONâ€‹â€‹â€‹â€‹â€‹â€‹â€‹ItemÂ 1â€‹Condensed Consolidated Financial Statements (unaudited)â€‹â€‹â€‹â€‹Condensed Consolidated Balance Sheets as of September 30, 2024 and DecemberÂ 31, 2023â€‹1â€‹â€‹Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 â€‹2â€‹â€‹Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023 â€‹3â€‹â€‹Condensed Consolidated Statements of Changes in Shareholdersâ€™ Equity/(Deficit) for the Nine Months Ended September 30, 2024 and 2023 â€‹4â€‹â€‹Condensed Consolidated Statements of Changes in Shareholdersâ€™ Equity/(Deficit) for the Three Months Ended September 30, 2024 and 2023 â€‹5â€‹â€‹Condensed Consolidated

Statements of Cash Flows for the NineÂ Months Ended September 30, 2024 and 2023 â€·6â€·â€·NotesÂ to Condensed Consolidated Financial Statements â€·7ItemÂ 2â€·Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€·22ItemÂ 3â€·Quantitative and Qualitative Disclosures About Market Riskâ€·50ItemÂ 4â€·Controls and Proceduresâ€·51â€·â€·â€·â€·â€·PartÂ IIâ€·OTHER INFORMATIONâ€·â€·â€·â€·â€·â€·ItemÂ 1â€·Legal Proceedingsâ€·51ItemÂ 1Aâ€·Risk Factorsâ€·51Item 2â€·Unregistered Sales of Equity Securities and Use of Proceedsâ€·52ItemÂ 5â€·Other Informationâ€·52ItemÂ 6â€·Exhibitsâ€·53â€·â€·â€·â€·SIGNATURESâ€·54â€·â€·â€·i Table of ContentsPARTÂ IÂ - FINANCIAL INFORMATIONâ€·ITEMÂ 1Â - FINANCIAL STATEMENTSâ€·Soligenix, Inc. and SubsidiariesCondensed Consolidated Balance Sheetsâ€·â€·â€·â€·â€·â

the foreseeable future. The Companyâ€™s liquidity needs will be determined largely by the budgeted operational expenditures incurred in regards to the progression of its product candidates. Management believes that the Company has sufficient resources available to support its development activities and business operationsÂ and timely satisfy its obligations as they become due through the second quarter of 2025. The Company does not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support its operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern through 12 months after the date the financial statements are issued.â€‹To alleviate the conditions that raise substantial doubt about the Companyâ€™s ability to continue as a going concern, the Companyâ€™s plans include:â—Securing additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations.â—Securing additional proceeds from government contract and grant programs.â€‹â—Securing additional proceeds from the sale of shares of the Companyâ€™s common stock via the At Market Issuance Sales Agreement (â€œAGP Sales Agreementâ€) with A.G.P/Alliance Global Partners (â€œAGPâ€).â€‹â—Amending the loan agreement with Pontifax Medison Finance (â€œPontifaxâ€) (See Note 4) to reduce the conversion price in order to allow for conversion of a portion of the debt which will reduce the Companyâ€™s debt repayments.â€‹Other than the AGP Sales Agreement which was entered into on August 16, 2024 and the second amendment to the Pontifax loan agreement which was completed on October 8, 2024, none of these alternatives are committed at this time. There can be no assurance that the Company will be successful in obtaining sufficient funding on acceptable terms to fund continuing operations, if at all, identify and enter into any strategic transactions that will provide the capital that it will require, or achieve the other strategies to alleviate the conditions that raise substantial doubt about the Companyâ€™s ability to continue as a going concern. If none of these alternatives are available, or if available, are not available on satisfactory terms, the Company will not have sufficient cash resources and liquidity to fund its business operations for at least the 12 months following the date the financial statements are issued.Â The failure to obtain sufficient capital on acceptable terms when needed may require the Company to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives andÂ its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. In addition, the perception that the Company may not be able to continue as a going concern may cause others to choose not to deal with it due to concerns about its ability to meet its contractual obligations. Â The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. â€‹As of SeptemberÂ 30,Â 2024, the Company had cash and cash equivalents of $9,840,177 as compared to $8,446,158 as of DecemberÂ 31,Â 2023. As of SeptemberÂ 30,Â 2024, the Company had working capital of $5,776,645 as compared to working capital of $3,355,212 as of DecemberÂ 31,Â 2023.â€‹8 Table of ContentsThe Companyâ€™s plans with respect to its liquidity management include, but are not limited to, the following:â—The Company has up to approximately $554,000 in active government grant funding still available as of SeptemberÂ 30,Â 2024 to support its associated research programs through May 2026, provided the federal agencies do not elect to terminate the grants for convenience. The Company plans to submit additional contract and grant applications for further support of its programs with various funding agencies. However, there can be no assurance that the Company will obtain additional governmental grant funding. â—The Company will continue to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expects to continue to do so for the foreseeable future.â—The Company will continue to pursue Net Operating Loss (â€œNOLâ€) sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program if the program is available.â—The Company plans to pursue potential partnerships for pipeline programs as well as continue to explore merger and acquisition strategies. However, there can be no assurances that the Company can consummate such transactions.â—The Company completed a public offering on April 22, 2024 of 204,694 shares of its common stock, pre-funded warrants to purchase 537,500 shares of its common stock and common warrants to purchase up to 742,194 shares of its common stock at a combined public offering price of $6.40. The pre-funded warrants have an exercise price of $0.02. The common warrants have an exercise price of $6.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to the Company from this offering were approximately $4.75 million before deducting commissions and other estimated offering expenses of approximately $0.45 million. The Company plans to use the proceeds for further support of its programs, as well as for working capital. â—The Company entered into a warrant inducement agreement (the â€œInducement Agreementâ€) on July 9, 2024 with certain holders (the â€œHoldersâ€) of the Companyâ€™s existing Warrant to Purchase Shares of Common Stock (â€œExisting Warrantsâ€) to purchase shares of common stock of the Company. In consideration of the Holdersâ€™ agreement to exercise their Existing Warrants, the Company (i) decreased the exercise price of the Existing Warrants from $6.40 per share to $6.00 per share and (ii) issued new warrants (â€œNew Warrantsâ€) to the Holders to purchase a number of shares of common stock equal to 150% of the number of shares of common stock issued upon exercise of the Holdersâ€™ Existing Warrants. Pursuant to the Inducement Agreement, the Holders agreed to exercise for cash their Existing Warrants to purchase up to 703,125 shares of the Companyâ€™s common stock at a reduced exercise price of $6.00 per share on July 9, 2024, the date of the Inducement Agreement, until 1:30 p.m., Eastern Time. The total gross proceeds to the Company was approximately $4.2 million from the exercise of the Existing Warrants before deducting financial advisory fees and other expenses. The Company plans to use the proceeds for further support of its programs, as well as for working capital. â—The Company has up to approximately $4.7 million remaining from the AGP Sales Agreement as of November 1, 2024 under the prospectus supplement dated August 16, 2024. From October 1, 2024 through November 1, 2024, the Company sold 229,078 shares of common stock pursuant to the AGP Sales Agreement at a weighted average price of $4.72 per share for total gross proceeds of approximately $1.1 million.â—The Company is currently evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate such a transaction, or consummate a transaction at favorable pricing.9 Table of Contentsâ€‹Managementâ€™s business strategy can be outlined as follows:â—Following agreement from the EMA on the key design components for the second confirmatory Phase 3 placebo-controlled FLASH2 clinical trial of HyBryteâ„¢ in CTCL and positive primary endpoint results from the first Phase 3 FLASH study, initiate the FLASH2 study, while at the same time, continuing discussions with the FDA on potential modifications to the development path to adequately address their feedback. â—Expanding development of synthetic hypericin under the research name SGX302 into psoriasis with the conduct of a Phase 2a clinical trial, following the positive Phase 3 FLASH study and positive proof-of-concept demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.â—Following feedback from the United Kingdom (â€œUKâ€) Medicines and Healthcare products Regulatory Agency (â€œMHRAâ€) that a second Phase 3 clinical trial of SGX942 (dusquetide) in the treatment in oral mucositis would be required to support a marketing authorization; design a second study and attempt to identify a potential partner(s) to continue this development program.â—Expanding development of dusquetide under the research name SGX945 into BehÃ§etâ€™s Disease by conducting a Phase 2a clinical trial, where previous studies with dusquetide in oral mucositis have validated the biologic activity in aphthous ulcers induced by chemotherapy and radiation.â—Continue development of the Companyâ€™s heat stabilization platform technology, ThermoVaxÂ®, in combination with its programs for RiVaxÂ® (ricin toxin vaccine), and filovirus vaccines (targeting Ebola, Sudan, and Marburg viruses and multivalent combinations), with United States (â€œU.S.â€) government or non-governmental organization funding support.â—Continue to apply for and secure additional government funding for the Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts and/or procurements.â—Pursue business development opportunities for pipeline programs, as well as explore all strategic alternatives, including but not limited to merger/acquisition strategies.â—Acquire or in-license new clinical-stage compounds for development, as well as evaluate new indications with existing pipeline compounds for development.â€‹Reverse Stock Splitâ€‹On June 5, 2024, the Company completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of one-for-sixteen, whereby every sixteen shares of the Companyâ€™s issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock without any change in the par value per share. No fractional shares were issued as a result of the reverse stock split. Any fractional shares that would otherwise have resulted from the reverse stock split were rounded up to the next whole number. The Companyâ€™s common stock began trading on The Nasdaq Capital Market on a reverse split basis at the market opening on June 6, 2024. All share and per share data have been restated to reflect this reverse stock split.â€‹10 Table of ContentsNoteÂ 2. Summary of Significant Accounting PoliciesPrinciples of ConsolidationThe condensed consolidated financial statements include Soligenix,Â Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.Operating SegmentsOperating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: Specialized BioTherapeutics and Public Health Solutions.Cash and Cash EquivalentsThe Company considers all highly liquid investments with maturities of threeÂ months or less when purchased to be cash equivalents.Contracts and Grants ReceivableContracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for credit losses has been established. If amounts become uncollectible, they are charged to operations.Impairment of Long-Lived AssetsOffice furniture and equipment and right of use assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.The Company did not record any impairment of long-lived assets for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023.Fair Value of Financial InstrumentsFair Value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on SeptemberÂ 30,Â 2024. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.Fair Value valuation techniques include a three level hierarchy based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to 11 Table of Contentsunadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).The three levels of the fair value hierarchy are as follows:â—Level 1Â â€” Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.â—Level 2Â â€” Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.â—Level 3Â â€” Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.â€‹The carrying amounts reported in the condensed consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable, accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments.The carrying amount reported in the condensed consolidated balance sheet as of SeptemberÂ 30,Â 2024 for the convertible debt is its fair value which totals $2,059,309 and was approximately equivalent to the face value of the convertible debt at SeptemberÂ 30,Â 2024. The fair value estimate represents a Level 3 measurement in the fair value hierarchy.â€‹A roll forward of the fair value of convertible debt to SeptemberÂ 30,Â 2024 is as follows:â€‹â€‹â€‹

threeÂ months, unless otherwise extended by the Board.From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed under the Companyâ€™s 2015 Equity Incentive Plan (the â€œ2015 Planâ€). The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestricted stock to the Companyâ€™s employees and non-employees (including consultants). The shares issued under the 2015 Plan are registered on FormÂ S-8 (SEC File No.Â 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificates reflecting such shares reflect a Securities Act of 1933, as amended restrictive legend. Stock compensation expense for equity-classified awards to non-employees is measured on the date of grant and is recognized when the services are performed.There were no options issued during the three months ended SeptemberÂ 30,Â 2024 and 2023.The fair value of each option grant made during the nine months ended SeptemberÂ 30,Â 2024 and 2023 was estimated on the date of each grant and recognized as share-based compensation expense ratably over the option vesting periods, which approximates the service period. Foreign Currency Transactions and TranslationIn accordance with FASB ASC 830 Foreign Currency Matters, the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency, the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statements of the UK subsidiary are translated into U.S. dollars and consolidated into the Companyâ€™s financials, with related translation adjustments reported as a cumulative translation adjustment, which is a component of accumulated other comprehensive income. During the nine months ended SeptemberÂ 30,Â 2024 and 2023, the Company recognized a foreign currency transaction gain of $575 and a foreign currency transaction loss of ($3,046), respectively, in the accompanying condensed consolidated statements of operations. During the nine months ended SeptemberÂ 30,Â 2024 and 2023, the Company recognized foreign currency transaction gains of $2,257 and $310, respectively, in the accompanying condensed consolidated statements of operations.â€‹Loss Per ShareBasic earnings per share (â€œEPSâ€) is computed by dividing loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Included within the Companyâ€™s weighted average common shares outstanding (basic and diluted) for the three and nine months ended SeptemberÂ 30,Â 2024, are common shares issuable upon the exercise of the pre-funded warrants as these pre-funded warrants are exercisable at any time for nominal consideration. The following table summarizes outstanding instruments which were not included in the computation of diluted EPS as to do so would have been antidilutive:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of SeptemberÂ 30,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â Common stock purchase warrantsâ€‹ 1,467,581â€‹ 408,640â€‹Stock optionsÂ 56,427Â 12,843Â Convertible debtÂ 75,710Â 1,172,645Â TotalÂ 1,599,718Â 1,594,128Â â€‹Use of Estimates and AssumptionsThe preparation of financial statements requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.14 Table of Contentsâ€‹â€‹â€‹Note 3. Accrued Expensesâ€‹The following is a summary of the Companyâ€™s accrued expenses:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Company entered into the 2024 Amendment to the Loan Agreement. The 2024 Amendment reduced the conversion price with respect to the remaining principal amount outstanding to (i) $3.81 for the first 501,648 shares of the Companyâ€™s common stock issuable upon conversion and (ii) $4.23 with respect to all shares of the Companyâ€™s common stock issuable upon conversion thereafter. The remaining terms of the agreement remain in effect without modification.Sales Pursuant to the AGP ATMâ€‹From October 1, 2024 through November 1, 2024, the Company sold 229,078 shares of common stock pursuant to the AGP ATM at a weighted average price of $4.72 per share for total gross proceeds of approximately $1.1 million.â€‹â€‹â€‹21 Table of ContentsITEMÂ 2Â â€“ MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSThe following discussion and analysis provides information to explain our results of operations and financial condition. You should also read our unaudited condensed consolidated interim financial statements and their notes included in this FormÂ 10-Q, and our audited consolidated financial statements and their notes, Risk Factors and other information included in our Annual Report on FormÂ 10-K for theÂ year ended DecemberÂ 31,Â 2023. We provide addresses to internet sites solely for the information to investors. We do not intend any addresses to be active links or to otherwise incorporate the contents of any website into this report.Cautionary NoteÂ Regarding Forward-Looking StatementsThis Quarterly Report on FormÂ 10-Q contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current expectations about our future results, performance, prospects and opportunities. These forward-looking statements are not guarantees of future performance and are subject to significant risks, uncertainties, assumptions and other factors, which are difficult to predict and may cause actual results to differ materially from those expressed in, or implied by, any forward-looking statements. The forward-looking statements within this report may be identified by words such as â€œbelieves,â€ â€œanticipates,â€ â€œexpects,â€ â€œintends,â€ â€œmay,â€ â€œwould,â€ â€œwillâ€ and other similar expressions. However, these words are not the exclusive means of identifying these statements. Statements that are not historical facts are based on our current expectations, beliefs, assumptions, estimates, forecasts and projections for our business and the industry and markets related to our business and are forward-looking statements.Actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect these actual outcomes and results include, without limitation:â—uncertainty as to whether our product candidates will be sufficiently safe and effective to support regulatory approvals;â—uncertainty inherent in developing therapeutics and vaccines, and manufacturing and conducting preclinical and clinical trials;â—our ability to obtain future financing or funds when needed, either through the raising of capital, the incurrence of convertible or other indebtedness or through strategic financing or commercialization partnerships;â—our ability to secure government grants or contracts to support our vaccine development;â—our ability to maintain our listing on The Nasdaq Capital Market and meet its listing requirements;â—that product development and commercialization efforts will be reduced or discontinued due to difficulties or delays in clinical trials or a lack of progress or positive results from research and development efforts;â—maintenance and progression of our business strategy;â—the possibility that our products under development may not gain market acceptance;â—our expectations about the potential market sizes and market participation potential for our product candidates may not be realized;â—our expected revenues (including sales, milestone payments and royalty revenues) from our product candidates and any related commercial agreements of ours may not be realized;22 Table of Contentsâ—the ability of our manufacturing partners to supply us or our commercial partners with clinical or commercial supplies of our products in a safe, timely and regulatory compliant manner and the ability of such partners to timely address any regulatory issues that have arisen or may arise in the future;â—competition existing today or that may arise in the future, including the possibility that others may develop technologies or products superior to our products; â—the effect that global pathogens could have on financial markets, materials sourcing, service providers, patients, clinical study sites, governments and population (e.g. Covid-19); andâ—other factors, including those â€œRisk Factorsâ€ set forth under PartÂ II, ItemÂ 1A. â€œRisk Factorsâ€ in this Quarterly Report and in our Annual Report on FormÂ 10-K for theÂ year ended DecemberÂ 31,Â 2023.Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances occurring subsequent to the filing of this FormÂ 10-Q with the United States (â€œU.S.â€) Securities and Exchange Commission (the â€œSECâ€) or for any other reason. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.Note Regarding Reverse Stock Splitâ€‹On June 5, 2024, we completed a reverse stock split of our issued and outstanding shares of common stock at a ratio of one-for-sixteen, whereby every sixteen shares of our issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock without any change in the par value per share. No fractional shares were issued as a result of the reverse stock split. Any fractional shares that would otherwise have resulted from the reverse stock split were rounded up to the next whole number. Our common stock began trading on The Nasdaq Capital Market on a reverse split basis at the market opening on June 6, 2024. All share and per share data have been restated to reflect this reverse stock split.Our Business OverviewWe are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryteâ„¢ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (â€œCTCLâ€). With agreement from the European Medicines Agency (â€œEMAâ€) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryteâ„¢ in theÂ treatment of CTCL patients with early-stage disease, we are targeting to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026. Upon successful completion of the second Phase 3 study, called â€œFLASH2â€ (Fluorescent Light Activated Synthetic Hypericin 2), regulatory approval will be sought to support potential commercialization worldwide. Â Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator technology, and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer and aphthous ulcers in BehÃ§etâ€™s Disease.Our Public Health Solutions business segment includes development programs for RiVaxÂ®, our ricin toxin vaccine candidate and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and vaccine programs, targeting filoviruses (such as Marburg and Ebola) and CiVaxâ„¢, our vaccine 23 Table of Contentscandidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of the vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVaxÂ®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (â€œNIAIDâ€), the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.An outline of our business strategy follows:â—Following agreement from the EMA on the key design components for the second confirmatory Phase 3 placebo-controlled FLASH2 (Florescent Light Activated Synthetic Hypericin 2) clinical trial of HyBryteâ„¢ in CTCL and positive primary endpoint results from the first Phase 3 FLASH study, initiate the FLASH2 study, while at the same time, continuing discussions with the U.S. Food and Drug Administration (â€œFDAâ€) on potential modifications to the development path to adequately address their feedback.â—Expanding development of synthetic hypericin under the research name SGX302 into psoriasis with the conduct of a Phase 2a clinical trial, following the positive Phase 3 FLASH study and positive proof-of-concept demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.â—Following feedback from the United Kingdom (â€œUKâ€) Medicines and Healthcare products Regulatory Agency (â€œMHRAâ€) that a second Phase 3 clinical trial of SGX942 in the treatment of oral mucositis would be required to support a marketing authorization; design a second study and attempt to identify a potential partner(s) to continue this development program.â—Expanding development of dusquetide under the research name SGX945 into BehÃ§etâ€™s Disease by conducting a Phase 2a clinical trial, where previous studies with dusquetide in oral mucositis have validated the biologic activity in aphthous ulcers induced by chemotherapy and radiation.â—Continue development of our heat stabilization platform technology, ThermoVaxÂ®, in combination with programs for RiVaxÂ® (ricin toxin vaccine), and filovirus vaccines (targeting Ebola, Sudan, and Marburg viruses and multivalent combinations), with U.S. government and non-governmental organization funding support.â—Continue to apply for and secure additional government funding for each of our Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts and/or procurements.â—Pursue business development opportunities for pipeline programs, as well as explore all strategic alternatives, including but not limited to merger/acquisition strategies.â—Acquire or in-license new clinical-stage compounds for development, as well as evaluate new indications with existing pipeline compounds for development.Corporate InformationWe were incorporated in Delaware in 1987 under the name Biological Therapeutics,Â Inc. In 1987, we merged with Biological Therapeutics,Â Inc., a North Dakota corporation, pursuant to which we changed our name to â€œImmunotherapeutics,Â Inc.â€ We changed our name to â€œEndorex Corp.â€ in 1996, to â€œEndorex Corporationâ€ in 1998, to â€œDOR BioPharma,Â Inc.â€ in 2001, and finally to â€œSoligenix,Â Inc.â€ in 2009. Our principal executive offices are located at 29 Emmons Drive, SuiteÂ B-10, Princeton, New Jersey 08540 and our telephone number is (609) 538-8200.24 Table of ContentsOur Product Candidates in DevelopmentThe following tables summarize our product candidates under development:Specialized BioTherapeutics Product Candidatesâ€‹â€‹â€‹Soligenix Product CandidateÂ Â Â Therapeutic IndicationÂ Â Â Stage of DevelopmentHyBryteâ„¢â€‹Cutaneous T-Cell Lymphomaâ€‹Phase 2 trial completed; demonstrated significantly higher response rate compared to placebo; Phase 3 trial completed; demonstrated statistical significance in primary endpoint in March 2020 (Cycle 1) and demonstrated continued improvement in treatment response with extended treatment in April 2020 (Cycle 2) and October 2020 (Cycle 3); NDA submitted to FDA December 2022; FDA RTF letter received February 2023; second Phase 3 trial based upon EMA-accepted protocol targeted to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026; discussions continue with FDA on modifying the development path to adequately address FDAâ€™s preference for a longer duration comparative study over a placebo-controlled trial.â€‹â€‹â€‹â€‹â€‹SGX302â€‹Mild-to-Moderate Psoriasisâ€‹Positive proof-of-concept demonstrated in a small Phase 1/2 pilot study; Phase 2a protocol and Investigation New Drug (â€œINDâ€) clearance received from the FDA; Phase 2a study remains ongoing having demonstrated biological effect in Cohort 1 and clinically meaningful benefit in Cohort 2â€‹â€‹â€‹â€‹â€‹SGX942â€ â€‹Oral Mucositis in Head and Neck Cancerâ€‹Phase 2 trial completed; demonstrated significant response compared to placebo with positive long-term (12 month) safety also reported; Phase 3 clinical trial results announced December 2020: the primary endpoint of median duration of severe oral mucositis (â€œSOMâ€) did not achieve the pre-specified criterion for statistical significance (pâ‰¤0.05); although biological activity was observed with a 56% reduction in the median duration of SOM from 18 days in the placebo group to 8 days in the SGX942 treatment group; analyzed full dataset from Phase 3 study and designing a second Phase 3 clinical trial; continued development contingent upon identification of partnershipâ€‹â€‹â€‹â€‹â€‹25 Table of Contentsâ€‹â€‹Soligenix Product CandidateÂ Â Â Therapeutic IndicationÂ Â Â Stage of DevelopmentSGX945â€‹Aphthous Ulcers in BehÃ§etâ€™s Diseaseâ€‹Phase 2a protocol and IND clearance received from the FDA; Phase 2a study to be initiated in 4Q 2024â€‹â€‹â€‹â€‹â€‹Public Health Solutionsâ€ â€‹â€‹â€‹Soligenix Product CandidateÂ Â Â IndicationÂ Â Â Stage of DevelopmentThermoVaxÂ®â€‹Thermostability of vaccines for Ricin toxin, Ebola, and Marburg virusesâ€‹Pre-clinicalâ€‹â€‹â€‹â€‹â€‹RiVaxÂ®â€‹Vaccine against Ricin Toxin Poisoningâ€‹Phase 1a, 1b, and 1c trials completed, safety and neutralizing antibodies for protection demonstratedâ€‹â€‹â€‹â€‹â€‹SGX943â€‹Therapeutic against Emerging Infectious Diseasesâ€‹Pre-clinicalâ€‹â€‹â€‹â€‹â€‹ Contingent upon continued government contract/grant funding or other funding source.Specialized BioTherapeutics OverviewSynthetic Hypericin Synthetic Hypericin is a potent photosensitizer that is topically applied to skin lesions, taken up by cutaneous T-cells and then activated by safe visible light. Hypericin is also found in several species of Hypericum plants, although the active moiety used in HyBryteâ„¢ and SGX302 is chemically synthesized by a proprietary manufacturing process and not extracted from plants. Importantly, hypericin is optimally activated with visible light thereby avoiding the negative consequences of ultraviolet (â€œUVâ€) light. Other light therapies using UVA or UVB light can result in serious adverse effects including secondary skin cancers. Combined with photoactivation, in clinical trials synthetic hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. In both settings, it appears that the mode of action is an induction of cell death in a concentration as well as a light dose-dependent fashion. These effects appear to result, in part, from the generation of singlet oxygen during photoactivation of hypericin.Synthetic hypericin is one of the most efficient known generators of singlet oxygen, the key component for phototherapy. The generation of singlet oxygen induces necrosis and apoptosis in cells. The use of topical synthetic hypericin coupled with directed visible light results in generation of singlet oxygen only at the treated site. We believe that the use of visible light (as opposed to cancer-causing UV light) is a major advance in photodynamic therapy. In a small published Phase 1/2 proof of concept pilot clinical study using synthetic hypericin twice weekly for six weeks, statistically significant efficacy was demonstrated in patients with CTCL (58.3% response, p=0.04) and psoriasis (80% response, p<0.02). Subsequently, a Phase 3 study in CTCL has further confirmed the biological efficacy of synthetic hypericin (termed HyBryteâ„¢ in the context of CTCL).26 Table of ContentsHyBryteâ„¢Â â€“ for Treating Cutaneous T-Cell LymphomaHyBryteâ„¢ is a novel, first-in-class, PDT that utilizes safe visible light for activation. The active ingredient in HyBryteâ„¢ is synthetic hypericin, a photosensitizer which is topically applied to skin lesions and then activated by visible fluorescent light 16 to 24 hours later. Based on the positive and previously published Phase 1/2 results, we initiated our Phase 3 clinical study of HyBryteâ„¢ for the treatment of CTCL during DecemberÂ 2015 and completed the trial in 2020. This trial, referred to as the â€œFLASHâ€ (Fluorescent Light Activated Synthetic Hypericin) study, aimed to evaluate the response to HyBryteâ„¢ as a skin directed therapy to treat early stage CTCL. We completed the study with approximately 35 CTCL centers across the U.S. participating in this trial. The Phase 3 protocol was a highly powered, double-blind, randomized, placebo-controlled, multicenter trial that enrolled 169 subjects (166 evaluable). The trial consisted of three treatment cycles, each of eight weeks duration. Treatments were administered twice weekly for the first six weeks and treatment response was determined at the end of the eighth week. In the first treatment cycle, approximately 66% of subjects received HyBryteâ„¢ and 33% received placebo treatment of their index lesions. In the second cycle, all subjects received HyBryteâ„¢ treatment of their index lesions, and in the third cycle, all subjects received HyBryteâ„¢ treatment of all of their lesions. The majority of subjects enrolled elected to continue into the third optional, open-label cycle of the study. Subjects were followed for an additional sixÂ months after their last evaluation visit. The primary efficacy endpoint was assessed on theÂ percentage of patients in each of the two treatment groups (i.e., HyBryteâ„¢ and placebo) achieving a partial or complete response of the treated lesions, defined as a â‰¥ 50% reduction in the total Composite Assessment of Index Lesion Disease Severity (â€œCAILSâ€) score for three index lesions at the Cycle 1 evaluation visit (Week 8) compared to the total CAILS score at baseline. Secondary endpoints for the trial included the duration of responses, the extent of the regression of the tumors, and the safety of the treatment. We continue to work closely with the Cutaneous Lymphoma Foundation, as well as the National Organization for Rare Disorders.Positive primary endpoint analysis for the Phase 3 study for HyBryteâ„¢ was completed in MarchÂ 2020. The study enrolled 169 patients (166 evaluable) randomized 2:1 to receive either HyBryteâ„¢ (116 patients) or placebo (50 patients) and demonstrated a statistically significant treatment response (p=0.04) in the CAILS primary endpoint assessment at 8 weeks for Cycle 1. A total of 16% of the patients receiving HyBryteâ„¢ achieved at least a 50% reduction in their index lesions compared to only 4% of patients in the placebo group at 8 weeks. HyBryteâ„¢ treatment in the first cycle was safe and well tolerated.Analysis of the second open-label treatment cycle (Cycle 2) was completed in April 2020, showing that continued treatment with HyBryteâ„¢ twice weekly for an additional 6 weeks (12 weeks total) increased the positive response rate to 40% (p<0.0001 compared to placebo and p<0.0001 compared to 6-weeks treatment). After the subsequent additional 6-week treatment, the response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold. Treatment responses were assessed at Week 8 (after 6 weeks of treatment) and at Week 16 (after 12 weeks of treatment). A positive response was defined as an improvement of at least 50% in the CAILS score for the three index lesions evaluated in both Cycles 1 and 2. The data continued to indicate that HyBryteâ„¢ was safe and well tolerated.Analysis of the optional third open-label treatment cycle (Cycle 3) was completed in October 2020. Cycle 3 was focused on safety and all patients could elect to receive HyBryteâ„¢ treatment of all their lesions for an additional 6 weeks or up to 18 weeks in total. Of note, 66% of patients elected to continue with this optional safety cycle of the study. Of the subset of patients that received HyBryteâ„¢ throughout all three cycles of treatment (18 weeks), 49% of them demonstrated a treatment response (p=0.046 vs. patients completing 12 weeks of HyBryteâ„¢ treatment in Cycle 2; p<0.0001 vs. patients receiving placebo in Cycle 1). Moreover, in a subset of patients evaluated in this cycle, it was demonstrated that HyBryteâ„¢ is not systemically available, consistent with the general safety of this topical product observed to date. At the end of Cycle 3, HyBryteâ„¢ continued to be well tolerated despite extended and increased use of the product to treat multiple lesions.In addition, continued analysis of results from the protocol mandated efficacy cycles (Cycles 1 and 2) of the study revealed that 12 weeks of treatment (Cycle 2) with HyBryteâ„¢ is equally effective on both patch (response 27 Table of Contents37%, p=0.0009) and plaque (response 42%, p<0.0001) lesions when compared to Cycle 1 placebo lesion responses, further demonstrating the unique benefits of the more deeply penetrating visible light activation of hypericin.Following the first Phase 3 study of HyBryteâ„¢ for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support marketing approval. Â With agreement from the

EMA on the key design components, the confirmatory Phase 3 trial will be a randomized, double-blind, placebo-controlled, multicenter study treating approximately 80 subjects with early-stage CTCL. It will evaluate the efficacy and safety of HyBryteâ„¢ topically applied to CTCL lesions twice weekly for 18 weeks, with each application followed 21 (Â±3) hours later by the administration of safe, visible light at a wavelength of 500 to 650 nm. The light will be administered starting at 6 J/cm2 twice weekly. This will be increased upwards by 2 J/cm2 until: 1) the patient experiences a Grade 1 erythema, 2) the patient reaches the maximum dose of 30 J/cm2, or 3) the patient cannot tolerate the treatment time, whichever comes first. All of the patientâ€™s lesions that are readily available for exposure to the visible light source will be treated and three to five index lesions of each patient will be prospectively identified and indexed for the modified composite assessment of index lesions severity (â€œmCAILSâ€) evaluation prior to randomization (baseline). The primary efficacy endpoint will be assessed on the percent of patients in each of the two treatment groups (i.e., HyBryteâ„¢ and placebo) achieving a Partial or Complete Response (yes/no) of the treated lesions defined as a â‰¥ 50% reduction in the total mCAILS score for the three to five index lesions following 18 weeks of treatment compared to the total mCAILS score at baseline.Â Other secondary measures will assess treatment response (including duration), degree of improvement, time to relapse and safety.Â Following treatment, all patients will be followed every four weeks for a total of 12 weeks (through Week 30). The Data Monitoring Committee will conduct one (1) interim analysis when approximately 60% of the total subjects have completed the primary endpoint evaluation. The primary efficacy endpoint and the key safety endpoints will be analyzed. A sample size recalculation may be performed after examining the assumptions or the trial halted for either futility, safety concerns, or overwhelming efficacy. The Company, participating clinical investigators, and any personnel involved in trial conduct will remain blinded to study treatment until completion of the trial.HyBryteâ„¢ has received Orphan Drug designation as well as Fast Track designation from the FDA. The Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition to providing a seven-year term of market exclusivity for HyBryteâ„¢ upon final FDA approval, Orphan Drug designation also positions us to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of FDA user fees for the potential submission of a NDA for HyBryteâ„¢, and certain tax credits. In addition, Fast Track is a designation that the FDA reserves for a drug intended to treat a serious or life-threatening condition and one that demonstrates the potential to address an unmet medical need for the condition. Fast Track designation is designed to facilitate the development and expedite the review of new drugs. For instance, we were eligible to submit a NDA for HyBryteâ„¢ on a rolling basis, permitting the FDA to review sections of the NDA prior to receiving the complete submission. Additionally, NDAs for Fast Track development programs ordinarily will be eligible for priority review. HyBryteâ„¢ for the treatment of CTCL also was granted Orphan Drug designation from the EMA Committee for Orphan Medical Products and Promising Innovative Medicine (â€œPIMâ€) designation from the MHRA, as well as Innovation Passport under the Innovative Licensing and Access Pathway (â€œILAPâ€) in the UK.During JanuaryÂ 2021, we signed an exclusive Supply, Distribution and Services Agreement with The Daavlin Distributing Co. (â€œDaavlinâ€), securing long-term supply and distribution of a commercially ready light device, which is an integral component of the regulatory and commercial strategy for HyBryteâ„¢ for the treatment of CTCL. Pursuant to the agreement, Daavlin will exclusively manufacture the proprietary light device for use with HyBryteâ„¢ for the treatment of CTCL. Upon approval of HyBryteâ„¢ by the FDA, we will promote HyBryteâ„¢ and the companion light device, and facilitate the direct purchase of the device from Daavlin. Daavlin will exclusively distribute and sell the HyBryteâ„¢ light device to us, physicians and patients.In AprilÂ 2021, the FDA conditionally accepted HyBryteâ„¢ as the proposed brand name for SGX301 or synthetic hypericin, in the treatment of early stage CTCL. The name HyBryteâ„¢ was developed in compliance with the 28 Table of ContentsFDAâ€™s Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names. The FDAâ€™s conditional approval validates HyBryteâ„¢ as a proprietary name that is consistent with the FDAâ€™s goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use. Final approval of the HyBryteâ„¢ proprietary name is conditioned on FDA approval of the product candidate, SGX301.In MayÂ 2021, HyBryteâ„¢ was awarded an "Innovation Passport" for the treatment of early stage CTCL in adults under the UKâ€™s ILAP. The decision to award the Innovation Passport to the HyBryteâ„¢ program was made by the Innovative Licensing and Access Pathway Steering Group, which is comprised of representatives from MHRA, the National Institute for Health and Care Excellence (â€œNICEâ€), and the Scottish Medicines Consortium (â€œSMCâ€). ILAP was launched at the start of 2021 to accelerate the development and access to promising medicines, thereby facilitating patient access to new medicines. The pathway, part of the UKâ€™s plan to attract life sciences development in the post-Brexit era, features enhanced input and interactions with the MHRA, NICE, and SMC. The innovation passport designation is the first step in the ILAP process and triggers the MHRA and its partner agencies to create a target development profile to chart out a roadmap for regulatory and development milestones with the goal of early patient access in the UK. Other benefits of ILAP include a 150-day accelerated assessment, rolling review and a continuous benefit risk assessment.In June 2021, we received a Paediatric Investigation Plan (â€œPIPâ€) waiver from the EMA for HyBryteâ„¢. As part of the regulatory process for the registration of new medicines with the EMA, pharmaceutical companies are required to provide a PIP outlining their strategies for investigation of the new medicinal products in the pediatric population. In some instances, a waiver negating the need for a PIP for certain conditions may be granted by the EMA when development of a medicine for use in children is not feasible or appropriate, as is the case for HyBryteâ„¢ in CTCL which is extremely rare in children.In September 2021, we were granted orphan drug designation for the active ingredient hypericin for the treatment of T-cell lymphoma, extending the target population beyond CTCL as previously granted by the FDA.In July 2022, the results of our successful Phase 3 FLASH study evaluating HyBryteâ„¢Â for the treatment of CTCL were published in the Journal of the American Medical Association (JAMA) Dermatology.In July 2022, we received agreement from the FDA on an initial pediatric study plan (â€œiPSPâ€) for HyBryteâ„¢ for the treatment of CTCL. The agreed iPSP stipulates that we intend to request a full waiver of pediatric studies upon submission of the NDA. Agreement with FDA on an iPSP is one of the regulatory requirements that must be met prior to submitting a NDA.In September 2022, the FDA awarded an Orphan Products Development grant to support the evaluation ofÂ HyBryteâ„¢Â for expanded treatment in patients with early-stage CTCL. The grant, totalingÂ $2.6 millionÂ over four years, was awarded to a prestigious academic institution that was a leading enroller in theÂ published positive Phase 3 FLASHÂ study in the treatment of early stage CTCL.In December 2022, we submitted the HyBryteâ„¢ NDA for the treatment of CTCL with the FDA.In February 2023, we received a RTF letter from the FDA for the HyBryteâ„¢ NDA. Upon preliminary review, the FDA determined that the NDA was not sufficiently complete to permit substantive review. In April 2023, the United States Adopted Names (â€œUSANâ€) Council approved the use of the nonproprietary name of â€œhypericin sodiumâ€ for the novel active ingredient in both HyBryteâ„¢ (research name SGX301) for the treatment of CTCL and SGX302 for the treatment of mild-to-moderate psoriasis.In April 2023, we had a Type A meeting with the FDA to clarify and respond to the issues identified in the RTF letter received from the FDA and to seek additional guidance concerning information that the FDA would require for a resubmitted NDA to be deemed acceptable to file, in order to advance HyBryteâ„¢ towards marketing approval and U.S. commercialization. In order to accept an NDA filing for HyBryteâ„¢, the FDA is requiring 29 Table of Contentspositive results from a second, Phase 3 pivotal study in addition to the Phase 3, randomized, double-blind, placebo-controlled FLASH study previously conducted in this orphan indication.Â Based on this feedback, we have decided to collaboratively engage in discussions with the FDA in order to define the protocol and evaluate the feasibility of conducting the additional clinical trial.In MayÂ 2023, we were granted a follow-on Type A meeting with the FDA to initiate formal discussions regarding the protocol design of a second, Phase 3 pivotal study evaluating HyBryteâ„¢ in the treatment of CTCL in support of potential FDA marketing approval. While discussions have been collaborative, the FDA has expressed a preference for a longer duration comparative study over a placebo-controlled trial. Â Given the shorter time to potential commercial revenue and the similar trial design to the first FLASH study afforded by the EMA accepted protocol, we determined to initiate the FLASH2 study in support of worldwide potential approval. At the same time, we will continue discussions with the FDA on modifying the development path to adequately address their feedback.In August 2023, patient enrollment was opened for the investigator-initiated study (â€œIISâ€). IIS is supported by an Orphan Products Development grant of $2.6 million over four years awarded by the FDA to a prestigious academic institution that was a leading enroller in theÂ published positive Phase 3 FLASHÂ study in the treatment of early stage CTCL. The IIS will evaluate the expanded treatment, including up to 12 months of treatment, with HyBryteâ„¢ in patients with early-stage CTCL.In March 2024, we received agreement from the EMA on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryteâ„¢ in theÂ treatment of CTCL patients with early-stage disease. This confirmatory 18-week study is expected to enroll approximately 80 patients inÂ the USÂ andÂ Europe and is targeted to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026.In JuneÂ 2024, we announced positive clinical results from a comparability study evaluating HyBryteâ„¢ versus ValchlorÂ® (mechlorethamine gel) in the treatment of early stage CTCL. The open-label study enrolled 10 patients (5 patients per group) with treatment success defined as a â‰¥50% improvement in a patientâ€™s cumulative mCAILS score after 12 weeks of topical treatment compared to Baseline. The study demonstrated that HyBryteâ„¢ treatment resulted in 60% of patients achieving a 50% or better improvement in their mCAILS score versus 20% of ValchlorÂ® patients. When comparing the tolerance of the topical therapies in this trial, it is notable that all patients tolerated HyBryteâ„¢ well and had no adverse events â€œRelatedâ€ to the therapy. In contrast, 60% of the ValchlorÂ® treated patients had at least one adverse event â€œRelatedâ€ to the therapy. These adverse events in the ValchlorÂ® group included rashes, application site sensitivity, allergic contact dermatitis, and dermatitis, with one patient requiring steroid treatment, one requiring temporary interruption of ValchlorÂ® treatment, and one requiring permanent discontinuation of ValchlorÂ®. No such instances were reported in the HyBryteâ„¢ group.In JulyÂ 2024, we announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryteâ„¢ treatment for up to 12Â months in patients with early stage CTCL. To date, the trial sponsored by Dr.Â Ellen Kim, has enrolled and treated six patients with HyBryteâ„¢ over a time period ranging up to 44 weeks. Patients have responded positively to HyBryteâ„¢ therapy with 75% (3 of the 4 subjects who have completed at least 12 weeks of therapy) already achieving â€œTreatment Successâ€, as predefined in the studyâ€™s protocol as â‰¥50% improvement in their cumulative mCAILS score compared to Baseline. Of the three Treatment Successes, two were achieved within the first 12 weeks of treatment and the third within 18 weeks. Of the remaining three patients, two have only recently started HyBryteâ„¢ therapy and have not yet reached their first efficacy evaluation visit (i.e., at Week 6) and the other had a substantial improvement documented at the Week 18 visit, but has not yet achieved the success threshold. In addition, HyBryteâ„¢ appears to be safe and well tolerated in all patients, with no treatment-related adverse events reported to date.In September 2024, the European Patent Office granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin".Â The newly issued patent's claims are directed to a novel, highly purified form of synthetic hypericin manufactured through a unique proprietary process.Â Synthetic hypericin is the active pharmaceutical ingredient inÂ HyBryteâ„¢, our photodynamic therapy for the treatment of CTCL, set to initiate a 30 Table of Contentsconfirmatory Phase 3 clinical trial before the end of the year. This new European granted patent (EP3423428) is a related patent to US Pat. No. 10,053,413, previously issued inÂ the U.S. Both patents are expected to expire in 2036, and form part of a larger patent family, including previously granted U.S. patents covering methods of use (US Pat. No. 7,122,518) and methods of synthesis (US Pat. No. 8,629,302), as well as other granted patents throughout the world.In October 2024, we established a partnership agreement with Sterling Pharma Solutions Limited (â€œSterlingâ€) to optimize and implement a commercially viable, scalable production technology for synthetic hypericin. We are currently working to transfer and optimize the manufacturing processes and analytics to enable GMP manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.We estimate the potential worldwide market for HyBryteâ„¢ is in excess of $250 million for the treatment of CTCL. This potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be realized.Cutaneous T-Cell LymphomaCTCL is a class of non-Hodgkinâ€™s lymphoma (â€œNHLâ€), a type of cancer of the white blood cells that are an integral part of the immune system. Unlike most NHLs, which generally involve B-cell lymphocytes (involved in producing antibodies), CTCL is caused by an expansion of malignant T-cell lymphocytes (involved in cell-mediated immunity) normally programmed to migrate to the skin. These skin-trafficking malignant T-cells migrate to the skin, causing various lesions to appear that may change shape as the disease progresses, typically beginning as a rash and eventually forming plaques and tumors. Mycosis fungoides (â€œMFâ€) is the most common form of CTCL. It generally presents with skin involvement only, manifested as scaly, erythematous patches. Advanced disease with diffuse lymph node and visceral organ involvement is usually associated with a poorer response rate to standard therapies. A relatively uncommon sub-group of CTCL patients present with extensive skin involvement and circulating malignant cerebriform T-cells, referred to as SÃ©zary syndrome. These patients have substantially graver prognoses (expected five-year survival rate of 24%), than those with MF (expected five-year survival rate of 88%).CTCL mortality is related to stage of disease, with median survival generally ranging from about 12Â years in the early stages to only 2.5Â years when the disease has advanced. There is currently no FDA-approved drug for front-line treatment of early stage CTCL. Treatment of early-stage disease generally involves skin-directed therapies. One of the most common unapproved therapies used for early-stage disease is oral 5 or 8-methoxypsoralen (â€œPsoralenâ€) given with ultraviolet A (â€œUVAâ€) light, referred to as PUVA, which is approved for dermatological conditions such as disabling psoriasis not adequately responsive to other forms of therapy, idiopathic vitiligo and skin manifestations of CTCL in persons who have not been responsive to other forms of treatment. Psoralen is a mutagenic chemical that interferes with DNA causing mutations and other malignancies. Moreover, UVA is a carcinogenic light source that when combined with the Psoralen, results in serious adverse effects including secondary skin cancers; therefore, the FDA requires a Black Box warning for PUVA.CTCL constitutes a rare group of NHLs, occurring in about 4% of the more than 1.7 million individuals living with the disease in the United States and Europe (European Union and United Kingdom). Â It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of CTCL that it affects approximately 31,000 individuals in the U.S. (based on SEER data, with approximately 3,200 new cases seen annually) and approximately 38,000 individuals in Europe (based on ECIS prevalence estimates, with approximately 3,800 new cases annually).31 Table of ContentsSGX302 â€“ for Treating Mild-to-Moderate PsoriasisSGX302 (synthetic hypericin) is a potent photosensitizer that is topically applied to skin lesions and taken up by cutaneous T-cells. With subsequent activation by safe, visible light, T-cell apoptosis is induced, addressing the dysregulated T-cells found in psoriasis lesions. Other PDTs have shown efficacy in psoriasis with a similar apoptotic mechanism, albeit using UV light associated with more severe potential long-term toxicities. The use of visible light in the red-yellow spectrum has the advantage of deeper penetration into the skin (much more than UV light) potentially treating deeper skin disease and thicker plaques and lesions, similar to what was observed in the positive Phase 3 FLASH study in CTCL. Further, this treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with both the frequently used DNA-damaging drugs and other phototherapies that are dependent on UVA or UVB exposure. The use of SGX302 coupled with safe, visible light also avoids the risk of serious infections and cancer associated with the systemic immunosuppressive treatments used in psoriasis. In September 2021, following the validation of synthetic hypericinâ€™s biologic activity in the positive Phase 3 FLASH study in CTCL, as well as positive proof-of-concept demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients, we decided to expand this novel therapy into a Phase 2a clinical trial in mild-to-moderate psoriasis. In June 2022, we received FDA IND clearance for our Phase 2a clinical trial (protocol number HPN-PSR-01) titled, "Phase 2 Study Evaluating SGX302 in the Treatment of Mild-to-Moderate Psoriasis." In December 2022, we initiated patient enrollment for the Phase 2a study (protocol number HPN-PSR-01) evaluatingÂ SGX302Â in the treatment of mild-to-moderate psoriasis. The Phase 2a clinical trial (protocol number HPN-PSR-01) will target enrollment of up to 42 patients ages 18 years or older with mild to moderate, stable psoriasis covering 2 to 30% of the body. In both Parts A and B, all patients will apply the study drug twice per week and activate the drug with visible light 24 Â± 6 hours later using the supplied visible light devices and according to the manufacturer's instructions. Patients will undergo treatments for a total of 18 weeks and, on completion, will be followed for a four-week follow-up period in which patients will not receive other psoriasis treatments. In Part A, five to ten patients will be assigned open-label SGX302 (0.25% hypericin) at the time of enrollment. Once the tolerability and response to SGX302 has been established, Part B of the protocol will commence. In Part B, patients will be randomized to double-blind treatment groups at a ratio 1:1 of active drug to placebo ointment. Active dermatologic assessment of treated lesions for adverse events will be performed immediately before and during light treatments. Patients will be assessed for overall disease status through four weeks of follow-up. Efficacy endpoints will include the extent of lesion clearance and patient reported quality of life indices. Routine safety data also will be collected.In October 2022, we announced the formation of a Medical Advisory Board to provide medical/clinical strategic guidance to advance the Phase 2a clinical development of SGX302 for the treatment of mild-to-moderate psoriasis.In July 2023, we expanded the Phase 2a trial ofÂ SGX302Â after demonstration of biological effect in the initial five subjects (Cohort 1). Â The study is expected to enroll at least an additional ten subjects, exploring the use of SGX302 in the standard of care psoriasis setting, prior to undertaking the larger phase of the study.In JanuaryÂ 2024, positive preliminary results of clinical success were demonstrated in the Cohort 2 subjects enrolled in the ongoing Phase 2a study. In the four evaluable patients from Cohort 2 (one patient withdrew

early in the treatment course for personal reasons unrelated to the study), two reached a disease status of â€œAlmost Clearâ€ represented by an Investigator Global Assessment score of 1, which is considered the standard clinical measure for treatment success in psoriasis. In addition, the Psoriasis Activity and Severity Index score, another well-characterized measure of treatment success, for patients in Cohort 2 had a mean drop of approximately 50% over the 18-week treatment. SGX302 therapy was well tolerated by all patients with no drug related adverse events identified.32 Table of ContentsWe estimate the potential worldwide market for SGX302 is in excess of $1 billion for the treatment of mild-to-moderate psoriasis. This potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be realized.PsoriasisPsoriasis is a chronic, non-communicable, itchy and often painful inflammatory skin condition for which there is no cure.Â Psoriasis has a significantly detrimental impact on patients' quality of life, and is associated with cardiovascular, arthritic, and metabolic diseases, as well as psychological conditions such as anxiety, depression and suicide.Â Many factors contribute to development of psoriasis including both genetic and environmental factors (e.g., skin trauma, infections, and medications).Â The lesions develop because of rapidly proliferating skin cells, driven by autoimmune T-cell mediated inflammation. Of the various types of psoriasis, plaque psoriasis is the most common and is characterized by dry, red raised plaques that are covered by silvery-white scales occurring most commonly on the elbows, knees, scalp, and lower back. Approximately 80% of patients have mild-to-moderate disease.Â Mild psoriasis is generally characterized by the involvement of less than 3% of the body surface area (â€œBSAâ€), while moderate psoriasis will typically involve 3-10% BSA and severe psoriasis greater than 10% BSA.Â Between 20% and 30% of individuals with psoriasis will go on to develop chronic, inflammatory arthritis (psoriatic arthritis) that can lead to joint deformations and disability.Â Studies have also associated psoriasis, and particularly severe psoriasis, with an increased relative risk of lymphoma, particularly CTCL.Â Although psoriasis can occur at any age, most patients present with the condition before age 35.Treatment of psoriasis is based on its severity at the time of presentation with the goal of controlling symptoms. It varies from topical options including PDT to reduce pain and itching, and potentially reduce the inflammation driving plaque formation, to systemic treatments for more severe disease. Most common systemic treatments and even current topical photo/photodynamic therapy such as UV A and B, carry a risk of increased skin cancer.Psoriasis is the most common immune-mediated inflammatory skin disease. According to the World Health Organization (â€œWHOâ€) Global Report on Psoriasis 2016, the prevalence of psoriasis is between 1.5% and 5% in most developed countries, with some suggestions of incidence increasing with time.Â It is estimated, based upon review of historic published studies and reports and an interpolation of data that psoriasis affects 3% of the U.S. population or more than 7.5 million people.Â Current estimates have as many as 60-125 million people worldwide living with the condition. The global psoriasis treatment market was valued at approximatelyÂ $15 billionÂ in 2020 and is projected to reach as much asÂ $40 billionÂ by 2027.DusquetideDusquetide (research name: SGX94) is an IDR that regulates the innate immune system to simultaneously reduce inflammation, eliminate infection and enhance tissue healing. Dusquetide is based on a new class of short, synthetic peptides known as IDRs. It has a novel mechanism of action in that it modulates the bodyâ€™s reaction to both injury and infection and is both simultaneously anti-inflammatory and anti-infective. IDRs have no direct antibiotic activity but modulate host responses, increasing survival after infections with a broad range of bacterial Gram-negative and Gram-positive pathogens including both antibiotic sensitive and resistant strains, as well as accelerating resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- or radiation-therapy. IDRs represent a novel approach to the control of infection and tissue damage via highly selective binding to an intracellular adaptor protein, sequestosome-1, also known as p62, which has a pivotal function in signal transduction during activation and control of the innate defense system. Preclinical data indicate that IDRs may be active in models of a wide range of therapeutic indications including life-threatening bacterial infections as well as the severe side-effects of chemo- and radiation-therapy. Additionally, due to selective binding to p62, dusquetide may have potential anti-tumor action.33 Table of ContentsDusquetide has demonstrated efficacy in numerous animal disease models including mucositis, oncology, colitis, skin infection and other bacterial infections and has been evaluated in a double-blind, placebo-controlled Phase 1 clinical trial in 84 healthy volunteers with both single ascending dose and multiple ascending dose components. Dusquetide was shown to have a good safety profile and be well-tolerated in all dose groups when administered by IV over 7Â days and was consistent with safety results seen in pre-clinical studies. We believe that market opportunities for dusquetide include, but are not limited to, oral and gastrointestinal mucositis, oncology (e.g., breast cancer), acute Gram-positive bacterial infections (e.g., methicillin resistant Staphylococcus aureus (â€œMRSAâ€)), acute Gram-negative infections (e.g., acinetobacter, melioidosis), and acute radiation syndrome.SGX942Â â€“ for Treating Oral Mucositis in Head and Neck CancerSGX942 is our product candidate containing our IDR technology, dusquetide, targeting the treatment of oral mucositis in head and neck cancer patients. Oral mucositis in this patient population is an area of unmet medical need where there are currently no approved drug therapies. Accordingly, we received Fast Track designation for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients from the FDA. In addition, dusquetide has been granted PIM designation in the UK by the MHRA for the treatment of SOM in head and neck cancer patients receiving chemoradiation therapy.We initiated a Phase 2 clinical study of SGX942 for the treatment of oral mucositis in head and neck cancer patients in DecemberÂ of 2013. We completed enrollment in this trial and released positive results in December 2015. In this Phase 2 proof-of-concept clinical study that enrolled 111 patients, SGX942, at a dose of 1.5 mg/kg, successfully reduced the median duration of SOM by 50%, from 18Â days to 9Â days (p=0.099) in all patients and by 67%, from 30Â days to 10Â days (p=0.040) in patients receiving the most aggressive chemoradiation therapy for treatment of their head and neck cancer. The p-values met the prospectively defined statistical threshold of p<0.1 in the study protocol. A less severe occurrence of oral mucositis, ulcerative oral mucositis (defined as oral mucositis with a WHO score â‰¥2 corresponding to the occurrence of overt ulceration in the mouth), was also monitored during the study. In the patients receiving the most aggressive chemoradiation therapy, the median duration of oral mucositis was found to decrease from 65Â days in the placebo treated patients to 51Â days in the patients treated with SGX942 1.5 mg/kg (p=0.099).In addition to identifying the best dose of 1.5 mg/kg, this study achieved all objectives, including increased incidence of â€œcomplete responseâ€ of tumor at the oneÂ month follow-up visit (47% in placebo vs. 63% in SGX942 at 1.5 mg/kg). Decreases in mortality and decreases in infection rate were also observed with SGX942 treatment, consistent with the preclinical results observed in animal models. Data from this Phase 2 trial are published in the Journal of Biotechnology.SGX942 was found to be generally safe and well tolerated, consistent with the safety profile observed in the prior Phase 1 study conducted in 84 healthy volunteers. The long-term (12Â month) follow-up data was consistent with the preliminary positive safety and efficacy findings. While the placebo population experienced the expected 12-month survival rate of approximately 80%, as defined in the Surveillance, Epidemiology, and End Results statistics 1975-2012 from the National Cancer Institute, the SGX942 1.5 mg/kg treatment group reported a 12-month survival rate of 93% (7% mortality in the SGX942 1.5 mg/kg group compared to 19% in the placebo group). Similarly, tumor resolution (complete response) at 12Â months was better in the SGX942 1.5 mg/kg treatment group relative to the placebo population (80% in the 1.5 mg/kg group compared to 74% in the placebo group). The long-term follow-up results from the Phase 2 study are published in Biotechnology Reports.In SeptemberÂ 2016, we and SciClone Pharmaceuticals,Â Inc. (â€œSciCloneâ€) entered into an exclusive license agreement, pursuant to which we granted rights to SciClone to develop, promote, market, distribute and sell SGX942 in defined territories. Under the terms of the license agreement, SciClone will be responsible for all aspects of development, product registration and commercialization in the territories, having access to data generated by us. In exchange for exclusive rights, SciClone will pay us royalties on net sales, and we will supply commercial drug product to SciClone on a cost-plus basis, while maintaining worldwide manufacturing rights.34 Table of ContentsBased on the positive and previously published Phase 2 results (Study IDR-OM-01), in July 2017, we initiated a Phase 3 clinical trial referred to as the â€œDOMâ€”INNATEâ€ (Dusquetide treatment in Oral MucositisÂ â€“ by modulating INNATE immunity) study. Approximately 50 U.S. and European oncology centers participated in this trial. The Phase 3 protocol (Study IDR-OM-02) was a highly powered, double-blind, randomized, placebo-controlled, multinational trial that sought to enroll approximately 260 subjects with squamous cell carcinoma of the oral cavity and oropharynx who were scheduled to receive a minimum total cumulative radiation dose of 55 Gy fractionated as 2.0-2.2 Gy per day with concomitant cisplatin chemotherapy given as a dose of 80-100 mg/m2 every third week. Subjects were randomized to receive either 1.5 mg/kg SGX942 or placebo given twice a week during and for two weeks following completion of chemoradiation therapy (â€œCRTâ€). The primary endpoint for the study was the median duration of SOM, which was assessed by oral examination at each treatment visit and then through six weeks following completion of CRT. Oral mucositis is evaluated using the WHO Grading system. SOM is defined as a WHO Grade of â‰¥3. Subjects are followed for an additional 12Â months after the completion of treatment.In AprilÂ 2019, the Paediatric Committee of the EMA approved our PIP for SGX942, a prerequisite for filing a Marketing Authorization Application (â€œMAAâ€) for any new medicinal product in Europe. The EMA also agreed that we may defer conducting the PIP until successful completion of our pivotal Phase 3 clinical trial of SGX942, which allowed us to file the adult indication MAA prior to completion of the PIP.In JuneÂ 2020, the pivotal Phase 3 DOMâ€”INNATE study (Study IDR-OM-02) completed enrollment of 268 subjects. In DecemberÂ 2020, the results of our Phase 3 clinical trial for SGX942 showed that the primary endpoint of median duration of SOM did not achieve the pre-specified criterion for statistical significance (pâ‰¤0.05); although biological activity was observed with a 56% reduction in the median duration of SOM from 18Â days in the placebo group to 8Â days in the SGX942 treatment group. Despite this clinically meaningful improvement, the variability in the distribution of the data yielded a p-value that was not statistically significant. Other secondary endpoints supported the biological activity of dusquetide, including a statistically significant 50% reduction in the median duration of SOM in the per-protocol population, which decreased from 18Â days in the placebo group to 9Â days in the SGX942 treatment group (p=0.049), consistent with the findings in the Phase 2 trial (Study IDR-OM-01). Similarly, incidence of SOM also followed this biological trend as seen in the Phase 2 study, decreasing by 16% in the SGX942 treatment group relative to the placebo group in the per-protocol population. The per-protocol population was defined as the population receiving a minimum of 55 Gy radiation and at least 10 doses of study drug (placebo or SGX942) throughout the intended treatment period, with no major protocol deviations (e.g. breaks in study drug administration longer than 8Â days between successive doses).Following analysis of the full dataset, including the 12-month long-term follow-up safety data in late 2021, we held a meeting with the MHRA to review the study results and to obtain further clarity on the future of the oral mucositis development program. The meeting was informative with the outcome being that based on the SGX942 biologic activity observed and the consistency in response between the Phase 2 and Phase 3 trials, the Phase 3 DOM-INNATE study could serve as the first of two Phase 3 studies required to support potential marketing authorization, assuming the second Phase 3 clinical trial achieves the required level of statistical significance in its primary endpoint. With the benefit of a robust preclinical and clinical data package for SGX942, we now will analyze the data to design a second Phase 3 study and will look to identify a potential partner(s) to continue this development program.â€‹In January 2022, dusquetide proved effective at reducing tumor size in nonclinical xenograft models. Recent studies, recapitulating results fromÂ previously published studies, have confirmed the efficacy of dusquetide as a stand-alone and combination anti-tumor therapy, with radiation, chemotherapy and targeted therapy, in the context of the MCF-7 breast cancer cell line. Of note, these results are consistent with a potential direct anti-tumor effect identified with SGX942 and is another important consideration in the oral mucositis treatment space.In June 2022, an article was publishedÂ describing the binding of our IDR, dusquetide, to the p62 protein. Dusquetide binds to p62 or SQSTM-1, a scaffold protein implicated in a number of intracellular signaling 35 Table of Contentsnetworks implicated in tumor cell survival, including autophagy. This publication elaborates on the direct interaction of dusquetide with p62, as well as some of the direct downstream consequences of that interaction, consistent with its observed anti-infective, anti-tumor and anti-inflammatory activities. This information advances the understanding of dusquetide's novel mechanism of action and supports the development of analogs related to dusquetide.We estimate the potential worldwide market for SGX942 is in excess of $500 million for the treatment of oral mucositis. This potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this potential market size based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be realized.Oral MucositisMucositis is the clinical term for damage done to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonly associated with the mouth, followed by the small intestine. We estimate, based upon our review of historic studies and reports, and an interpolation of data on the incidence of mucositis, that mucositis affects approximately 500,000 people in the U.S. perÂ year and occurs in 40% of patients receiving chemotherapy. Mucositis can be severely debilitating and can lead to infection, sepsis, the need for parenteral nutrition and narcotic analgesia. The gastrointestinal damage causes severe diarrhea. These symptoms can limit the doses and duration of cancer treatment, leading to sub-optimal treatment outcomes.The mechanisms of mucositis have been extensively studied and have been linked to the interaction of chemotherapy and/or radiation therapy with the innate defense system. Bacterial infection of the ulcerative lesions is regarded as a secondary consequence of dysregulated local inflammation triggered by therapy-induced cell death, rather than as the primary cause of the lesions.We estimate, based upon our review of historic studies and reports, and an interpolation of data on the incidence of oral mucositis, that oral mucositis is a subpopulation of approximately 90,000 patients in the U.S., with a comparable number in Europe. Oral mucositis almost always occurs in patients with head and neck cancer treated with radiation therapy (greater than 80% incidence of severe mucositis) and is common in patients undergoing high dose chemotherapy and hematopoietic cell transplantation, where the incidence and severity of oral mucositis depends greatly on the nature of the conditioning regimen used for myeloablation.SGX945Â â€“ for Treating Aphthous Ulcers in BehÃ§etâ€™s DiseaseSGX945 is our product candidate containing our IDR technology, dusquetide, targeting the treatment of aphthous Ulcers in BehÃ§etâ€™s Disease. BehÃ§etâ€™s Disease is an orphan disease and an area of unmet medical need.In NovemberÂ 2023, the FDA cleared the IND application for a Phase 2a clinical trial entitled, â€œPilot Study of SGX945 (Dusquetide) in the Treatment of Aphthous Ulcers in BehÃ§etâ€™s Disease.â€ The study is designed to evaluate the safety and potential efficacy of SGX945 (dusquetide) in the resolution of aphthous flares in BehÃ§etâ€™s Disease and is expected to begin patient enrollment in the second half of 2024.In JanuaryÂ 2024, SGX945 received Fast Track designation for the treatment of oral lesions of BehÃ§etâ€™s Disease from the FDA. In February 2024, we announced the formation of a Medical Advisory Board to provide medical/clinical strategic guidance to advance the clinical development of SGX945 for the treatment of BehÃ§et's Disease.We estimate the potential worldwide market for SGX945 is in excess of $200 million for the treatment of aphthous ulcers in BehÃ§etâ€™s Disease. This potential market information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this potential 36 Table of Contentsmarket size based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be realized. BehÃ§etâ€™s DiseaseBehÃ§etâ€™s Disease (â€œBDâ€) is commonly known as an inflammatory disorder of the blood vessels (vasculitis). Often first diagnosed in young adults, its effects and severity will wax and wane over time. Major signs and symptoms usually include mouth sores (approximately 95% of patients), skin rashes and lesions (approximately 50% of patients), genital sores (approximately 50% of patients), leg ulcers (approximately 40% of patients) and eye inflammation (approximately 15% of patients). It is a painful disease, directly impacting the patientâ€™s quality of life and ability to productively engage in life activities, including work.BD is thought to be an auto-immune disease with both genetic and environmental factors. It is most common along the â€œsilk roadâ€ in the Middle East and East Asia, including Turkey, Iran, Japan and China. There are approximately 18,000 known cases of BD in the U.S. and over 50,000 in Europe. There are as many as 1,000,000 people worldwide living with BD.There is no cure for BD, rather treatments are prescribed to manage symptoms. Treatments may include both maintenance therapies and those specifically addressing mucocutaneous flares (e.g., mouth ulcers, genital ulcers and leg ulcers). Corticosteroids are generally applied topically to sores and as eyedrops and may also be given systemically to reduce inflammation. Although used frequently, they have limited efficacy over the long-term and have significant side effects that become more concerning with more chronic use. Genital ulcers are often associated with significant genital scarring while leg ulcers can result in a post-thrombotic syndrome. Other treatments for BD flares involve suppressing the immune system with drugs (e.g., cyclosporine or cyclophosphamide). These drugs come with a higher risk of infection, liver and kidney problems, low blood counts and high blood pressure. Finally, anti-inflammatory drugs are also used, including anti-TNF medications. The only approved drug in BD is apremilast, which is used as a maintenance therapy to prevent formation of oral ulcers. Unfortunately, apremilast is associated with both high cost and side effects including diarrhea, nausea, upper respiratory tract infection and headache.Public Health Solutions OverviewThermoVaxÂ®Â â€“ Thermostability Platform TechnologyThermoVaxÂ® is a novel method for thermostabilizing vaccines with a variety of adjuvants, resulting in a single vial which can be reconstituted with water for injection immediately prior to use. One of the adjuvants utilized in ThermoVaxÂ® is aluminum salts (known colloquially as â€œAlumâ€). Alum is the most widely employed adjuvant technology in the vaccine industry.The value of ThermoVaxÂ® lies in its potential ability to eliminate the need for cold chain production, transportation, and storage for Alum-adjuvanted vaccines. This would relieve the high costs of producing and maintaining vaccines under refrigerated conditions. Based on historical reports from WHO and other scientific reports, we believe that a meaningful proportion of vaccine doses globally are wasted due to excursions from required cold chain temperature ranges. This is due to the fact that many vaccines need to be

maintained either between 2 and 8 degrees Celsius (â€œCâ€), frozen belowÂ -20 degrees C, or frozen belowÂ -60 degrees C, and even brief excursions from these temperature ranges usually necessitate the destruction of the product or the initiation of costly stability programs specific for the vaccine lots in question. ThermoVaxÂ® has the potential to facilitate easier storage and distribution of strategic national stockpile vaccines for ricin exposure in emergency settings.37 Table of ContentsThermoVaxÂ® development, specifically in the context of an Alum adjuvant, was supported pursuant to our $9.4 million NIAID grant enabling development of thermo-stable ricin (RiVaxÂ®) and anthrax vaccines. Proof-of-concept preclinical studies with ThermoVaxÂ® indicate that it is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions. These studies were conducted with our Alum-adjuvanted ricin toxin vaccine, RiVaxÂ® and our Alum-adjuvanted anthrax vaccine. Each vaccine was manufactured under precise lyophilization conditions using excipients that aid in maintaining native protein structure of the key antigen. When RiVaxÂ® was kept at 40 degrees C (104 degrees Fahrenheit (â€œFâ€)) for up to oneÂ year, all of the animals vaccinated with the lyophilized RiVaxÂ® vaccine developed potent and high titer neutralizing antibodies. In contrast, animals that were vaccinated with the liquid RiVaxÂ® vaccine kept at 40 degrees C did not develop neutralizing antibodies and were not protected against ricin exposure. The ricin A chain is extremely sensitive to temperature and rapidly loses the ability to induce neutralizing antibodies when exposed to temperatures higher than 8 degrees C. When the anthrax vaccine was kept for up to 16 weeks at 70 degrees C, it was able to develop a potent antibody response, unlike the liquid formulation kept at the same temperature. Moreover, we also have demonstrated the compatibility of our thermostabilization technology with other secondary adjuvants such as TLR-4 agonists.We also entered into a collaboration agreement with Axel Lehrer,Â PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (â€œJABSOMâ€), University of Hawaiâ€™i at Manoa (â€œUH Manoaâ€) and Hawaii Biotech,Â Inc. (â€œHBIâ€) to develop a heat stable subunit Ebola vaccine. Dr.Â Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept efficacy with subunit Ebola vaccines in non-human primates (â€œNHPâ€). The most advanced Ebola vaccines involve the use of vesicular stomatitis virus and adenovirus vectorsÂ â€“ live, viral vectors which complicate the manufacturing, stability and storage requirements. Dr.Â Lehrerâ€™s vaccine candidate is based on highly purified recombinant protein antigens, circumventing many of these manufacturing difficulties. Dr.Â Lehrer and HBI have developed a robust manufacturing process for the required proteins. Application of ThermoVaxÂ® may allow for a product that can avoid the need for cold chain distribution and storage, yielding a vaccine ideal for use in both the developed and developing world. This agreement has expired in accordance with its terms.In December 2010, we executed a worldwide exclusive license agreement with the University of Colorado (â€œUCâ€) for certain patents relating to ThermoVaxÂ® in all fields of use. In AprilÂ 2018, the UC delivered a notice of termination of our license agreement based upon our failure to achieve one of the development milestones: initiation of the Phase 1 clinical trial of the heat stabilization technology by MarchÂ 31, 2018. After negotiating with the UC, we and the UC agreed to extend the termination date to OctoberÂ 31, 2018 in order to allow us time to agree upon a potential agreement that would allow us to keep the rights to, and to continue to develop, the heat stabilization technology or a product candidate containing the heat stabilization technology in our field of use.During SeptemberÂ 2017, we were awarded funding of approximately $700,000 over fiveÂ years under a NIAID Research Project (R01) grant awarded to UH Manoa for the development of a trivalent thermostabilized filovirus vaccine (including protection against Zaire ebolavirus, Sudan ebolavirus and Marburg Marburgvirus). Previous collaborations demonstrated the feasibility of developing a heat stable subunit Ebola vaccine. Under the terms of the subaward, we will continue to support vaccine formulation development with our proprietary vaccine thermostabilization technology, ThermoVaxÂ®. Ultimately, the objective is to produce a thermostable trivalent filovirus vaccine for protection against Ebola and related diseases, allowing worldwide distribution without the need for cold storage. Based on current U.S. government needs, efforts have been expanded to focus on a monovalent or bivalent vaccine to specifically address Marburg marburgvirus.In OctoberÂ 2018, in a series of related transactions, (a)Â we and the UC agreed to terminate the original license agreement, (b)Â the UC and VitriVax,Â Inc. (â€œVitriVaxâ€) executed a worldwide exclusive license agreement for the heat stabilization technology for all fields of use, and (c)Â we and VitriVax executed a worldwide exclusive sublicense agreement, which was amended and restated in OctoberÂ 2020, for the heat stabilization technology for use in the fields of ricin and Ebola vaccines. We paid a $100,000 sublicense fee on the effective date of the sublicense agreement. Under the amended sublicense agreement to maintain the sublicense we are obliged 38 Table of Contentsto pay a minimum annual royalty of $20,000 until first commercial sale of a sublicensed product, upon which point, we shall pay an earned royalty of 2% of net sales subject to a minimum royalty of $50,000 eachÂ year. We are also required to pay royalty on any sub-sublicense income based on a decliningÂ percentage of all sub-sublicense income calculated within the contractual period until reaching a minimum of 15% after twoÂ years. In addition, we are required to pay VitriVax milestone fees of: (a)Â $25,000 upon initiation of a Phase 2 clinical trial of the sublicensed product, (b)Â $100,000 upon initiation of a Phase 3 clinical trial of the sublicensed product, (c)Â $100,000 upon regulatory approval of a sublicensed product, and (d)Â $1 million upon achieving $10 million in aggregate net sales of a sublicensed product in the U.S. or equivalent. To date none of these milestones have been met.In MarchÂ 2020, we entered into a research collaboration with Axel Lehrer,Â PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, JABSOM, UH Manoa to further expand the filovirus collaboration to investigation of potential coronavirus vaccines, including for SARS-CoV-2 (causing COVID-19). This research collaboration will utilize the technology platform developed in the search for filovirus vaccines and will use well-defined surface glycoprotein(s)Â from one or more coronaviruses, which are expected to be protective for COVID-19.During AprilÂ 2020, we obtained an exclusive worldwide license for CoVaccine HTâ„¢, a novel vaccine adjuvant, from SERB Pharmaceuticals (formerly BTG Specialty Pharmaceuticals, a division of Boston Scientific Corporation) (â€œSERBâ€), for the fields of coronavirus infection (including SARS-CoV-2, the cause of COVID-19), and pandemic flu. CoVaccine HTâ„¢ is a novel adjuvant, which has been shown to enhance both cell-mediated and antibody-mediated immunity. We and our collaborators, including UH Manoa and Dr.Â Axel Lehrer, have successfully demonstrated the utility of CoVaccine HTâ„¢ in the development of our heat stable filovirus vaccine program, with vaccine candidates against Ebola and Marburg virus disease. Given this previous success, CoVaccine HTâ„¢ will potentially be an important component of our vaccine technology platform currently being assessed for use against coronaviruses including SARS-CoV-2, the cause of COVID-19. The license agreement was executed between us and SERB, which owns the CoVaccine HTâ„¢ intellectual property.In SeptemberÂ 2020, the Journal of Pharmaceutical Sciences published a scientific article detailing the thermostabilization of the filovirus GP proteins and key assays describing their stability.During OctoberÂ 2020, Frontiers in Immunology published a scientific article describing CiVaxâ„¢, a prototype COVID-19 vaccine, using the novel CoVaccine HTâ„¢ adjuvant and demonstrating significant immunogenicity, including strong total and neutralizing antibody responses, with a balanced Th1 response, as well as enhancement of cell mediated immunity. These are all considered to be critical attributes of a potential COVID-19 vaccine.In DecemberÂ 2020, NIAID awarded us a Direct to Phase II Small Business Innovation Research (â€œSBIRâ€) grant of approximately $1.5 million to support manufacture, formulation (including thermostabilization) and characterization of COVID-19 and Ebola Virus Disease (â€œEVDâ€) vaccine candidates in conjunction with the CoVaccine HTâ„¢ adjuvant. This award also is supporting immune characterization of this novel, emulsified adjuvant that has unique potency and compatibility with lyophilization strategies to enable thermostabilization of subunit vaccines.During August 2021, positive data demonstrated the efficacy of multiple filovirus vaccine candidates in NHP, including thermostabilized multivalent vaccines in a single vial platform presentation. Collaborators at UH Manoa describe the potent efficacy of vaccine candidates protecting against three life-threatening filoviruses, Zaire ebolavirus, Sudan ebolavirus and Marburg Marburgvirus in an article titled "Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques from Ebola, Sudan, and Marburg Viruses", published in Frontiers in Immunology. These vaccine candidates contain highly purified protein antigens combined with the novel CoVaccine HTâ„¢ adjuvant, in both monovalent (single antigen) and bivalent (two antigen) formulations. Most recently, efforts to formulate all three antigens and adjuvant into a thermostable single-vial vaccine platform has also been shown to protect 75% of vaccinated NHPs against subsequent Sudan ebolavirus challenge, with further development to test efficacy against other filovirus infections ongoing.39 Table of ContentsDuring August 2021, Vaccine published a scientific article describing the formulation of single-vial platform presentations of monovalent (single antigen), bivalent (two antigens) and trivalent (three antigens) combinations of filovirus vaccine candidates.During September 2021, an accelerated preprint was posted on bioRxiv of pre-clinical immunogenicity studies for CiVaxâ„¢ (heat stable COVID-19 vaccine program) demonstrating durable broad-spectrum neutralizing antibody responses, including against the Beta, Gamma and Delta variants of concern. The scientific article was subsequently published on March 9, 2022 in ACS Infectious Diseases. The work is part of an ongoing collaboration with Axel Lehrer, PhD, Associate Professor at the Department of Tropical Medicine, Medical Microbiology and Pharmacology, JABSOM, UH Manoa. Development continues under a non-dilutive $1.5M grant from the NIAID awarded to us inÂ December 2020.In December 2021, 100% protection of NHPs against lethalÂ SudanÂ ebolavirus challenge was achieved using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with water immediately prior to use. This milestone is part of an ongoing collaboration with UH Manoa and further demonstrates the broad applicability of the vaccine platform, and its potential role in the U.S. government's initiative for pandemic preparedness.In May 2022, the U.S. Patent and Trademark Office issued a Notice of Allowance for the patent application titled â€œComposition and Methods of Manufacturing Trivalent Filovirus Vaccines.â€ The allowed claims are directed to unique, proprietary composition and methods directed to combinations of glycoprotein antigens with nano-emulsion adjuvants comprising sucrose fatty acid esters prior to lyophilization. The described vaccine platform has previously been successfully applied to filovirus vaccines (as mono-, bi- and tri-valent candidates for Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus) as well as SARS-CoV-2 vaccine. No currently licensed lyophilized vaccine that contains an adjuvant is presented in a single vial format and there are few reports of successfully using nano-emulsions in lyophilized formulations. Previous work has demonstrated the use of a single vial platform to co-lyophilize antigen(s)Â and a nano-emulsion adjuvant, CoVaccine HTâ„¢, maintaining key adjuvant stability characteristics including particle size and colloidal stability, as well as maintaining immunogenicity. This most recent milestone confirms that, in the context of lethal challenge with Sudan ebolavirus, complete protection is maintained with the thermostabilized formulation.In June 2022, 100% protection of NHPs against lethalÂ Marburg marburgvirusÂ challenge was achieved using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with sterile water immediately prior to use. This important milestone is part of an ongoing collaboration with UH Manoa, demonstrating the successful presentation of one or more antigen(s) within the same formulation while maintaining full potency and thermostability. It further demonstrates the broad applicability of the heat stable vaccine platform, and its potential role in the U.S. government's initiative forÂ pandemic preparedness.In September 2023, positive data demonstrated two-year stability of thermostabilized bivalent and trivalent filovirus vaccine candidates at temperatures of 40 degrees C (104 degrees F) when formulated in a single vial, needing reconstitution only with sterile water immediately prior to use. This important milestone is part of an ongoing collaboration with UH Manoa, demonstrating the successful presentation of one or more antigen(s) within the same formulation while maintaining full potency and thermostability. It further demonstrates the broad applicability of the heat stable vaccine platform, and its potential role in the U.S. government's initiative forÂ pandemic preparedness.In JanuaryÂ 2024, Vaccine published the preclinical efficacy results of our novel, single-vial, thermostabilized bivalent filovirus vaccine providing 100% protection against both Sudan ebolavirus (SUDV) and Marburg marburgvirus (MARV) infections. The manuscript was entitled â€œThermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infectionâ€.In April 2024, we received orphan drug designation for the active ingredient in SuVaxâ„¢, the subunit protein vaccine of recombinantly expressedÂ SUDV glycoprotein, for the prevention and post-exposure prophylaxis against SUDV infection.40 Table of ContentsIn April 2024, we received orphan drug designation for the active ingredient in MarVaxâ„¢, the subunit protein vaccine of recombinantly expressedÂ MARVÂ glycoprotein, for the prevention and post-exposure prophylaxis against MARV infection.Â In April 2024, we received notice of intent to grant additional patents based on our patent application titled â€œCompositions and Methods of Manufacturing Trivalent Filovirus Vaccinesâ€ in the United Kingdom and South Africa, with other international jurisdictions pending.RiVaxÂ®Â â€“ for Protection Against Ricin Toxin ExposureRiVaxÂ® is our proprietary vaccine candidate being developed to protect against exposure to ricin toxin and if approved, would be the first ricin vaccine. The immunogen in RiVaxÂ® induces a protective immune response in animal models of ricin exposure and functionally active antibodies in humans. The immunogen consists of a genetically inactivated ricin A chain subunit that is enzymatically inactive and lacks residual toxicity of the holotoxin. RiVaxÂ® has demonstrated statistically significant ($p < 0.0001$) preclinical survival results, providing 100% protection against acute lethality in an aerosol exposure non-human primate model (Roy et al, 2015, Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection, PNAS USA 112:3782-3787), and has also been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Results of the first Phase 1 human trial of RiVaxÂ® established that the immunogen was safe and induced antibodies that we believe may protect humans from ricin exposure. The antibodies generated from vaccination, concentrated and purified, were capable of conferring immunity passively to recipient animals, indicating that the vaccine was capable of inducing functionally active antibodies in humans. The outcome of this study was published in the Proceedings of the National Academy of Sciences (Vitetta et al., 2006, A Pilot Clinical Trial of a Recombinant Ricin Vaccine in Normal Humans, PNAS, 103:2268-2273). The second trial that was completed in SeptemberÂ 2012 and was sponsored by University of Texas Southwestern Medical Center (â€œUTSWâ€) evaluated a more potent formulation of RiVaxÂ® that contained an Alum adjuvant. The results of the Phase 1b study indicated that Alum-adjuvanted RiVaxÂ® was safe and well tolerated, and induced greater ricin neutralizing antibody levels in humans than adjuvant-free RiVaxÂ®. The outcomes of this second study were published in the Clinical and Vaccine Immunology.We have adapted the original manufacturing process for the immunogen contained in RiVaxÂ® for thermostability and large scale manufacturing and recent studies have confirmed that the thermostabilized RiVaxÂ® formulation enhances the stability of the RiVaxÂ® antigen, enabling storage for at least 1Â year at temperatures up to 40 degrees C (104 degrees F). The program will pursue approval via the FDA â€œAnimal Ruleâ€ since it is not possible to test the efficacy of the vaccine in a clinical study which would expose humans to ricin. Uniform, easily measured and species-neutral immune correlates of protection that can be measured in humans and animals, and are indicative of animal survival to subsequent ricin challenge, are central to the application of the â€œAnimal Rule.â€ Recent work has identified such potential correlates of immune protection in animals and work to qualify and validate these approaches is continuing, with the goal of utilizing these assays in a planned Phase 1/2 clinical trial with the thermostable RiVaxÂ® formulation. During SeptemberÂ 2018, we published an extended stability study of RiVaxÂ®, showing up to 100% protection in mice after 12Â months storage at 40 degrees C (104 degrees F) as well as identification of a potential in vitro stability indicating assay, critical to adequately confirming the long-term shelf life of the vaccine. We have entered into a collaboration with IDT Biologika GmbH (â€œIDTâ€) to scale-up the formulation/filling process and continue development and validation of analytical methods established at IDT to advance the program. We also initiated a development agreement with Emergent BioSolutions,Â Inc. (â€œEBSâ€) to implement a commercially viable, scalable production technology for the RiVaxÂ® drug substance protein antigen.The development of RiVaxÂ® has been sponsored through a series of overlapping challenge grants, UC1, and cooperative grants, U01, from the NIH, granted to us and to UTSW where the vaccine originated. The second clinical trial was supported by a grant from the FDAâ€™s Office of Orphan Products to UTSW. To date, we and UTSW have collectively received approximately $25 million in grant funding from the NIH for the development of RiVaxÂ®. In SeptemberÂ 2014, we entered into a contract with the NIH for the development of RiVaxÂ® pursuant 41 Table of Contentsto which we were awarded an additional $21.2 million of funding in the aggregate. The development agreements with EBS and IDT were specifically funded under this NIH contract.In 2017, NIAID exercised options to fund additional animal efficacy studies and good manufacturing practices compliant RiVaxÂ® bulk drug substance and finished drug product manufacturing, which is required for the conduct of future preclinical and clinical safety and efficacy studies. The exercised options provide us with approximately $4.5 million in additional non-dilutive funding, bringing the total amount awarded to date under this contract to $21.2 million, which expired in February 2021. The total award of up to $21.2 million supported the preclinical, manufacturing and clinical development activities necessary to advance heat stable RiVaxÂ® with the FDA. In addition to this funding for the development of RiVaxÂ®, biomarkers for RiVaxÂ® testing have been successfully identified, facilitating potential approval under the FDA Animal Rule.During DecemberÂ 2019, we initiated a third Phase 1 double-blind, placebo-controlled, randomized study in eight healthy adult volunteer subjects designed to evaluate the safety and immunogenicity of RiVaxÂ® utilizing ThermoVaxÂ®. During JanuaryÂ 2020, we suspended the study after Emergent Manufacturing Operations Baltimore LLC (â€œEMOBâ€), the manufacturer of the drug substance, notified us that, after releasing the final drug product to us, EMOB identified that the active drug substance tested outside the established specification parameters. Two subjects had received doses as part of the study before the manufacturer provided this notice. Those two subjects were monitored with no safety issues noted and data was captured in accordance with the study protocol. They did not receive further doses of study drug.During AprilÂ 2020, we received notification from NIAID that they would not be exercising the final contract option to support the conduct of a Phase 1/2 clinical study in healthy volunteers. As a result, the total contract award will not exceed $21.2 million. This contract expired in FebruaryÂ 2021.In November 2021, an article was published on pre-clinical

immunogenicity studies for RiVaxÂ® demonstrating enduring protection for at least 12 months post-vaccination. These results, coupled with the previous demonstration of efficacy in mice and NHPs as well as long-term thermostability (at least 1 year at 40 degrees C or 104 degrees F), reinforce the practicality of stockpiling and potentially utilizing the RiVaxÂ® vaccine in warfighters and civilian first responders without the complexities that arise for vaccines that require stringent cold chain handling.RiVaxÂ® has been granted Orphan Drug designation as well as Fast Track designation by the FDA for the prevention of ricin intoxication. In addition, RiVaxÂ® has also been granted Orphan Drug designation in the European Union (â€œEUâ€) from the EMA Committee for Orphan Medical Products.Assuming development efforts are successful for RiVaxÂ®, we believe potential government procurement contract(s)Â could reach as much as $200 million. This potential procurement contract information is a forward-looking statement, and investors are urged not to place undue reliance on this statement. While we have determined this potential procurement contract value based on assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or not be realized.As a new chemical entity, an FDA approved RiVaxÂ® vaccine has the potential to qualify for a biodefense Priority Review Voucher (â€œPRVâ€). Approved under the 21st Century Cures Act in late 2016, the biodefense PRV is awarded upon approval as a medical countermeasure when the active ingredient(s)Â have not been otherwise approved for use in any context. PRVs are transferable and can be sold, with sales in recentÂ years of approximately $100 million. When redeemed, PRVs entitle the user to an accelerated review period of nineÂ months, saving a median of sevenÂ months review time as calculated in 2009. However, FDA must be advised 90Â days in advance of the use of the PRV and the use of a PRV is associated with an additional user fee ($1.33 million for fiscalÂ year 2024).In July 2022, we signed a worldwide exclusive agreement to license and supply our ricin antigen, used in our RiVaxÂ® vaccine, to SERB, for development of a novel therapeutic treatment against ricin toxin poisoning. In pursuit of a ricin antidote, SERB will leverage its unique broad-spectrum polyclonal antibody platform, gained 42 Table of Contentsin its acquisition of BTG Specialty Pharmaceuticals. This specialized manufacturing process generates binding fragments from antibodies that are specific to a given antigen, helping to ensure potency and purity. This platform is currently used to manufacture two of SERBâ€™s currently marketed products, CroFabÂ® and DigiFabÂ®. In DecemberÂ 2022, we published a paper demonstrating statistically significant correlates of protection predicting survival after lethal aerosolized ricin challenge in non-human primates. The article titled â€œSerum antibody profiling identifies vaccine-induced correlates of protection against aerosolized ricin toxin in rhesus macaquesâ€ was published in the journal npj Vaccines.Ricin ToxinRicin toxin can be cheaply and easily produced, is stable over long periods of time, is toxic by several routes of exposure and thus has the potential to be used as a biological weapon against military and/or civilian targets. As a bioterrorism agent, ricin could be disseminated as an aerosol, by injection, or as a food supply contaminant. The potential use of ricin toxin as a biological weapon of mass destruction has been highlighted in a Federal Bureau of Investigation Bioterror report released in NovemberÂ 2007 titled Terrorism 2002-2005, which states that â€œRicin and the bacterial agent anthrax are emerging as the most prevalent agents involved in WMD investigations.â€ Al Qaeda in the Arabian Peninsula had threatened the use of ricin toxin to poison food and water supplies and in connection with explosive devices. Domestically, the threat from ricin remains a concern for security agencies. In AprilÂ 2013, letters addressed to the U.S. President, a Senator and a judge tested positive for ricin. As recently as SeptemberÂ 2020, ricin-laced letters addressed to the White House and others addressed to Texas law enforcement agencies were intercepted before delivery raising fresh concerns about the deadly toxin.The Centers for Disease Control and Prevention has classified ricin toxin as a Category B biological agent. Ricin works by first binding to glycoproteins found on the exterior of a cell, and then entering the cell and inhibiting protein synthesis leading to cell death. Once exposed to ricin toxin, there is no effective therapy available to reverse the course of the toxin. The recent ricin threat to government officials has heightened the awareness of this toxic threat. Currently, there is no FDA approved vaccine to protect against the possibility of ricin toxin being used in a terrorist attack, or its use as a weapon on the battlefield nor is there a known antidote for ricin toxin exposure.SGX943Â â€“ for Treating Emerging and/or Antibiotic-Resistant Infectious DiseasesSGX943 is an IDR, containing the same active ingredient as SGX942. Dusquetide is a fully synthetic, 5-amino acid peptide with high aqueous solubility and stability. Extensive in vivo preclinical studies have demonstrated enhanced clearance of bacterial infection with SGX943 administration. SGX943 has shown efficacy against both Gram-negative and Gram-positive bacterial infections in preclinical models, independent of whether the bacteria is antibiotic-resistant or antibiotic-sensitive.The innate immune system is responsible for rapid and non-specific responses to combat bacterial infection. Augmenting these responses represents an alternative approach to treating bacterial infections. In animal models, IDRs are efficacious against both antibiotic-sensitive and antibiotic-resistant infections, both Gram-positive and Gram-negative bacteria, and are active irrespective of whether the bacteria occupy a primarily extracellular or intracellular niche. IDRs are also effective as stand-alone agents or in conjunction with antibiotics. An IDR for the treatment of serious bacterial infections encompasses a number of clinical advantages including:â—Treatment when antibiotics are contraindicated, such as:obefore the infectious organism and/or its antibiotic susceptibility is known; oroin at-risk populations prior to infection.43 Table of Contentsâ—An ability to be used as an additive, complementary treatment with antibiotics, thereby:oenhancing efficacy of sub-optimal antibiotic regimens (e.g., partially antibiotic-resistant infections);oenhancing clearance of infection, thereby minimizing the generation of antibiotic resistance (e.g., in treating melioidosis); andoreducing the required antibiotic dose, again potentially minimizing the generation of antibiotic resistance.â—An ability to modulate the deleterious consequences of inflammation in response to the infection, including the inflammation caused by antibiotic-driven bacterial lysis.â—Being unlikely to generate bacterial resistance since the IDR acts on the host, and not the pathogen.Importantly, systemic inflammation and multi-organ failure is the ultimate common outcome of not only emerging and/or antibiotic-resistant infectious diseases, but also of most biothreat agents (e.g., Burkholderia pseudomallei), indicating that dusquetide would be applicable not only to antibiotic-resistant infection, but also to biothreat agents, especially where the pathogen is not known and/or has been engineered for enhanced antibiotic resistance.Intellectual PropertyIn addition to orphan drug exclusivity, we maintain patent and other intellectual property protection in the U.S. and other countries with respect to our technology and product candidates. We seek to protect our proprietary position in reliance upon trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties.Critical Accounting PoliciesOur managementâ€™s discussion and analysis of our financial condition and results of operations are based upon the accompanying condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the U.S. (â€œGAAPâ€). The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses, and the disclosure of contingent assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.Significant accounting policies are described in more detail in the notes to our financial statements appearing at the beginning of this Quarterly Report on FormÂ 10-Q.Material Changes in Results of OperationsThree and Nine Months Ended September 30, 2024 Compared to September 30, 2023For the three months ended SeptemberÂ 30,Â 2024, we had a net loss of $1,719,381 as compared to a net loss of $1,662,702 for the same prior year period, representing increased net loss of $56,679 or 3%. This increase in net loss was primarily due to decreases in gross profit and tax credits as well as an increase in operating expenses, offset by increases in interest income and the change in the fair value of debt during the three months ended SeptemberÂ 30,Â 2024. For the nine months ended SeptemberÂ 30,Â 2024, we had a net loss of $5,279,210 as compared to a net loss of $4,320,835 for the same prior year period, representing increased net loss of $958,375 or 22%. This increase in net loss was primarily due to decreases in gross profit and tax credits and an increase in operating expenses, offset by increases in interest income, the change in the fair value of debt 44 Table of Contentsand the recognition of an income tax benefit during the nine months ended SeptemberÂ 30,Â 2023 with no corresponding income tax benefit recognized during the nine months ended SeptemberÂ 30,Â 2024. Our revenues and associated costs incurred relate to government contracts, grants and subawards received to support the development of SGX943 for treatment of emerging and/or antibiotic-resistant infectious diseases; development of CiVaxâ„¢, our vaccine candidate for the prevention of COVID-19, and evaluation of HyBryteâ„¢Â for expanded treatment in patients with early-stage CTCL. For the three months ended SeptemberÂ 30,Â 2024 and 2023 we had no revenue as compared to revenue of $130,440 for the same prior year period, representing a decrease of $130,440 or 100%. We also incurred costs related to those revenues for the three months ended SeptemberÂ 30,Â 2023 of $110,441. Our gross profit for the three months ended SeptemberÂ 30,Â 2024 was $0 or 0% of total revenues, as compared to a gross profit of $19,999 or 15% of total revenues for the same period in 2023, representing a decrease of $19,999 or 100%. The decrease in revenue and gross profit during the three months ended SeptemberÂ 30,Â 2024 was primarily related to the conclusion of higher margin grants associated with the development of SGX943 and CiVaxâ„¢ and a decrease in revenue associated with the zero margin grant for the HyBryteâ„¢ investigator initiated study. For the nine months ended SeptemberÂ 30,Â 2024, we had revenues of $119,371 as compared to $594,547 for the same prior year period, representing a decrease of $475,176 or 80%. We also incurred costs related to those revenues for the nine months ended SeptemberÂ 30,Â 2024 and 2023 of $119,371 and $520,502, respectively, representing a decrease of $401,131 or 77%. Our gross profit for the nine months ended SeptemberÂ 30,Â 2024 was $0 or 0% of total revenues, as compared to a gross profit of $74,045 or 12% of total revenues for the same period in 2023, representing a decrease of $74,045 or 100%. The decrease in revenue and gross profit during the nine months ended SeptemberÂ 30,Â 2024 was primarily related to the conclusion of higher margin grants associated with the development of SGX943 and CiVaxâ„¢ and a decrease in revenue associated with the zero margin grant for the HyBryteâ„¢ investigator initiated study.Research and development expenses were $968,689 for the three months ended SeptemberÂ 30,Â 2024 as compared to $826,015 for the same period in 2023, representing an increase of $142,674 or 17%. The increase was primarily due to preliminary costs associated with the initiation of our Phase 2 study in BehÃ§etâ€™s Disease and the second confirmatory Phase 3 CTCL trial offset by an adjustment of estimated accruals for completed clinical trials. Research and development expenses were $2,564,887 for the nine months ended SeptemberÂ 30,Â 2024 as compared to $2,535,165 for the same period in 2023, representing an increase of $29,722 or 1%. The increase was primarily due to preliminary costs associated with the initiation of our Phase 2 study in BehÃ§etâ€™s Disease and the second confirmatory Phase 3 CTCL trial offset by an adjustment of estimated accruals for completed clinical trials.General and administrative expenses were $896,547 for the three months ended SeptemberÂ 30,Â 2024, as compared to $973,040 for the same period in 2023, representing a decrease of $76,493 or 8%. The decrease in general and administrative expenses for the three months ended SeptemberÂ 30,Â 2024 was primarily attributable to decreases in legal and professional fees. General and administrative expenses were $3,162,115 for the nine months ended SeptemberÂ 30,Â 2024, as compared to $3,098,949 for the same period in 2023, representing an increase of $63,166 or 2%. The increase in general and administrative expenses for the nine months ended SeptemberÂ 30,Â 2024 was primarily attributable to an increase in legal and professional fees associated with the 2024 annual meeting of stockholders, the April 2024 public offering and the June 2024 reverse stock split of our issued and outstanding shares of common stock.We recognized $0 and $260,933 of other income from the change in the fair value of the convertible debt on our accompanying condensed consolidated statements of operations during the three and nine months ended SeptemberÂ 30,Â 2024, respectively. As of SeptemberÂ 30,Â 2024, we determined the carrying amount of the convertible debt was approximately equivalent to the face value of the convertible debt. For the same prior year period, we recognized other loss of $72,463 and other income of $387,537, respectively from the change in fair value of the convertible debt on our accompanying condensed consolidated statements of operations. Interest income, net for the three months ended SeptemberÂ 30,Â 2024 was $78,836 as compared to $66,363 for the same period in 2023, representing an increase of $12,473 or 19%. The increase is primarily associated with 45 Table of Contentsa reduction in interest expense based on the repayment of $6 million of the convertible debt principal balance. Interest income, net for the nine months ended SeptemberÂ 30,Â 2024 was $143,603 as compared to ($97,399) for the same period in 2023, representing an increase of $241,002 or 247%. The increase is primarily associated with a reduction in interest expense based on the repayment of $6 million of the convertible debt principal balance.Financial ConditionCash and Working CapitalAs of SeptemberÂ 30,Â 2024, we had cash and cash equivalents of $9,840,177 as compared to $8,446,158 as of DecemberÂ 31,Â 2023, representing an increase of $1,394,019 or 17%. As of SeptemberÂ 30,Â 2024, we had working capital of $5,776,645 as compared to working capital of $3,355,212 as of DecemberÂ 31,Â 2023, representing an increase of $2,421,433 or 72%. The increase in cash and cash equivalents was primarily related to cash received from financing activities offset by cash used in operating activities during the nine months ended SeptemberÂ 30,Â 2024. The increase in working capital is primarily the result of an increase in cash and cash equivalents from financing activities of approximately $9.2 million before deducting commissions and other estimated offering expenses offset by convertible debt principal repayments of approximately $686,000, and cash used in operating activities during the nine months ended SeptemberÂ 30,Â 2024.Based on our operating budget, current rate of cash outflows, cash on hand, and proceeds from government contract and grant programs, we believe that we have sufficient resources available to support our development activities and business operationsÂ and timely satisfy our obligations as they become due through the second quarter of 2025.Â We do not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support our operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern through 12 months after the date that the financial statements are issued.To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, our plans include:â—Securing additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations.â—Securing additional proceeds from government contract and grant programs.â€‹â—Securing additional proceeds from the sale of shares of our common stock via the At Market Issuance Sales Agreement (â€œAGP Sales Agreementâ€) with A.G.P/Alliance Global Partners (â€œAGPâ€).â€‹â—Amending the loan agreement with Pontifax Medison Finance (â€œPontifaxâ€) (See Note 4) to reduce the conversion price in order to allow for conversion of a portion of the debt which will reduce the Companyâ€™s debt repayments.â€‹Other than the AGP Sales Agreement which was entered into on August 16, 2024 and the second amendment to the Pontifax loan agreement which was completed on October 8, 2024, none of these alternatives are committed at this time. There can be no assurance that we will be successful in obtaining sufficient funding on acceptable terms to fund continuing operations, if at all, identify and enter into any strategic transactions that will provide the capital that we will require, or achieve the other strategies to alleviate the conditions that raise substantial doubt about our ability to continue as a going concern. If none of these alternatives are available, or if available, are not available on satisfactory terms, we will not have sufficient cash resources and liquidity to fund our business operations for at least the 12 months following the date the financial statements are issued.Â The failure to obtain sufficient capital on acceptable terms when needed may require us to delay, limit, or eliminate the development of business opportunities and our ability to achieve our business objectives andÂ our competitiveness, and our business, financial condition, and results of operations will be materially 46 Table of Contentsadversely affected. In addition, the perception that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability to meet our contractual obligations.Â The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.â€‹Our plans with respect to our liquidity management include, but are not limited to, the following:â—We have up to approximately $554,000 in active government grant funding still available as of SeptemberÂ 30,Â 2024 to support our associated research programs through May 2026, provided the federal agencies do not elect to terminate the grants for convenience. We plan to submit additional contract and grant applications for further support of our programs with various funding agencies. However, there can be no assurance that we will obtain additional governmental grant funding;â—We have continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expect to continue to do so for the foreseeable future;â—We will continue to pursue NOL sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program if the program is available;â—We plan to pursue potential partnerships for pipeline programs as well as continue to explore merger and acquisition strategies. However, there can be no assurances that we can consummate such transactions;â—We completed a public offering on April 22, 2024 of 204,694 shares of our common stock, pre-funded warrants to purchase 537,500 shares of our common stock and common warrants to purchase up to 742,194 shares of our common stock at a combined public offering price of $6.40. The pre-funded warrants have an exercise price of $0.02. The common warrants have an exercise price of $6.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to us from this offering were approximately $4.75 million before deducting commissions and other estimated offering expenses of approximately $0.45 million. We plan to use the proceeds for further support of our programs, as well as for working capital; â—We entered into a warrant inducement agreement (the â€œInducement Agreementâ€) on July 9, 2024 with certain holders (the â€œHoldersâ€) of our existing Warrant to Purchase Shares of Common Stock (â€œExisting Warrantsâ€) to purchase shares of our common stock. In consideration of the Holdersâ€™ agreement to exercise their Existing Warrants, we (i) decreased the exercise price of the Existing Warrants from $6.40 per share to $6.00 per share and (ii) issued new warrants (â€œNew Warrantsâ€) to the Holders to purchase a number of shares of common stock equal to 150% of the number of shares of common stock issued upon exercise of the Holdersâ€™ Existing Warrants. Pursuant to the Inducement Agreement, the Holders agreed to exercise for cash their Existing

Warrants to purchase up to 703,125 shares of our common stock at a reduced exercise price of $6.00 per share on July 9, 2024, the date of the Inducement Agreement, until 1:30 p.m., Eastern Time. The total gross proceeds to us was approximately $4.2 million from the exercise of the Existing Warrants before deducting financial advisory fees and other expenses. We plan to use the proceeds for further support of our programs, as well as for working capital; â—We have up to approximately $4.7 million remaining from the AGP Sales Agreement as of November 1, 2024 under the prospectus supplement updated August 16, 2024. From October 1, 2024 through November 1, 2024, we sold 229,078 shares of common stock pursuant to the AGP Sales Agreement at a weighted average price of $4.72 per share for total gross proceeds of approximately $1.1 million; and47 Table of Contentsâ—We are currently evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that we can consummate such a transaction, or consummate a transaction at favorable pricing.July 2024 Warrant Inducementâ€‹On July 9, 2024, we entered into the Inducement Agreement with the Holders of the Companyâ€™s Existing Warrants to purchase shares of our common stock. Pursuant to the Inducement Agreement, the Holders agreed to exercise for cash their Existing Warrants to purchase up to 703,125 shares of common stock at a reduced exercise price of $6.00 per share on July 9, 2024, the date of the Inducement Agreement, until 1:30 p.m. Eastern Time. The aggregate gross proceeds received by us was approximately $4.2 million from the exercise of the Existing Warrants offset by total issuance costs of approximately $7.5 million. Issuance costs include financial advisory, banker, and legal fees of approximately $0.4 million and the fair value of the warrant modification and the fair value of the New Warrants issued totaling approximately $7.2 million. Because the modification represented a short-term inducement, we applied modification accounting guidance related to the fair value of the modification associated with the warrants that were exercised under the Inducement Agreement. Accordingly, we recognized the incremental fair value of the modification of the Existing Warrants exercised along with the fair value of the New Warrants issued as compared to the original warrants, together totaling approximately $7.2 million, as an issuance cost of the warrant exercise. Per the terms of the Inducement Agreement, we issued an aggregate of 1,054,688 New Warrants.â€‹The fair value of New Warrants issued under the Inducement Agreement was estimated using the Black-Scholes warrant-pricing model and the following assumptions:â—a dividend yield of 0%;â—an expected life of 5 years;â—volatility of 127.25%; andâ—risk free interest rate of 4.24%.ExpendituresUnder our budget and based upon our existing product development agreements and license agreements, we expect our total research and development expenditures for the next 12Â months to be approximately $7 million before any contract or grant reimbursements, all of which relates to the Specialized BioTherapeutics business segment. We anticipate contract and grant reimbursements revenue in the next 12Â months of approximately $0.3 million to offset research and development expenses in the Specialized BioTherapeutics business segment.48 Table of ContentsThe table below details our costs for research and development by program and amounts reimbursed for the nine months ended SeptemberÂ 30,Â 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Research & Development ExpensesÂ â€‹Â Â Â â€‹Â Â RiVaxÂ® and ThermoVaxÂ® Vaccinesâ€‹$ 165,183â€‹$ 100,613SGX942 (Dusquetide)â€‹Â (435,562)â€‹Â (47,088)HyBryteâ„¢ (SGX301 or synthetic hypericin)â€‹Â 2,411,168â€‹Â 2,147,245Otherâ€‹Â 424,098â€‹Â 334,395Totalâ€‹$ 2,564,887â€‹$ 2,535,165â€‹â€‹â€‹â€‹â€‹â€‹â€‹Reimbursed under Government Contracts and Grantsâ€‹Â Â Â â€‹Â Â Â RiVaxÂ® and ThermoVaxÂ® Vaccinesâ€‹$ â€”â€‹$ â€”CiVaxâ„¢â€‹â€‹ â€”â€‹â€‹ 260,778SGX943â€‹Â â€”â€‹Â 35,429HyBryteâ„¢ (investigator-initiated study)â€‹â€‹ 119,371â€‹â€‹ 224,295Totalâ€‹â€‹ 119,371â€‹â€‹ 520,502Grand Totalâ€‹$ 2,684,258â€‹$ 3,055,667â€‹Contractual ObligationsWe have commitments of approximately $205,000 as of SeptemberÂ 30,Â 2024 over the next five years for several licensing agreements with partners and universities. Additionally, we are party to other agreements which include cash milestone payments, royalties and other fees payable, which are all contingent upon clinical or commercialization success. There can be no assurance that clinical or commercialization success will occur.We currently lease office space pursuant to a lease which expires in October 2025 and requires monthly rent of $11,367 through October 2024 and $11,625 per month thereafter.In SeptemberÂ 2014, we entered into an asset purchase agreement with Hy Biopharma pursuant to which we acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharmaâ€™s synthetic hypericin product. As consideration for the assets acquired, we initially paid $275,000 in cash and issued 771 shares of common stock with a fair value based upon our stock price on the date of grant of $3.75 million. These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in our research and development activities and do not have alternative future use.In JanuaryÂ 2020, our Board of Directors authorized an amendment to Dr.Â Schaberâ€™s employment agreement to increase the number of shares of common stock from 21 to 2,084, issuable to Dr.Â Schaber immediately prior to the completion of a transaction, or series or a combination of related transactions, negotiated by our Board of Directors whereby, directly or indirectly, a majority of our capital stock or a majority of our assets are transferred from us and/or our stockholders to a third party.In MarchÂ 2020, we filed a prospectus supplement covering the offer and sale of up to 8,151 shares of our common stock which were issued to Hy Biopharma. We were required to issue the shares to Hy Biopharma as payment following the achievement of a milestone under the asset purchase agreement, specifically, the Phase 3 clinical trial of HyBryteâ„¢ being successful in the treatment of CTCL. The number of shares of our common stock issued to Hy Biopharma was calculated using an effective price of $614.40 per share, based upon a formula set forth in the asset purchase agreement.Provided the final success-oriented milestone of FDA approval is attained, we will be required to make a payment of up to $5 million, if and when achieved. The potential future payment will be payable in our common stock, not to exceed 19.9% of our outstanding stock. As of SeptemberÂ 30,Â 2024, no other milestone or royalty payments have been paid or accrued.49 Table of ContentsIn DecemberÂ 2020, we entered into a $20 million convertible debt financing agreement with Pontifax (the â€œLoan Agreementâ€). Under the terms of the Loan Agreement, we had access to up to $20 million in convertible debt financing in three tranches, which will mature on JuneÂ 15, 2025 and had an interest-only period for the first twoÂ years with a fixed interest rate of 8.47% on borrowed amounts and an interest rate of 1% on amounts available but not borrowed as an unused line of credit fee. After the interest-only period, the outstanding principal was to be repaid in quarterly payments of $1 million each commencing in the first quarter of 2023. The agreement is secured by a lien on substantially all of our assets, other than intellectual property. Upon the closing of this transaction, we borrowed the first tranche of $10 million. We did not utilize our option to draw the second or third tranche of $5 million each, which expired on DecemberÂ 15, 2021 and March 15, 2022, respectively.In April 2023, we entered into an amendment to the Loan Agreement (the â€œ2023 Amendmentâ€). The 2023 Amendment called for the immediate payment of $5 million of the outstanding principal balance and any accrued interest, waived any prepayment charge in connection with the repayment of this amount and resulted in an outstanding principal balance of $3 million. The 2023 Amendment also provided for interest only Â through June 30, 2024, reduced quarterly principal repayments to $750,000, and eliminated the minimum cash covenant. Further, the 2023 Amendment reduced the conversion price with respect to the remaining principal amount to (i) 90% of the closing price of our common stock on the day before the delivery of a conversion notice with respect to the first 36,790 shares of our common stock issuable upon conversion and to (ii) $27.20 with respect to all shares of our common stock issuable upon conversion thereafter. The remaining terms of the agreement remained unmodified.On January 3, 2024, Pontifax delivered a conversion notice to us electing to convert a portion of the remaining principal balance into shares of our common stock. Upon conversion, we issued 9,139 shares of our common stock at $10.88 per share, reducing the remaining principal balance by $99,416. â€‹On April 15, 2024, Pontifax delivered a conversion notice to us electing to convert a portion of the remaining principal balance into shares of our common stock. Upon conversion, we issued 27,651 shares of our common stock at $5.60 per share, reducing the remaining principal balance by $154,840. â€‹The 2023 Amendment resulted in the extinguishment of the original convertible debt for accounting purposes. We elected to account for the amended convertible debt using the fair value option. As of SeptemberÂ 30,Â 2024, we determined the carrying amount of the convertible debt was approximately equivalent to the face value of the convertible debt. We recognized $0 and $260,933 of other income from the change in the fair value of the convertible debt in our accompanying condensed consolidated statements of operations during the three and nine months ended SeptemberÂ 30,Â 2024, respectively. â€‹In October 2024, we entered into an amendment (the â€œ2024 Amendmentâ€) to the Loan Agreement, as amended. The 2024 Amendment reduced the conversion price with respect to the remaining principal amount outstanding to (i) $3.81 for the first 501,648 shares of our common stock issuable upon conversion and (ii) $4.23 with respect to all shares of our common stock issuable upon conversion thereafter. The remaining terms of the agreement remain in effect without modification.â€‹ITEMÂ 3Â â€“ QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKOur primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are in short-term marketable securities, in addition to the foreign exchange rate fluctuations related to our foreign currency transactions. We do not have any derivative financial instruments. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure.50 Table of ContentsITEMÂ 4Â â€“ CONTROLS AND PROCEDURESEvaluation of Disclosure Controls and ProceduresWe maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) are (1) recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.As of SeptemberÂ 30,Â 2024, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in RulesÂ 13a-15(e)Â and 15d-15(e)Â under the Exchange Act) using the criteria set forth by the Committee of Sponsoring Organization of the Treadway Commission (â€œCOSOâ€) in Internal Control â€“ Integrated Framework (2013 Framework). Our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded, based upon the evaluation described above, that as of SeptemberÂ 30,Â 2024, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that such material information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.â€‹Changes in Internal ControlsThere were no changes in our internal controls over financial reporting identified in connection with the evaluation of such internal controls that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.â€‹PARTÂ IIÂ - OTHER INFORMATION.ITEMÂ 1Â â€“ LEGAL PROCEEDINGSFrom time to time, we are a party to claims and legal proceedings arising in the ordinary course of business. Our management evaluates our exposure to these claims and proceedings individually and in the aggregate and allocates additional monies for potential losses on such litigation if it is possible to estimate the amount of loss and if the amount of the loss is probable.ITEMÂ 1AÂ â€“ RISK FACTORSOur business faces significant risks. These risks include those disclosed in ItemÂ 1A of our Annual Report on FormÂ 10-K for the fiscalÂ year endedÂ DecemberÂ 31,Â 2023. If any of the events or circumstances described in the referenced risks actually occur, our business, financial condition or results of operations could be materially adversely affected and such events or circumstances could cause our actual results to differ materially from the results contemplated by the â€œforward-lookingâ€ statements contained in this report. Further, additional risks not presently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business, financial condition and results of operations. We do not undertake to update any of the â€œforward-lookingâ€ statements or to announce the results of any revisions to these â€œforward-lookingâ€ statements, except as required by law.51 Table of ContentsThe following risks should be read in conjunction with the other information set forth in this Quarterly Report as well as in our Annual Report on FormÂ 10-K for the fiscalÂ year endedÂ DecemberÂ 31,Â 2023 and in our periodic reports on FormÂ 10-Q and FormÂ 8-K.Shareholders may suffer substantial dilution related to issued pre-funded warrants, common stock warrants, options and convertible notes.As of November 1, 2024, we had a number of agreements or obligations that may result in dilution to investors. These include:â€‹â—common stock warrants to purchase a total of 1,467,581 shares of our common stock at a current weighted average exercise price of $11.01;â€‹â—options to purchase approximately 56,427 shares of our common stock at a current weighted average exercise price of $84.96; andâ€‹â—convertible promissory notes issued to Pontifax Medison Finance, of which there was $1,372,873 of principal and $10,195 of accrued interest outstanding, which notes are convertible at $3.81 per share for the first 501,648 shares and $4.23 with respect to all shares thereafter; andâ€‹â—5,943,706 shares of common stock available for future issuance under our 2015 Equity Incentive Plan.â€‹We have granted, and expect to grant in the future, options to purchase shares of our common stock to our directors, employees and consultants under our incentive compensation plan. To the extent that pre-funded warrants, common stock warrants, options or convertible promissory notes are exercised or converted, our stockholders will experience dilution and our stock price may decrease.Additionally, the sale, or even the possibility of the sale, of the shares of common stock underlying these pre-funded warrants, common stock warrants, options and convertible promissory notes could have an adverse effect on the market price for our securities or on our ability to obtain future financing.ITEMÂ 2Â â€“ UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSâ€‹None.ITEMÂ 5Â â€“ OTHER INFORMATIONâ€‹During the quarter ended SeptemberÂ 30,Â 2024, no directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) of the Company adopted or terminated any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408(a) of Regulation S-K.â€‹â€‹52 Table of Contentsâ€‹ITEMÂ 6Â â€“ EXHIBITSâ€‹â€‹â€‹â€‹EXHIBITÂ NO.Â Â Â DESCRIPTIONâ€‹â€‹â€‹â€‹31.1â€‹Certification of Chief Executive Officer pursuant to Exchange Act ruleÂ 13(a)-14(a)Â (under SectionÂ 302 of the Sarbanes-Oxley Act of 2002).â€‹â€‹â€‹â€‹31.2â€‹Certification of Chief Financial Officer pursuant to Exchange Act ruleÂ 13(a)-14(a)Â (under SectionÂ 302 of the Sarbanes-Oxley Act of 2002).â€‹â€‹â€‹â€‹32.1â€‹Certification of Chief Executive Officer pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002.â€‹â€‹â€‹â€‹32.2â€‹Certification of Chief Financial Officer pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002.â€‹â€‹â€‹â€‹101.INSâ€‹Inline XBRL Instance Documentâ€‹â€‹â€‹101.SCHâ€‹Inline XBRL Taxonomy Schemaâ€‹â€‹â€‹101.CALâ€‹Inline XBRL Taxonomy Calculation Linkbaseâ€‹â€‹â€‹101.DEFâ€‹Inline XBRL Taxonomy Definition Linkbaseâ€‹â€‹â€‹101.LABâ€‹Inline XBRL Taxonomy Label Linkbaseâ€‹â€‹â€‹101.PREâ€‹Inline XBRL Taxonomy Presentation Linkbaseâ€‹â€‹â€‹104â€‹Cover Page Interactive Data File (embedded within the Inline XBRL document)â€‹â€‹â€‹53 Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.â€‹â€‹â€‹â€‹SOLIGENIX,Â INC.â€‹November 8, 2024By /s/ Christopher J. Schaberâ€‹Christopher J. Schaber,Â PhDâ€‹President and Chief Executive Officerâ€‹(Principal Executive Officer)â€‹November 8, 2024By /s/ Jonathan Guarinoâ€‹Jonathan Guarinoâ€‹Chief Financial Officer, Senior Vice President,â€‹and Corporate Secretaryâ€‹(Principal Financial and Accounting Officer)â€‹â€‹â€‹54 EX-31.1 2 sngx-20240930xex31d1.htm EX-31.1 EXHIBIT 31.1â€‹CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)OF THE SECURITIES EXCHANGE ACT OF 1934â€‹I, Christopher J. Schaber, Ph.D., certify that:â€‹1.I have reviewed this Quarterly Report on Form 10-Q of Soligenix, Inc. for the fiscal quarter ended September 30, 2024;â€‹2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;â€‹4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:â€‹a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹c.Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹d.Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andâ€‹5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which

are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹â€‹November 8, 2024Â Â /s/ Christopher J. Schaberâ€‹â€‹Christopher J. Schaber, Ph.D.â€‹â€‹President and Chief Executive Officerâ€‹ EX-31.2 3 sngx-20240930xex31d2.htm EX-31.2 EXHIBIT 31.2â€‹CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)OF THE SECURITIES EXCHANGE ACT OF 1934â€‹I, Jonathan Guarino, certify that:â€‹1.I have reviewed this Quarterly Report on Form 10-Q of Soligenix, Inc. for the fiscal quarter ended September 30, 2024;â€‹2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;â€‹4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:â€‹a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹c.Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹d.Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andâ€‹5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹â€‹November 8, 2024Â Â /s/ Jonathan Guarinoâ€‹â€‹Jonathan Guarinoâ€‹â€‹Senior Vice President and Chief Financial Officerâ€‹ EX-32.1 4 sngx-20240930xex32d1.htm EX-32.1 EXHIBIT 32.1â€‹CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTEDPURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with this Form 10-Q of Soligenix, Inc. (the â€œCompanyâ€) for the fiscal quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, that:â€‹1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; andâ€‹2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹â€‹November 8, 2024Â Â /s/ Christopher J. Schaberâ€‹â€‹Christopher J. Schaber, Ph.D.â€‹â€‹President and Chief Executive Officerâ€‹ EX-32.2 5 sngx-20240930xex32d2.htm EX-32.2 EXHIBIT 32.2â€‹CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTEDPURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with this Form 10-Q of Soligenix, Inc. (the â€œCompanyâ€) for the fiscal quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, that:â€‹1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; andâ€‹2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹November 8, 2024Â Â /s/ Jonathan Guarinoâ€‹â€‹Jonathan Guarinoâ€‹â€‹Senior Vice President and Chief Financial Officerâ€‹ EX-101.SCH 6 sngx-20240930.xsd EX-101.SCH 995200100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 995200500 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Commitments and Contingencies - Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200205 - Statement - Condensed Consolidated Statements of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) link:presentationLink link:calculationLink link:definitionLink 995200405 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Summary of Significant Accounting Policies - Fair value of convertible debt (Details) link:presentationLink link:calculationLink link:definitionLink 99940203 - Disclosure - Summary of Significant Accounting Policies - Loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Operating Segments (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Operating Segments link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Operating Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 sngx-20240930_cal.xml EX-101.CAL EX-101.DEF 8 sngx-20240930_def.xml EX-101.DEF EX-101.LAB 9 sngx-20240930_lab.xml EX-101.LAB Document And Entity Information Document Information [Table] Document Information [Line Items] Document And Entity Information Document Type Document Type Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Unbilled Receivables, Current Unbilled revenue Research and development incentives receivable Research and development incentives receivable, current Deferred Costs, Current Deferred issuance cost Prepaid Expense, Current Prepaid expenses and other current assets Assets, Current Total current assets Deposits Assets, Noncurrent Security deposit Property, Plant and Equipment, Net Office furniture and equipment, net Operating Lease, Right-of-Use Asset Right-of-use lease assets Capitalized Contract Cost, Net, Noncurrent Research and development incentives receivable, net of current portion Assets Total assets Identifiable Assets Liabilities and Equity [Abstract] Liabilities and shareholders' equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Employee-related Liabilities, Current Accrued compensation Operating Lease, Liability, Current Lease liabilities, current Convertible Debt, Current Convertible debt Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Non-current liabilities: Outstanding principal Convertible debt Operating Lease, Liability, Noncurrent Lease liabilities, net of current portion Liabilities Total liabilities Commitments and contingencies Commitments and contingencies (Note 6) Stockholders' Equity Attributable to Parent [Abstract] Shareholders' equity: Preferred Stock, Value, Issued Preferred stock, 350,000 shares authorized; none issued or outstanding at September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Common stock, $.001 par value; 75,000,000 shares authorized; 2,295,304 and 648,761 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total shareholders' equity Liabilities and Equity Total liabilities and shareholders' equity Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock spilt effective from June 5, 2024 Condensed Consolidated Statements of Operations Product and Service [Axis] Product and Service [Domain] Grant revenue Revenues Revenues Total revenues Cost of Revenue Cost of revenues Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Income (loss) from Operations Nonoperating Income (Expense) [Abstract] Other income (expense): Foreign Currency Transaction Gain (Loss), before Tax Foreign currency transaction gain (loss) Interest Income (Expense), Nonoperating, Net Interest income (expense), net UK research and development incentives. Uk Research And Development Incentives Research and development incentives Amount of income related to employee retention credit under CARES Act. Employee retention credit, CARES ACT CARES Act Employee Retention Credit Other Nonoperating Income (Expense) Other income Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Loss on extinguishment of debt Amount of expense (income) related to adjustment to fair value of convertible debt. Fair Value Adjustment of Convertible Debt Change in fair value of convertible debt Change in fair value of convertible debt Adjustment to fair value Nonoperating Income (Expense) Total other income Other (Expense) Income, Net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net loss before income taxes Income Tax Expense (Benefit) Income tax benefit Net Income (Loss) Available to Common Stockholders, Basic Net loss applicable to common stockholders Earnings Per Share, Basic Basic net loss per share (in Dollars per share) Earnings Per Share, Diluted Diluted net loss per share (in Dollars per share) Weighted Average Number of Shares Outstanding, Basic Basic weighted average common shares outstanding (in Shares) Weighted Average Number of Shares Outstanding, Diluted Diluted weighted average common shares outstanding (in Shares) Condensed Consolidated Statements of Comprehensive Loss Net loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustments Foreign currency translation adjustment Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) Equity Components [Axis] Equity Component [Domain] Preferred Stock Common Stock Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Class of Stock [Axis] Class of Stock [Domain] Series D Preferred Stock Sale of Stock [Axis] Sale of Stock [Domain] Represents the information pertaining to public offering. Public Offering Public offering At market issuance sales is where sales agent will sell shares on behalf of the company. At Market Issuance Sales [Member] At Market Issuance sales Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents the information pertaining to pre-funded warrants. Pre-funded Warrant [Member] Pre-funded warrants Represents information pertaining to the new warrants. New Warrants [Member] New Warrants Represents information pertaining to the existing warrants. Existing Warrants [Member] Existing Warrants Shares, Outstanding Balance (in Shares) Balance (in shares) Temporary Equity, Carrying Amount, Attributable to Parent Balance Balance Temporary Equity, Shares Outstanding Balance (Shares) Balance (Shares) Stock issued during period value pursuant to market sales agreement. Stock Issued During Period Value Pursuant To Market Sales Agreement Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement Stock issued during period shares pursuant to market sales agreement. Stock Issued During Period Shares Pursuant To Market Sales Agreement Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock pursuant to At Market Issuance Sales Agreement Stock Issued During Period, Shares, New Issues Number of shares issued Issuance of common stock pursuant to At Market Issuance Sales Agreement (in shares) Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance costs associated with sales of common stock pursuant to At Market Issuance Sales Agreement Issuance costs Value of stock classified as temporary equity issued to shareholders as a dividend during the period. Temporary Equity, Stock Issued During Period, Value, Stock Dividend Redemption of Series D preferred stock The value of stock and pre-funded warrants issued during the period. Stock and Pre-funded Warrants Issued During Period, Value Issuance of common stock and pre-funded warrants in connection with public offering The number of stock and pre-funded warrants issued during the period. Stock and Pre-funded Warrants Issued During Period, Shares Issuance of common stock and pre-funded warrants in connection with public offering (in shares) Value of shares issued during the period as a result of reverse stock split Stock Issued During Period, Value, Reverse Stock Splits Fractional shares issued in reverse stock split Stock Issued During Period, Shares, Reverse Stock Splits Fractional shares issued in reverse stock split (in shares) Stock Issued During Period, Value, Issued for Services Issuance of common stock to vendors Stock Issued During Period, Shares, Issued for Services Issuance of common stock to vendors (in shares) Value of stock issued during the period on exercise of warrants. Stock Issued During Period, Value, Exercise Of Warrants Issuance of common stock upon exercise of warrants Number of shares issued on exercise of warrants. Stock Issued During Period, Share Exercise Of Warrants Issuance of common stock upon exercise of warrants (in shares) Issuance of common stock upon exercise of warrant Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing warrants. Includes, but is not limited to, legal and accounting fees and direct costs associated with warrant issuances. Adjustments to Additional Paid in Capital, Warrants Issued, Issuance Costs Issuance costs associated with warrant inducement Adjustments to Additional Paid in Capital, Warrant Issued Warrant modification - incremental fair value Stock Issued During Period, Value, Purchase of Assets Fair value of shares issued in connection with asset purchase Issuance of common stock for purchase option Stock Issued During Period, Shares, Purchase of Assets Issuance of shares for assets (in shares) Issuance of common stock for purchase option (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of common stock associated with conversion of debt Stock Issued During Period, Shares, Conversion of Convertible Securities Number of shares issued on exercise of warrants Issuance of common stock associated with conversion of debt (in shares) APIC, Share-based Payment Arrangement, Increase for Cost Recognition Share-based compensation expense Condensed Consolidated Statements of Cash Flows Represents the member

information pertaining to B. Riley Sales Agreement. At Market Issuance Sales Agreement Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Cost, Depreciation and Amortization Amortization and depreciation Amortization and Depreciation Expense Operating Lease, Right-of-Use Asset, Amortization Expense Non-cash lease expense Share-based Payment Arrangement, Noncash Expense Share-based compensation Share-Based Compensation Issuance of Stock and Warrants for Services or Claims Issuance of common stock to vendors for services The issuance of common stock for purchase option. Issuance of Common Stock for Purchase Option Issuance of common stock for purchase option Amortization of Debt Issuance Costs and Discounts Amortization of deferred issuance costs associated with convertible debt Change in operating assets and liabilities: Increase (Decrease) in Accounts and Other Receivables Contracts and grants receivable Increase (Decrease) in Prepaid Expense Prepaid expenses and other current assets Increase (Decrease) in Other Receivables Research and development incentives receivable Increase (Decrease) in Operating Lease Liability Operating lease liability Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Increase (Decrease) in Other Employee-Related Liabilities Accrued compensation Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net cash flows from operating activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Proceeds from issuance of common stock pursuant to FBR At-the-Market Sales Agreement, Proceeds From Issuance Of Common Stock Pursuant To Market Sales Agreement Proceeds from issuance of common stock pursuant to At Market Issuance Sales Agreement Payments of Stock Issuance Costs Stock issuance costs associated The amount of proceeds from issuance of common stock and warrants. Proceeds from Issuance of Common Stock and Warrants Proceeds from issuance of common stock and pre-funded warrants Proceeds from Warrant Exercises Proceeds from the exercise of pre-funded warrants Proceeds From Exercise Of Warrants Proceeds from the exercise of warrants The cash outflow for the cost incurred directly with the issuance and modification of warrants as per the inducement agreement. Payments Of Warrant Issuance Costs Upon Inducement Issuance costs associated with warrant inducement Repayments of Convertible Debt Convertible debt repayments Repayment of debt principal Net Cash Provided by (Used in) Financing Activities Net cash flows from financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Effect of exchange rate on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental information: Income Taxes Paid Cash paid for state income taxes Cash paid for interest Additional Cash Flow Elements [Abstract] Cash paid for lease liabilities: Amount of cash outflow from operating lease. Operating Lease Paid Operating lease Noncash Investing and Financing Items [Abstract] Non-cash investing and financing activities: Debt Conversion, Converted Instrument, Amount Pontifax conversion of portion of debt principal into common stock Deferred issuance cost reclassified to additional-paid-in capital. NoncashOrPartNoncashDeferredIssuanceCostReclassifiedToAdditionalPaidInCapital Deferred issuance cost reclassified to additional paid-in capital The amount of redemption of preferred stock. Redemption of Preferred Stock Redemption liability for Series D preferred stock The amount of stock issuance costs included in accounts payable. Stock Issuance Costs Included in Accounts Payable Offering costs included in accounts payable The amount of incremental fair value of warrants recognized as issuance cost of the warrant exercise. Issuance Cost Of Warrant Exercise Warrant modification - incremental value Nature of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Nature of Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Debt Debt Disclosure [Text Block] Debt Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Shareholders' Equity Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Operating Segments Segment Reporting Disclosure [Text Block] Operating Segments Subsequent Events Subsequent Events [Text Block] Subsequent Events Consolidation, Policy [Policy Text Block] Principles of Consolidation Segment Reporting, Policy [Policy Text Block] Operating Segments Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Licensing, Contracts and Grants Receivable Contracts and Grants Receivable Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of Long-Lived Assets Fair Value Measurement, Policy [Policy Text Block] Fair Value of Financial Instruments Deferred Charges, Policy [Policy Text Block] Deferred Issuance Costs Disclosure of accounting policy for change in accounting estimate. Change In Accounting Estimates [Policy Text Block] Change In Accounting Estimates Revenue [Policy Text Block] Revenue Recognition Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Share-based Payment Arrangement [Policy Text Block] Share-Based Compensation Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Transactions and Translation Earnings Per Share, Policy [Policy Text Block] Loss Per Share Use of Estimates, Policy [Policy Text Block] Use of Estimates and Assumptions Convertible Debt [Table Text Block] Schedule of fair value of convertible debt Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive outstanding instruments which were not included in the computation of diluted EPS Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Contractual Obligation, Fiscal Year Maturity [Table Text Block] Schedule of contractual obligation Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of operating segments Collaborative Arrangement and Arrangement Other than Collaborative [Table] Counterparty Name [Axis] Counterparty Name [Domain] Represents information pertaining to the National Institute of Health. NIH HyBryte HyBryte Represents the information pertaining to common warrants. Common Warrants [Member] Common warrants Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Subsequent Event Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Nature of business: Number of Operating Segments Number of operating segments Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Revenue from collaborative arrangement Guarantee Obligations Term Duration Guarantee Obligations Term Duration Term (in years) The amount of working capital, carrying value. Working Capital Carrying Value Working capital Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. Government Grants Receivable Current Government grant funding Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of common warrants to purchase shares issued Share Price Shares issued price per share Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Warrants and Rights Outstanding, Term Expiration term of warrants Proceeds from Issuance of Common Stock Total gross proceeds The percentage of the number of shares issued on existing warrants that is agreed to be issued as part of new warrants as per the inducement agreement. Class of Warrant or Right, Percentage Of Existing Warrant Shares To New Warrant Share Issues Percentage of numbers of shares issued upon exercise of existing warrants The aggregate value of common shares reserved for future issuance as per the agreement. Common Stock, Value Of Shares Reserved for Future Issuance Aggregate value of shares remaining from agreement Represents the weighted average share price for shares issued. Weighted average price Weighted average price Weighted average price (per share) Schedule of Finite-Lived Intangible Assets [Table] Title of Individual [Axis] Title of Individual [Domain] Directors Restructuring Type [Axis] Type of Restructuring [Domain] Termination benefits Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Convertible Debt [Member] Convertible debt Finite-Lived Intangible Assets [Line Items] Summary of Significant Accounting Policies Impairment of Intangible Assets, Finite-lived Impairment of long-lived assets Convertible Debt, Fair Value Disclosures Convertible debt fair value Amount of adjustment to estimated accrued clinical trial expenses. Adjustment To Estimated Accrued Clinical Trial Expenses Adjustment to estimated accrued clinical trial expenses Estimated period over which an employee is required to provide service in exchange for equity-based payment award. Share - Based Compensation Arrangement Service Period Requisite period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights Option vesting rights Period from grant date that an equity based award expires. Share based Compensation Expiration Period Expiration period Foreign Currency Transaction Gain (Loss), Realized Foreign currency transaction gain (loss) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of options issued Schedule of Long-term Debt Instruments [Table] Debt instruments Convertible Debt. Convertible debt at fair value as of June 30, 2024 Convertible debt at fair value as of December 31, 2023 Debt Instrument, Repaid, Principal Principal Repayments Schedule of potentially dilutive adjustments to the weighted average number of common shares excluded from the calculation [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrants Common stock purchase warrants Convertible debt securities Convertible debt Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Securities excluded Accrued Professional Fees, Current Clinical trial expenses Other Accrued Liabilities, Current Other Represents the member information pertaining to Pontifax Medison Finance. Pontifax Medison Finance [Member] Pontifax Scenario [Axis] Scenario [Domain] Represents the member information pertaining to first shares of common stock issuable upon conversion. First 36,790 shares of common stock issuable upon conversion Represents information relating to the conversion price as per the loan agreement amendment for the first tranche. Loan Agreement Amendment 2024, Conversion Price, Tranche One [Member] Conversion price for First 501,648 shares Represents information relating to the conversion price as per the loan agreement amendment for the second tranche. Loan Agreement Amendment 2024, Conversion Price, Tranche Two [Member] Conversion price for Remaining shares Debt Instrument [Axis] Debt Instrument, Name [Domain] First tranche. First Tranche [Member] First tranche Second tranche. Second Tranche [Member] Second tranche Third Tranche [Member] Third tranche Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum Debt instrument, face amount Debt instrument, face amount Represents the number of tranches. Number of Tranches Number of tranches The period during which payment on the debt is for interest only, and payments of principal are deferred until after this period. Debt Instrument, Period Principal Payment Deferred Interest-only period Debt Instrument, Interest Rate, Stated Percentage Interest rate percentage Line of Credit Facility, Commitment Fee Percentage Unused line of credit fee, as a percent Debt Instrument, Periodic Payment, Principal Outstanding principal periodic payment Convertible Notes Payable Convertible note Amount repaid Amount repaid Represents the reduction in conversion price to percentage of closing price of the common stock on the day before the delivery of the conversion notice. Reduction in conversion price as percentage of closing price of the common stock on the day before the delivery of the conversion notice Reduction in conversion price as percentage of closing price of the common stock on the day before the delivery of the conversion notice Represents the reduction in conversion price. Reduction in conversion price Reduction in conversion price Shares Issued, Price Per Share Fair value per share Debt Instrument, Convertible, Conversion Price Conversion price The total number of shares that the holder of the debt instrument would receive if the debt was converted to equity. Debt Instrument, Convertible, Number of Shares To Be Issued Common stock issuable upon conversion Schedule of Stock by Class [Table] Represents the information pertaining to pre-funded warrants. Pre-funded warrants Represents information pertaining to the warrant modification and the new warrants. Warrant Modification And New Warrants [Member] Warrant modification and the new warrants Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Expected Dividend Rate [Member] Dividend yield Measurement Input, Expected Term [Member] Expected Term Measurement Input, Price Volatility [Member] volatility Measurement Input, Risk Free Interest Rate [Member] Risk free interest Class of Stock [Line Items] The percentage of the gross proceeds from sale of stock to be paid as compensation to the counter party as per the terms of stock transaction. Sale Of Stock, Compensation Percentage On Gross Proceeds Percentage of gross proceeds from sales of shares under ATM The total costs of issuance of warrants incurred by the entity during the period. Warrant Issuance Costs Total issuance costs The amount of financial and legal fees incurred upon the issuance of warrants by the entity during the period. Warrant Issuance Costs, Financial And Legal Fees Financial advisory, banker, and legal fees Warrants and Rights Outstanding New warrants issued The number of warrants issued that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. Warrants and Rights, Issued Shares Aggregate warrants issued (shares) Warrants and Rights Outstanding, Measurement Input Warrants and rights outstanding The aggregate value of shares to be issued or sold by the entity as per the stock transaction. Sale of Stock, Aggregate Value of Shares To Be Issued in Transaction Aggregate offering price Other Commitments [Table] Category of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased [Domain] Research and Development Arrangement [Member] Information pertaining to Asset Purchase Agreement. Asset Purchase Agreement [Member] Scenario, Plan [Member] Represents information relating to rent from period November 2024. For Period From November 2024 [Member] Other Commitments [Line Items] Contractual Obligation Contractual obligation Total Amount of lease rental per month Lease Rental Per Month Lease rent per month Payments to Acquire Productive Assets Cash paid to acquire intangible asset Common Stock Issued Effective Price Per Share Effective price per share (in dollars per share) Asset Acquisition, Consideration Transferred, Contingent Consideration Contingent consideration Percentage of ownership outstanding stock. Percentage Of Ownership Outstanding Stock Ownership of company outstanding Long-term Purchase Commitment [Table] Lease Agreements [Member] Long-term Purchase Commitment [Line Items] Contractual Obligation, Fiscal Year Maturity Schedule [Abstract] Contractual Obligation, to be Paid, Remainder of Fiscal Year October 1 through December 31, 2024 Contractual Obligation, to be Paid, Year One 2025 Contractual Obligation, to be Paid, Year Two 2026 Contractual Obligation, to be Paid, Year Three 2027 Contractual Obligation, to be Paid, Year Four 2028 Schedule of Segment Reporting Information, by Segment [Table] Consolidation Items [Axis] Consolidation Items [Domain] Operating Segments [Member] Corporate [Member] Segments [Axis] Segments [Domain] BioTherapeutics. Specialized BioTherapeutics [Member] Public Health Solutions [Member] Segment Reporting Information [Line Items] Segment reporting Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event EX-101.PRE 10 sngx-20240930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Document And Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-14778 Â Entity Registrant Name SOLIGENIX,Â INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 41-1505029 Â Entity Address, Address Line One 29 EMMONS DRIVE Â Entity Address, Address Line Two SUITEÂ B-10 Â Entity Address, City or Town PRINCETON, Â Entity Address, State or Province NJ Â Entity Address, Postal Zip Code 08540 Â City Area Code 609 Â Local Phone Number 538-8200 Â Title of 12(b) Security Common Stock, par value $.001 per share Â Trading Symbol SNGX Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 2,509,499 Entity Central Index Key 0000812796 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details

Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: sngx_DocumentAndEntityInformationAbstract Namespace Prefix: sngx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 9,840,177 $ 8,446,158 Unbilled revenue Â 171,254 Research and development incentives receivable, current Â 23,894 Deferred issuance cost 126,385 Â Prepaid expenses and other current assets 340,330 866,014 Total current assets 10,306,892 9,507,320 Security deposit 22,777 22,777 Office furniture and equipment, net 7,162 11,927 Right-of-use lease assets 140,148 229,834 Research and development incentives receivable, net of current portion Â 25,468 Total assets 10,476,979 9,797,326 Current liabilities: Â Â Accounts payable 891,227 1,111,226 Accrued expenses 1,363,235 2,418,002 Accrued compensation 84,362 251,115 Lease liabilities, current 132,114 121,765 Convertible debt 2,059,309 2,250,000 Total current liabilities 4,530,247 6,152,108 Non-current liabilities: Â Â Convertible debt Â 1,010,934 Lease liabilities, net of current portion 11,544 111,862 Total liabilities 4,541,791 7,274,904 Commitments and contingencies (Note 6) Shareholders' equity: Â Â Preferred stock, 350,000 shares authorized; none issued or outstanding at September 30, 2024 and December 31, 2023, respectively Common stock, $.001 par value; 75,000,000 shares authorized; 2,295,304 and 648,761 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively [1] 2,295 649 Additional paid-in capital [1] 236,878,806 228,203,706 Accumulated other comprehensive income 37,473 22,243 Accumulated deficit (230,983,386) (225,704,176) Total shareholders' equity 5,935,188 2,522,422 Total liabilities and shareholders' equity $ 10,476,979 $ 9,797,326 [1] Adjusted to reflect the reverse stock split of one-for-sixteen effective June 5, 2024 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3 + Details Name: us-gaap_CapitalizedContractCostNetNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredCostsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99

-Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ReceivablesLongTermContractsOrPrograms Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_UnbilledReceivablesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3

Condensed Consolidated Balance Sheets (Parenthetical) Sep. 30, 2024 $ / shares shares Dec. 31, 2023 $ / shares shares Condensed Consolidated Balance Sheets Â Â Preferred stock, shares authorized 350,000 350,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value (per share) | $ / shares $ 0.001 $ 0.001 Common stock, shares authorized 75,000,000 75,000,000 Common stock, shares issued 2,295,304 648,761 Common stock, shares outstanding 2,295,304 648,761 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Total revenues Â $ 130,440 $ 119,371 $ 594,547 Cost of revenues Â (110,441) (119,371) (520,502) Gross profit Â 19,999 Â 74,045 Operating expenses: Â Â Â Â Research and development $ 968,689 826,015 2,564,887 2,535,165 General and administrative 896,547 973,040 3,162,115 3,098,949 Total operating expenses 1,865,236 1,799,055 5,727,002 5,634,114 Loss from operations (1,865,236) (1,779,056) (5,727,002) (5,560,069) Other income (expense): Â Â Â Â Foreign currency transaction gain (loss) 575 (3,046) 2,257 310 Interest income (expense), net 78,836 66,363 143,603 (97,399) Research and development incentives Â 4,729 (25,488) 17,386 CARES Act Employee Retention Credit 66,444 120,771 66,444 120,771 Other income Â Â 43 43,223 Loss on extinguishment of debt Â Â Â (393,791) Change in fair value of convertible debt Â (72,463) 260,933 387,537 Total other income 145,855 116,354 447,792 78,037 Net loss before income taxes (1,719,381) (1,662,702) (5,279,210) (5,482,032) Income tax benefit Â Â Â 1,161,197 Net loss applicable to common stockholders $ (1,719,381) $ (1,662,702) $ (5,279,210) $ (4,320,835) Basic net loss per share (in Dollars per share) [1] $ (0.78) $ (2.56) $ (3.84) $ (10.05) Diluted net loss per share (in Dollars per share) [1] $ (0.78) $ (2.56) $ (3.84) $ (10.05) Basic weighted average common shares outstanding (in Shares) [1] 2,203,929 648,860 1,376,568 429,773 Diluted weighted average common shares outstanding (in Shares) [1] 2,203,929 648,860 1,376,568 429,773 Grant revenue Â Â Â Â Total revenues Â $ 130,440 $ 119,371 $ 594,547 [1] Adjusted to reflect the reverse stock split of one-for-sixteen effective June 5, 2024 X - DefinitionAmount of income related to employee retention credit under CARES Act. + ReferencesNo definition available. + Details Name: sngx_EmployeeRetentionCreditCaresAct Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of convertible debt. + ReferencesNo definition available. + Details Name: sngx_FairValueAdjustmentOfConvertibleDebt Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUK research and development incentives. + ReferencesNo definition available. + Details Name: sngx_UkResearchAndDevelopmentIncentives Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting

Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 1 -SubTopic 20 -Topic 940 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net amount of nonoperating interest income (expense). + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_GrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Parenthetical) Jun. 05, 2024 Condensed Consolidated Statements of Operations Â Reverse stock spilt effective from June 5, 2024 0.0625 X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Loss - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Condensed Consolidated Statements of Comprehensive Loss Â Â Â Â Net loss $ (1,719,381) $ (1,662,702) $ (5,279,210) $ (4,320,835) Other comprehensive income (loss): Â Â Â Â Foreign currency translation adjustments 9,874 18,257 15,230 (429) Comprehensive loss $ (1,709,507) $ (1,644,445) $ (5,263,980) $ (4,321,264) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) - USD ($) Preferred Stock Series D Preferred Stock Public Offering Preferred Stock Series D Preferred Stock Common Stock Public Offering Common Stock At Market Issuance sales Common Stock Pre-funded warrants Common Stock New Warrants Common Stock Existing Warrants Common Stock Additional Paid-In Capital Public Offering Additional Paid-In Capital At Market Issuance sales Additional Paid-In Capital Pre-funded warrants Additional Paid-In Capital New Warrants Additional Paid-In Capital Existing Warrants Additional Paid-In Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Public Offering At Market Issuance sales Pre-funded warrants New Warrants Existing Warrants Total Balance at Dec. 31, 2022 Â Â Â Â Â Â Â $ 182 Â Â Â Â Â Â $ 217,067,691 $ 24,747 $ (219,563,446) Â Â Â Â Â Â $ (2,470,826) Balance (in shares) at Dec. 31, 2022 Â Â Â Â Â Â Â 181,898 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance at Dec. 31, 2022 Â $ 43 Â Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement Â Â Â $ 53 Â Â Â Â Â Â $ 3,091,409 Â Â Â Â Â Â Â Â $ 3,091,462 Â Â Â Â Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement (in shares) Â Â Â 53,202 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance costs associated with sales of common stock pursuant to At Market Issuance Sales Agreement Â Â Â Â Â Â Â $ (834,061) (95,348) Â Â Â Â Â Â Â $ (834,061) (95,348) Â Â Â Â Redemption of Series D preferred stock Â $ (43) Â Issuance of common stock and pre-funded warrants in connection with public offering Â Â $ 144 Â Â Â Â Â Â 8,495,673 Â Â Â Â Â Â Â 8,495,817 Â Â Â Â Â Issuance of common stock and pre-funded warrants in connection with public offering (in shares) Â Â 143,844 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock to vendors Â Â Â Â Â Â Â $ 3 Â Â Â Â Â Â 72,997 Â Â Â Â Â Â Â 73,000 Issuance of common stock to vendors (in shares) Â Â Â Â Â Â Â 3,125 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock upon exercise of warrants Â Â Â Â Â Â Â $ 265 Â Â Â Â Â 3,034 Â Â Â Â Â Â Â 3,299 Issuance of common stock upon exercise of warrants (in shares) Â 0 Â Â Â Â Â 264,714 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock for purchase option Â Â Â Â Â Â Â $ 2 Â Â Â Â Â 49,998 Â Â Â Â Â Â Â 50,000 Issuance of common stock for purchase option (in shares) Â Â Â Â Â Â 1,978 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based compensation expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â 229,076 Â Â Â Â Â Â Â 229,076 Foreign currency translation adjustment Â Â Â Â Â Â Â Â Â Â Â Â Â Â (429) Â Â Â Â Â (429) Net loss Â Â Â Â Â Â Â Â Â Â Â Â Â Â (4,320,835) Â Â Â Â Â (4,320,835) Balance at Sep. 30, 2023 Â Â Â Â Â Â Â $ 649 Â Â Â Â Â Â 228,080,469 24,318 (223,884,281) Â Â Â Â Â 4,221,155 Balance (in Shares) at Sep. 30, 2023 Â Â Â Â Â Â Â 648,761 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2023 Â $ 0 Â Balance (Shares) at Sep. 30, 2023 Â 0 Â Balance at Jun. 30, 2023 Â Â Â Â Â Â Â $ 615 Â Â Â Â Â Â 228,015,103 6,061 (222,221,579) Â Â Â Â Â 5,800,200 Balance (in shares) at Jun. 30, 2023 Â Â Â Â Â Â Â 615,236 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock upon exercise of warrants Â Â Â Â $ 34 Â Â Â Â Â Â $ (34) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock upon exercise of warrants (in shares) Â Â Â Â 33,525 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based compensation expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â 65,400 Â Â Â Â Â Â Â 65,400 Foreign currency translation adjustment Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 18,257 Â Â Â Â Â Â Â 18,257 Net loss Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1,662,702) Â Â Â Â Â (1,662,702) Balance at Sep. 30, 2023 Â Â Â Â Â Â Â $ 649 Â Â Â Â Â Â 228,080,469 24,318 (223,884,281) Â Â Â Â Â 4,221,155 Balance (in Shares) at Sep. 30, 2023 Â Â Â Â Â Â Â 648,761 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2023 Â $ 0 Â Balance (Shares) at Sep. 30, 2023 Â 0 Â Balance at Dec. 31, 2023 Â Â Â Â Â Â Â $ 649 Â Â Â Â Â Â 228,203,706 22,243 (225,704,176) Â Â Â Â Â 2,522,422 Balance (in shares) at Dec. 31, 2023 Â Â Â Â Â Â Â 648,761 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance at Dec. 31, 2023 Â $ 0 Â Balance (Shares) at Dec. 31, 2023 Â 0 Â Issuance of common stock pursuant to At Market Issuance Sales Agreement Â Â Â $ 15 Â Â Â Â Â Â 58,421 Â Â Â Â Â Â Â 58,436 Â Â Â Â Issuance of common stock pursuant to At Market Issuance Sales Agreement (in shares) Â Â Â 14,883 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance costs associated with sales of common stock pursuant to At Market Issuance Sales Agreement Â Â Â Â Â Â Â Â Â Â Â Â Â Â (625,065) (1,947) Â Â Â Â Â Â (625,065) (1,947) Â Â Â Â Issuance of common stock and pre-funded warrants in connection with public offering $ 0 Â $ 205 Â Â Â Â Â $ 4,741,195 Â Â Â Â Â Â Â $ 4,741,400 Â Â Â Â Issuance of common stock and pre-funded warrants in connection with public offering (in shares) 0 Â 204,694 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Fractional shares issued in reverse stock split Â Â Â Â Â Â Â $ 115 Â Â Â Â Â (115) Â Â Â Â Â Â Â Â Â Â Â Â Fractional shares issued in reverse stock split (in shares) Â Â Â Â Â 114,735 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock upon exercise of warrants Â Â Â Â $ 537 $ 35 $ 703 Â Â Â Â $ 8,063 $ 222,787 $ 4,218,047 Â Â Â Â Â $ 8,600 $ 222,822 $ 4,218,750 Â Issuance of common stock upon exercise of warrants (in shares) Â Â Â Â 537,500 34,816 703,125 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance costs associated with warrant inducement Â Â Â Â Â Â Â Â Â Â Â Â Â Â (7,552,457) Â Â Â Â Â Â Â (7,552,457) Warrant modification - incremental fair value Â Â Â Â Â Â Â Â Â Â Â Â Â Â 7,177,683 Â Â Â Â Â Â Â 7,177,683 Issuance of common stock associated with conversion of debt Â Â Â Â Â Â Â $ 36 Â Â Â Â Â 254,220 Â Â Â Â Â Â Â 254,256 Issuance of common stock associated with conversion of debt (in shares) Â Â Â Â Â Â Â 36,790 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-based compensation expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â 174,268 Â Â Â Â Â Â Â 174,268 Foreign currency translation adjustment Â Â Â Â Â Â Â Â Â Â Â Â Â Â 15,230 Â Â Â Â Â 15,230 Net loss Â Â Â Â Â Â Â Â Â Â Â Â Â Â (5,279,210) Â Â Â Â Â (5,279,210) Balance at Sep. 30, 2024 Â Â Â Â Â Â Â $ 2,295 Â Â Â Â Â 236,878,806 37,473 (230,983,386) Â Â Â Â Â 5,935,188 Balance (in Shares) at Sep. 30, 2024 Â Â Â Â Â Â Â 2,295,304 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2024 Â $ 0 Â Balance (Shares) at Sep. 30, 2024 Â 0 Â Balance at Jun. 30, 2024 Â Â Â Â Â Â Â $ 1,542 Â Â Â Â Â 232,699,640 27,599 (229,264,005) Â Â Â Â Â 3,464,776 Balance (in shares) at Jun. 30, 2024 Â Â Â Â Â Â Â 1,542,480 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock pursuant to At Market Issuance Sales Agreement Â Â Â $ 15 Â Â Â Â Â 58,421 Â Â Â Â Â Â Â 58,436 Â Â Â Â Issuance of common stock pursuant to At Market Issuance Sales Agreement (in shares) Â Â Â 14,883 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance costs associated with sales of common stock pursuant to At Market Issuance Sales Agreement Â Â Â Â Â Â Â Â $ (1,947) Â Â Â Â Â Â $ (1,947) Â Â Â Â Issuance of common stock upon exercise of warrants Â Â Â Â Â $ 35 $ 703 Â Â Â Â $ 222,787 $ 4,218,047 Â Â Â Â Â $ 222,822 $ 4,218,750 Â Issuance of common stock upon exercise of warrants (in shares) Â Â Â Â Â 34,816 703,125 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance costs associated with warrant inducement Â Â Â Â Â Â Â Â Â Â Â Â Â Â (7,552,457) Â Â Â Â Â Â Â (7,552,457) Warrant modification - incremental fair value Â Â Â Â Â Â Â Â Â Â Â Â Â Â 7,177,683 Â Â Â Â Â Â Â 7,177,683 Share-based compensation expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â 56,632 Â Â Â Â Â Â Â 56,632 Foreign currency translation adjustment Â Â Â Â Â Â Â Â Â Â Â Â Â Â 9,874 Â Â Â Â Â Â Â 9,874 Net loss Â Â Â Â Â Â Â Â Â Â Â Â Â Â (1,719,381) Â Â Â Â Â (1,719,381) Balance at Sep. 30, 2024 Â Â Â Â Â Â Â $ 2,295 Â Â Â Â Â Â Â $ 236,878,806 $ 37,473 $ (230,983,386) Â Â Â Â Â $ 5,935,188 Balance (in Shares) at Sep. 30, 2024 Â Â Â Â Â Â Â 2,295,304 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2024 Â $ 0 Â Balance (Shares) at Sep. 30, 2024 Â 0 Â X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing warrants. Includes, but is not limited to, legal and accounting fees and direct costs associated with warrant issuances. + ReferencesNo definition available. + Details Name: sngx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedIssuanceCosts Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of stock and pre-funded warrants issued during the period. + ReferencesNo definition available. + Details Name: sngx_StockAndPreFundedWarrantsIssuedDuringPeriodShares Namespace Prefix: sngx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe value of stock and pre-funded warrants issued during the period. + ReferencesNo definition available. + Details Name: sngx_StockAndPreFundedWarrantsIssuedDuringPeriodValue Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued on exercise of warrants. + ReferencesNo definition available. + Details Name: sngx_StockIssuedDuringPeriodShareExerciseOfWarrants Namespace Prefix: sngx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares pursuant to market sales agreement. + ReferencesNo definition available. + Details Name: sngx_StockIssuedDuringPeriodSharesPursuantToMarketSalesAgreement Namespace Prefix: sngx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued during the period on exercise of warrants. + ReferencesNo definition available. + Details Name: sngx_StockIssuedDuringPeriodValueExerciseOfWarrants Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value pursuant to market sales agreement. + ReferencesNo definition available. + Details Name: sngx_StockIssuedDuringPeriodValuePursuantToMarketSalesAgreement Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of shares issued during the period as a result of reverse stock split + ReferencesNo definition available. + Details Name: sngx_StockIssuedDuringPeriodValueReverseStockSplits Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock classified as temporary equity issued to shareholders as a dividend during the period. + ReferencesNo definition available. + Details Name: sngx_TemporaryEquityStockIssuedDuringPeriodValueStockDividend Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-

gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TemporaryEquitySharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) (Parenthetical) Jun. 05, 2024 Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) Â Reverse stock spilt effective from June 5, 2024 0.0625 X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Operating activities: Â Â Net loss $ (5,279,210) $ (4,320,835) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Amortization and depreciation 4,765 4,964 Non-cash lease expense 89,686 82,500 Share-based compensation 174,268 229,076 Issuance of common stock to vendors for services Â 73,000 Issuance of common stock for purchase option Â 50,000 Loss on extinguishment of debt Â 393,791 Change in fair value of convertible debt (260,933) (387,537) Amortization of deferred issuance costs associated with convertible debt Â 12,518 Change in operating assets and liabilities: Â Â Contracts and grants receivable 171,254 49,079 Prepaid expenses and other current assets 525,684 (310,229) Research and development incentives receivable 51,879 92,092 Operating lease liability (89,969) (80,458) Accounts payable and accrued expenses (1,391,432) (2,382,708) Accrued compensation (166,753) (281,149) Net cash flows from operating activities (6,170,761) (6,775,896) Financing activities: Â Â Proceeds from issuance of common stock pursuant to At Market Issuance Sales Agreement 58,436 3,091,462 Proceeds from issuance of common stock and pre-funded warrants 4,741,400 8,495,817 Proceeds from the exercise of warrants 4,450,172 3,299 Issuance costs associated with warrant inducement (374,774) Â Convertible debt repayments (686,436) (7,000,000) Net cash flows from financing activities 7,519,211 3,709,688 Effect of exchange rate on cash and cash equivalents 45,569 5,127 Net increase in cash and cash equivalents 1,394,019 (3,061,081) Cash and cash equivalents at beginning of period 8,446,158 13,359,615 Cash and cash equivalents at end of period 9,840,177 10,298,534 Supplemental information: Â Â Cash paid for state income taxes 42,162 13,006 Cash paid for interest 183,771 488,011 Cash paid for lease liabilities: Â Â Operating lease 102,300 99,975 Non-cash investing and financing activities: Â Â Pontifax conversion of portion of debt principal into common stock 254,256 Â Deferred issuance cost reclassified to additional paid-in capital 228,161 2,339 Redemption liability for Series D preferred stock Â 43 Offering costs included in accounts payable 83,810 46,180 Warrant modification - incremental value 7,177,683 Â At Market Issuance Sales Agreement Â Â Financing activities: Â Â Stock issuance costs associated (44,522) (93,009) Public Offering Â Â Financing activities: Â Â Stock issuance costs associated $ (625,065) $ (787,881) X - DefinitionAmount of expense (income) related to adjustment to fair value of convertible debt. + ReferencesNo definition available. + Details Name: sngx_FairValueAdjustmentOfConvertibleDebt Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of incremental fair value of warrants recognized as issuance cost of the warrant exercise. + ReferencesNo definition available. + Details Name: sngx_IssuanceCostOfWarrantExercise Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe issuance of common stock for purchase option. + ReferencesNo definition available. + Details Name: sngx_IssuanceOfCommonStockForPurchaseOption Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDeferred issuance cost reclassified to additional-paid-in capital. + ReferencesNo definition available. + Details Name: sngx_NoncashOrPartNoncashDeferredIssuanceCostReclassifiedToAdditionalPaidInCapital Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow from operating lease. + ReferencesNo definition available. + Details Name: sngx_OperatingLeasePaid Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for the cost incurred directly with the issuance and modification of warrants as per the inducement agreement. + ReferencesNo definition available. + Details Name: sngx_PaymentsOfWarrantIssuanceCostsUponInducement Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: sngx_ProceedsFromExerciseOfWarrants Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of proceeds from issuance of common stock and warrants. + ReferencesNo definition available. + Details Name: sngx_ProceedsFromIssuanceOfCommonStockAndWarrants Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance of common stock pursuant to FBR At-the-Market Sales Agreement, + ReferencesNo definition available. + Details Name: sngx_ProceedsFromIssuanceOfCommonStockPursuantToMarketSalesAgreement Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of redemption of preferred stock. + ReferencesNo definition available. + Details Name: sngx_RedemptionOfPreferredStock Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of stock issuance costs included in accounts payable. + ReferencesNo definition available. + Details Name: sngx_StockIssuanceCostsIncludedInAccountsPayable Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdditionalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic

10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in employer-related costs classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in receivables classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4JReference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4KReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=sngx_AtMarketIssuanceSalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=sngx_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of Business 9 Months Ended Sep. 30, 2024 Nature of Business Â Nature of Business NoteÂ 1. Nature of BusinessBasis of PresentationSoligenix,Â Inc. (the â€œCompanyâ€) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments: Specialized BioTherapeutics and Public Health Solutions.The Companyâ€™s Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryteâ„¢ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (â€œCTCLâ€). With agreement from the European Medicines Agency (â€œEMAâ€) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryteâ„¢ in theÂ treatment of CTCL patients with early-stage disease, the Company is targeting to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026. Upon successful completion of the second Phase 3 study, called â€œFLASH2â€ (Fluorescent Light Activated Synthetic Hypericin 2), regulatory approval will be sought to support potential commercialization worldwide.Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, the Companyâ€™s first-in-class innate defense regulator technology, and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer and aphthous ulcers in BehÃ§etâ€™s Disease. The Companyâ€™s Public

Health Solutions business segment includes development programs for RiVaxÂ®, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVaxâ„¢, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of the vaccine programs incorporates the use of the Companyâ€™s proprietary heat stabilization platform technology, known as ThermoVaxÂ®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (â€œNIAIDâ€), the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.The Company primarily generates revenues under government grants and contracts. The Company was awarded a subcontract that originally provided for approximately $1.1 million from a U.S. Food and Drug Administration (â€œFDAâ€) Orphan Products Development grant over four years for an expanded study of HyBryteâ„¢ in the treatment of CTCL. The Company will continue to apply for additional government funding.The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, development of new technological innovations, dependence on key personnel, protections of proprietary technology, compliance with the FDA regulations, and other regulatory authorities, litigation, and product liability.Results for the three and nine months ended SeptemberÂ 30,Â 2024 are not necessarily indicative of results that may be expected for the full year.LiquidityThe Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within oneÂ year after the date the condensed consolidated financial statements are issued. As of SeptemberÂ 30,Â 2024, the Company had an accumulated deficit of $230,983,386. During the nine months ended SeptemberÂ 30,Â 2024, the Company incurred a net loss of $5,279,210 and used $6,170,761 of cash in operating activities. The Company expects to continue to generate losses in the foreseeable future. The Companyâ€™s liquidity needs will be determined largely by the budgeted operational expenditures incurred in regards to the progression of its product candidates. Management believes that the Company has sufficient resources available to support its development activities and business operationsÂ and timely satisfy its obligations as they become due through the second quarter of 2025. The Company does not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support its operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about the Companyâ€™s ability to continue as a going concern through 12 months after the date the financial statements are issued.â€‹To alleviate the conditions that raise substantial doubt about the Companyâ€™s ability to continue as a going concern, the Companyâ€™s plans include:â—Securing additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations.â—Securing additional proceeds from government contract and grant programs.â€‹â—Securing additional proceeds from the sale of shares of the Companyâ€™s common stock via the At Market Issuance Sales Agreement (â€œAGP Sales Agreementâ€) with A.G.P/Alliance Global Partners (â€œAGPâ€).â€‹â—Amending the loan agreement with Pontifax Medison Finance (â€œPontifaxâ€) (See Note 4) to reduce the conversion price in order to allow for conversion of a portion of the debt which will reduce the Companyâ€™s debt repayments.â€‹Other than the AGP Sales Agreement which was entered into on August 16, 2024 and the second amendment to the Pontifax loan agreement which was completed on October 8, 2024, none of these alternatives are committed at this time. There can be no assurance that the Company will be successful in obtaining sufficient funding on acceptable terms to fund continuing operations, if at all, identify and enter into any strategic transactions that will provide the capital that it will require, or achieve the other strategies to alleviate the conditions that raise substantial doubt about the Companyâ€™s ability to continue as a going concern. If none of these alternatives are available, or if available, are not available on satisfactory terms, the Company will not have sufficient cash resources and liquidity to fund its business operations for at least the 12 months following the date the financial statements are issued.Â The failure to obtain sufficient capital on acceptable terms when needed may require the Company to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives andÂ its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. In addition, the perception that the Company may not be able to continue as a going concern may cause others to choose not to deal with it due to concerns about its ability to meet its contractual obligations. Â The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. â€‹As of SeptemberÂ 30,Â 2024, the Company had cash and cash equivalents of $9,840,177 as compared to $8,446,158 as of DecemberÂ 31,Â 2023. As of SeptemberÂ 30,Â 2024, the Company had working capital of $5,776,645 as compared to working capital of $3,355,212 as of DecemberÂ 31,Â 2023.â€‹The Companyâ€™s plans with respect to its liquidity management include, but are not limited to, the following:â—The Company has up to approximately $554,000 in active government grant funding still available as of SeptemberÂ 30,Â 2024 to support its associated research programs through May 2026, provided the federal agencies do not elect to terminate the grants for convenience. The Company plans to submit additional contract and grant applications for further support of its programs with various funding agencies. However, there can be no assurance that the Company will obtain additional governmental grant funding. â—The Company will continue to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expects to continue to do so for the foreseeable future.â—The Company will continue to pursue Net Operating Loss (â€œNOLâ€) sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program if the program is available.â—The Company plans to pursue potential partnerships for pipeline programs as well as continue to explore merger and acquisition strategies. However, there can be no assurances that the Company can consummate such transactions.â—The Company completed a public offering on April 22, 2024 of 204,694 shares of its common stock, pre-funded warrants to purchase 537,500 shares of its common stock and common warrants to purchase up to 742,194 shares of its common stock at a combined public offering price of $6.40. The pre-funded warrants have an exercise price of $0.02. The common warrants have an exercise price of $6.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to the Company from this offering were approximately $4.75 million before deducting commissions and other estimated offering expenses of approximately $0.45 million. The Company plans to use the proceeds for further support of its programs, as well as for working capital. â—The Company entered into a warrant inducement agreement (the â€œInducement Agreementâ€) on July 9, 2024 with certain holders (the â€œHoldersâ€) of the Companyâ€™s existing Warrant to Purchase Shares of Common Stock (â€œExisting Warrantsâ€) to purchase shares of common stock of the Company. In consideration of the Holdersâ€™ agreement to exercise their Existing Warrants, the Company (i) decreased the exercise price of the Existing Warrants from $6.40 per share to $6.00 per share and (ii) issued new warrants (â€œNew Warrantsâ€) to the Holders to purchase a number of shares of common stock equal to 150% of the number of shares of common stock issued upon exercise of the Holdersâ€™ Existing Warrants. Pursuant to the Inducement Agreement, the Holders agreed to exercise for cash their Existing Warrants to purchase up to 703,125 shares of the Companyâ€™s common stock at a reduced exercise price of $6.00 per share on July 9, 2024, the date of the Inducement Agreement, until 1:30 p.m., Eastern Time. The total gross proceeds to the Company was approximately $4.2 million from the exercise of the Existing Warrants before deducting financial advisory fees and other expenses. The Company plans to use the proceeds for further support of its programs, as well as for working capital. â—The Company has up to approximately $4.7 million remaining from the AGP Sales Agreement as of November 1, 2024 under the prospectus supplement dated August 16, 2024. From October 1, 2024 through November 1, 2024, the Company sold 229,078 shares of common stock pursuant to the AGP Sales Agreement at a weighted average price of $4.72 per share for total gross proceeds of approximately $1.1 million.â—The Company is currently evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate such a transaction, or consummate a transaction at favorable pricing.â€‹Managementâ€™s business strategy can be outlined as follows:â—Following agreement from the EMA on the key design components for the second confirmatory Phase 3 placebo-controlled FLASH2 clinical trial of HyBryteâ„¢ in CTCL and positive primary endpoint results from the first Phase 3 FLASH study, initiate the FLASH2 study, while at the same time, continuing discussions with the FDA on potential modifications to the development path to adequately address their feedback. â—Expanding development of synthetic hypericin under the research name SGX302 into psoriasis with the conduct of a Phase 2a clinical trial, following the positive Phase 3 FLASH study and positive proof-of-concept demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.â—Following feedback from the United Kingdom (â€œUKâ€) Medicines and Healthcare products Regulatory Agency (â€œMHRAâ€) that a second Phase 3 clinical trial of SGX942 (dusquetide) in the treatment in oral mucositis would be required to support a marketing authorization; design a second study and attempt to identify a potential partner(s) to continue this development program.â—Expanding development of dusquetide under the research name SGX945 into BehÂ§etâ€™s Disease by conducting a Phase 2a clinical trial, where previous studies with dusquetide in oral mucositis have validated the biologic activity in aphthous ulcers induced by chemotherapy and radiation.â—Continue development of the Companyâ€™s heat stabilization platform technology, ThermoVaxÂ®, in combination with its programs for RiVaxÂ® (ricin toxin vaccine), and filovirus vaccines (targeting Ebola, Sudan, and Marburg viruses and multivalent combinations), with United States (â€œU.S.â€) government or non-governmental organization funding support.â—Continue to apply for and secure additional government funding for the Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts and/or procurements.â—Pursue business development opportunities for pipeline programs, as well as explore all strategic alternatives, including but not limited to merger/acquisition strategies.â—Acquire or in-license new clinical-stage compounds for development, as well as evaluate new indications with existing pipeline compounds for development.â€‹Reverse Stock Splitâ€‹On June 5, 2024, the Company completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of one-for-sixteen, whereby every sixteen shares of the Companyâ€™s issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock without any change in the par value per share. No fractional shares were issued as a result of the reverse stock split. Any fractional shares that would otherwise have resulted from the reverse stock split were rounded up to the next whole number. The Companyâ€™s common stock began trading on The Nasdaq Capital Market on a reverse split basis at the market opening on June 6, 2024. All share and per share data have been restated to reflect this reverse stock split. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies NoteÂ 2. Summary of Significant Accounting PoliciesPrinciples of ConsolidationThe condensed consolidated financial statements include Soligenix,Â Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation.Operating SegmentsOperating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: Specialized BioTherapeutics and Public Health Solutions.Cash and Cash EquivalentsThe Company considers all highly liquid investments with maturities of threeÂ months or less when purchased to be cash equivalents.Contracts and Grants ReceivableContracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for credit losses has been established. If amounts become uncollectible, they are charged to operations.Impairment of Long-Lived AssetsOffice furniture and equipment and right of use assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.The Company did not record any impairment of long-lived assets for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023.Fair Value of Financial InstrumentsFair Value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on SeptemberÂ 30,Â 2024. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.Fair Value valuation techniques include a three level hierarchy based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).The three levels of the fair value hierarchy are as follows:â—Level 1Â â€” Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.â—Level 2Â â€” Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.â—Level 3Â â€” Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.â€‹The carrying amounts reported in the condensed consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable, accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments.The carrying amount reported in the condensed consolidated balance sheet as of SeptemberÂ 30,Â 2024 for the convertible debt is its fair value which totals $2,059,309 and was approximately equivalent to the face value of the convertible debt at SeptemberÂ 30,Â 2024. The fair value estimate represents a Level 3 measurement in the fair value hierarchy.â€‹A roll forward of the fair value of convertible debt to SeptemberÂ 30,Â 2024 is as follows:â€‹â€‹â€‹

the accompanying condensed consolidated statements of operations during the three and nine months ended SeptemberÂ 30,Â 2024, respectively. Â Revenue RecognitionThe Companyâ€™s revenues include revenues generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants. The Company also records revenue from contracts with customers in accordance with applicable accounting guidance which requires an entity to recognize revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of this guidance, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of this guidance, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Certain amounts received from or billed to customers in accordance with contract terms are deferred and recognized as future performance obligations are satisfied. All amounts earned under contracts with customers other than sales-based royalties are classified as licensing revenue. Sales-based royalties under the Companyâ€™s license agreements would be recognized as royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue.Research and Development CostsResearch and development costs are charged to expense when incurred in accordance with applicable accounting guidance. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs.Share-Based CompensationStock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of oneÂ year (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then 25% each subsequentÂ year for a period of threeÂ years. These options have a ten-year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within threeÂ months, unless otherwise extended by the Board.From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed under the Companyâ€™s 2015 Equity Incentive Plan (the â€œ2015 Planâ€). The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestricted stock to the Companyâ€™s employees and non-employees (including consultants). The shares issued under the 2015 Plan are registered on FormÂ S-8 (SEC File No.Â 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificates reflecting such shares reflect a Securities Act of 1933, as amended restrictive legend. Stock compensation expense for equity-classified awards to non-employees is measured on the date of grant and is recognized when the services are performed.There were no options issued during the three months ended SeptemberÂ 30,Â 2024 and 2023.The fair value of each option grant made during the nine months ended SeptemberÂ 30,Â 2024 and 2023 was estimated on the date of each grant and recognized as share-based compensation expense ratably over the option vesting periods, which approximates the service period. Foreign Currency Transactions and TranslationIn accordance with FASB ASC 830 Foreign Currency Matters, the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency, the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statements of the UK subsidiary are translated into U.S. dollars and consolidated into the Companyâ€™s financials, with related translation adjustments reported as a cumulative translation adjustment, which is a component of accumulated other comprehensive income. During the nine months ended SeptemberÂ 30,Â 2024 and 2023, the Company recognized a foreign currency transaction gain of $575 and a foreign currency transaction loss of ($3,046), respectively, in the accompanying condensed consolidated statements of operations. During the nine months ended SeptemberÂ 30,Â 2024 and 2023, the Company recognized foreign currency transaction gains of $2,257 and $310, respectively, in the accompanying condensed consolidated statements of operations.â€‹Loss Per ShareBasic earnings per share (â€œEPSâ€) is computed by dividing loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Included within the Companyâ€™s weighted average common shares outstanding (basic and diluted) for the three and nine months ended SeptemberÂ 30,Â 2024, are common shares issuable upon the exercise of the pre-funded warrants as these pre-funded warrants are exercisable at any time for nominal consideration. The following table summarizes outstanding instruments which were not included in the computation of diluted EPS as to do so would have been antidilutive:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of SeptemberÂ 30,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â Common stock purchase warrantsâ€‹ 1,467,581â€‹ 408,640â€‹Stock optionsÂ 56,427Â 12,843Â Convertible debtÂ 75,710Â 1,172,645Â TotalÂ 1,599,718Â 1,594,128Â â€‹Use of Estimates and AssumptionsThe preparation of financial statements requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses 9 Months Ended Sep. 30, 2024 Accrued Expenses Â Accrued Expenses Note 3. Accrued Expensesâ€‹The following is a summary of the Companyâ€™s accrued expenses:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â Clinical trial expensesâ€‹$ 951,029â€‹$ 1,993,784â€‹Otherâ€‹Â 412,206â€‹Â 424,218â€‹Totalâ€‹$ 1,363,235â€‹$ 2,418,002â€‹â€‹ X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Debt 9 Months Ended Sep. 30, 2024 Debt Â Debt NoteÂ 4. DebtIn DecemberÂ 2020, the Company entered into a $20 million convertible debt financing agreement with Pontifax (the â€œLoan Agreementâ€). Under the terms of the Loan Agreement, the Company had access to up to $20 million in convertible debt financing in three tranches, which will mature on JuneÂ 15, 2025 and had an interest-only period for the first twoÂ years with a fixed interest rate of 8.47% on borrowed amounts and an interest rate of 1% on amounts available but not borrowed as an unused line of credit fee. After the interest-only period, the outstanding principal was to be repaid in quarterly payments of $1 million each commencing in the first quarter of 2023. The agreement is secured by a lien on substantially all of the Companyâ€™s assets, other than intellectual property. â€‹Upon the closing of this transaction, the Company borrowed the first tranche of $10 million, had the option to draw the second tranche of $5 million at any time during the initial 12 months of the loan and the third tranche of $5 million upon filing of the new drug application for HyBryteâ„¢, subject to certain conditions. The Company elected to let the options to borrow both the second and third tranches expire as of December 15, 2021 and March 15, 2022, respectively.â€‹In April 2023, the Company entered into an amendment to the Loan Agreement (the â€œ2023 Amendmentâ€). The 2023 Amendment called for the immediate payment of $5 million of the outstanding principal balance and any accrued interest, waived any prepayment charge in connection with the repayment of this amount and resulted in an outstanding principal balance of $3 million. The 2023 Amendment also provided for interest only Â through June 30, 2024, reduced quarterly principal repayments to $750,000, and eliminated the minimum cash covenant. Further, the 2023 Amendment reduced the conversion price with respect to the remaining principal amount to (i) 90% of the closing price of the Companyâ€™s common stock on the day before the delivery of a conversion notice with respect to the first 36,790 shares of the Companyâ€™s common stock issuable upon conversion and to (ii) $27.20 with respect to all shares of the Companyâ€™s common stock issuable upon conversion thereafter. The remaining terms of the agreement remained unmodified. â€‹On January 3, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Companyâ€™s common stock. Upon conversion, the Company issued 9,139 shares of the Companyâ€™s common stock at $10.88 per share, reducing the remaining principal balance by $99,416. â€‹On April 15, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Companyâ€™s common stock. Upon conversion, the Company issued 27,651 shares of the Companyâ€™s common stock at $5.60 per share, reducing the remaining principal balance by $154,840. â€‹The 2023 Amendment resulted in the extinguishment of the original convertible debt for accounting purposes. The Company elected to account for the amended convertible debt using the fair value option. As of SeptemberÂ 30,Â 2024, the Company determined the carrying amount of the convertible debt was approximately equivalent to the face value of the convertible debt. The Company recognized $0 and $260,933 of other income from the change in the fair value of the convertible debt in its accompanying condensed consolidated statements of operations during the three and nine months ended SeptemberÂ 30,Â 2024, respectively. â€‹In October 2024, the Company entered into an amendment (the â€œ2024 Amendmentâ€) to the Loan Agreement, as amended. The 2024 Amendment reduced the conversion price with respect to the remaining principal amount outstanding to (i) $3.81 for the first 501,648 shares of the Companyâ€™s common stock issuable upon conversion and (ii) $4.23 with respect to all shares of the Companyâ€™s common stock issuable upon conversion thereafter. The remaining terms of the agreement remain in effect without modification. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1IReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1IReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity 9 Months Ended Sep. 30, 2024 Shareholders' Equity Â Shareholders' Equity NoteÂ 5. Shareholdersâ€™ EquityCommon StockThe Company completed a public offering on April 22, 2024 of 204,694 shares of its common stock, pre-funded warrants to purchase 537,500 shares of its common stock and common warrants to purchase up to 742,194 shares of its common stock at an offering price of $6.40. The pre-funded warrants have an exercise price of $0.02. The common warrants have an exercise price of $6.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to the Company from this offering were approximately $4.75 million before deducting commissions and other estimated offering expenses payable by the Company of approximately $0.45 million.Common stock transactions for the nine months ended SeptemberÂ 30,Â 2024 are as follows:â€”The Company issued Pontifax 9,139 shares of fully vested common stock pursuant to conversion of a portion of the convertible debt principal balance at a conversion price of $10.88 per share on January 3, 2024. The conversion price was based on 90% of the closing price of the Companyâ€™s common stock on the day before the delivery of the conversion notice.â€”The Company issued Pontifax 27,651 shares of fully vested common stock pursuant to conversion of a portion of the convertible debt principal balance at a conversion price of $5.60 per share on April 15, 2024. The conversion price was based on 90% of the closing price of the Companyâ€™s common stock on the day before the delivery of the conversion notice.â€”The Company sold 204,694 shares of common stock and 537,500 pre-funded warrants pursuant to the April 2024 public offering for $6.40 per share on April 22, 2024.â€”The Company issued 97,375 shares of common stock pursuant to the exercise of pre-funded warrants associated with the April 2024 public offering with an exercise price of $0.02 on April 22, 2024.â€”The Company issued 69,125 shares of common stock pursuant to the exercise of pre-funded warrants associated with the April 2024 public offering with an exercise price of $0.02 on June 11, 2024.â€”The Company issued 117,000 shares of common stock pursuant to the exercise of pre-funded warrants associated with the April 2024 public offering with an exercise price of $0.02 on June 14, 2024.â€”The Company issued 130,000 shares of common stock pursuant to the exercise of pre-funded warrants associated with the April 2024 public offering with an exercise price of $0.02 on June 20, 2024.â€”The Company issued 124,000 shares of common stock pursuant to the exercise of pre-funded warrants associated with the April 2024 public offering with an exercise price of $0.02 on June 25, 2024.â€”The Company issued 703,125 shares of common stock pursuant to the exercise of warrants associated with the April 2024 public offering with an exercise price of $6.00 on July 10, 2024.â€”The Company issued 31,250 shares of common stock pursuant to the exercise of warrants associated with the April 2024 public offering with an exercise price of $6.40 on July 10, 2024.â€”The Company issued 2,190 shares of common stock pursuant to the exercise of warrants associated with the April 2024 public offering with an exercise price of $6.40 on July 11, 2024.â€”The Company issued 1,376 shares of common stock pursuant to the exercise of warrants associated with the April 2024 public offering with an exercise price of $6.40 on July 23, 2024.â€”The Company sold 14,883 shares of common stock pursuant to the AGP Sales Agreement at a weighted average price of $3.93 per share.The issuance of the Companyâ€™s common stock in connection with the convertible debt financing agreement as described above was exempt under Section 3(a)(9) of the Securities Act of 1933, as amended.â€‹The issuances of the Companyâ€™s common stock in connection with the April 2024 public offering and upon the exercise of warrants described above were registered

on a Registration Statement on Form S-1.â€‹The issuance of the Companyâ€™s common stock pursuant to the AGP Sales Agreement described above was registered on a Registration Statement on Form S-3.â€‹AGP At Market Issuance Sales Agreementâ€‹In August 2024, the Company entered into the AGP Sales Agreement to sell shares of the Companyâ€™s common stock from time to time, through an â€œat-the-marketâ€ equity offering program (the â€œAGP ATMâ€). In connection with the sale of shares via the AGP ATM, the Company determines, among other things, the number of shares to be issued, the time period during which sales may be requested to be made, limitation on the number of shares that may be sold in any one trading day, and any minimum price below which sales may not be made. Pursuant to the terms, AGP is entitled to compensation for its services in an amount up to 3% of the gross proceeds from the sale of shares under the AGP ATM. The Company has no obligation to sell any shares under the AGP ATM, and may suspend solicitation and offers at any time. The AGP ATM may be terminated by the Company or AGP upon notice, or at any time under certain circumstances, including but not limited to the occurrence of a material adverse change in the Company. The AGP ATM will terminate upon the earliest of (a) December 15, 2026, (b) the sale of all of the shares of common stock subject to the AGP ATM, (c) the termination of the AGP Sales Agreement as permitted therein, or (d) the mutual agreement of the parties.â€‹The AGP Sales Agreement provides for the offer and sale of shares of common stock having an aggregate offering price of up to $5.8 million. As of November 1, 2024, there was approximately $4.7 million available for future sale of common stock pursuant to the AGP ATM.â€‹July 2024 Warrant Inducementâ€‹On July 9, 2024, the Company entered into the Inducement Agreement with the Holders of the Companyâ€™s Existing Warrants to purchase shares of common stock of the Company. Pursuant to the Inducement Agreement, the Holders agreed to exercise for cash their Existing Warrants to purchase up to 703,125 shares of common stock at a reduced exercise price of $6.00 per share on July 9, 2024, the date of the Inducement Agreement, until 1:30 p.m. Eastern Time. The aggregate gross proceeds received by the Company was approximately $4.2 million from the exercise of the Existing Warrants offset by total issuance costs of approximately $7.5 million. Issuance costs include financial advisory, banker, and legal fees of approximately $0.4 million and the fair value of the warrant modification and the fair value of the New Warrants issued totaling approximately $7.2 million. Because the modification represented a short-term inducement, the Company applied modification accounting guidance related to the fair value of the modification associated with the warrants that were exercised under the Inducement Agreement. Accordingly, the Company recognized the incremental fair value of the modification of the Existing Warrants exercised along with the fair value of the New Warrants issued as compared to the original warrants, together totaling approximately $7.2 million, as an issuance cost of the warrant exercise. Per the terms of the Inducement Agreement, the Company issued an aggregate of 1,054,688 New Warrants.â€‹The fair value of the New Warrants issued under the Inducement Agreement was estimated using the Black-Scholes warrant-pricing model and the following assumptions:â—a dividend yield of 0%;â—an expected life of 5 years;â—volatility of 127.25%; andâ—risk free interest rate of 4.24%.â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies. Â Commitments and Contingencies NoteÂ 6. Commitments and ContingenciesContractual ObligationsThe Company has commitments of approximately $205,000 as of SeptemberÂ 30,Â 2024 over the next five years for several licensing agreements with partners and universities. Additionally, the Company is party to other agreements which include cash milestone payments, royalties and other fees payable, which are all contingent upon clinical or commercialization success. There can be no assurance that clinical or commercialization success will occur.The Company currently leases office space pursuant to a lease which expires in October 2025 and requires monthly rent of $11,367 through October 2024 and $11,625 per month thereafter.In SeptemberÂ 2014, the Company entered into an asset purchase agreement with Hy BiopharmaÂ Inc. (â€œHy Biopharmaâ€) pursuant to which the Company acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharmaâ€™s synthetic hypericin product. As consideration for the assets acquired, the Company paid $275,000 in cash and issued 771 shares of common stock with a fair value based on the Companyâ€™s stock price on the date of grant of $3.75 million. These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in the Companyâ€™s research and development activities and do not have alternative future use. In MarchÂ 2020, the Company issued 8,151 shares of common stock to Hy Biopharma as payment for achieving a milestone: the Company determining the Phase 3 clinical trial of HyBryteâ„¢ to be successful in the treatment of CTCL. The number of shares of common stock issued to Hy Biopharma was calculated using an effective price of $614.40 per share, based upon a formula set forth in the purchase agreement.Provided the sole remaining future success-oriented milestone of FDA approval is attained, the Company will be required to make an additional payment of $5 million, if and when achieved. Such payment will be payable in restricted securities of the Company provided such number of shares does not exceed 19.9% ownership of the Companyâ€™s outstanding stock. As of SeptemberÂ 30,Â 2024, no other milestone or royalty payments have been paid or accrued.As a result of the above agreements, the Company has the following contractual obligations:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Research andÂ Â Â Â â€‹Â Â Â Â Â Â Â Â Â â€‹YearÂ Â Â Â DevelopmentÂ Â Â Â LeasesÂ Â Â Â TotalOctober 1 through December 31, 2024â€‹$ 21,000â€‹$ 34,617â€‹$ 55,6172025â€‹Â 46,000â€‹Â 116,250â€‹Â 162,2502026â€‹Â 46,000â€‹Â â€”â€‹Â 46,0002027â€‹â€‹ 46,000â€‹â€‹ â€”â€‹â€‹ 46,0002028â€‹â€‹ 46,000â€‹â€‹ â€”â€‹â€‹ 46,000Totalâ€‹$ 205,000â€‹$ 150,867â€‹$ 355,867â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Operating Segments 9 Months Ended Sep. 30, 2024 Operating Segments Â Operating Segments NoteÂ 7. Operating SegmentsThe Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Three Months Ended â€‹Â Â Â Â SeptemberÂ 30,Â â€‹Â Â Â Â Â 2024Â Â Â Â 2023Revenuesâ€‹â€‹Â Â Â Â â€‹Â Â Specialized BioTherapeuticsâ€‹$ â€”â€‹ â€”Public Health Solutionsâ€‹â€‹ â€”â€‹â€‹ 130,440Totalâ€‹$ â€”â€‹ 130,440â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Income (loss) from Operationsâ€‹Â Â Â Â â€‹Â Â Â Â Specialized BioTherapeuticsâ€‹$ (834,654)â€‹$ (705,753)Public Health Solutionsâ€‹â€‹ (57,611)â€‹â€‹ (24,819)Corporateâ€‹Â (972,971)â€‹Â (1,048,484)Totalâ€‹$ (1,865,236)â€‹$ (1,779,056)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Amortization and Depreciation Expenseâ€‹Â Â Â Â â€‹Â Â Â Â Specialized BioTherapeuticsâ€‹$ 953â€‹$ 954Public Health Solutionsâ€‹â€‹ 158â€‹â€‹ 159Corporateâ€‹Â 478â€‹Â 476Totalâ€‹$ 1,589â€‹$ 1,589â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Other (Expense) Income, Netâ€‹Â Â Â Â â€‹Â Â Â Â Specialized BioTherapeuticsâ€‹$ 1,409â€‹$ 1,683Corporateâ€‹Â 144,446â€‹Â 114,671Totalâ€‹$ 145,855â€‹$ 116,354â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Share-Based Compensationâ€‹Â Â Â Â â€‹Â Â Â Â Specialized BioTherapeuticsâ€‹$ 20,598â€‹$ 27,427Public Health Solutionsâ€‹â€‹ 618â€‹â€‹ 994Corporateâ€‹Â 35,416â€‹Â 36,979Totalâ€‹$ 56,632â€‹$ 65,400â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Nine Months Ended â€‹â€‹Â Â Â Â SeptemberÂ 30,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023â€‹Revenuesâ€‹â€‹Â Â Â Â â€‹Â Â â€‹Specialized BioTherapeuticsâ€‹$ 119,371â€‹$ 223,870â€‹Public Health Solutionsâ€‹â€‹ â€”â€‹â€‹ 370,677â€‹Totalâ€‹$ 119,371â€‹$ 594,547â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Income (loss) from Operationsâ€‹Â Â Â Â â€‹Â Â Â Â Specialized BioTherapeuticsâ€‹$ (1,978,464)â€‹$ (2,227,430)â€‹Public Health Solutionsâ€‹â€‹ (165,660)â€‹â€‹ (26,639)â€‹Corporateâ€‹Â (3,582,878)â€‹Â (3,306,000)â€‹Totalâ€‹$ (5,727,002)â€‹$ (5,560,069)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Amortization and Depreciation Expenseâ€‹Â Â Â Â â€‹Â Â Â Â Specialized BioTherapeuticsâ€‹$ 2,859â€‹$ 2,979â€‹Public Health Solutionsâ€‹â€‹ 476â€‹â€‹ 496â€‹Corporateâ€‹Â 1,430â€‹Â 1,489â€‹Totalâ€‹$ 4,765â€‹$ 4,964â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Other (Expense) Income, Netâ€‹Â Â Â Â â€‹Â Â Â Â Specialized BioTherapeuticsâ€‹$ (22,397)â€‹$ 17,696â€‹Corporateâ€‹Â 470,189â€‹Â 60,341â€‹Totalâ€‹$ 447,792â€‹$ 78,037â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Share-Based Compensationâ€‹Â Â Â Â â€‹Â Â Â Â Specialized BioTherapeuticsâ€‹$ 62,210â€‹$ 82,281â€‹Public Health Solutionsâ€‹â€‹ 1,823â€‹â€‹ 2,982â€‹Corporateâ€‹Â 110,235â€‹Â 143,813â€‹Totalâ€‹$ 174,268â€‹$ 229,076â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â As ofâ€‹Â Â Â Â â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â Identifiable AssetsÂ â€‹Â Â Â â€‹Â Â Â Specialized BioTherapeuticsâ€‹$ 45,674â€‹$ 272,099â€‹Public Health Solutionsâ€‹Â 2,387â€‹Â 3,976â€‹Corporateâ€‹Â 10,428,918â€‹Â 9,521,251â€‹Totalâ€‹$ 10,476,979â€‹$ 9,797,326â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContentReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events Â Subsequent Events NoteÂ 8. Subsequent EventsAmendment to the Pontifax Loan and Security Agreementâ€‹On October 8, 2024, the Company entered into the 2024 Amendment to the Loan Agreement. The 2024 Amendment reduced the conversion price with respect to the remaining principal amount outstanding to (i) $3.81 for the first 501,648 shares of the Companyâ€™s common stock issuable upon conversion and (ii) $4.23 with respect to all shares of the Companyâ€™s common stock issuable upon conversion thereafter. The remaining terms of the agreement remain in effect without modification.Sales Pursuant to the AGP ATMâ€‹From October 1, 2024 through November 1, 2024, the Company sold 229,078 shares of common stock pursuant to the AGP ATM at a weighted average price of $4.72 per share for total gross proceeds of

approximately $1.1 million.â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (1,719,381) $ (1,662,702) $ (5,279,210) $ (4,320,835) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Principles of Consolidation Principles of ConsolidationThe condensed consolidated financial statements include Soligenix,Â Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation. Operating Segments Operating SegmentsOperating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: Specialized BioTherapeutics and Public Health Solutions. Cash and Cash Equivalents Cash and Cash EquivalentsThe Company considers all highly liquid investments with maturities of threeÂ months or less when purchased to be cash equivalents. Contracts and Grants Receivable Contracts and Grants ReceivableContracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for credit losses has been established. If amounts become uncollectible, they are charged to operations. Impairment of Long-Lived Assets Impairment of Long-Lived AssetsOffice furniture and equipment and right of use assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment.The Company did not record any impairment of long-lived assets for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023. Fair Value of Financial Instruments Fair Value of Financial InstrumentsFair Value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on SeptemberÂ 30,Â 2024. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.Fair Value valuation techniques include a three level hierarchy based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).The three levels of the fair value hierarchy are as follows:â—Level 1Â â€” Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.â—Level 2Â â€” Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.â—Level 3Â â€” Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Companyâ€™s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.â€‹The carrying amounts reported in the condensed consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable, accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments.The carrying amount reported in the condensed consolidated balance sheet as of SeptemberÂ 30,Â 2024 for the convertible debt is its fair value which totals $2,059,309 and was approximately equivalent to the face value of the convertible debt at SeptemberÂ 30,Â 2024. The fair value estimate represents a Level 3 measurement in the fair value hierarchy.â€‹A roll forward of the fair value of convertible debt to SeptemberÂ 30,Â 2024 is as follows:â€‹â€‹â€‹

been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants. The Company also records revenue from contracts with customers in accordance with applicable accounting guidance which requires an entity to recognize revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of this guidance, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of this guidance, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Certain amounts received from or billed to customers in accordance with contract terms are deferred and recognized as future performance obligations are satisfied. All amounts earned under contracts with customers other than sales-based royalties are classified as licensing revenue. Sales-based royalties under the Companyâ€™s license agreements would be recognized as royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue. Research and Development Costs Research and Development CostsResearch and development costs are charged to expense when incurred in accordance with applicable accounting guidance. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs. Share-Based Compensation Share-Based CompensationStock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of oneÂ year (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then 25% each subsequentÂ year for a period of threeÂ years. These options have a ten-year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within threeÂ months, unless otherwise extended by the Board.From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed under the Companyâ€™s 2015 Equity Incentive Plan (the â€œ2015 Planâ€). The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestricted stock to the Companyâ€™s employees and non-employees (including consultants). The shares issued under the 2015 Plan are registered on FormÂ S-8 (SEC File No.Â 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificates reflecting such shares reflect a Securities Act of 1933, as amended restrictive legend. Stock compensation expense for equity-classified awards to non-employees is measured on the date of grant and is recognized when the services are performed.There were no options issued during the three months ended SeptemberÂ 30,Â 2024 and 2023.The fair value of each option grant made during the nine months ended SeptemberÂ 30,Â 2024 and 2023 was estimated on the date of each grant and recognized as share-based compensation expense ratably over the option vesting periods, which approximates the service period. Foreign Currency Transactions and Translation Foreign Currency Transactions and TranslationIn accordance with FASB ASC 830 Foreign Currency Matters, the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency, the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statements of the UK subsidiary are translated into U.S. dollars and consolidated into the Companyâ€™s financials, with related translation adjustments reported as a cumulative translation adjustment, which is a component of accumulated other comprehensive income. During the nine months ended SeptemberÂ 30,Â 2024 and 2023, the Company recognized a foreign currency transaction gain of $575 and a foreign currency transaction loss of ($3,046), respectively, in the accompanying condensed consolidated statements of operations. During the nine months ended SeptemberÂ 30,Â 2024 and 2023, the Company recognized foreign currency transaction gains of $2,257 and $310, respectively, in the accompanying condensed consolidated statements of operations. Loss Per Share Loss Per ShareBasic earnings per share (â€œEPSâ€) is computed by dividing loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Included within the Companyâ€™s weighted average common shares outstanding (basic and diluted) for the three and nine months ended SeptemberÂ 30,Â 2024, are common shares issuable upon the exercise of the pre-funded warrants as these pre-funded warrants are exercisable at any time for nominal consideration. The following table summarizes outstanding instruments which were not included in the computation of diluted EPS as to do so would have been antidilutive:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of SeptemberÂ 30,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â Common stock purchase warrantsâ€‹ 1,467,581â€‹ 408,640â€‹Stock optionsÂ 56,427Â 12,843Â Convertible debtÂ 75,710Â 1,172,645Â TotalÂ 1,599,718Â 1,594,128Â â€‹ Use of Estimates and Assumptions Use of Estimates and AssumptionsThe preparation of financial statements requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates. X - DefinitionDisclosure of accounting policy for change in accounting estimate. + ReferencesNo definition available. + Details Name: sngx_ChangeInAccountingEstimatesPolicyTextBlock Namespace Prefix: sngx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for deferral and amortization of significant deferred charges. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredChargesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2 + Details Name: us-gaap_ReceivablesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContentReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11:

http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Schedule of fair value of convertible debt A roll forward of the fair value of convertible debt to SeptemberÂ 30,Â 2024 is as follows:â€‹â€‹â€‹

https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3 + Details Name: us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRatio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4 + Details Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=sngx_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_SubsidiarySaleOfStockAxis=sngx_AtMarketIssuanceSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sngx_PreFundedWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sngx_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sngx_ExistingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=sngx_HybryteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=sngx_NationalInstitutesOfHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) shares Sep. 30, 2023 USD ($) shares Sep. 30, 2024 USD ($) segment Sep. 30, 2023 USD ($) Summary of Significant Accounting Policies Â Â Â Â Number of operating segments | segment Â Â 2 Â Impairment of long-lived assets $ 0 $ 0 $ 0 $ 0 Adjustment to estimated accrued clinical trial expenses 375,000 Â $ 1,300,000 Â Requisite period (in years) Â Â 3 years Â Option vesting rights Â Â 25% Â Expiration period Â Â 10 years Â Foreign currency transaction gain (loss) $ 575 $ (3,046) $ 2,257 $ 310 Number of options issued | shares 0 0 Â Â Convertible debt Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Convertible debt fair value $ 2,059,309 Â $ 2,059,309 Â Termination benefits Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Expiration period Â Â 3 months Â Directors Â Â Â Â Summary of Significant Accounting Policies Â Â Â Â Requisite period (in years) Â Â 1 year Â X - DefinitionAmount of adjustment to estimated accrued clinical trial expenses. + ReferencesNo definition available. + Details Name: sngx_AdjustmentToEstimatedAccruedClinicalTrialExpenses Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionEstimated period over which an employee is required to provide service in exchange for equity-based payment award. + ReferencesNo definition available. + Details Name: sngx_ShareBasedCompensationArrangementServicePeriod Namespace Prefix: sngx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity based award expires. + ReferencesNo definition available. + Details Name: sngx_SharebasedCompensationExpirationPeriod Namespace Prefix: sngx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + ReferencesNo definition available. + Details Name: us-gaap_ConvertibleDebtFairValueDisclosures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of realized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossRealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionDescription of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Fair value of convertible debt (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Debt instruments Â Â Â Â Convertible debt repayments Â Â $ (686,436) $ (7,000,000) Adjustment to fair value Â $ 72,463 (260,933) $ (387,537) Convertible debt Â Â Â Â Debt instruments Â Â Â Â Convertible debt at fair value as of December 31, 2023 Â Â 3,260,934 Â Convertible debt repayments Â Â (254,256) Â Adjustment to fair value $ 0 Â (260,933) Â Principal Repayments Â Â (686,436) Â Convertible debt at fair value as of June 30, 2024 $ 2,059,309 Â $ 2,059,309 Â X - DefinitionAmount of expense (income) related to adjustment to fair value of convertible debt. + ReferencesNo definition available. + Details Name: sngx_FairValueAdjustmentOfConvertibleDebt Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncluding the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_ConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of principal of debt repaid. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_DebtInstrumentRepaidPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Loss per share (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Securities excluded 1,599,718 1,594,128 Common stock purchase warrants Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Securities excluded 1,467,581 408,640 Employee Stock Option Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Securities excluded 56,427 12,843 Convertible debt Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Securities excluded 75,710 1,172,645 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Accrued Expenses Â Â Clinical trial expenses $ 951,029 $ 1,993,784 Other 412,206 424,218 Total $ 1,363,235 $ 2,418,002 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Details) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended Oct. 08, 2024 Apr. 15, 2024 Jan. 03, 2024 Oct. 31, 2024 Apr. 30, 2023 Dec. 31, 2020 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Debt instruments Â Â Â Â Â Â Â Â Â Â Â Â Outstanding principal Â Â Â Â Â Â Â Â Â Â Â Â $ 1,010,934 Repayment of debt principal Â Â Â Â Â Â Â Â Â Â Â Â $ 686,436 $ 7,000,000 Â Change in fair value of convertible debt Â Â Â Â Â Â Â $ (72,463) 260,933 $ 387,537 Â Convertible debt Â Â Â Â Â Â Â Â Â Â Â Â Debt instruments Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, face amount Â Â Â Â Â Â $ 20,000,000 Â Â Â Â Â Â Number of tranches Â Â Â Â Â three Â Â Â Â Â Â Interest-only period Â Â Â Â Â Â 2 years Â Â Â Â Â Â Interest rate percentage Â Â Â Â Â Â 8.47% Â Â Â Â Â Â Unused line of credit fee, as a percent Â Â Â Â Â Â 1.00% Â Â Â Â Â Â Outstanding principal periodic payment Â Â Â Â Â Â $ 1,000,000 Â Â Â Â Â Â Repayment of debt principal Â Â Â Â Â Â Â Â Â 254,256 Â Â Change in fair value of convertible debt Â Â Â Â Â Â Â Â $ 0 Â $ 260,933 Â Â Convertible debt | Maximum Â Â Â Â Â Â Â Â Â Â Â Â Debt instruments Â Â Â Â Â Â Â Â Â Â Â Â Debt instrument, face amount Â Â Â Â Â Â 20,000,000 Â Â Â Â Â Â Convertible debt | First tranche Â Â Â Â Â Â Â Â Â Â Â Â Debt instruments Â Â Â Â Â Â Â Â Â Â Â Â Convertible note Â Â Â Â Â Â 10,000,000 Â Â Â Â Â Â Convertible debt | Second tranche Â Â Â Â Â Â Â Â Â Â Â Â Debt instruments Â Â Â Â Â Â Â Â Â Â Â Â Convertible note Â Â Â Â Â Â 5,000,000 Â Â Â Â Â Â Convertible debt | Third tranche Â Â Â Â Â Â Â Â Â Â Â Â Debt instruments Â Â Â Â Â Â Â Â Â Â Â Â Convertible note Â Â Â Â Â Â $ 5,000,000 Â Â Â Â Â Â Convertible debt | Pontifax Â Â Â Â Â Â Â Â Â Â Â Â Debt instruments Â Â Â Â Â Â Â Â Â Â Â Â Outstanding principal periodic payment Â Â Â Â Â Â $ 750,000 Â Â Â Â Â Â Â Â Â Amount repaid Â Â Â Â Â 5,000,000 Â Â Â Â Â Â Â Â Outstanding principal Â Â Â Â Â $ 3,000,000 Â Â Â Â Â Â Â Â Fair value per share Â $ 5.60 $ 10.88 Â Â Â Â Â Â Â Â Â Repayment of debt principal Â $ 154,840 $ 99,416 Â Â Â Â Â Â Â Â Â Issuance of common stock associated with conversion of debt (in shares) Â 27,651 9,139 Â 36,790 Â Â Â Â Â Â Â Convertible debt | Pontifax | First 36,790 shares of common stock issuable upon conversion Â Â Â Â Â Â Â Â Â Â Â Â Debt instruments Â Â Â Â Â Â Â Â Â Â Â Â Reduction in conversion price as percentage of closing price of the common stock on the day before the delivery of the conversion notice Â Â Â Â Â 90.00% Â Â Â Â Â Â Reduction in conversion price Â Â Â Â Â $ 27.20 Â Â Â Â Â Â Â Convertible debt | Pontifax | Conversion price for First 501,648 shares | Subsequent Event Â Â Â Â Â Â Â Â Â Â Â Â Debt instruments Â Â Â Â Â Â Â Â Â Â Â Â Conversion price $ 3.81 Â Â $ 3.81 Â Â Â Â Â Â Â Â Common stock issuable upon conversion 501,648 Â Â 501,648 Â Â Â Â Â Â Â Â Convertible debt | Pontifax | Conversion price for Remaining shares | Subsequent Event Â Â Â Â Â Â Â Â Â Â Â Â Debt instruments Â Â Â Â Â Â Â Â Â Â Â Â Conversion price $ 4.23 Â Â $ 4.23 Â Â Â Â Â Â Â Â Â X - DefinitionThe total number of shares that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesNo definition available. + Details Name: sngx_DebtInstrumentConvertibleNumberOfSharesToBeIssued Namespace Prefix: sngx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe period during which payment on the debt is for interest only, and payments of principal are deferred until after this period. + ReferencesNo definition available. + Details Name: sngx_DebtInstrumentPeriodPrincipalPaymentDeferred Namespace Prefix: sngx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the reduction in conversion price. + ReferencesNo definition available. + Details Name: sngx_DebtInstrumentReductionInConversionPriceNotice Namespace Prefix: sngx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionRepresents the reduction in conversion price to percentage of closing price of the common stock on the day before the delivery of the conversion notice. + ReferencesNo definition available. + Details Name: sngx_DebtInstrumentReductionInConversionPricePercentageOfClosingPriceClosingPriceOfCommonStockOnDayBeforeDeliveryOfConversionNotice Namespace Prefix: sngx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of convertible debt. + ReferencesNo definition available. + Details Name: sngx_FairValueAdjustmentOfConvertibleDebt Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the number of tranches. + ReferencesNo definition available. + Details Name: sngx_NumberOfTranches Namespace Prefix: sngx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_ConvertibleNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments applied to principal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data

Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=sngx_FirstTrancheMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=sngx_SecondTrancheMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=sngx_ThirdTrancheMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=sngx_PontifaxMedisonFinanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=sngx_NumberOfFirstEquityInstrumentsCommonStockIssuableUponConversionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=sngx_LoanAgreementAmendment2024ConversionPriceTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=sngx_LoanAgreementAmendment2024ConversionPriceTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholders' Equity (Details) 1 Months Ended 3 Months Ended 9 Months Ended Jul. 23, 2024 $ / shares shares Jul. 11, 2024 $ / shares shares Jul. 10, 2024 $ / shares shares Jul. 09, 2024 USD ($) Y $ / shares shares Jun. 25, 2024 $ / shares shares Jun. 20, 2024 $ / shares shares Jun. 14, 2024 $ / shares shares Jun. 11, 2024 $ / shares shares Apr. 22, 2024 USD ($) $ / shares shares Apr. 15, 2024 $ / shares shares Jan. 03, 2024 $ / shares shares Nov. 01, 2024 USD ($) $ / shares shares Aug. 31, 2024 USD ($) Apr. 30, 2023 shares Sep. 30, 2024 USD ($) shares Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) shares Jul. 08, 2024 $ / shares Class of Stock [Line Items] Â Â Â

types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sngx_ExistingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sngx_NewWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sngx_WarrantModificationAndNewWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=sngx_PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sngx_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=sngx_CommonWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=sngx_AtMarketIssuanceSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=sngx_PontifaxMedisonFinanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Details) - USD ($) 1 Months Ended 9 Months Ended Mar. 31, 2020 Sep. 30, 2014 Sep. 30, 2024 Sep. 30, 2023 Jun. 21, 2022 Other Commitments [Line Items] Â Â Â Â Â Contractual obligation Â Â $ 355,867 Â Â Lease rent per month Â Â Â Â $ 11,367 Fair value of shares issued in connection with asset purchase Â Â Â $ 50,000 Â For Period From November 2024 [Member] Â Â Â Â Â Other Commitments [Line Items] Â Â Â Â Â Lease rent per month Â Â Â Â $ 11,625 Research and Development Arrangement [Member] Â Â Â Â Â Other Commitments [Line Items] Â Â Â Â Â Contractual obligation Â Â $ 205,000 Â Â Asset Purchase Agreement [Member] Â Â Â Â Â Other Commitments [Line Items] Â Â Â Â Â Cash paid to acquire intangible asset Â $ 275,000 Â Â Â Issuance of shares for assets (in shares) Â 771 Â Â Â Fair value of shares issued in connection with asset purchase Â $ 3,750,000 Â Â Â Issuance of common stock pursuant to At Market Issuance Sales Agreement (in shares) 8,151 Â Â Â Â Effective price per share (in dollars per share) $ 614.40 Â Â Â Â Ownership of company outstanding Â Â 19.90% Â Â Maximum | Asset Purchase Agreement [Member] | Scenario, Plan [Member] Â Â Â Â Â Other Commitments [Line Items] Â Â Â Â Â Contingent consideration Â Â $ 5,000,000 Â Â X - ReferencesNo definition available. + Details Name: sngx_CommonStockIssuedEffectivePricePerShare Namespace Prefix: sngx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of lease rental per month + ReferencesNo definition available. + Details Name: sngx_LeaseRentalPerMonth Namespace Prefix: sngx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of ownership outstanding stock. + ReferencesNo definition available. + Details Name: sngx_PercentageOfOwnershipOutstandingStock Namespace Prefix: sngx_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of contingent consideration recognized as part of consideration transferred in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_ContractualObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementScenarioAxis=sngx_ForPeriodFromNovember2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=sngx_AssetPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Maturity (Details) Sep. 30, 2024 USD ($) Contractual Obligation, Fiscal Year Maturity Schedule [Abstract] Â October 1 through December 31, 2024 $ 55,617 2025 162,250 2026 46,000 2027 46,000 2028 46,000 Total 355,867 Research and Development Arrangement [Member] Â Contractual Obligation, Fiscal Year Maturity Schedule [Abstract] Â October 1 through December 31, 2024 21,000 2025 46,000 2026 46,000 2027 46,000 2028 46,000 Total 205,000 Lease Agreements [Member] Â Contractual Obligation, Fiscal Year Maturity Schedule [Abstract] Â October 1 through December 31, 2024 34,617 2025 116,250 Total $ 150,867 X - DefinitionAmount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_ContractualObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationDueInFourthYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationDueInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationDueInSecondYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date

(rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationDueInThirdYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of contractual obligation to be paid in remainder of current fiscal year. + ReferencesNo definition available. + Details Name: us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_LeaseAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Operating Segments (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) segment Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Segment reporting Â Â Â Â Â Number of operating segments | segment Â Â 2 Â Â Revenues Â $ 130,440 $ 119,371 $ 594,547 Â Income (loss) from Operations $ (1,865,236) (1,779,056) (5,727,002) (5,560,069) Â Amortization and Depreciation Expense 1,589 1,589 4,765 4,964 Â Other (Expense) Income, Net 145,855 116,354 447,792 78,037 Â Share-Based Compensation 56,632 65,400 174,268 229,076 Â Identifiable Assets 10,476,979 Â 10,476,979 Â $ 9,797,326 Operating Segments [Member] | Specialized BioTherapeutics [Member] Â Â Â Â Â Segment reporting Â Â Â Â Â Revenues Â Â 119,371 223,870 Â Income (loss) from Operations (834,654) (705,753) (1,978,464) (2,227,430) Â Amortization and Depreciation Expense 953 954 2,859 2,979 Â Other (Expense) Income, Net 1,409 1,683 (22,397) 17,696 Â Share-Based Compensation 20,598 27,427 62,210 82,281 Â Identifiable Assets 45,674 Â 45,674 Â 272,099 Operating Segments [Member] | Public Health Solutions [Member] Â Â Â Â Â Segment reporting Â Â Â Â Â Revenues Â 130,440 Â 370,677 Â Income (loss) from Operations (57,611) (24,819) (165,660) (26,639) Â Amortization and Depreciation Expense 158 159 476 496 Â Share-Based Compensation 618 994 1,823 2,982 Â Identifiable Assets 2,387 Â 2,387 Â 3,976 Corporate [Member] Â Â Â Â Â Segment reporting Â Â Â Â Â Income (loss) from Operations (972,971) (1,048,484) (3,582,878) (3,306,000) Â Amortization and Depreciation Expense 478 476 1,430 1,489 Â Other (Expense) Income, Net 144,446 114,671 470,189 60,341 Â Share-Based Compensation 35,416 $ 36,979 110,235 $ 143,813 Â Identifiable Assets $ 10,428,918 Â $ 10,428,918 Â $ 9,521,251 X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=sngx_BioTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=sngx_PublicHealthSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46

R35.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions 1 Months Ended 3 Months Ended 9 Months Ended Oct. 08, 2024 Nov. 01, 2024 Oct. 31, 2024 Sep. 30, 2024 Sep. 30, 2024 Common Stock | At Market Issuance sales Â Â Â Â Â Subsequent Event Â Â Â Â Â Number of shares issued Â Â Â 14,883 14,883 Weighted average price Â Â Â Â Â $ 3.93 Subsequent Event | At Market Issuance sales Â Â Â Â Â Subsequent Event Â Â Â Â Â Number of shares issued Â Â Â 229,078 Â Â Â Â Weighted average price Â $ 4.72 Â Â Â Â Total gross proceeds Â $ 1.1 Â Â Â Subsequent Event | Convertible debt | Pontifax | Conversion price for First 501,648 shares Â Â Â Â Â Subsequent Event Â Â Â Â Â Conversion price $ 3.81 Â $ 3.81 Â Â Common stock issuable upon conversion 501,648 Â 501,648 Â Â Subsequent Event | Convertible debt | Pontifax | Conversion price for Remaining shares Â Â Â Â Â Subsequent Event Â Â Â Â Â Conversion price $ 4.23 Â $ 4.23 Â Â X - DefinitionThe total number of shares that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesNo definition available. + Details Name: sngx_DebtInstrumentConvertibleNumberOfSharesToBeIssued Namespace Prefix: sngx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents the weighted average share price for shares issued. + ReferencesNo definition available. + Details Name: sngx_WeightedAverageSharePrice Namespace Prefix: sngx_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=sngx_AtMarketIssuanceSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=sngx_PontifaxMedisonFinanceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=sngx_LoanAgreementAmendment2024ConversionPriceTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=sngx_LoanAgreementAmendment2024ConversionPriceTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{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

(W7TDVG:7K[YLA.7S;I=OEG\)A]UBLU]_#[3%_?\] M[P^7&K"ZY=Z91FHS5%-134,U'=4,5#-1;8YJ%JK9J.:@FHMJ'JKY9ZW23*5(MM6KJ !TS1+4(U6)42U M1;7LVLQ7\ZPL(!&[&TC<_""LM_OVZQ? 1WA!4FZ&: MBFH:JNFH9J":B6IS5+-0S48U!]5<5/-0S4>U0&SVB-PILC28R+6+9D-TW C5 M8E1+4"U%M>R6^:H^?;KL'9&Z>T?>/& MRI]^%N3!Z0%K&E6"G+ M..:3N_5'RF1<[QZ?HZ-: MJ&:CFH-J+JIYJ.:C6H!J(:I%J!:C6H)J*:IEE%:-/:F,O>["CUY'4VBSQUE[M^YMW_<8P=$ 5U314TU'-0#43U>:H9J&:C6H.JKFHYJ&:CVH!JH6H%J%:C&H) MJJ6HEE%:-
>7*6@^1N];C)>"NUY$=VN(A-6_ ;L0=6LV!:AJJZ:AFH))G-4 MLU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RRBM&G=E)TCQY8T'=?/GS)664 MZZ1ZIQRIS5!-134-U714,U#-
/&N54V1BO:L*'=)"-1O5'%1S4-YV$&+4O=2#@73I MOF:I[."0NCLXWIXAVY?'4=<3!NW>0+49JJFHIJ&:CFH&JIE2\T[\(F$D>50/ M&;2)5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46UC-*JL5?
6>4@_6.?1JQ*X M>Y#>(8@6>:":BFK:6:L\VJ362*BC(QJH9J+:'-4L5+-;9NJN/E4..J2+:AZJ M^:@6H%J(:A&JQ:B6H%J*:AFE57.M;.>0NMLY^.+@[@%[9QS:W8%J*JII4O.>
M=5D>UA^(HJ.#&JAFHMH MU&QD&V5P:!^AHT<-$"U$-4B5(M1+4&U%-6RJSM2-HKB2:7I1]R=^E'5UM5]ZI](PO59JBFHIJ&:CJJ&:AF MHMH$4-J,U1344U#-1W5#%0SS]K5MBIT5
O5;%1S4,U%-0_5?%0+4"U$ MM0C58E1+4"U%M8S2JK%7]GC(M_5XW!1U:'W'6>M]JT('5%%-0S4=U0Q4,U%M MCFH6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEJ!:BFH9I553KJSO*+Z\Z>"NUY%=
MI]D[[I3&44 C[L@!55334$U'-0/53%2;HYJ%:C:J.:CFHIJ':CZJ!:@6HEJ$ M:C&J):B6HEI&:=6X*WM%Y-MZ18J4F^7+(N7$CI1#NT10;89J*JIIJ*:CFH%J MYEF[O1ZV@*+>PX:YVGR-
6#E334$U'-0/53%2;HYJ%:C:J.:CF MHIJ':CZJ!:@6HEJ$:C&J):B6HEI&:=64*\LZY.ZRCK939-?C#FWKD)LW;S?B M#JW@0#4-U714,U#-1+4YJEFH9J.:@VHNJGFHYJ:-@&HAJD6H%J-:@FHIJF64
M5HV[LM!#[B[TN-C5^/2\._[D(!RVPL>#X"QV?^0'X77Q:+'.]\+'+[L\OU3X MT3UR[U!$"S]033UK;X]/ZX\QT= 1=50S4,U$M3FJ67*S16 X4:3:YZLV.JB# M:BZJ>:CFHUJ :B&J1>T[4OVYCZ:
(]*:IEE%;),:6L\5"Z:SR@'+M61-R] M%7TS#=5FJ*8JS3O7164RJ9T7UJ!!=50S4,U$M3FJ6:AFHYJ#:BZJ>:CFHUJ
M:B&J1:@6HUJ":BFJ9916#J=VBB[2.HIJ*:AFHZJAFH9J+:7&FILQA)P\&H=DQNM2TH3I5: MG:"-;IV#:BZJ>:CFHUJ :N&M^TATVSX2HUN7H%J*:AFE53-,*C.LNY_DXH'> M8G,O%"/>?
7[>W!\3[>71,L4!W7*[V>3+4T?Q*>B>GG]?KY:%\#G?K39?6C-+ MNG;)R:?N#>T=1,T!I4%M9U31(354TU'-0#43U>8M4Z6,%5&<-O(%[1Y!-0?5
M7%3S4,U'M0#5P@N[4J/R/T*'C5$M0;44U3)*JZ9562NB=->* _O2ZNI'E*U MJT<+=6]T[^1]#B@=N^B4>GBAO2.HIJ.:@6HFJLU1S4(U&]4<5'-1S4,U']4" M5
M1+4*U&-425$M1+:.T:@R6O2/%EUTQJ.T6IT!;K,_))):R*8"QRKXBR7?XU MW^WS'T;+,>%"[[--$MWV.:A:JV2W_')/! MJ/;OX;0L)4G2>%*; +=E.442)X/Z]00>^B)\5 M0+42U"-7BMLD?U<_-)>V3
M/Y%JCV1++TS^>%@#,^I%5- (RZ(/I;OHH_\;^=4C&[0.!-5FJ*:BFG;6AM4W M]6%]#]1;EI.5B3BJO[4W%RO>VD5I6'JW1VL\4,U"-1O5'%1S42G>-QY5+W<_!):PV]_+RQ>NH[4>]#9#-175 M-
%334?5;': M"5\7Z^>\-=W0@Y4FZ&:BFH:JNFH9J":B6IS5+-0S48U!]5<5/.49G%6!R/ M1_4[^WUTV #50E2+4"U&M0354E3+;MB5*MDV+-L\AC_8YE$_CEMN-\?++([1 M5RQZG__>>AS7/5K?
I$.U&:JIJ*:AFHYJ!JJ99ZUR8JSVZ>D<'=%"-1O5'%1S M4JJ:BFH9J.:@:JF:@V1S4+U6Q45 VSLMICV%WMH6UW^>K+1E@^ M[W;Y9OF7<-@M-OOU]T!;W/_?
_YPZ;J2;KEWIJ%M'JBFHIJ&:CJJ&:AFHMH< MU2Q4LU'-0347U3Q4\X?-UAUQ*,FUX_P '31$M0C58E1+4"U%M>SJU%<3K6SI M*+[L2C0W/PCK[;[UMJSN57M'%JG-
4$U%-0W5=%0S4,U$M3FJ6:AFHYJ#:BZJ M>:CFHUIPUBJ7U@VE\502:QD8HN-&J!:C6H)J*:IEM\Q7-;C*'HYA=P_'FR=3 M1_G3SX(\.#VJ4VD-,K1D)5FJ*:BFH9J.JH9J&:>M>KMG/5NWSDZIH5J-
JHY MJ..BFC=L%J)(\GRGDP&H_I'AB#NTYP/5-%334MC)4 MI/JGEVCEI'ZK9J.:@FHMJWK#9TR#)TF@Z'2F-NZ9;%AT/I]/Z2;+F8G>2-)4*
ML/[,VA!]+1&JQ:B6H%J*:EG+C,G*2!F/+]SM/"J[.D;=71UO3Y+MRR.IJQG3 MS?;-&%2;H9J*:AJJZ:AFH)HY:MZ@?\P895* F1D=UD(U&]4<5'-1S4,U']4" M5
M1+4*U&-425$M1+:.T:NZ5+1^C'VSY>'K>'7]R$ Y;X>-!^'CEUU^L7>X>^3>T8BV?*":M:JAQ'5=W<-'5%'-0/53%2;HYHU:O:* M#"">*)%8GRT8'=5#-134/U7Q4"U M1+6H?4>]MZW%Z*
)]J6HEE%:-<>D,L>Z M2SF@'+O67-6]%;TS#>WQ0#5UU'+'N3*I]ZMJZ* ZJAFH9J+:'-4L5+-1S4$U M%]4\5/-1+4"U$-4B5(M1+4&U%-4R2JN&9%GV,>HN^[CR.)G]*0O_!0>":%$(
MJLU0344U#=5T5#-0S42U..!99^WMP?V=.*T_ZM)&!W50S44U#]5\5 M0+42U MZ+8=*48'35 M1;6,TJII6!:%%%_^T"%CKR<]=P_2.]Q(;89J*JIJ*:?M5! MU"V+M3Z(&MVX.:I9J&:CFH-
J+JIYJ.:C6H!J(:I%J!:C6H)J*:IEE%9-NK)# M9-3=(8(\B+I[C-[AAA:*H)J*:AJJZ:AFH)J):G-4LU#-1C4'U5Q4\T;-DI@+ M#Z)&QPU0+42U"-5B5$M0+46U[)9]J9IP95O(J+LMY)]*$'6WWSO=2&V&:BJJ
M::BFHYJ!:BJS5'-0C4;U1Q4JOFC9@'%=#*NU5T'Z)@A MJD6H%J-:@FHIJF779KZ29^.R=V3++FX[N>AW:=9]JXTYI' 8TXHX<4$4U#=5T5#-0S42U.:I9J&:CFH-J+JIY
MJ.:C6H!J(:I%J!:C6H)J*:IEE/8][M[O'_+\,%L<%A]^>5I\R9W%[LMJLQ?6 M^>>"'_P\+D)EM_KR\K-8?OTZSOQG?#[]G#8/IZ^?,@7]_GNN$#Q_;[>'E MF_>%_VV[^^,TQH?_!U!+ P04 "
"\@&A9S\C$)R " "2! & 'AL M+W=O.F/# M0K1$_864H6JQ4V'B>K3\TCC?*6+7;V3H/:HZ@3HC\RP[EYW25I1%NEOYLG!;
M,MKBRD/8=IWRCY=HW'XAIN+IXD9O6HM7LBQZM<$UTJ]^Y=F3ARRU[M &[2QX M;!;BR_3BP&0CX \\1X*)997BE19>+<"Z,Y6S22 MU(1FSE#>Z8)P*/274'H=>&)L&TZA#XUT'W%"$9_LY
MT!*?$H%X@;ORFR2G>?S0NZ.B==\+(KJ_9VMNVZ^OUBT>9;OF/M.UGS"GY9RV;' M.OC:;!9MW7!6Z)MVY0*'8;S8,5'-[F[TM8?F[D;NNU)4_*$)VOUNQYIO'W@I
MGV]G:'X\$5LMIVZL+B[]=F&KWCW>_W0P+?%T4LA=KQJA:R"AJ]O9_?H_9)F MZ@9M\1_!G]N3SX&"\BCE5_7E(X_!Z>SX M3'7CZ>>#]T\:/(!Y9"U?RO(/473;VUDZ"PJ^9ONR^R*??
^8#H$CYRV79ZK_! M\V ;H)WW9R-]P,$>Q$U?]G+\- G-P ?NPWX.$&/+Z!.FX@PPU$ ^TCT[^ MLH[=W33R.6B4-7A3'_38Z+L!C:A4&E== [*N*^[6\]J@*3P(H!/K2Q%P3KX
MLNK@'V2K:P.Y#I:LW0:?(-M,]^7WT,_O[7?]PL.GB\>*SN[_] M!<7AOVP8K^3L##$](J8^[W>_0IDI9=O:0/9WQOI.54N>[N813C*,PIO%TRD MBR$E.$Q)=#0\"RXZ!A=YTW%?
_!>63S^':PDE)Y=5+DH>5$/4ZJKZG*O9O5=+ M0%2!?&T2HVLF\4K.SL8I/HY3[$WB_4XVG?@?ZZMJ54 1A*?D0E^P(>_=12<) MHTDGG8)/"$ M6]N6*]# -
J5@CZ)T\RSR2I*+05[)V_E8&$F"O$RNU';7@+#HH6\:IL0)D"T7 M3PPR;<4?64@"$D/'4WAJ1X$D,D?ZC#! ?GGPT/":B>+ MGWDLMOR!MH3F,E0 M9/IL6H.?RH (1W$Z"7YJ-
RHYK)=OUEBG4F&>9ED\ M"=9F%]+(M=B-ID!^47&?YW*O)G7-OJD!U&ZF _5+A?@CT>[H-3TE\CN(8^&(4J\T0IPA1Q[S&AN^QG^]_ M/30N:]V6KQNYL_8NUO"G7#V/40**$HWCMUDF201JV@'
\#R&7EKX)"J@OUB535!QCI^7JO M-H6"9]9H4K1"HI;&DR(:CG<4+(8IS:(4.=0<-OR-_?Q]#@I($&H:;W+1:F#> MX"WT3*,0)>/R9C$D.'/5"T/CV$_CG_UR]%62%-:7N>9S&EM5B,4S"T-
V_84/SV$_SMGJ^M11(M:_Q3-D\BE&$T*>=30Y*$69RZF-/P/O;S_D_K-<]UN\E?\E[P Q5QU9%J5&J9 MZP_\SSU(K=*9BBFYTRB:Z!>+682P8WD3P__$S_\]": +&RVTQ(6ADRG7@X"A
M(1H';S&IHEHE1!<2O"I:N@ /6!8](ZI*32=($T@%(0LKCBGGIY3& M*!IO2UD,$2%1]J8.'$8M M>* MS@?#* /B5P8/LNK$FKT,./YKML]:JVW1PY8H*+2Z@1HA:ETLB>DY[1&L0S0S M #BB.!HK-
G]P;ST>-8*"^@7%1^MNK]IP*D&!B[6 GP M*PJA1@/0JZ4]U]*C M%D =UI/5J7[.$63YMUF1XBCDZ!&8U" _QOC""[[3IR5F+TH7HQ40,K2E'U4_ M-\!VYL__C$NG.)TJ$4H<.(T&H7X-
\AM(VD:MUKYC@NE9[HO^D)B-=KFL"*?: M(B7I]/1[:@9:*W7T$]3H#^K?:/AC:.AVLH!IEO?G#_->W0ZJ1!^E6$.?;@HD M()
[B=+R]Y8_AK-OUR.(P=0])XV\Z(W^G%4^]'"A0HURH_R6'5^^BT:N^KW M M;^>HC0BB_LV,E=XZCU3O':T00]8N@U_JZJ=:WD[1VW4#O6KG;?,S-[CV0M0,8[" MR2LU-L,D3=+)ML'BY'7
'6\V^BW)-M"B:D&#K\%E^"Z!!=/T;TSV7SI9ZY<.'V77R9W^N.6LX(TR@-_7 M4G:'+^H!Q_=6[_X/4$L#!!0 (+R :%D>GPS]010 !(Z 9 >&PO M=V]R:W-H965T>5 MR6XF\8XGF_L5(B$).R3!$*
]VE]_3S<>)"7:X]VJ]:U*QA(?0*/1??ITH_7B MSC1?[$8I)[Z6165?'FRZL3%-*AZ_-^LC6C9(YOU06 M1XO9[.RHE+HZ>/6"KUTWKUZ8UA6Z4M>-L&U9RF[6A7F[N7!_"!>^*37&T<7
MCEZ]J.5:W2CW6WW=X-M1&B77I:JL-I5HU.KEP=7\V>L3>IX?^+M6=[;W6=!* MEL9\H2_Y2\/9B20*E3F: 2)/[?JC2H*&@AB_!'&/$A3THO]SW'T][QVK&4I
MK7ICBM]U[C8O#RX.1*Y6LBW<)W/W087UG-)XF2DL_RON_+/SRP.1M=:9,KP, M"4I=^;_R:]#[X6+V3TO+,(+"Y;;3\12OI5.OGK1F#O1T-,8C3[P4OEM'"MQ;WK'UQY#
NW3W*PABO_1B+>\:X%!]-Y396 MO*MRE0_?/X(\2:A%%.KUXL$!;U0]%<>SB5C,%B<%GG,XQW_1XOT8YR, MCT'.\FT&M5Z:\3\5.53<43MU'BA^\N%HO9\S>FK&6UY6_S
MYT\%7I>BD$X=6@=G%4MMZHV$6V2J=3J3AA_TK6Z,7F:.2N<$0Z(DXOC(7BNK8*?67&W4?C]^%^:OQ)M50*G M2I7SC)52^51\AM!!6D$HY/ _AKPSP>/%,FK!JC7@Q-EGXJ967@S(^5H;#-'(
MFA=B6=+K=EGH3'Q0LG ;TE-+"K.#R4@U_/GJL'!=N>F=>QHI32W]-&9.]GD MHL8F5DY[?29M^?W"_GW8OFZV3F'NDXO%<_%$DA)K0_JF#XU6#M_]*EFR =S\
M^+_'L[DP0.$M/%!!)K'9UJK1F:Z$-;ENRZ<3[&QE().H-\:9?(NW\9SC=6P% M%A+VRT%HTOO86*QKF$<._(+*K%PI<:NM7A9*%(2,L(N&QO[S;J @%GK9*5, M:\7GPPS0+
(IM"2E**9Y$0_S\YN=HA5/Q.PTNUXU2/*J,24/^][%ZA4LY"/9 M!JE<7,&TLVT:Y]W'JV3,T"6]]$5ML1E6KRLV7E.1<9!4$M*]%O\T!O?C9(_4GQT]%KJD"(^>SP;[LJ MZ2V7PPYL%\S#*WJ^B$ZP
@IL(0_%3+'V2X2A\I&.O<,4EZ>G5\^!RAE'K-Z9^&3M7:2 MHFQ,!(MM4@[E)>422HCI8.VI)#8>(9C2+S8S1XQFI6AH[P1,HI 6(*D#*[(R M"]&WH\!=VHD).6C[-W-B8LG#84504+"WZ8/KP#L9
Q(3O!X%2HR1AO/[+/MPIV(KN1!% _!M78W(5 JZPPH/2R#'[IRP*KF"R#_)Y@0DY4;C$;9 M8\PQ(_&\^O%Z]UXBHDQPKJ8_3J^/KH+^Q(^%64+<:SAS1:E";YPNGJU=\%6I MF"&R<(6AV)<$X4FNR?
96(/V4Z%!"!O8)E8:/#R39GMR #'%MZ.0I$TR%S4Q> M@7UA,(?IX"(%LH:R L<.9.X85']/<7),X!.^L'LJ.,[=1F<;'WUZ$^SN 3 : MJ%INV7>[?\:N)#TT6}UW&(E&5"W0(8D*.JW8-
#BSF9Y'0$>YWZ"U)ISQ$ M"&))A[L*3C,P=.5!LA* 9LX0<[B(Q*$B0N07#Q!!%@?;9JYH X\KP;OI90YX ME)\C"#&8TEU,N23""?2P;<-[MQ<:8Q2W;4:<%-22MV9)M2VRCEZ4"2F%X IW M!IKC
R>"/P=MNAT!BQ]+\0+NOR()L<_XF)/[KT+1@O3KM4O"C*.'%YH%#;F> M-RF/7_ZN=M$B@$H-Z"I%J&Q#?(?]LP_CJJL,+O_ FY/Q4^K;^UKHB6\#E)> M=R'F$!UU(:AAT@%]&4Z-
L".3_5V^ESGT^!#VI.-Y<5,I^H^QGC^'!H@5%D9E M97(YML.AP'[7QXP0B4[%Y!0.0;E3,(:!)C!HK@JYG?B\X MM3<7F{$7F<09-3 V^J52%'L0$1H/MKLK6/H:HH=FFE$!F;F.16IIU* Z#D15
MH8"5?" 3DQ-D MT*<7(0MZBP7XJ>$\U?&_4AN@$U>1\0?3MG\\F9R>GNU.//7P\.3Y%C@^(MO%>:E%/<2^S9?8 !=2CAD7-T>%UVN7"P)5^ABR&C7Z7SF7\ Z2Y1V*TBM74H M-
O:KJJ>G)Y/9;";B88S:*^TFKF =05,7J^0]"M]--F&6)M- M'9.4C\ 9 MM]<^R[B$#@=IU'Z60;79X%)^W%7;>/X15MC5,_R">%MO9:.IWA]5%\6?B@_F M#G&EF80*WN-Y70B?HQ5B^M+?
JNFH#>S5G0GA0^:G*_ "IUF,4G<,$;K;'VCG> M5=9#3 !^]#DW33P!Z"5[HHY9#//#4H6-M2:KAPZ4L!ZU%IJP#$^_0^_ #45 MU7ZF@EQ,<7[Y-9T(53#.LILNOHR8WNO9F6.M:T5%^
M9WAPQSLZ"Y5VH!BHO8!2$8";=3R.RK#IELVH1Z,?8YLC]3AZBHJXU](C./?8 M#!C_^$J[5$FFMEZH%\I.R?D4(?D 50G MEXV' J _,C,]B3X_/)Z? NOO'2 T'N# ZA,?0\Y/%9/Z@,)PBA;H+G;+O+-'G
MS11*SJ8G,^$!:DQ\ICM\]$2'^E;UWIQ-9XOPYJ[$#[S%\]6$7R2[3T'"8^QT MNJ0^"1\<@M<2[5Y19 B'8;& HF/M@U("+X@S'HO([U+%)>3/<>O#^]Q9$M1Q MQX<9P\!T,C_3>=]2T7 -I)%25/09
M& MV?0DS7!/B'"$#"X2#^HR3P.ZBD_X^:G M[H'] A,T]Y<62[T,?L2Q"=2-(\G&%#E7F'JC??#7N@'&BV+JJ[:\#;\',2'S M=721F^04;[Q9WK!#I(Z*G7>[R?I^UGG6P*N&\G 6% ^Z9#],]=8!@7NJ8T
, M3H$'=2/VY!GRQ2?Z*Z>T/!?O::I8$8YCQ=1G M=Y(A %DX IC0Y61V?G&?4]8[;C6Z(++G.VXW)M9%A8=UWYZAHT7/GIF0CUG> M?ASM->:,[PM"/1\-5ZX8=+WU=^V4ZJO-06X$O0G")Q[="
M2CHF5UGKD\#2UPY92"R/N$X.;I/"5O$4J1+2JYFZW=5<7 MZ,ZZ$_QTG5R>DV^CG*$K/O?.0'F^[;+\]ZDZ.];@^/'JX;;%F'>%0X_'-C^^ M__GJYL-"9!"+VX <52K'&Z*X.9%;<+A1[E:%]C*B/'F-
K72I$)K$YCZ_-#]/ MYGNNZ/ 1@\1T/X@1;MUM-%4E7#C=*Q6?H$SZYQBYMED;...@O8B2U91LE29/ M=;0$M8-N.DFOPGIR"J*>*^7C-J^]A=S9I,E..3 MRHBV=[?-F-4A_N/R7PVL M4T
@;ZO<]"&%+24@VX\T/P* $CDA\X<0K^^>:5;0^Q>G8[8=51F M9Q^_55S[^BONYK@42=)O?TW4J&OHI37XILF,<"UUCW_J.L=V>G>,?OC4-0LR M*LCH'U%)^X8?VDJ?=*VF3_?; ?F@=- U>L?
5UZ6*YQMYOW@F 6UTRLS.[;O; M?-7Z>?3D)%BW7])1L=L7+M+QW'$EX8E]_JS$;/1HQ^@C++C77?N X5XBV6+# M?:#SE9J-@A'SFN\W8M_DCXSYENMLM'P*$>P*/7GV%")"%B##,?
ZG/G@QQ)&?,@_+V)>MW1U1CMW-!O&*SC6GTXE:## M"OKIU* UDDZ"2]-KW24T'/1VA!.97C5RK]WWB4<8A_A=00\9. MZ@9K#M',HASMM M4UC\-W_QL5_>7H?
4,G5(T^M'W(%C2)YR"[7OOZ7&,' B@:D:+06.*#/L0!(MT-P=RO?/J?LM/?M=P*%R>'1?U3 UH63^A)9.N:M#](6;\BF;CPFY,6=&K:-> V^_4_VTM7T@\&ULS5MM MN?:W_S:F$Y]W-2-?
W.R[KKMU^?GOER; MC?83MS4-WBQ=N]$=?K:K<[]MC:YXTJ8^GTVGS\\WVC8G;U_SL ?MV]>N[VK; MF/>M\OUFH]O'=Z9VNS[6G?TX/SMZZU>F7O3_;)]W^+7>:)2V8UI MO'6-:LWRSSD]4V?
O.;<)D<+"QC?RO/P8Y9!.NITR^'H=Q2W=M58Y>V MU$VG;LK2]4UGFY5Z[VI;6N-?GW=8CV:=EX'V.Z$].T+[I?K1-=W:JV^;RE3C M^>?
@,S$[B\R^FWV2X+W93M1\6JC9=';Y"7KSM/DYTYO_6S8OM"\/TR9C^MIO M=6G>G,!:O&D?S,G;K[ZX>#Y]]0G.+Q/GEY^B_K_D_-.T?W*=4;.)^OPUU/O6 M-J7=UO@3HV]=X_&FTFQW/Z^-
*ATTH/&FHK_"._Q8VD9CGJZ5[_MMYY!4IU M7QEUCV$KT]B/A;IKRDFA=%,IBP&[M:OK1_ZYT;^ZUG;@<=> GN\7WE96M^!I MHFYJT,T8MTUGVM)MMKK!;-
F^9$S)=JQNOV4UXM=8/1BV,:92I+2R..=48"! _D M8>NTPS+?X43]?6M:S1*Y-RO9Q?#(QT>Z-:>0O;"/TB!/7\!M0U%B.^-NVUANE M%_"?V*@MUYB_U2!E,FG91KPQB=>"\
(.VM5[41G5KW=$3\Z#KGADGQP?&5WVM MV7WAY>(1XW F:VN6RB4^*U-:=K4;_9MI"^7:].@,CVC(JG7]ML#R_*:B1VOH M;>>4KFM7$I.0D>O;$HI 3\%>4]D'6_5TQB((.4>PY;WQGF@0-
V"#]]24AL1! MC\+X*6O0;3@WI@;JI B!=SHTG*U3WFOZ MSI9R_ [?!?18?6]TW:U)[WHF.E&WVJ]Y!/_Q[>^]A5SYQ*62!G 4^M)"FJ- M, #MK"U&TSX?
C._D_'<6U^9J/336BJ5TZ]88M1$O"8'#@$B_H7M;"\&MR6*P ML05.BS@P P<3LC+H;1E4^&]08?SYP90&0T@7QN]7\KX=WC/;GM59;\06JAY: MUKJ->H)N=['6?R,CN2GN^^96IEH\ZN?
[F[NOBGDN'UGN[[C0\3H0N%4,=R+ M8?=MBQU!Q_&0#DP.WKH*RE^I'DZB!8MVL^A;S^Y@6&G4('*Z,S"FA:UK$1 1 M@N9M#<=XM7(/IFUH/M0.T*)A)P6=HW$L;785$"92U:[N:
M#0:09PD#G; #;$GYZ\=~:+[.U9?UA+SS4H$7]JV[#>005/R@\]RMV!_Q=0DCYKE$386CIY9X[\:P%V"BHKV MQLKJ>_C:,-Q\+(VIO,R!0F\D6O4L2FBIJ1P*\)R162YQ_A!5U[5VT7?BBU%.
MD$^<75J_B=[-?-R*BAVC!T_-[@ R:L8R2CR+VMF672Z@V:>_"=#M257J\A^C#.AP@__3R!"-(#HVN'\D@&C@@[^%> M8%1PCJZ&N>9!^M>^.NCU*U8'VD!+>OCX/QYYW*"X6-
I$@\@;?:TA1(IHO07J M6$!I(ZCD@?AC/E'?D0C^&??Z70]^=W!Q;2\N/1L#\6;!G3U;2S;(*KYS?5T% M93;,)2D(4A'RF4ETV)!X,X(C.!4Z..OAY0CA4,1L, HNDOS1@%C2N0&L_09" M0
N(;'+GCN8U\9H#]UE:1'TFJAOH'-0"SST 6WL'3OVG ..8<_D$A8RS;;OO,B-N>A*:]N@6E%"QC:$[?#+\!1X=W@1XR M70HN446@ AH4.LWJRB$XWVQ"7J7_\!9M.0;0U6]*+H0PB2EV0? MQ_U"9!
<;<2* D[TQSW"+JDJN\&DV.%$HU^2/8:P2#&6X<$97%G%YIVY&!P8 ML!)-)M#2<3HW%N$LB?!.3LT%&J+-$TUB.ZP8W4#"<83D?PME M+*]06?APQ#H1T,DW\-4ELA>7\$5FE55E\
P/"8>":YG9E@$1CA@.\1HT8 E],NU>,M0O.GV#B?']I2RA<=1+ S0 M:P8!1YSB/6 U0%Z'%Y2B(\")E0C&C,SMBSTB<^9E6^L2$!AH@'PS%N1XR4XJ
MFR(NK&5*OM^2XF,44MML3+!3'3/I49K/R/:C*?LAMN0,[.O;/.G;+P=6Y2&#F=0GD(=AI%@QMN-I?0_ M#R&4Z2!+@?V#WV:,P9A@=EZBZM@H6?P?D=)DJ#*P*L>Q=!4>9^
M)_<849QTV!&9=I_A;P4U2(2U3Q#LX):#"PCJ0$ #JMh>96T)!?8C!K,P$E?; M,G:2NDLNQ0!]CNVZX1*&K$]JDL%=UK07KWPHD42,RPE$6D#]}#K /2[O!%[^ MR+J(&7"P! (C\(X^()0T@L-
0E%O3PI'\(4TGOJ?S5U+Q&R=T/@2GP=:.E 07 MNN:]24>"$^I8A-DO@119&>)@B:.@FH"AD^?W%1V8VP8QE"0"@B;Y^%05W.K' M]*0E/TWI&KCU4H:,3ZF&A\1)'8:V>53/R,5WS&GV-
,!:5(U=@3[9(7_K_^ AP'9I?[X;U_HEL7G.?+^ M7V_R/W734Q)C'L[HKZ;_#:G#NV!M\2'91-(O3G$VP1*2[*5G ESP24+#RS+H MV@7O8SZ0!Q H+W:VUZFO_'1!P._)OCC@.[>'C#& T2^A"!GSZ?
%R_E#]NQT M=G59S*Z>/QL]XV'ST;/GU\^+R_EHW.!)ALTB]!,NN@,(87'<<@EY5';76]MQ MX@XD#+Z1S"(FKW1= !FY)?467$>)T]"OHD.)>8)MJS.*G<#$QF2X/.%[1#@' MV-:%S &NY
QT.7OBI.0Q8N!FQ49?19YMY%G*WK1V+6E//B'@/^JQ=503QJ'B M\O HPTW[JQ4A4 AY(B1E,8D(?HTG:U=3] Y (E((3:RJ+R-Y7556D=2<@%4H@X*O'FMR
M=8I*,W*T2:D658A.H<654Z=56EA'A%Z@?#_5*FQ&%7&-II*1&6O)C$;!S(LX=%,F/ ^QZLBZ\9DTE!$)IL;+$4+=""F!"?!B<#0 MCT^;Q#9&6IW%00 ^ M+AD*OEY8&CNPZ+VJ[2)881-9Z*N8,P)
H-G1\NS]&PAV?##8R#@[)N^^#]YR:,]%6'= B4.9+>KZH;L? MA_?Q5&N/C*,B7E!D(+O;D%<,1:S0OI5R=)M=0?FD9T]G0-)/-\$D79!+%2GX M4?E +AH9HZ,E:)5[7QI\)WFC=HZXE[E-R4N/0
M+2U!+"$NT45<.,)P7A-U?W"J+)WI;(}40@*'O * "XVCK"V>[5^H/2;5"%9. MX;DEY2#_FZ)]#-N\$^4(R_/=-7:[=21T\:YA4MV= F'M"-U+!(7Z0K/H'7I M43H&:=^WH>^1G0X%,\P9FS'-C]
<9XK;I0LMXWX16,W#]30:N)1O^< Q[#YEA M=G\H()[@22.4^L,P9')\=3ZDO5CI^](TC*4;TF!NBV40>[D'@T!S<8L+<'AX;I4 M155&*@5PE9?=*W]#?C/8,R74 ML=!
0.:C:4NZ"'1^#ZSH.OJZO&,7"\]D8L0*8]/)'OU &].EMD%XF7,+,)=N MQ],U185EVH[OES#$BKDNY6) 'X\X(77:F%VBD^H LHEE3\I/E&+V$M_.\Y3 ME'S,K"()-;OZC[@]WM9@1PV_XQ"47>-
C]O;YEFR17J6L([+ >86&1V[.>&IM MEP("R-TYJA;Y<"4CWF E_T ?.60\NW80*G?#PB8*,3,]C,V'JM@=DTANX3O" MG1/Q$Y%%QC.P%YNCV.'&: %ORU?$V*'O2%_,QTY2X9#IO7.ZI0H%7^"T&\&!
M^'_LC_@T.,F'B89[C[]5*ZJPDPWEH7Q\F W75)$&Q3917W=RT\B/NR'+$3 1 M]YM"TZ'X,)M>7/$=6WC N]B>4>]KR/"4QM/ V?05#Z.G_/OB5;B9D1YG>6D$
M=*P]=,4O5\%BM%UZ4PPQ649JOI.Z/VSO3E/B?U *+DZXYFQX[>A"9D%'<^0\XZVIK#Y I3Y'G5<2)*.JWHNV4)&5*PJ=21> ^*(U^?FP M0+P7I-6]*>-%YYN2Q7_Q+:=#'BHNI.)"Q\F?
+E@.C/!L31M\]B=O MU!:AU0&OQ+" !,,@@6L($? $\ W =49U1=H0EWHDPDCCX^#+-A$1Y-HQI.:8 M1XPWC@)N/:X(!,M+11ZYNRW?)W)^FHMD?..:+8DX@@1\LXX*44"B$&""JK# MFP
0<\@X0OHSU#?IWA2/A4/\ZWK'-PR%N1@5Y?SIYW&%U?%BXLJ%Z\F('* M%=(FZD%=%%1-=L?L9U$C_G@J',3!F\.I MH)15J7%$]!54=@\Y5$$2]9C'*]!RTRI^Y4-5H;3O MR:%O%
<^SSTTW!ODE?53+Q)I.OCQ-3]-WNS?RN>HP7#[Z_1'I*=6D:[/$U.GD MQ=6)?)D2?W1NRQ^O+ES7N0W_2?T%T](O%\Z;"S\H 72U\QO_QM02P,$% M @ O(!H640N$I6" @ *08 !D
!X;"]W;W)K&ULK57;SK0O2+O:^G2^6YDNA1[73&-Q+4QJZI?%IC)0XK+_*. MCENV*[5U!.FRH3N\0_VMN9'&"GJ6G-7(%),<)!8K[R):K!,;[P*^,SRHP1QL M)ELA[JWQ*5]YH16$%6;:,E S/.
&J\H2&1D_.TZOW)("A _C^P>7N\EE2Q5N M1/6#Y[I<>3,/U&3N4EU31=2G$ ::,-FYVX5!W:B&/<7L]=EF:5&9Q. M+[),[C&']T=SS0K5,M*U:X%6<>P;AG(&PQSN!9([Y[_C J.DED:.D M-3E)>(?-
"."+0!Q*2Y 1?W*<8.[[X'U)L&9+7&6QA+%1#,UQYYN4KE _HI6?O MHDEX?D)?TNM+3K'_E;[3#)^%1HA'\)()SM[-2!B?P]<2H1"5J4#&=\ 4T&,5 M@BA F]6-
J!0^GRP@FIZ;@(X*.ZI%S_6_1W/=&NLM2G?G1^\E9ITS\O^ V(=A M/S%LS%&PC%:@)3-??)GX>YB/(S\D\X$G\N?SV)_.DM[WQ9R [*TD(CX))\\V M27P2S9X/4VBSU9
OGL0^B<<#'_&3:.:'(7FI_;7W$@S*MT:Y5 MW'O[/GC1EO]S>-M$KZG<,:Z@PL) P]%T[(%L&U-K:-&X9K 5VK06-RU-+T=I M \QZ(&PO=V]R:W-H965T0%FMBW:0WM==&_;SXK-
Q+JU+:\D3R;WZ_M0LAUG-@EV#RU0W)?$+R)%/B0? M4K[=:O/>YD1./)=%9>]&N7/UJ^G4ICF5TDYT317>K+4II<.MV4QM;4AF7J@L MIDD474Y+J:K1_:U_]L;\WB_X3='6#JX%>[+2^CW?
M_)C=C2(VB I*'6N0^'NBUU04K AF?&AUCOHM67!XW6G_WOL.7U;2TFM=_*XR ME]^-EB.1T5HVA?M5;W^@UI\%ZTMU8?VOV(:\6PDTL8Z7;,"L*!45?B7SRT. M X%E=$(@:042;W?
8R%OYK73R_M;HK3"\&MKXPKOJI6&B)F MT5@D43(_HV_6NS7S^F:?Z5:0FA^7X@)X96N9TMT(&[)/-'H_JLOXLOHYHQv- M\JZF^3GM)VTZ+_4O[4C,)X*EQ8\5_E,J5V08*>#EH(+!J+9_%

MUZSZJR^621+=_*1E)1ZZA?YA?//-1+Q#^(VW 3N75NBUOSE;*4-4@%+9*F;REF_WV"O7B+VR_M53U(5DIU<-4Y4V@T4L0[15(W% M#6<$2Z>(K0(81!/QL'8M\,<<"HB#@JV#*8Q;;10
K"7H17K@5P1*K:5BO\2' M1AIH87FYXY#Y2%[$?5!(N)4EWBW#T.'5RO-(D![-A'_QJM]5BDK+*4-)^9J M!S0+117#8)L5F^>4++ Q?KKL:3.%LRR^N@$2UI)#H#5>LL\ML@43>P./:H,6
M9=QNXK,UFMV(=[4.!J:%MFROUPQ#.&NL]/W@,"M[Y =I$#(L-('GY]@GDH>W M]FT%6&9&;OTC^*D1^J'DHL=0.L$[.;0TD36&S0KQ4PR!B!-1!DYM82BXB#B3 M?'GERIQ2W+"W:U7TCI*HT TSTZ"XZ[I0]?26:S$?WI0Z$^,L6UWI;1BT"UP3E>ERM9 "!JN6/' M'&F: >V Z"0 ""]KKMVP19I+LZ&6-JMVUO'$Q7OMUW4E$-C';P.UF%W\'@S2 M>;O8E5GGRE$T9&$U%^.3REI0>@+TW
3BULTF#]S<]7H.;M:D$!B04+Y];[(/ ML8NK132.(DBR]50HS$/2M46+:U4V)6)BF:J>""W#3<3WC6':".GQPN!N9\4 MON?X41/;PU\/89MX7=88XC'W$)\63ZSX6GTCXJ,ONS!WW!/4G> VYE3F0J?3 M]Z(EK4R"CPCX4;B%HS!MQRKDT$YTC%.&!@:;78ZOKB-AD2%D/\D"96WC.Y+G ME,%>OH[91?AXD5Q-T+!?[LL,_F=LQ>$BR?TM9-D>](,98]]@P@+$L:E*G:FU MHFQ/$K]@%I
54FLG9EW&]2-."RT7U1%@6RP/^,^;H;L)!6*U-FY0V\CR/+P\@#CS<$O; &<+)U?AR$7\NQ(O)9?0_(QPOYN/E/-I#?(1MA^3-.NF9 MH6N4S?=T#]HQ:@.2+([,U.!G]!@F+V](8VIMZ73/;]?VSWOV\
0^8RXU'U->R:5QNS\425P;4>P+W?FT18# MC]'/"BC9C M^3"2(H0:0]W:Z#)HQ(@:6O)+%$X8CI6*#P2 V. *OO+X1)4-"%M=J,RW.G1H M1_V(SH.O##/88*0,)R2VM>*C0SM6AG
=@_[D>/5+ZG1[U]Q_ZH#U8I2:?SQ* M'9 !QO[0$Y*J'R_F?U&W'HXZ;>>^F$V6\8N3X"**QY?SY9_604/[G$]0R'^S M[LDI2.LU&\.6 1\1>FDX.TR.??Z8#KXZE80AE+^ML9U .'R ZI_VG^\>PE>K
M_?+P[0\#/VC*XF"QAF@TN5J,A G?T*-T[7_AH7SA=.EO\Q)9F1X =ZOM7;= M#6_0?]2_P-02P,$% @ O(!H6=^7C(C\'0 PB(!D !X;"]W;W)K M&ULU5II<]LX$OTK*.58NTJF*>]P%!]5=B:SDZE*
MUA5G-Y\A$!*P!@D% "5K?_UV-WA*LJ+,U%1YOE@F"31>7Z^!]J_6VCS:A1". M;/4JL]>=A7/+=^?G-EZ(E-M +T4&3V;:I-S!I9F?VZ41/*%)J3J/PG!TGG*9 M6ZNZ-Z]N;G2N5,R$_>&V3Q-
N=G<":77]SQ12\?EY7$BY\U*B9Z1,V"><N85E'{}).WYYX"H@A65L.ZB M@P(?Q#)@_;#+HC :')#7K]3LD[S^GU332QGLEX()\LXN>2RN.Y !5IB5Z-R\ HT4L?? M?=4;A9<', XJC(-
#TH_&>%C*9^T$&P:L*>WMJW'4N[@L9++W.DTA(1Z;5@,OTHXD3#.EOE4R9CIV4P8F$ &XUE2 MWM@K(E_BY<4@ZO8.@F'<@:Q:)] G%CCP]2@8A '98A_A(FE%8V) M81!&?N(VP
.3<#6V%,9#[3+X4P[C4R683%.12.Z$VI#NXFDI8<@,^(MM!#>6 MS8Q.F8-5I;4YST!N L,]$*<=5VQNM+6PIHZ%2,AA_-:3IP.=M"&)&60!2SU'"3(>< @ M3J13 %32")F9XQP%IAD<5R"6Z;
MU$F'P:C ML&UQ3X6]X= 1X!:*PA[FWF'LRN\Y\&BO M=X0FO=Y%-VR5[1>IRN 85:!"O'Q5HO 85:+!WT&5X1&J7(3]/YHK?P'^40!6 M)?Q0BWK'N*+?ZT;#/^2)OP3^X"2AXU[Z9:(_BIV@8HQ>
(OJH?P@]E6;@K/&X M?RSXVW_>LP>N8.3MW B1"GA$.YDU-23P+ >; CYO(NH'DWY=C?WNI3I('+,? MD1EN-K*BLU+99V>3-9,9R$3[\!JFYXRDYPS6(B&>#KIV+*:8 J[HLM"XH@W
+X2O)*1YC>MD0BP!(IG',M!#PH M,B .VW"*S^;6C\UR.O'6$D&YJ2A(T0\AG2'WI4Y8DGON6LAX05@L2^F(=[_ MGOL#EY>0\@OLI&0JG8^ (NAW%UP ^11"B,T@J^B(#V4?HB?!]> 8TZ7@
MD4SSM&"G*7:)=P#!::8$$;#[K8!&JX#Z:#.)AW\GG?*XL9TE,NL!XS$$^T'8 MM9-("00,+9F#+-]!ZE='M*WN2=5NV7*89ZN&RX(6G2\@CS+--+#&W*,H(Y7(
M_AD9WC:HM\TM*)"@(65<6IXZ+1A\UK>S-N12OW AH72 #QBJ8=L=%T-CB;S\ M6;&+]QH"""UPQ\#E'9I0FSE/KB$Z[8+Q8Y>3,:>[(/Q0;WNZXD(Z!JHTH6(HS M;.P8":=MGN
9%6K%@F=0E&36Q-768BW!4I4.#:;E1D$-H (!8+](F+?Z2G. MXZ,N.YF>MOS%05+AVF?]JLVG_X7T;-(D^>(D/JW"#'$T>@I[2Z_%Y)3D"T@
M/X7,R+0GB9>3YBY',U0S"F%+;K"PM9E^WPH0E"L)C%WUOD@8*"RVHG-;Q05? M^:H%JX.X.1IUMQ?J4^'U,!C7#;A;$089:H.W<[=F:N/+Q6[CL.H;\A67BMI^
MB'@&^IO:,3^L5914I4W\%@I+\3=?88%8DSQNEY-_%5NM2?>8>M(04-NX(NC? M? /]N9+RX0EJ(EKOV[ZV]#-N:,O:);1]B+HM-!0\E&K5I@--&W-+J*7Y ;"B M7W[X@$6;2(/-7I$\>R)JMR%WB)
[X$#N@%I O-M+>]4%6D ;L \=-1\:^5IQ6 MQ^H6*1M(>[G:Y;:]X1A5X5AQ>7/#AM>[-H/DL+"!0?G44Z\V7K&V]'A[G8N@ MT;7^V![M*5.4>V)/A=)] \5PRK-
'83SQ*U!6L9D0^Q8(@T&=5QDQ#)MQ6]^,;*UE!+T? MR_RK)+O0!G920(M@A#((VFD]JP"E)UN(XQB+,Z*8YS(A6QJA>*/,["K3EK#G
M$%>_0<*M"FW(RTA(&L5X7[@"$0(D@W5/;=H*0##J>2;_YUD?2GU0H"KKR,,9G MHZ]&Q94NCYC'>Y#3CA?*2J,H&SF'Z%.5#4 '/1=^& ECA N#5M9.@^V8*U$# MKQ66I
W:819H6K*$WZY24'/"X: [&H];RK;+Y7&&.>QC?QBMWF'EU*G'P7>* MQX]G#_%"8STNU#U#/L01X%*AZARC5TQD35@3SK7XLJI^X<19(K&&P^B-% KW M&PO=V]R M:W-H965T7%;
M%I4[G^3>UR?SN5,YE=+-3$T5OF3&EM+CU6[GKK8DTR!4%O,DBM;S4NIJ%^879[71X(E+*9%/XCV;W MACI_5HRG3.""7[%K]RZ@437.F[QWGI3C 2.HT<$DDQA@"7:WBH*5
MKZ27%V?6[(3EW4#CA^!JD(9QNN*@?/(67S7D_,65*4OMP;)W0E:IN#*5U]66 M*J7)GK@+ENXY!&X%^() '(G?JY22@_EYS!ML"_I[;M,G@3\1/5, M+**I2*)D^03>8O!W$? 6_\;?
V4,.MWC+A_&X9DY<+16=3U 4CNP-32Z>?Q>O MH],GK%T.UBZ?0O_GT7D:[A?C2:QGXDG8\&91+8TLQ(=-H;>2Z\>)SSFQ9"VK MO/# KNO4B M0VV*/4GK!#J-
<(2OT%]HQ0V@V@JYM42MLIWVN:BE]179UH&F@KAUVG,0QRTU!TPY(6A*P #1UY'K1U.A#"E'1"K[!3::0K-*RT\& MEMEKSZ6W $ MS1HX]L_B>+I8'\%N:YIM/I9L
9*C<4@S#'#A,D\P>ZWU2A[DBWA>'H84 M2K WA4EL;<4\893!!96SW4-\VZQYLQ>7VM2Y1$,'LIJ)'YY_=YPDT>GX2UB* M3W\|8*)E8*Q:JN!Q*A19C_G'-LAJJY$$K1G(%M0$W!K2Q?*0"!5Q8(FE F63
MLAI6D"+[*U.7'8'MUNO!M/CHU FW!U'DM1+Y'AJT@GXH2QOE40%7-8G:TXA(LX$'(7XYG M:9I0K*$Z8,NVI8UL[K[2J-7?,'U(6'03PC>4VPII\KFTJOC;H!$@I:.*LXD8U
M8BA4#BJO<2&W'G3B49WAJ*&'H*<&!>S1,V^X(T!G)?DH(K+&-S:H"%G^/F"A M*J+[32N0?SR-5X_2#P8.$DJZOF.%T$N5:[H);?2NIYT<:$D)AN& T9-
T'$VA8'B>GK!H\=1TG:XJ>+8*]GT*7WV^>M>VH*H)A8RU M1USIW+WOT8XGCBQ4TU9*TPZ%2E"643C9]=F$Q%G'R]DR"OTD*)EVR1CZKV1& M2L
(;A1X]GEO\K==8R:NK;E!':5A@S,H;4M\V&7U70 [WW\R5G,W2D=C]:\ M?O6RG8TH"QY TG.ON%][?;YU733X7\HO%%K:.,^&H+*70VU,AO"@,.7IU76[9$:^VF\/[83*W M];4A4! :64A[91MF
MC<9!V.ZKU%%P MF-N&BN/<4R[]C8WK YWX9?M%?!N>WN1QAS9:IS7"\H@&F&(3MIS1__B31TN MA!OC<;T,CSGN\V1Y [YG!O>$[H45#/\AN/@+4$L#!!0 (+R :%F&4C=< M@@4 +L4 9
>&PO=V]R:W-H965TLJSPM[T9LZ55X.!368Z5 ,;2E+J D8FI39@A,A!KM*B-[RN:??5\-K,7986^KY"=I[GJOIQIS.SN.G1WIKP M-9W.G"<,AM>EFNJ1=G^7]Q7T!ALIXS37A4U-@2H]N>G=TJL[X>?
7$ Y)!<(V MOI&WY,&8[[[S<7S3(UXAG>G$>0D*FD?]5F>9%P1J_+>2V=LLZ1F;WVOI?]6V M@RT/RNJW)OLW';O932_JH;&>J'GFOIK%![VR) .#R$I/9^A\MEG-IW$/)W#]3
MKYA!@SPMEJUZ6N'08(C(0:V8F"UWLN%:BW?*:>&UY59H,K/!FG^HS:UY@;E MTL)ORLA5,)H"GQM^*76E7%I,T4A/ 6QGKP<.Y/K10;*2<;>4P0[(B-$G4[B9 M1>^+L1[O\@] GXU2;*W4'>L4.-
+E)>($(T:8Z)#'-T;R6AY_EI%+&:)=A@^. M*UNJ1- TP/NMKAYU;_CZ%97D38>&8J.AZ))^I(;=,CX;IU%XB?9EH6\SC=Z: MO%3%#^0CU<'/(K=36#)((2 M8T%!Z]>:I(G*LA](66M@90?
K+E(0G<*$E8@'V^)B:E* V2-[$Q5,-UO2YK M8M/*S$M(&K8$CO0ATPCR%V2>$N8[-)D7=4Z >;K0%1CA#'HP('4?ATOT^E7$ M"\ S[/;;K-
)Z)U0V0^#P3N[:J_6MZ30GKEH+>0A#TS3B5=:ZXGGDNBA^+Q.0:763&VCZ:5"9?.WR; MOL?AH\S"B6)!=_63$6^RD0D#TR&V?@%&=-]>$> H")H4*C$'[,^U M>>0S[)]W<
:UZ4$+%\ZQWD&,X*#.&H20BQ8>+1K2+KO&G$L6B#C 19TBQB7 M$& Q'F"!Q)*S!@'B3)#ST]3OVL]0O-MK07=-V*\-\IO:\2)'DECS,&S&CO$ M.([",+23/K1D\)."
[X;8^_NK#>QH$L<"!"%L$TZH)2?6% I^!GE<[E85AIGW M=$[Z)^-X0<$GI21M!<9[;[P=:"DT'#(>@_V+^DT:)Q(3TA"Y5W*@"(+"A+#^ M+C60!!,9GU]R7J8$G9AU("G&.WV?"T[="%]@]FBQ[$"?
^AUO]AK%YU?$!0YE ML-./Y?EI^SFEZT2'9PSS.&RZ"84#42HI:1 @$EFTM?/H\Q".&@E_4PIP'+$.D"DE<&3MCC]BX6^]5?"]EYW.7RGDQ61=M7(CV,XRL']4OF;X*VU
MVIU[58!SE0Q%$QLXP)/X^"0"01)M'99# NI,''!98A&.&Z>=& >,8A8<#A// M%,J=U ;G;HB<$'.VMXMMKQ>#QH-2KJMI_6SF[]OSPBW?EC;4SE-I(Y6IHJMHU!5@0C*>
(L24YBR;B*%K.PMS*+F6Z=X I7 M!FPK)3.W%RCT;AZET=W&5U[5SF_$BUG#*ERC^]ZL#*WB@:7@$!7E6H'!)%X0"<^<9&/UM\1*%\$0DXU?/&0TN MO>'^]QW[NQ
[Q;)A%B^U^,D+5\^C:00%EJP5[JO>?< ^GF//EVMAPR L.FQ* MX+RU3LO>F!1(KKI_=M/G8<]@FCQAD/4&6=#=.0HJWS#'%C.C=V \FMC\1P@U M6),XKOREK)VA4TYV;K%N-Q9_M:@V83G.
(ZI]BV:+T>+%L_0D.3\@<#((G!QB_SN!ARD^:XH(%I M=R%'@>12RX:I6R L&BR JY[=0Q[[#*X&]A%\>XPDEC8G)@_/M=JB"8W?&)XC M-86K"6$;:N8[3H-^Z'!5>8S*>
<,$,*E;XJ+I8QU%Y@\)_9* @N?CT30%FF+! MMN3&.CA.TJ.3R11LS8@;=+D?FL] >GIN28R4)(1:.,\&;FW+-@*A;6AO3Z?/ MXTON'4U&V?B18";$?W%#E1C[2TIZE\3[)-
"6',C9<)$=@.X'L"R]&*^,\@-2 M%[SD.?/#D>]&"9*V:@WYO;^VY?L5+#]=##=7PSF@YU$/.U0,!C6ZK&C[K+%8K4H(,M>'R6G^PE_$'7SA'OF@,$N#%@]$$:YH/>BKPSBH(R?9M"0Y\#; M7;)V5
Z5T=824.>(1?#'&EK=3I*::H*$7+01_FGAH[W]JQ$4X5W MQ-\955LW;(?=X:E:=A/Z'MZ]\,5O4$L#!!0 (+R :%D V1QH@ (+P' M 9 >&PO=V]R:W-H965T2F++*EXGD+!=Q/'< :..NWR=*>/ 45C1-
2Q!W5<+ MM2JW]{09+W[GJ W!/ _<"$%#",Z-T&\(-G5R5() MO9MKGHH6!EM)5J L&^.)8#B7*8EQL!Z!+=+V-T\?%SB)4.9B@X:82GM3!Y M1=A'MYRI3*(Y2R'MX,>G^5V?ET MORN=_XL^?
W/THV+X[;7[5L]_R[5W778M%W3+F68VEA5-8.+H;B5!;,&)/GWP M!N[7KDJ_IUC\GF+S=Q([NI.@O9/@E'KT4T^%&Y;P$M#%#RYEYY^NEAA8"3,# MMM&E-_2N_)$7XNUAC;N @P$9NN08&'<
^V1X13SW&#CO 8^<4=^OP76>>.# M=E2"6-LY(%"'-TS53[3UMJ/FVG;8%_ZI-YYY'?Y8CZ9ZDOR3K^?:+17KG$E4 MP$]'&ULG95-CYLP$$#_BD6EGG8#(5]M"DC)ME5SV"I*MNW9P0-8:VQJF[#[
M[VL;0M,J8:59() M66)MIC+W524!$Y=4,C\,@KE?8LJ])'}K6YE$HM:,ZOQ0@+.=;$CL!58(&*3:$K"Y'>$!&+,@H_&[8WK]EC;Q?'RB?W6UFUH.6,&# M8+\HT47L??
0@0S73.]$\PVZ>F:6EPJFW!4U;>SDHX?26FE1=LG&H*2\O>.7 M[AS.$@SG1% V2-MK0[,"5ZK*-'.7VI>RU-$^IR=/) MQAPO 8F>)":4YV@E)>8YF&/7*O*UV<'&^6E'6[>T\
IM@AX%UX5'T$@!\F"^ M;\QZO?'DMPX'@7NH1F@2W*$P"*<#O$E?[L3Q)E=XE\J\0X=7M.&$'BFI,/M4 M=0N=7H;:[V:I*IQ"[)D/0X$\@I>\?S>>!Y\&E*>]G2(GNQ]F!@<'&;WXW-M MM"*BTO\?
0YBO"5]R& MF6^Y+7JWQ=K)UI4KML&PO=V]R:W-H965TM:R8(WK;:2NCIZ]8*? MO:]?O3!=6^I*O:]%TZU6LMZ^5J79O#P:'_D'' 1BV=*#LUU9TJ2X($//YR0(_"F;0Q _=E#?\?
$@YB9;-2=*?];%^WRY='U MD2C47'9E^\%L?E*.H N"EYNRX7_%QJZ].#\2>=>T9N4V X.5KNS_\I-C1++A M>K1GP\1MF##>]B#&\HULY:L7M=F(FE8#&OW
I/)N(*5']NUNEJ(]Z;4N5:-./8 /7MQUN)H G"6NV->VV,F M>XZY$;^8JETVXFU5J**__PPH![PG'N_7DX, ']3Z5$Q'F9B,)N<'X$T#'Z8, M;_K-?!@BWL(^'X9-BO5CLY:Y>GD$S6E4_:B.7OWPW?AR]/P
YN:'4/UJ8.+WI1*YP?U5C2KH)_<.O\QU);%/E)I M\0!:VS8"D,JN4.(!RQ:JTI\R<5_EIYF052$T%FR6IBRW_M*_FEJW8+_FPKP MFF[6Z$++&OP^%;N(V+R5F1^=&6I(GZ8BM^
+@FBB4OK6C=*R!GL,=BM\R7VKR5 J>3.=&6M.UVR M!N!'J4LY*Y5HE[*E)^I1EAVSC^PHV+?H2LG6$*]G6ZR#9"RUF@L3\"Q4KMET MK^1'56?"U.'1"1[1DD5MNG6&X_E-
08^6X'9KA"Q+DQ.2N"G3U3G$D9X"O:K0 MC[KH2-(L(ZPT :VF44U#, @;H,$T5;DB=M CM_Z4Y?C.20]# W021X<[B0XD MS(AV8Q)Z/-]_%]K16S3_P(_7FL#<+5HJ<.KJ,'DXMX8EL%?R'[
+^/&#RA4.@6@/\>N; (K^^X5]7\?WS,F& MC8Y<68M5=-#"VJS($PR=Z1J_BY^1R/YZ_Q-#RP-L?O7K_>W]F\RJ0]/JMFM9
MR+ZY!Z+&^L^>WJ&DR&#&'H(6(BXI3<1]9E.PDPJDNS,UKB:CX[9L3R&6]<+2&*W!(7&\#N)X?5!Z M[]%.NF86XZ9^-M7BY&>PKA"WP'M8?;\)H/AM#F<)%G5U!0$!:<1HTK%U,)HU
M!:RTNR,78;>Q'L,S:(A4"7C6S43[S_O4(V)C\OK@OXYXD&XK2 *66S=4$S^K MA96%7-=YM*U5#D_*#0;>'8Q[#]D70-JK@C'9XK9;L@_0(I(P4].^]:87 M" O^10![_"B)'R7SPQ'FI)%1XY\J9#R4+
BBC?6GZ> >W7+U*5>]:.P>Z-C* MACD=LQ**HQN..B@.(N,UATB"56U;ZUG76M]I4H LA.R%NI5N2.K3VDK)GAP MKFPTP:.JSZ. L]7$TH4V.(FXSGZ5#0V?#4O!^D'P L?L[='V0L_GT#92J)EJ M-
Z0]]'@.=KIS.++ZZN-/Q0/SH9+EEG2T@DUL&E@\Z#EU]!TQ\9^>6^]"Q'4/NUUW>\/#;P8JDC6X]21,9!]0DVE@S=N8KBR%5;!F9#ECA%X$"?'"NZ>BL.-[4EO0",[D6&.M:6G4K1_Y
M3J=$WC_QI>3Q4ER8"?1@(M:FT4R&VS3(AM/T[JW=IBVMRI<5XC85\S+I-*.$ M4:38#A86<=DV\A &G1PQGZ6K=+1" "$A!:R>++*P0YXI=:DK+A*EPMDE,J4]@=\#'T"(<+=:6S?.]B22
MN6#WUO*S!>ZOM8$2B32H["I9_-DU=+]_=::U893U7*Z2Y(ZP=D83?KC3TAL? M"GB=BG#MY&=F\G@5^&?!L,+:/SW_*6T.R+0'Q)*5W&03Q"/J3*2:KD@2SA1% M(9GYX;N;RZN;Y\+C]\-
WUY/QY+GXK[^!Z.#;:[4V-6=1M $$+ITE\C:$DKN< M]&._7? (J.5U2(743?[+<(FB"J;P2#8[D:]7;(T.F]-KI^CEA.8LH+5.S$Q MN#!$E;298JF6RQ-]%DX""^_MK1FG0[)ZDFLAP4'7>"PIY#9MJ-
WI<%DQSL M;R:4A,Y#1M.P3)=3.5 .PUHN>..:/;P*IS*[$)1P+KTR1M4M$(-(;%)U#[$B' <81 Z6 F80[Y,C;>+5Y0R0D.SFJ)#7T]Z[FGN;'-ML8T/II UV':ZR MYT>CH4SM3FHQ/#OILGW
W'Z&O;51@_6P^DE@'U&;0X"; M'H*)&_&GK3EVLA6\E(LN]-E'=<7%,'L^B4D2A;.D73UO7+'-A]Z!O@ZE'.8 BJ0M#!'OR0!/>H^ES6\'NYYF- MR9-ILKXQ+#[Z"MEN_RI*"S6
Q**/JB:*;Y_<%79A9.S;DQ (* M3=+UH.6Y^H<%^"N/YR0BKB MBWG;:"=[]G2 E5_'2=.%O8\4S+-Q53,69Y*4A :G-J:5T(KO)]GH MXB:;CFZ8(QNJ^$<&P/C'FXHBF:M^4OOD4*C14(+P>U^@?7I
K+#Y ;4;!L*V M0\8@RNNMJ!&G$2IKM\+^^P) U_ ?P\%TG/YZ7_] MH#MF7\.>]_^:R/^454<]QZF[H[_AL2A]=.V_Q#THD@7YSBK)PF!-[;'B#B M@H. XLO[)"7R*]]$'!KMGX8T!V[P:4<0#
(]V#DY'*4 MW4S/DV?'DXOS;')Q^:SWC)=->\\NKR^S\VEO7;0D[MF!DM!X%#ONHX/UFS<* MX0/%5O<(9)BE=U2P\VRJ?Q6D?@=*KG7+903$Y> B4FM$* M99HC3S)QZ9J:B M%"YVNDE$?-
:BZ^*$/#DB=*62+"%D& "W!D%DZ_(8&+83P.5OB4GFC98 -B!>4"^I@YIYVF!/;^$+F=RG M[)!F3:)F30YJU@=J"\&3?+#=D7VC,U\.93!YJNVZ6(@-#Z(QX40S]E4'$PH; M?;K-
G[4C9HS=&L@UW1'(R_S[FXEL*].5OB<)'SDW/A M:DJJ E&@[8N#G*T42,4UL@I;"Z]#0Q!";N%W72^N8P0 <40H$ DR>GSA0H6O?@3MYN5-):Z[DHMC6P ? M&.9[9"[?^*R+#5:V;
(QS74W_MG=M*T\+4F[,Y5K:P/Z57\)PE+@PPC/Q](M. MNS6<086(:[G"E2=86QA2VW ,/H[E^ M;WM&+FUD+KFZ?>-EB+\UV#P962'DNV;.F/%72N"Y\NV+F^DPN^3@\%8$\M5
M@9PZ45CV'W5-D-*Z:.!'V&TER]5M.'?.8=^L!X.:>9N*LD:2:?,Q6[*D M%FBKUDC,CO4S\S+I-*.$ M4:38#A86<=DV\A &G1PQGZ6K=+1" "$A!:R>++*P0YXI=:DK+A*EPMDE,J4]@=\#'T"(<+=:6S?.]B22
MN6#WUO*S!>ZOM8$2B32H["I9_-DU=+]_=::U893U7*Z2Y(ZP=D83?KC3TAL? M"GB=BG#MY&=F\G@5^&?!L,+:/SW_*6T.R+0'Q)*5W&03Q"/J3*2:KD@2SA1% M(9GYX;N;RZN;Y\+C]\-
WUY/QY+GXK[^!Z.#;:[4V-6=1M $$+ITE\C:$DKN< M]&._7? (J.5U2(743?[+<(FB"J;P2#8[D:]7;(T.F]-KI^CEA.8LH+5.S$Q MN#!$E;298JF6RQ-]%DX""^_MK1FG0[)ZDFLAP4'7>"PIY#9MJ-
WI<%DQSL M;R:4A,Y#1M.P3)=3.5 .PUHN>..:/;P*IS*[$)1P+KTR1M4M$(-(;%)U#[$B' <81 Z6 F80[Y,C;>+5Y0R0D.SFJ)#7T]Z[FGN;'-ML8T/II UV':ZR MYT>CH4SM3FHQ/#OILGW
W'Z&O;51@_6P^DE@'U&;0X"; M'H*)&_&GK3EVLA6\E(LN]-E'=<7%,'L^B4D2A;.D73UO7+'-A]Z!O@ZE'.8 BJ0M#!'OR0!/>H^ES6\'NYYF- MR9-ILKXQ+#[Z"MEN_RI*"S6
Q**/JB:*;Y_<%79A9.S;DQ (* M3=+UH.6Y^H<%^"N/YR0BKB MBWG;:"=[]G2 E5_'2=.%O8\4S+-Q53,69Y*4A :G-J:5T(KO)]GH MXB:;CFZ8(QNJ^$<&P/C'FXHBF:M^4OOD4*C14(+P>U^@?7I
K+#Y ;4;!L*V M0\8@RNNMJ!&G$2IKM\+^^P) U_ ?P\%TG/YZ7_] MH#MF7\.>]_^:R/^454<]QZF[H[_AL2A]=.V_Q#THD@7YSBK)PF!-[;'B#B M@H. XLO[)"7R*]]$'!KMGX8T!V[P:4<0#
(]V#DY'*4 MW4S/DV?'DXOS;')Q^:SWC)=->\\NKR^S\VEO7;0D[MF!DM!X%#ONHX/UFS<* MX0/%5O<(9)BE=U2P\VRJ?Q6D?@=*KG7+903$Y> B4FM$* M99HC3S)QZ9J:B M%"YVNDE$?-
:BZ^*$/#DB=*62+"%D& "W!D%DZ_(8&+83P.5OB4GFC98 -B!>4"^I@YIYVF!/;^$+F=RG M[)!F3:)F30YJU@=J"\&3?+#=D7VC,U\.93!YJNVZ6(@-#Z(QX40S]E4'$PH; M?;K-
G[4C9HS=&L@UW1'(R_S[FXEL*].5OB<)'SDW/A M:DJJ E&@[8N#G*T42,4UL@I;"Z]#0Q!";N%W72^N8P0 <40H$ DR>GSA0H6O?@3MYN5-):Z[DHMC6P ? M&.9[9"[?^

W/7P#RU!VO7P#JU@;UK8'=7:?)*@^&NP;#;P'BEP6C78-1=I?$K M#<:[!N-3>YCL&DRZ#>S77KC!\RLW.+G)RXO=?;5?72W]^>76#U[O5YL\O^#Z MYA6_VKX7-
V]D)ZNRF^LB_Z(5S?*UU_RPJ89-^_K].ULVA?NQ*NJ_SNIVU;E3]=75=U#L]S5=*>Y6\UX1=.U-%]6CZ7F M+N_$74][3]W>/-8^4+>?*-I?U<_,R]-C/#\][PTE&*WGE]I@\B_-&!B6]MM'
M1_OQAY^T'[0KK7S,"E'N_NE9T]MC\+*&[1W\JN*HE7>KXE(SC.]8/5<-_Y(_ MU:NG?P?LJ>&/8G6IF8,._*KFGZZ9SUK?V^:[5DH\U'NHZJ2M#IGUC$YX-^K/
MZ]FN5X\4G_*^'I\B)6K)$=-ZT_2CFY:>SAC]C%3 YLOX9FY<\^CX]FDWOKWI M6;GW6\3J1YJ#IS?E*IN*MQ?UT5$IBB=Q.NEXBV5?O/+>O%)%$W%UV6,8DY).:2F+?%AOO%8@XF
M8],<#^6B\4(,>S2P]%'G"4FA;J5"'+X4XE*]BQ65 M%BZG^4)H/R9YV7NEX+V2.+<,2J<+AP?OD9WTX M-$:#SCXNZ!%M8S0Q]&GP'I$RS0&8].6%XS(#8Y)+"&Q%,*D^AJ]U-?H:'U-
ML_)16Y?UKFZVW#N2W5SHGE6SWE/U]TKVW)HC,8?$7!+S2,PGL6!T6+M#?308 M#3NC0=BWX&ADCR>=G49$KEY,8@F)I1 FU>[XI7;'RMJ];>HV6]YM"UC\L9X]
M9?/FW+.O7I74N?5*8@Z)N23FC0_>[).Q-=!'H\XNX<7/8\=Z9I3^HE7Q:4BF/R4AP397'\GA>? MF[W8-%-O-JFS>5Q)*X-R2(#&'Q%P2\R8'+ZL]&@V'5N?0S2<[#4[L-"0[C4@L
M)K%DAR\\%(V?Q82L/ >I4O-?&U7GA6;I847V?E MYFSS2U84V2O'KKN^FTULCQ(N.Z/_K7H-SRYR4G-1S4,U']4"5 M1+4*U&-42 M5$LI31X-C'8T,)2CP:_BJ2Y_H955/OVLE:O9O-
+$_;W81">U^R)?:-%Z*;1= M**FWYI4]G'T L-4F>P/(X'(P-#ICB(/VZ]*:AVH^J@6H%J):A&HQJB6HEE*: M7/5M_DE7ABUNO"+;1*2S>6>O/VN"U_*(,)|5VH_UX]L%?VK2$J^?"Z"1J9VV
M?S8YZ(X":!(*U3Q4\U$M0+40U2)4BU$M0;64TN11H,U$Z>I0U(?UI_ELJOVG MWMT7]8%];T&C\2=44^7]G;7NZO MQX'GRWK'+_BC(2Y4U#_U]V?
HUDR5/-1+4"U$-4B5(M1+4&UE-+DVF[S6Y3I; MUD?MT[Q\91>.!N90S=$/0U%6;U&C:3A4\U$M7]3Y<:F->@F MOR-T[6)42U MI31Y&I V.&>H@W/O*BW-BL_-
%Y^>2[+,YOUGS6KJW))$-0?5 M7%3S4,U'M0#50E2+4"U&M0354DJ3!X$V3V?HQ)5T@TP-W:*:@VHNJGFHYJ-: M@&HAJD6H%J-:@FHIF(G358E1+4"VE-+D&VSR;H:+1;
[4/C:1M=X* M1'-IJ.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6DIIC.+:HYJ.:B MFH=J/JH%J!:B6H1J,:HEJ)92FES_;8S-4,_^]7<%V=7=GCU@H+DW5'-1S4,U M']6"G2;-
U:!;H"Y<1B':X1J,:HEJ)92FCP4M(DV0YUHVS\3YO[A'"[&CR[M^S@&ZJY].:AFH]J :J%]!:A6HQJ":JEE"8/!6W@S1@A9P5HT W5'%1S4U M -5"5(M0+4:U!-522I/KOPW>F>K@W?
>3M-^NS,&H_- M3A8/[30XK=,0[31"M1C5$E1+*4TNW[U[<*HS>[]O;I]=UVOV)(IF-MKM6?RQ M,W>U>G8%L[?E9._+R=Z8D[TS)WMK3O/@BH=Y.3FH<_:FF^Q=-]G;;K+WW?P[
M(GIF&]$SE1&@FX_K3Z7X8]W<--E]:OY_YND[&5>Z134'U5Q4\U#-1[4 U4)4 MBU M1K4$U5)*D\>%-KIG(C/0F6@2#]4<5'-1S4,U']4"5 M1+4*U&-425$LI M3:[_-J]G'KE?Z/>_?
P4(B'K!+:4S9?B[U]>2$6V6S9W"UJHYJ"::QZ&^*S+D=&M;N+'7N[D,A?KY?+^_J2M_+UI[PW3JU>VZEHYJ#:BZJ>:CFHUJ :B&J1:@6 MHUJ":BFER2-"F[JSD-2=A:;N4,U!-1?
5/%3S42U M1#5(E2+42U!M932Y/IO M4W?6J:F[Z3:3_W)<4.7::EU,'[-FSHV3+^FKNSM[H$ 3>=9A ,TVFQGH.U_& M07OU4,U'M0#50E2+4"U&M0354DJ3AX VN6>=--
O>F2<$:&X/U1Q451S4,U%-0_5?%0+4"U$M0C58E1+4"VE-'DP:*-]MD%-8K3#!-522I,+O8WLVC8RW9Z-IN]0S4$U%]4\5/-1 M+4"U$-4B5(M1+4&UE-
+D^F\S>K8ZH_>K>!++M=A>X9_F\WGV*2^R:O8DM,U! M_L.K_.HX;.'!#2XAVHNJGFHYJ-:L-..SD$6HMU&J!:C6H)J*:7)U=YF\NPC ML^Z)8K&YV?TWD17E3[UEC>;Q4,U!-1?
5/%3S42TX\JZPMF^'WKTZFKU#M1C5 M$E1+*4VN\S9[9Q_)WH5!;VVC4^JAFH-J+JIYJ.:C6H!J(:I%J!:C6H)J*:7) M]=X&[>P)H-U4$] M/W\2Q;(Y4]<>FD_FM":7]\J,&VKJW$$
U1Q4@Q-[M#=%>(U2+42U!M932MH5[53X*43E9E=U<+T3Q(&[%?%YJTWR]K)J]]]ZC6B'N MZ\+6W[PS+JX.'O?T-[[>\WB@OPDWCU^U_,WU*GL0:58\S):E-A?W=5>#RY%]
MH17-;+S/OU3YZNV%?%]RJLJ7VQ^?!39G2B:!>J_W^=Y]?Q+T\&^OB\V9R; M_P-02P,$% @ O(!H62Y.XC_^! :I !D !X;"]W;W)K&ULM5EM<]HX$/XK&M_+1#+
M_(8AY("9@'US_=!K)ESO/@NS M@*ZV124!R4Q__$DV,9@($?>4+V ;[:/=9]R3NW1IF3' I. M:($8+(;.G7^;!)XR*$?\36#'CZZ1"F5&Z5=U\W$^=#SE$620"@6!Y=<6)I!E
M"DGZ\6T/ZM1S*L/CZV?TW\O@93 SS&%"LW_(7*R&SHV#YK# FTP\T-T?L \H M4G@IS7CYB7;5V*CKH'3#!(#PQ M"+TS!IV]0>=TAN",0;0W*$-WJ]A+XF(L\&C Z XQ-
5JBJ8N2_=):\D4*52A3 MP>2O1-J)T;0J$$07:$J6!5F0%!<"W:4IW12"%$MT3S.2$N#H*@:!2<;?#5PA M9U;V;KJ?95S-$IR9)42?:"%6'"7%'.8:^]ALWS?8NS+B.NS@>QQ8 2(KS
#KG%O\GJT\#):_$.^P5*^GT(#E_R &1D_&.^QH0I5A7K&2V6'S*Y#,X1YAR$]CVH +M' 7G- M@"871\071R2F8SI%U(NW6D76.D=_-_Y=141BHH BZ(7+-5H&G*-O([E0:R'V1(M,"
(_X5%N;+B^$W1?I#3L19YW2H/1G[9EU'W!AQ]ZWHM}$TN3-BCNU13WC!0_ MP+<-X40 DF\OH7-T10KT!)CI%V C6-MWUB98; XSK&+2-4]+7C38OZG9OS&Z M]7E=
[F.WJK1EWV1JOZDM7R-,6]YM@L7F (/H%QWGECQH<-ZO.>\;74H>UT2M M4Y+WJN1U?!LAVO)M$RPV!^=[YPO=DAL-TGWOH \HV=2<$DY54BUP1@4Z9/L
MV;C@N!)R2ZDUT55&^9EMO_>BDT:]Z*1U:P9]"+U.]V09TPP+@JAWTI(UHT+_ MS&KF'ZD@_]5[)14W1X1SM9!]/[^-'^\Q(\B??E(/:L[8;%3GEJ3Q^# 8V#D
M<4*++3!!9AE(N3[3B[-$&U?8:MHL56TQ!9:,QD'@>:_I4+SK4HTJVBQ5;3$ M%EHS30>9YIMUVND[@Q921* MSC:@S4OG99OTHG[H]4][CU7E]=II$UO3-MD\ M2##?K,'^
I:3HMI%S*" !='OV\PPKU M&IC5:LN_QV+(]M.2K+OCH.JI_6 M1\-WY8'HR?.Q?SOQ-<]C_S:I#GX/\-4Y]"?,ED2*[0P6W*JPZVJUN M!%V79YH#]M%_4$L#!!0 (+R :%D^ MA>4QQ , ' 3
9 >&PO=V]R:W-H965TI3F?6TT,TQR:S'38QNVF-&32$D.&X*-/ A?> MN$8JE!VEW]3-[\G<**TSU %%"A>3%.N_Z-+-=>Q4'SB@F:5L5Q! M1O+R$W^OA&@82$ZW@5L9N-
<&_@T#KS+PWNK!KPS\MWH(*@,=NEW&KH6+L,"+ M&:,7Q-1L25,76GUM+?4BN=HH6\'DMT3:B<6VW""([M&6'*R)S'.!7J,8WK* M!MKXPN?=X$4JSR3G@IUD MM1"*
[\EP>\FJ,+WP LC\UB6N25AD$K8V!&NEP:_3 MX/?1%ZOKGQZ# O^XF9%>V-",F(1%)2S4,'6FG1=WX23TO7!FGYMB=\P;._JO MGM@2,JB%#'J%?$S^EC56"8<$1?
NZOG6IV$L:JF+P*]"QZX=>.^RHG!4TPW9# M9^I=S5N_IMUYDW'@C;O5"6MUPD';K$N57L)054S"(I.PM2%8*PWC.@WC=Q?= MLV%"Q3<*B:4=U#WPWN#[\##EMB3UR
M7EX0'&-'9(5J'D1..YA5O[>A$E:T_SXA3;EMB]AXRQKUBKAA)()@5/TU+M9 M^S%#=ZM16E316EIW/JR9]6RKVA M>U=5/D:GPY>EB-.L8C MU4[2'8L7?-
F+^H+903[;Y2#NLFV^!=02P,$% @ O(!H665\N%QT P 7PX !D !X M;"]W;W)K&ULS5=-;^,V$/TKA H4+=!&WY*=V@(2 M;XHNL(L::[0]%#W0\M@B(HDJ2=G9?]\AIV+=,,"BIO>
4EOMES45"%0W&P926 [DQ0D=N>XT1V M05EI)0LSMQ;)@M,E$;I?6G?N[#D[QX)CJ5+>>)/>O!QM[0V\4< /5 M#?&=GXCG>,$ G]6WA_LC=I/Q.7]_@^:_@W:&(.Y;7VJQD VDMF-
)B/CRE>8T9 MD[W@!5GQHJH5-<;&2CQ04:+TDJQ1ZXW1^N]/"$P^*BCD/T,J-RR"81;Z++B5 M%4UA:>''+D$IC*X+G"]\[H>R[!C&8ZRQ((56"O\/--'4M4BS?
H(2A>.CJ84;"*PGF!Q)U@\A:/CETX-HCB.?KDN M<&91X P;>M:1G(V2?"BJG'\%K*BQ].^5KMP0S5&8MY9E(K!>QO,NX_F[\%\ M2L$F NL)YCKGNX(SA9-
;E$N+AE'@Q5=&'EB&YW+@#QO9O;C1N/]S-I='$(IM M<\ +W58-4AR%>&M5ID+K)^R=$_;>A9-;&E.)-A%:7[3SO:2V\UV7=*=Z0VNYN]U]V1: M@#-,TWI]IN+
2DERV".D&ULK55=;YLP%/TK%INF5MH*&,C7 *E-5FT/TZ)F MW9X=P-<^Y_@<)[[$>RY>9 Z@T*%@I4R<7*EJ MXKHRRZ$@\HY74.J5-1<%4;H4&U=6 LC*D@KF8L\;N
6AI9/&=FXNTIAO%:,E MS 62VZ(@XN\#,+Y/'-\Y3CS13:[,A)O&%=G M1S-1>Z[]R30R> OX16$O.V-DDBPY?S'%MU7B>,80,,B442#ZM8,I,&:$M(T_C:;3 M;FF(W?
%1_=%FUUF61,*4L]]TI?+$&3EH!6NR9>J)[[]"D\<:S#B3]HGV-388 M.BC;2L6+AJP=%+2LW^30G$.'X(>O$'!#P&\E! TAL$%K9S;6C"B2QH+OD3!H MK68&]FPL6Z>AI?
D5%TKH5:IY*KW/,K&%%?IRT/\+"1+=S$ 1RN0M^H2>%S-T M_XV=I7>R>#=K%%]J%7Q*ZH+J.Y0X'U$V,-A#WUZG3Z#3--]2P].Z:[.UX;$ M;4AL]8(WANP+5"N$_0KF+DUD13)
(''U9)(@=..F'=_[^]P7[S^)G80-VK#! M:?5TJB=H1AA2@NHG7,E<"PVLD+GNNW0<^1X>Q^ZNF^82YH_'P7 4MK@3HV%K M-+QJ](?*0?39JFE19[_0Q]@;G-GJ@>$0^Z-
^5U'K*KKJZB=7A/6YBBY/(1@$ M.(C.;%WB<.B// ^?^7([E]8TS.]$;&@I$8.U9GIW0RTDZB94%XI7]AXON=)= MP0YSW;=!&(!>7W.NCH5I#>V7(/T'4$L#!!0 (+R :%F"NQ%6$ P $6K
M 9 >&PO=V]R:W-H965TYK&8Z-)B!12=C)3#]\)2PC!/)U/_V16,3SN\(MPV,=P1/IZBG-ON8+(0KEVVJ9Y->]15&L+_O]?+80JRB_2-CN!7+9265 MV_%[C?9VWM@R\?
S%V4B]MT^?]X7BRN>Y.>,A?WT699?$Z?7%$_ MH&'ES=)EOOV_\E3?=]!39IN\2%?UX'(+5G'R_&?TK?Y'[U0C5<&:/4 [=0! M>CU /W6 40\P#@<,7QDPK <,3YUA5 \8G3I@7
\8G[I)DWK Y-09IO6 Z:DS MJ(.79VYPZASJ[LD^^=E67YYN=?M\]Y]?6-M7I1D5T%\I,IBBA>YC\K[Y7?OIC*3__\^:I?E'IU MG_ZLEJQG27M%4I5?
TJ18Y(J5S,6\8[PK'Z_:+PO'S^5C.^7/Y7=CT9[^=% MU*3@K[/B0AE,WBG:0#,ZMN=6/OS#.KM0U.&KPTWY<#]*RMGU5X=;)VR\KKXZ MW#YAX_7!=KC>,=R1#S?%;#?
[H.NE(!_^1:QWLW=MO'?Z*Z-]]\V>_"VVKX\O%&':B#J5[NIA[$CC<)7 H3>!GL8Z^5WM');TO#^'*:8TAU+LW!R2 MF$EB%HG9)..0F$MB'HGYPZ-
7^V@R,O31[L7^G+#CNXT'V_:]PNA;6LE;+1+ MV$B:L-M%E#R(1%?'=4FR#UQ4WJ7QNW$C,)#&+ MQ&P2?N7[SW<;[MU-&Y5[C8.[!<>:/AD/]?%[CJ!'
MT,K1>)>CL3Q')^1%*IR;%Q(S223FDUA 8B&$M1(ZW25T*MV"B3T7;DDG0DE M6J6;I'-_*M7.32N)F21FD9A-8L[T:%VF#;J.<%QR5H_$?!(+2"R$L%82U4'S MZ>- FL7_;%9W(JN.!
(LL2F8+T;F_E"/G1A#53%2S4,U&->'3V6QR(3H_-B7 MW H/U7Q4"U MI+1V-/>* :KT^?220I1N\3Y-EM^5M2186HXCDK
MU[+10]=OX(]RZNR(DIJ):A;JV:CFU)JJ[BUD!Q>#B7'P!J.+3NNAFH]J :J% ME-9.9%.T4:4M@9O?DDTNYDIU_:CC4S,XT*Y%^*=$N5*])+1SH"B#1Q4,U'-
M0C4;U9Q:J]9=^P%5#^.)%FQ0S4>U -5"2FO'LVG9]'^A9E.O:^.94C< .M.) M%F]0S4>U']5L5'/4KO)'U[M Z+0>JOFH%J!:2&GM?#8=!4MXU\/G=#OF+"SNH/.&=.W5-
QT<]K^2C_*'\$GV+5YM5 M9\[0O@^JF:AFH9J-:@ZJN:CFH9J/:@&JA936#FY3_5'?WOU1T?(/JIFH9J&: MC6H.JKFHYJ&:CVH!JH64UHYKTP-
2V2*0G#L[NF@5"-4L5+-1S:FUUH%8=QT(MG==#-1_5 E0+*:W]K^Z;3I F+Y)T+'_M.,N+EXI05S3EY+G11#43U2Q4LU'-
M0347U3Q4\U$M0+60TMKQ;7I#FOKF1;"&=H90S40U"]5L5'-0S44U#]5\5 M0 M+:2T=ER;'I$F[Q'M[VV3M.C>NZ+](50S4:CFHUJ M:B&EM?/;-
(PTX^TK7[1+A&HFJEFH9J.:@VHNJGFHYJ-:@&HAI;7CV_25M/';U[UH2PG5 M3%2S4,U&-0?57%3S4,U'M0#50DIKQ[5I*6G26L5IZUZTI81J)JI9J&:CFE-K M^^W75]:]:
$)U7Q4"U MI+1V$IL"DB8O('6L>S^E21'?1]\Z0XGVCU#-1#4+ MU6Q4/.25T<[2:AFHIJ%:C:J.:CFHIJ' M:CZJ!:@64EH[KDTG29>?_N:O_]MO.7QVB-&F$JI9J&;76NNLY,/CE:N#SNJB
MFH=J/JH%J!9E30>)EW>0/FPK]THFUE'<>8XQ^?BS4X@6D%#-0C5;/ZX, M=1Y .NBT+JIYJ.:C6H!J(:6U8[AWI3!Y_^CD"Q')G;/CR%XQC+UD&'O-,/UH MIZAWQY&]
(!A[13#VDF#L-<'8BX+]'74BO:D3Z=+^PXW=G'*A7*DJ^2+*.M^K ME3-GI_%9F^SO,BX.3G)A=MQ)'5Q,)NV[6>B6V:CFH)J+:AZJ^:@6H%I(:>V(M-
14@'3WGD%P[.VG'%VY2A\;$&!R&[?A^TZFAC@[#AA9X4,U!-1?5/%3S42U MM9#2VF%K6CZZO.7CY?DF2F/U"816JS11\B*=?56B/$]G<52(N?(4%XOZ[$+; MZ[R_Q/*G.'G>
>9=5Z;^*)_Y[&!V7"]J/!JA[D\OMM4U:>'L43;.QUSZJ/Q M]&C]B-9R4,U#-1_5 E0+*:V=MZ:6HY]&J&73Q=W_Z1:'[TK7SUUM(Z"&5>) MK89OUN5M32P[(X@6?
%#-1#4+U6Q4U:0'I\A;09S'?S(IJM1OO[V2K M0]'J=$3YWL4=MGOH99K7[] ^KZ6+A6COMLLOJMOFT7?E3MRGF7C^5BSCDO[> M#-G-E*1%:77^FD K1ZAFHJ%:G:M'9Q*?
GJX3$>K1*CFH9J/:@&JA936BK_1 M5(D,^>F.I/'ORJ3<.S>3J&:BFH5J=JWMOVFMC2^T@TRB<[JHYJ&:CVH!JH64 MULYDTQ$^NMS'UL?3PX'Z;F1,7@ZH_U"^;.YR\?
NF>HO9>GRE M8R3?F+,#C7:,4,U"-1O5'%1S4@8W.Z:":BVH>JOFH%J!:2&GM>#4-)$/>0+K]JQ\&U6Z[=ZJ6"^/# MU)%E$A/5K!,?
@XW.ZJ":BVH>JOFH%J!:2&GMW#6U)./T,Q.=>/CY6:RB.*G> M%S[OT!-M-*&:B6H6JMFHYJ":BVH>JOFH%J!:2&GMT#?U*&/T]D-/M.>$:B:J M6:AFHYJ#:BZJ>:CFHUJ
:B&EM>/:M*N,4]I5/SCT'!\=N!D7FGZX"$:[3JAF MG?0(;'1.!]5<5/-0S4>U -5"2GN.5S]?"%&841'=7*U$]B!NQ7*9ET>1FZ2H M)MF[5NEUW>ZKE\'V]GXS[0! !D !X
M;"]W;W)K&ULK=UI;]O6@L;QKT)X+F9:X-86J=6= M-$:[OO2.\7%8%[0TK$M1(M+4DX"],,/)=.B*%.TU/[[HI%M\GJQ*)Y^OKG)IXJBF>;7ZR>Q*K]RO\Z6:5%^F#W< MY$^92&>
[G9:+&Z77&]TLT_GJZN.'W>?"[..']:98S%KU$_'\X;'8?N+FXX>G]$$DHOC74YB5']WLE=E*5;Y?+V2,G'_R]4G M^>=D,MCNL-OB?^;B:W[P6-J^E+OU^LOV
VOVRU5O^XS$0DR++9&6?SR+SV*Q MV$KE_BC0J_V8VYW/'S\JNN[%U^^F+LT%Y_7B]_GL^+QEZO)E303]^EF4<3K MKZ:H7M!PZTW7BWSW?
^EKM6WO2IIN\F*]K'8NG\%ROGKY,_U6?2,.=N@K)W90 MJAV4CUSOW#'D_<$^^VC+KX=;/C[>IY_8ZP&7CX^X'?V;EY_>W8^^FA;IQP_9^JN4;;V#77[L]B]_XN>K;=0E159^=5[N
M5WQ,'M-,/*X7,Y'E_R5I?VSFQ7?I!U44Z7R1__CAIBC'V&YY,ZT\[\533.GOBS MY*U7Q6,N:=N9F+7L'W;OWW]O_ZA[_]N._6_*[\W^&Z2\?H-^53I!>[.XEI3^ M/R6EIPRD?
T@W4K[]EN75'RW/\/,9H"Q? *KG@+T+0.T,L'=;@?]*5.F'?_PH M_?LL6G^/7I7?S>$%S]4X![SDQ9MG@/+@ M Z![SD>-O=X*>GK'S)RM'A.0=V MSH#E2PZ.^\Y+3\N7WKOD9\?
K!OWUU**_HIWS/8O/A_OO/\WDG-"9O/F[TA'A_?WON/Z. M[I^@/R_2/)?6]U)2K*=?I/]URZ]+5B&6^?^U/,]?7[!!.[;]I\?/^5,Z%;]< ME?^VR$7V+*X^_N=_R*/>?[?]+B QE<0T$M-)S"
QD\0L$K-)S"$QE\0\$O-) M+""QD,0B$HM)+(&P1HX/]CD^Z-?_JV22_,\WXB9])3-IT)Z$MG++PKISY._ M-%YBO=_^--9)3"4QC<1T$C-(S"0QB\3L%VRRP[83C<\?1]>##S?/AVE-#NB2
MF$=B/HD%)!:26$1B,8DE$-9(Z^$^K8>=:?W;ND9?N[!.5V503[=YD6]#NBV; M.Z5+LYG$5!+37K#1032,A[WM?\UXT,E!#1(S2SYWF^SK[_4[I+5U]$]D\I7\&&/ZD]: MMI"J7&Z=
M>.XD+LU<$E-)3",QG<0,$C-)S"(QF\0<$G-)S",QG\0"$@M)+"*QF,02"&ND M]^T^O6_)^T)NR1PG,97$-!+322>R;91/U\OE>B5]K<['I6(M/6VRZ6.:B]?[
M'5_N'VE+^.Y1+HUX5%-13:NTPTGM<:\O*\.C"1)T5 /53%2S4,U&-0?57%3S M4,U'M0#50E2+4"U&M832FFE*4$F2WYE5$=ET7@;VRRU^9:KOX_R]F_RZY8L3 MG-145-
,J[7"R;70A21>4[K,Y_)Y_72_V38N&U'=FM"= MXURJOFH%J!:B&H1JL6HEE!:,]#K3J3<6=7YZ(NOG5_,*?1'B2J::BFHYJ!:B:J6:AFHYJ#:BZJ M>:CFHUJ
:B&J1:@6HUI":]X:YD5AJ5[:2FHIJ&:CJJ&:AFHIJ% M:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J)936S/:Z1BEW]R@_/3QDXB$M1#VU4C7@ M?WB9!V]IGYI?N]&+(Q[M5**:5FF'ES+EWG
PFDR.IUG06B6JF:AFH9J-:@ZJ MN:CFH9J/:@&JA:@6H5J,:@FE-=.[+EG*W2W+PVD6Z4])G3_/9V(UD[[/Q:+] M'A2T58EJ*JIJ*:CFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!:C6D)IS72O
MVYCR&)UW0>N7J*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:HE ME-;,]KK:*7=W._=G[=LW0\FV*R:42;\I\J+\>+YZ:,UWM.J):BJJ:95V..GR
MYJX6M,.):B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUI":=SZ5[L[G.[,MY;G\OULS'NU[HIJ*:EJE':CFHUJ :B&J M1:@6HUI":UU8;1\"-_G.^DIJ*:5FFW!U,M\K4R?O/FB.BH
M!]J9J&:AFHUJ#]IYJ.:AFH]J :J%]!:A6HQJ":4UD[NN@RK===^C*>99XGG^1 M[C,AI/F]$.6 16MVHVU05%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1 M+4*U&-422FLF?%T954;HO
M:&$4U%=4T5--1S4 U$]4L5+-1S4$U%]4\5/-1 M+4"U$-4B5(M1+:&T9K;7A5'EK/4[+YIW04NCJ*:BFE9IA_,NO>O>0!DWJ;X M]KW05^+K_MVY6C,
<+8:BFHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ M$:K%J)906C/IZPZI@BX+JJ 54E1344U#-1W5#%0S4+^;0\'I\7V8DI\F]AXJA&6Z"HIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!
MJH6H%J%:C&H)I37S7*GS7"&G5_IH91355%334$U'-0/53%2S4,U&-0?57%3S M4,U'M0#50E2+4"U&M832FME>5T;[W8N*:J]K0CJE\^EN9>C#Y;"E&^EEQ:+6 MG$?
KHZBFHIJ&:CJJ&:AFHIJ%:G:E'2Z3WKON*"C'+3U[G1+NAJ*:BFH9J.JH9J&:BFH5J=J4=7FT> MC(=OKS8[Z+ NJGFHYJ-:@&HAJD6H%J-:0FG-S*YKG_WNE4*M/-^DJZF0INN\
M.)W6:-L3U514TU!-1S4#U4Q4LU#-KK1&6K>&-=KC1#4/U7Q4"U M1+6HT@[? MN>YD ;F*BFHIJ&:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J)936 M3/FZI]F?
H+>7H,U,5%-134,U'=4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U M&-422FMF>]W,[+^SNN=F>2>R;;A/U\OE>E7?75*LI:=--GU,UHS
M'VULHIJ*:AJJZ:AFH))A:JV9766+JIOYWR/IY#0;N8J.:AFH]J :J%]!:A M6HQJ":4UTGQ0=S$'W5W,M_,QGYNIWI;=W>:EV8UJ*JIJ*:CFH%J)JI9J&:C MFH-
J+JIYJ.:C6H!J(:I%J!:C6D)IS82OJYL#F9R+&: U3E1344U#-1W5#%0S M4U -5"5(M0+4:U MA-*::5X7-P?=Q2EV1=12/O;$/-TT=[4[*8NCFRTJ8EJ&JKIJ&:@FHEJ
M%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J)906C/8ZT9G^9"<@AF@V4YJ*JIJ*:C MFH%J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%J!:C6D)IS6RO6YZ#[I;G>8VA;N3B M2$?[G:BFH9J.:@:JF:AFH9J-
:@ZJN:CFH9J/:@&JA8.WG5WY=C!NSIE%9VT5 MMVQU.^P/)D=E(>H%-+.U;F,.NMN8HJOF5)O<.TJEW MW>LWPRE !PU1+4*U&-422FN6>MT '70W0#\]/&3B(2U$?
=/ARQL5GCIU1HN? MJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J?J4=GE(>)RT+F 3HL"&J1:@6HUI" M:*/37F]+FG/Y?];8QSM>**:BFH:JNFH9J":
MB6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6HEE!:,^OKCN< 77US@'8Y44U%-0W5 M=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+**V1[<.Z\3E\9_7-_3WC
M[IX7WBU=ENNHJ*:AFHZJAFH9J*:A6HVJCFHYJ*:5VF'=\ KFUO?'0!SD=' M#5 M1+4(U6)42RBMF=AU@W/8O?CF)6\DWDU='-EH?1/5-%334G\M1[=]I[XIN+L76/<'&4HZU,5-
-034T\5& M'$R;9&*9SE?;VU=V=R*FY79BN;T$>NK,'&ULHIJ*:AJJZ:AFH)J:A;JV:CF MH)J+:EZE-1JOFH M%J!:B&H1JL6HEE!:,]OK,N9P2-ZW,D1;F:BFHIJ&:CJJ&:AFHIJ%:C:J.:CF
MHIJ':CZJ!:@6HEJ$:C&J)936S/:Z##KL+H.>N&]%6J\D\4UDTWF^FYWI>M_R MJA$NSGNT (IJ&JKIJ&:@FHEJ%JK9J.8,WZX$J8Q'PZ,%'MV6S6[E_FUS*P]] M:CZJ!2VOH#\:WQI-
YH3HH!&JQ:B64%HS>>O&YK"[L:FG\ZR:_MY?OGS_ZB5: MVT0U%=4T5--1S4 U$]4L5+-1S:FTPRN$P^O1<=*^W4CN74\FQU&+UBQ1+4"U M$-4B5(M1+:&T9B+77S6J-G-
\O1&KYHV1+55%334$U'-0/53%2S4,U& M-0?57%3S4,U'M0#50E2+4"U&M832FF%>ERV':-ERB)8M44U%-0W5=%0S4,U$ M-0O5;%1S4,U%-0_5?
%0+4"U$M0C58E1+**V1[:.Z;#GZ2V7+2R:MNT>X-.]1 M344U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U:/2VO-HR/Q^C@R:4U@SR
MNH,YZNY@[M_SJEYK+=^=KF^>VK.\-7[=]T[>]MHXZRMS+.VLL[:RCYK*P?]7KBHYJ&:MCVH!JH6H%J%:C&H)I37SL6Y2CKX/-#T,MJO1#45U314TROM<$)-5@9OWH39 M:-
NN__:-FLVV[>3QF^VLENU&MV_F\>R6S6[_?'P.#'1?B*]>:CFHUJ :B&J M:1@6HUI":8W$'-?]Q'%W/_%H0M@77SOO@N]6+LU&5%-134,U'=4,5#-1S4(U M&]4<5'-1S4,U']4"5
M1+4*U&-422FMF>UU9',OD3/ 8+2>BFHIJ&JKIJ&:@ MFHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J)906C/;E3K;NRN,?V,F>/QV\:O1
M]5%#_,Y&ZGG;*1UOY"+PQ:M$Z*:B6H6JMFHYJ":BVH>JOFH%J!:B&H1JL6H MEE!:,VSK.N&X>PU(9%JY&J,Y[3D>'>?NVZT4^?B=5=26K;9W+O:.HQ=M^Z&:
M@6HFJEFH9J.:@VHNJGFHYJ-:@&IAVP_@8"(?_31'YVT6H\\MH;1F6-;IO/+A M!3/*X>9N,9^6V7@OLOGJH349.\&+)QY(344U#=5T5#-0S40U"]5L5'-0S44U M#]5\5
M0+42U"-5B5$LHK1GO=8-OC*ZP.$:[>]BFHIJ&:CJJ&:AFHIJ%:C:J M.:CFHIJ':CZJ!:@6HEJ$:C&J)936S/:Z'3C^2RLLMN8Z6@E$-175-%334NRWIJA[

M9<;_+);ZY6.R@0[JHYJ&:CVH!JH6H M%]%:C&H)I37CN^[SC<]?QK$,[$^%Y*79%U%(^RN.>;HX$=]HGP_55%334$U' M-0/53%2S4,U&-0?
57%3S4,U'M0#50E2+4"U&M832FCE?]Q+'Z J/8[2!B&HJ MJFFHJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:0FF-;)_4#"S3J?198^O$Z*__!4QO,NFW]\
M=U*\>X2+$QKM0**:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^]@6H%J):5&F'ETWZ MU[=O5.L+%N8VNSHAJ&JKI MJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J)906C/?ZSKE!%V=
<8*NSHAJ M*JII]*:CFH%J)II9J&:CFH-J+]IYJ.:C6H![(:I%J!:C6D)IS6ROVY_EPZYS M]UC,-M-B7IZ^SU?2=`?FGF_>IF*27/I2613L2]VTS/;-OUBG6]77M_?OE@\
MBF;%OGRP_=PL_2[=B?MU)EX^%(MY27^O=]F/M%H7I=7ZBZ3SJ5_\BX345%33 M4$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+*DWN'7SD?QSO/O\327?KHE@O=P\?
13H3V7:#\NOWZW7Q^L%V@*_K[,ONY7S\?U!+ P04 M" "\@&A9EH,3]>@% !X+ &0 'AL+W=O+8A>,1-M$)%(E*;L% M]N-'2HIDQ0H3 R<7L23K/$?4R_77.R%?
%1;2C7ZD:5<70ZV6N<7PZ&*MS0C_MZDSDE)MOUD(F1)M3N1FJ7%*2E$%9.O0|;SK,"..#Y:*\=BN7"U'HE'%Z*Y$J MLHS(G]2KB\' M5_@B\D%.8!Z+H2J3_L$1O+P?S
4KHFA2IOA/[C[0NT,3R8I&J M\C_:U_=Z Q072HNL#C9/D#%>?9(?]8LX"#"<_@"_#O"?!XQ?"!C5 :.W9AC7 M >.W9IC4 9.W!DSK@&GY[JN75;
[I@&BR7$BQ1]+>;6CVH)2KC#8OF'%;L^ZU M--\R$Z>7*Y%E3)NJHA4B/$$KP37C&\IC1A5Z%U!-6*K>H]_1U_L O?OU_6*H M35H;/(SK%-=5"O^%%!C=&.A6H9
G-.F)#]SQYX[XH2EN4V;_JYJ;<,^&XW%?<=X<[O>%AV\/'_6$1^[P/PM^AORJ[+[C M78Z:^C,J>:,7>%_TEDIT6(N^?3:WH$^:9NK?OLI2\<;]/-N17JB"6.#I:__8*GWA]]2D'" DA8" F+@&
=A<>-PF,7?6E[!&D&@(*D2#RD;$/L MD-"GK)-SJK*0L*"'34N8'6MWR]%D,I_,%L/=H6:0.2,@6$>S2:/9Q*G99VH& M6S/P:DG*H8)"R A(60L&AR5)3\7V3&\14@X\%9I#*@P)"R!A(20L
H)U%#YO M%#X'&5:=E%-UA80%D+ 0$A:=]PRK4W_2/ZQBKUW>>D()DQF8H;)>H&G2PP)"VH:8?=G^]-CF:R(6C6"(K6E:ZUCK#3MUA> ME:N8VWH5@ZXVDKZA/P;UCT!I
2@M!*5%4+2NUJV)A,?0_3&HG01*"T!I(2@M M@J)UA6Z=)^RVGE9$;5%.6(*T0"3^7C!)$>/:3+;80THKZZ)7;U S"A_;-/[L MN$,-0+.&H+0(BM95LK6DL-
N3^]1407A\Z$BMA:P$5.@=X_75_I^$0 VHFC8Y M4',VP\^E!'660&D1%*TK9>M!X5=,*&A[T9WO9'EGQ_[\K,?("T#3A]"T"(K6
ME;@UG[#3^>BTUM@,LT9+I47\:&6TWVC;'U]I=$/DHQ&WN?V>I*8NM'.OU]KU M_*@ESO'D65-6[+:LO>TZE MVK*\;LHYX3^1*+0R#UKP]J5X'2
E!:"$J+H&A=H5M3RW>;6LT&.FVGU8HE5+[H M2+I1)TL,ZF75M*.?UH\L2="T$12M4F]XL#$RHW)3:F%51IB"ZVJ/6W.UV29[M56X.?7;]&E^L<,_U %^$U2;8%E_MR37S[
WC"J5T;5)Y9S,S99;5-M?]1(N\ MW);Y(+0667FXI<14%WN#^7XMA'XZL0F:S<;+_P%02P,$% @ O(!H6;R> M-AIH P N@T !D !X;"]W;W)K&ULO9=O;]L,P M$,;_BA40
@F6V&W2;K21ME4()":FE3]"B!=N>FTLDCC8;CN^/;:3)84F+IN M-VWLY+GG+K%_N4QV7'R3*8!"MWE6R*F7*E6>^;Y,4LBI/.$E%/K,BHN<*CT4 M:U^6 NC2BO+,)T$0^3EEA1=/[-
RUB"=\HS)6P+5 *($$K*;>.3Z](%9@K_C(8"?WCI$I M9<'Y-S-XLYQZ@V@)*[K)U W?O8:ZH-#$2W@F[2_:5==&H8>2C50\K\4Z@YP5 MU3^]K6_$GH"0'@&I!<3F71G9+&=4T7@B^
X)<[6.9@YLJ5:MDV.%>2IS)?19 MIG4JON1YSI2^S4HB6BS1)2\4*]90) PD>H&NJ-H(IGZ@M5-0E&7RV<17VM>H M_;3VN*@\2(_",H3- B>(Q*0(?
HPGZ&GCW\+X^NTF]Q)DSNQ<0>]N1=*Z,>Z MH1EZM\C8FIH'_1R]8C+14Y^!BC;_N5[/RTT&Z,OY0EK9UZY**L=AMZ/9(F>R MI E,/;T')
(@M>/&31S@*7CKJ&33U#%S1XW>)X@L0"",5"KY9IV@&">1F:H"K MN]>5GR:RF)CV*R$R;X7IS$+2BQFY2]/,&' MK"1!V, 8TA*[%SM<"H.I)7/APQWKH9FMAB\?
GQI.P*TI];HV$WT MA+C]/#],NQM04A+:.+$92\ ;MDO78AN0_JZ$-+RD[CYV;O@:]U^DX7#X/ - MZN]UXN:KYHJ*-2LDRF"EA<')2.ZU;>']2ZX F$NT.=7
MG*N[@>GWF\^U^"=02P,$% @ O(!H69]_ACQW!P :C(!D !X;"]W M;W)K&ULM5MK;]LV%/TK@C<,+=#4?$BDE"4&$CW0 M?F@;U.OV8=@'Q69B87IXDIQTQ7[\]$_2X>"S* MOZL-
8[7U-4OSZG*VJ>OM^7Q>K38LBZNWQ9;E_).IHLSBFK\M[^?5MF3QNAV4 MI7,$)EG<9+/%A?MMIMR<5'LZC3)V4UI5;LLB\M_KUE:/%[.X.QIP^?D?E,W M&^:+BVU\SY:I_K*]*?
F[^9YEG60LKY(BMTIV=SF[@N<11LV %O%[PAZK@]=6 MD\IM4?S=O'F_OIR!9H]8RE9U0Q'S?P_,9VG:,/']^UC-@,/7S^Q1VWR M/)G;N&)^D?Z1K.O-Y&8#Z >C8 ;@?
@(4!&#PSP.X'V,=&W30T_I72,MX9)MWUH8O+$00+;U91E8KWY6Y>4?3X,U-,$) W+5G? *NM#,7D5ZFH"M. W4T8RTQ_NIA5M>, .SNM7GQ]6=;E,T44\VGCL)6 M4S3+ZGFUC5?
LIE#07X8Y MGNW8= R+#&4P4I;LE25:9=_GJR)CUJNTJ*K7UEU99%9_;"URI=Q$RND,NL1! MF{RS\HDT/<\@I1YP!&"@ #H440#$Z:P".H3WHIX@[#;E$P6E>T&I5M"KK#E] M?
(N[!C1?6P'C459)MR'\RGOKBJF$I5)VT'&%$/QC0($,LBEQ!#*$5((_8@I#: M5$\|4TMT+Z6]%_%1O^(K]JE?LM=7-U#?61Z9<49*<.H"[#X_=;F>:**WEY%3ZOBE(V M#B%8R-
F74<2Q@;A"RBA(;41<04 9AI 'J+|$1-H<3U00@L%K /T:N>:)07*7 MQ+4, ^#?/H^*W6!IO:A]P=-S0:-RH9SL\%/"0%*.A>F/! M#\P=U' U97?WYP?6='|_\69MN6V6TS3YQ]?
T=5+\QI>)>,MV=;(:8,KZ;(-. M[12,L@5&V4*C;)$IMO%D0.-D0# NQWH.4I4UR18890N-LD6FV,:U':PVU)H^ M;5^O'SJYI$9-=L|V;B,4!D"!0PB[5#A:1J;V;ERG+P1Q#O3N>;
*@[#W/7&P3 ML8_R54 *'.I@H5]0 :%'75OL24,5$B%$;2RI^A*6%0Z>%>I-Z\E.H.<]S- 3 M!?.5(+&-58"0ZTAM@0(E-0^1/MM3U1Q*M0;U8EV ,IF$=I
:L04*.)*B=@E[_VM3/)%AAE"XVR M1:;8QM?$!A^,P(\[632X_I&V0*C;*%1ML@4V]BV@^5'>LNO*YZY5 M.$@<0L0N04E("!;;5GW"IPHZ,%RD=[@GFP"DL)B,V'@I09*D,L@6S["&*I#4
MN>IS/57+P:8BO4V=TKDBV242*,DG@SQ/I% *$'01%O537(WU7"0*^!*.% V. M%,D=Z9$]*U+X0>Q243R3%UZ#HV*&1F-&BICT;40]JR)KVM37)%AAE"XVR1:;8QK4= M+#WZCJ6?
W/S(EO?,H\@3SP/[*B $MLM_Q:,- HD=%[E4O'2J1&) @'@M-M*G M?;JL@W]'>O[^>@LD7QVV11E\)4B\Q40!@M+YXE")$N^NB/39GJ@F'DPPUE^, MGG@>%"LN#MO\1[Q;1X6#-
A%G ,\7=!XW&= M9<\R@;8R/6DUEP?;_)-LJZR-J7&Q:O6=D ^.=W15$_O6D"[']\O6?P/4$L# M!!0 (+R :%D\|SB0O0 (8B 9 >&PO=V]R:W-
H965TJ13Q5[U:IN@=]YZ)FN=GOG.D)4JH$X M2=3>JOWQFP"-XF!&M|^-0N!]#N2%G'!@O*?LA:\)$>@USPH^,=9";&Y-D|=K MDF/>HQM2R"U+RG(LY"I;F7S#"$Y*49Z9CF4-
S!RGA3$=EVV/;#JF6Y&E!7ED MB& S'+-_[DE&]Q/#-MX:GM+56]@&X!69$_&\>61RS6PH29J3@]>T0(PL M)\:=?1O9OA*4>_R=DCT_6D;]5!:4OJB5+|G$L-01D8S$0B&P_-N1&?]-
'Y2V61Y"G1?6/7^N..!+8WAF!4PN<4T'_C,"M!>ZE$;Q: MX%'T:H5\+^I<*!K5@4/9IU5EE3P=8X,F8T3UB:FI)4PNE7:5:=G!:]"MK+IC< MFD]=E,ZW"TY^;$DA4+B3QQQ]#(C ;
<8_H<_H>1Z@CQ\^H0_(1'R-&>$H+=!S MD0I^(QOE\D.:9?(*X6-3R*-13#.N(\^JR,Z9R#9ZH(58[_Y* M'^GU(XW>E+W8=*7SUI7WCA;X+18]9/DWR+$&=2,YKD<=^:"QB_H7W0GT
-F+W*@_<+Y M%A"U4!]RSXW57DEW+QR!NCSU(#V%A 60L! 2%@'!6I[V&T_[VMOWZS9?$(;HLLD: M\K;M'*3OM:!KK86$!9"PL(+U2YB:[>VFMN?[[MC<'7OVJ[U:9@P;,P9;,[Z7
MLRN2(+PC3,X6T8:E,>GR0LNYU@M(6)"R%A407SCRQS>Z,SC@T;QX9:QTZ' MQ"LSH!9^K8V0L 2%D+"(B!8RVZ_L=M_=P;T(3V%A 60L! 2%@'!6IZ.&D]' M4!E0"[K6VM%/&
<1Q1M:0;R>: #)F" F+@& MTVSK\#1L >5*/>A:VVK<1KQ M>D/GQ#70F"$H+8*BM8T[*F/86N/^H@)G:,4HY](S&A.2=.9&/>9]V^KBBG,\ M8^O9I[9!Q@Q!:1$4K6V;<[#-
N7:F,Z.%O/=$NL@(2LA"-3W20]1+_-IL+>N: MY:V)EI2A*&5+:X(3PM0.[O2C140VQA#Z7T/_;RAGF.TQ)_U?#LI1NZUCE]- M XMAA<.Z6$:#K)";FHF("YC,-&?!
(Q5#,J:"3Q0'5D9S+E8NW(' M!"%"K0I M5F.E#9'JR<%MUX,ZKG5R+@ME<[L,[O>D'KX'K'M@D O1&.P0%Q@-2JHU4_+& M=.Q@&WP&!77[?E4:AS-%5^U.EVP(]F:23 J5,M6D:9-
U:#00+ ,[BL_F<-=% M&0*H=9&;1LKIK)#4>E@SZH:1G3(A]N A_YGM:"^SK3VU.RJ;IC%4-YV,ZX^ ^ MMIK3WI:-7J0;E/RQT%)69CK2]]%6V*UB&5 ;_C)K#&#J;5R=EJ58?19\)G/F
M)G]TPM& KGG!O%#\R62#4IF: %,D>&1*\^EVY+>BY3U;ZG4Y+3/<<^<$/?_; M=9XQR105VZ9-[;_E57ZQXZCW6I;MM\J^8;_'^LW]UDUV3\%D? HF3Z(F^Z=@
M,CD!D[U7^]8\:#*L3QE;1YF=@TP3#>#_"0_X&@J-DF#R8(+S67=F_,T9?+9 M><;(:SHQ?PKMZ)OQ*W#O?12NWU/AYO^#HS]02P,$% @ O(!H69>*NQS M $P(L !?
3T\$MP>:4#M.*2VBZD8_1\2:5K5N %(MB6/ M:(7->=I3W;+T]!;X"O M.DQO0FE(2S,.\W2?S+W\PPU1>5*(Y5;&GC3YZYVXS$G1H2)8%II%R=.B':5_
M'4*:F:^]C5(5[-0NF;6/>IE:M8:6&56 M +86*>WUAFG-N$RN+G=]S70:/B@+I>5*ND)?\,3AU?RI]XDPPV?<\'M^RAI M[P4DL:2U_P#JE'22XA9J=AIU8+'@[Q5L@)IH"+NSBC!*\=1
MD1LFF"R!!) 4@:0=0OZB 62.0.:=0!8>Q[T:0/81R'Z'D'N1'""0@RXA\P!R MB$ .NX3L!Y"G".1IEY"# /(,@3SK$G(80)XCD.=Q(>^9;300M2 WC>$2C G7 M[QZV@/?BDA5-73/]
[M$*OI35O[R=X+ M'Z:6:+);QC"W(0MFD"RR0HH5T[!2H@)M/T)2^-2AI -$T<6W1QUS:UO9 B3 M[;=]768%LN3[DXF)(XMLCHL^Z1MS4PIEW'H70F*&R"(K8BH-=Q\%>=2L\K-
[K35S M_[V#&<8$D44V!+H.[Z56%-,%[5(7>\D5Q71[_LNR(G;X0DPGT- =$L2?4^" MK(?D),3$E$(C*^5P13P:2CU+EF&+RV(HY
MDL8>I\0.DT<_^4(6\/U#):>>^1)BHH=?'7CFV(QCHLDCB^8@!S^,B'DF M;SV3[@Z/*U@X857WKGOCRDLFRIDF_K+=U_8'/B5=-$+:=8M3N+WIVC M7_T&4$L#!!0 (+R :%E+BJ
+&PO7W)E:',O=V]R M:V)O;VLN>&UL+G)E;'-V$UNPC 0AN&K1#X SLS9E9P&K;MA67" *AB#RI]A5 MX?:-PB)\41?=(,\]1=Y^N3(+UZ;VQ;7UR;T:I\$10CMA]4^+UR5
M^5G3NKI_%$QL8.8@CB M^$$"01(: Y!_A!"PA:Q]:0M R?M *@E;Q@]80M(X?M(&@3?P@2E'&5$'2 M!&L%6A-R30]\)@2;%(A-2#8I,)L0;5*@-B';I,!M0KA)@=R$=),"NPGQ)@5Z
M,^K-"O1FU]L5Z,V3GVT%>C/]S0KT9M2;%>C-]#K$!O1KU9 M@=Z,>K,"O07U%@5Z"^HM"O06U%L4Z"V3PQ(%>@QI+0KT%M1;WIFW#X_2^;'G MN<;]WTEUZ-
]UX_;#\GES\D$-.%LX8-W_ E!+ P04_" "\@&A9WR$G&Y(! M #Y%0 $P %M#;VYT96YT7U1Y<&5S72YX;6S-F,UNPC 0A%\ERA418Z>E M/P(N;:\MA[Z FVR(11);MJ'P]G7"C]2*1B
J=2ZQ$N ,C+W2=\CD?6O(19NZ M:MPT+KTWCXRYK*1:ND0;:L).H6TM?7BU"V9DMI0+8F(T&K-,-YX:/_2M1CR;
M/%,A5Y6/7C;ALU.ZF<:6*A='3[O"UFL:2V,JE4D?]MFZR7^X#/<.2>CL:ERI MC!N$@IB==&AW?C?8][VMR5J54S27UK_*.E2Q3<6&UL4$L! A0#% M @ O(!H60)FM.'G!0 WQ\ !@
("!#@@ 'AL+W=O&PO=V]R:W-H965T&UI4$L! A0#% @ O(!H6=5E6MSC' YOT! !@ M ("![24 'AL+W=O&PO=V]R:W-H965T&UI4$L! A0#% M @ O(!H61Z?#/U!% $CH !D ("!GTX
'AL+W=O,B/P) #"(@ &0 M@(%)@@ >&PO=V]R:W-H965T&UI4$L! A0#% @ O(!H6892-UR"!0 NQ0 !D M ("!/), 'AL+W=O&PO=V]R M:W-H965T< !X;"]W;W)K&UL M4$L! A0#% @
O(!H60!ZCZM# @ B@8 !D ("!/I\ M 'AL+W=O&PO=V]R:W-H965T&UI4$L! A0#% @ MO(!H64,WD:%] @ V04 !D ("!3[L 'AL+W=O&PO=V]R:W-H965T&UI4$L! A0#% @
O(!H6&PO=V]R:W-H965T4QQ , ' 3 9 " @23; !X;"]W;W)K&UL4$L! A0#% @ O(!H665\N%QT P 7PX !D M ("!']\ 'AL+W=O&PO=V]R:W-H M965T&UI4$L! M A0#% @
O(!H683K*R:W&0 Y>0! !D ("!E/$ 'AL M+W=O@% M !X+ &0 @(&""P$ >&PO=V]R:W-H965T&UI4$L! A0#% @ O(!H M69]_ACQW!P :C(!D ("!0!4! 'AL+W=O&PO=V]R:W-H965T(A
0!X;"]S='EL M97,N>&UI4$L! A0#% @ O(!H69>*NQS $P(L M (!3B4! %]R96QS+RYR96QS4$L! A0#% @ O(!H6;+.T;(X P RQ< M \ (!-R8! 'AL+W=O7!E&UI4$L%!@ K - "L I L HM
0 $! end XML 48 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by
government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show=
{};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE')
{var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }
.report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color:
#2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height:
150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */
.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px
solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color:
#000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /*
word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover {
background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0;
} /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-
color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */
.report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; }
.report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width:
17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; }
.report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 194 235 1 true 46 0 false 6 false false R1.htm 995200090 -
Document - Document And Entity Information Sheet http://soligenix.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false
R2.htm 995200100 - Statement - Condensed Consolidated Balance Sheets Sheet http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets Condensed
Consolidated Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet
http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false
R4.htm 995200200 - Statement - Condensed Consolidated Statements of Operations Sheet http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations
Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 995200205 - Statement - Condensed Consolidated Statements of Operations
(Parenthetical) Sheet http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical Condensed Consolidated Statements of Operations
(Parenthetical) Statements 5 false false R6.htm 995200300 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet
http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 6 false
false R7.htm 995200400 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) Sheet
http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit Condensed Consolidated Statements of Changes in
Shareholders' Equity/(Deficit) Statements 7 false false R8.htm 995200405 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit)
(Parenthetical) Sheet http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficitParenthetical Condensed Consolidated
Statements of Changes in Shareholders' Equity/(Deficit) (Parenthetical) Statements 8 false false R9.htm 995200500 - Statement - Condensed Consolidated Statements of Cash
Flows Sheet http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 9 false false
R10.htm 995210101 - Disclosure - Nature of Business Sheet http://soligenix.com/role/DisclosureNatureOfBusiness Nature of Business Notes 10 false false R11.htm 995210201
- Disclosure - Summary of Significant Accounting Policies Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant
Accounting Policies Notes 11 false false R12.htm 995210301 - Disclosure - Accrued Expenses Sheet http://soligenix.com/role/DisclosureAccruedExpenses Accrued Expenses
Notes 12 false false R13.htm 995210401 - Disclosure - Debt Sheet http://soligenix.com/role/DisclosureDebt Debt Notes 13 false false R14.htm 995210501 - Disclosure -
Shareholders' Equity Sheet http://soligenix.com/role/DisclosureShareholdersEquity Shareholders' Equity Notes 14 false false R15.htm 995210601 - Disclosure - Commitments
and Contingencies Sheet http://soligenix.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 995210701 -
Disclosure - Operating Segments Sheet http://soligenix.com/role/DisclosureOperatingSegments Operating Segments Notes 16 false false R17.htm 995210801 - Disclosure -
Subsequent Events Sheet http://soligenix.com/role/DisclosureSubsequentEvents Subsequent Events Notes 17 false false R18.htm 995410 - Disclosure - Pay vs Performance
Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 18 false false R19.htm 995445 - Disclosure - Insider Trading Arrangements
Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm 99920202 - Disclosure - Summary of Significant
Accounting Policies (Policies) Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies

(Policies) Policies http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPolicies 20 false false R21.htm 99930203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPolicies 21 false false R22.htm 99930303 - Disclosure - Accrued Expenses (Tables) Sheet http://soligenix.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://soligenix.com/role/DisclosureAccruedExpenses 22 false false R23.htm 99930603 - Disclosure - Commitments and Contingencies (Tables) Sheet http://soligenix.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://soligenix.com/role/DisclosureCommitmentsAndContingencies 23 false false R24.htm 99930703 - Disclosure - Operating Segments (Tables) Sheet http://soligenix.com/role/DisclosureOperatingSegmentsTables Operating Segments (Tables) Tables http://soligenix.com/role/DisclosureOperatingSegments 24 false false R25.htm 99940101 - Disclosure - Nature of Business (Details) Sheet http://soligenix.com/role/DisclosureNatureOfBusinessDetails Nature of Business (Details) Details http://soligenix.com/role/DisclosureNatureOfBusiness 25 false false R26.htm 99940201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 99940202 - Disclosure - Summary of Significant Accounting Policies - Fair value of convertible debt (Details) Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails Summary of Significant Accounting Policies - Fair value of convertible debt (Details) Details 27 false false R28.htm 99940203 - Disclosure - Summary of Significant Accounting Policies - Loss per share (Details) Sheet http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails Summary of Significant Accounting Policies - Loss per share (Details) Details 28 false false R29.htm 99940301 - Disclosure - Accrued Expenses (Details) Sheet http://soligenix.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://soligenix.com/role/DisclosureAccruedExpensesTables 29 false false R30.htm 99940401 - Disclosure - Debt (Details) Sheet http://soligenix.com/role/DisclosureDebtDetails Debt (Details) Details http://soligenix.com/role/DisclosureDebt 30 false false R31.htm 99940501 - Disclosure - Shareholders' Equity (Details) Sheet http://soligenix.com/role/DisclosureShareholdersEquityDetails Shareholders' Equity (Details) Details http://soligenix.com/role/DisclosureShareholdersEquity 31 false false R32.htm 99940601 - Disclosure - Commitments and Contingencies (Details) Sheet http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://soligenix.com/role/DisclosureCommitmentsAndContingenciesTables 32 false false R33.htm 99940602 - Disclosure - Commitments and Contingencies - Maturity (Details) Sheet http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails Commitments and Contingencies - Maturity (Details) Details 33 false false R34.htm 99940701 - Disclosure - Operating Segments (Details) Sheet http://soligenix.com/role/DisclosureOperatingSegmentsDetails Operating Segments (Details) Details http://soligenix.com/role/DisclosureOperatingSegmentsTables 34 false false R35.htm 99940801 - Disclosure - Subsequent Events (Details) Sheet http://soligenix.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://soligenix.com/role/DisclosureSubsequentEvents 35 false false All Reports Book All Reports sngx-20240930.xsd sngx-20240930_cal.xml sngx-20240930_def.xml sngx-20240930_lab.xml sngx-20240930_pre.xml sngx-20240930x10q.htm http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT {


```
"version": "2.2", "instance": { "sngx-20240930x10q.htm": { "nsprefix": "sngx", "nsuri": "http://soligenix.com/20240930", "dts": { "schema": { "local": [ "sngx-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] }, "calculationLink": { "local": [ "sngx-20240930_cal.xml" ] }, "definitionLink": { "local": [ "sngx-20240930_def.xml" ] }, "labelLink": { "local": [ "sngx-20240930_lab.xml" ] }, "presentationLink": { "local": [ "sngx-20240930_pre.xml" ] }, "inline": { "local": [ "sngx-20240930x10q.htm" ] } }, "keyStandard": 190, "keyCustom": 45, "axisStandard": 18, "axisCustom": 0, "memberStandard": 24, "memberCustom": 22, "hidden": { "total": 25, "http://fasb.org/us-gaap/2023": 20, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 194, "entityCount": 1, "segmentCount": 46, "elementCount": 456, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 546, "http://xbrl.sec.gov/dei/2023": 30, "http://xbrl.sec.gov/ecd/2023": 4, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://soligenix.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_tU2VzWghcEKJNGub49pRyg", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_YcqzhL3yykiYEIMOMwVe6Q", "name": "us-gaap:UnbilledReceivablesCurrent", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_tU2VzWghcEKJNGub49pRyg", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_2oBPuvJ5402-0NNzNpAfTA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_tU2VzWghcEKJNGub49pRyg", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Unit_Standard_shares_2oBPuvJ5402-0NNzNpAfTA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "995200200 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023__ZRWKXnqdEmvMKCh-pZx5Q", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023__ZRWKXnqdEmvMKCh-pZx5Q", "name": "us-gaap:CostOfRevenue", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical", "longName": "995200205 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)", "shortName": "Condensed Consolidated Statements of Operations (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": null, "uniqueAnchor": null }, "R6": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "longName": "995200300 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ooMmjpa4JEWJQJu0x0Kcqg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ooMmjpa4JEWJQJu0x0Kcqg", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "unique": true } }, "R7": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "longName": "995200400 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit)", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UBRYLgWUpE6JM4HONSxigQ", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UBRYLgWUpE6JM4HONSxigQ", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficitParenthetical", "longName": "995200405 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": null, "uniqueAnchor": null }, "R9": { "role": "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200500 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://soligenix.com/role/DisclosureNatureOfBusiness", "longName": "995210101 - Disclosure - Nature of Business", "shortName": "Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://soligenix.com/role/DisclosureAccruedExpenses", "longName": "995210301 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true
```

```
}, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://soligenix.com/role/DisclosureDebt", "longName": "995210401 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://soligenix.com/role/DisclosureShareholdersEquity", "longName": "995210501 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://soligenix.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210601 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://soligenix.com/role/DisclosureOperatingSegments", "longName": "995210701 - Disclosure - Operating Segments", "shortName": "Operating Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://soligenix.com/role/DisclosureSubsequentEvents", "longName": "995210801 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ooMmjpa4JEWJQJu0x0Kcqg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ooMmjpa4JEWJQJu0x0Kcqg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ooMmjpa4JEWJQJu0x0Kcqg", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://soligenix.com/role/DisclosureAccruedExpensesTables", "longName": "99930303 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "99930603 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://soligenix.com/role/DisclosureOperatingSegmentsTables", "longName": "99930703 - Disclosure - Operating Segments (Tables)", "shortName": "Operating Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "longName": "99940101 - Disclosure - Nature of Business (Details)", "shortName": "Nature of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_VxCQyLWAbUaOJvzkzpWdrg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_YcqzhL3yykiYEIMOMwVe6Q", "name": "sngx:WorkingCapitalCarryingValue", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "unique": true } }, "R26": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_VxCQyLWAbUaOJvzkzpWdrg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ooMmjpa4JEWJQJu0x0Kcqg", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "p", "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "unique": true } }, "R27": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails", "longName": "99940202 - Disclosure - Summary of Significant Accounting Policies - Fair value of convertible debt (Details)", "shortName": "Summary of Significant Accounting Policies - Fair value of convertible debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:RepaymentsOfConvertibleDebt", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_F2ijQLOCF0KqkQY1za6pbw", "name": "us-gaap:ConvertibleDebt", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "unique": true } }, "R28": { "role": "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails", "longName": "999940203 - Disclosure - Summary of Significant Accounting Policies - Loss per share (Details)", "shortName": "Summary of Significant Accounting Policies - Loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_2oBPuvJ5402-0NNzNpAfTA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_2oBPuvJ5402-0NNzNpAfTA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique":
```

```
true } }, "R29": { "role": "http://soligenix.com/role/DisclosureAccruedExpensesDetails", "longName": "99940301 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_9_30_2024_tU2VzWghcEKJNGub49pRyg", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_tU2VzWghcEKJNGub49pRyg", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://soligenix.com/role/DisclosureDebtDetails", "longName": "99940401 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_12_31_2023_YcqzhL3yykiYElMOMwVe6Q", "name": "us-gaap:LongTermDebt", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_kwPDhmdYO0WWMTkVA2HKfg", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "unique": true } }, "R31": { "role": "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "longName": "99940501 - Disclosure - Shareholders' Equity (Details)", "shortName": "Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_4_22_2024_5wM_fIcxMkOaEEdLojYdpw", "name": "us-gaap:SharePrice", "unitRef": "Unit_Divide_USD_shares_VT76DrMJb0yp4bbBiAjsbg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_9_2024_To_7_9_2024_PFPs44zXLUW9x-BCvVTIYA", "name": "sngx:WarrantIssuanceCosts", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "unique": true } }, "R32": { "role": "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99940601 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_9_30_2024_tU2VzWghcEKJNGub49pRyg", "name": "us-gaap:ContractualObligation", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_21_2022_aDYji-bYREmgw-f68FgeWg", "name": "sngx:LeaseRentalPerMonth", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "unique": true } }, "R33": { "role": "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails", "longName": "99940602 - Disclosure - Commitments and Contingencies - Maturity (Details)", "shortName": "Commitments and Contingencies - Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_9_30_2024_tU2VzWghcEKJNGub49pRyg", "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_tU2VzWghcEKJNGub49pRyg", "name": "us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "longName": "99940701 - Disclosure - Operating Segments (Details)", "shortName": "Operating Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_Jaeb72aibEOKfgyANR86fA", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_VxCQyLWAbUaQJvzkzpWdrg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ooMmjpa4JEWJQJu0x0Kcgg", "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization", "unitRef": "Unit_Standard_USD_7EVwmeb4J0O3wbrdBcE3mQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "unique": true } }, "R35": { "role": "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "longName": "99940801 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_sngx_AtMarketIssuanceSalesMember_DJw3EN5zyUOhCILTuhQlOA", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_2oBPuvJ5402-0NNzNpAfTA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "sngx-20240930x10q.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r15" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r576" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://soligenix.com/role/DisclosureAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/DisclosureAccruedExpensesDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Clinical trial expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r24", "r25", "r80", "r138", "r424", "r456", "r457" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r9", "r25", "r377", "r380", "r406", "r452", "r453", "r678", "r679", "r680", "r691", "r692", "r693" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r627" ] }, "us-gaap_AdditionalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalCashFlowElementsAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Additional Cash Flow Elements [Abstract]", "terseLabel": "Cash paid for lease liabilities:" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r75", "r576", "r740" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r354", "r355", "r356", "r467", "r691", "r692", "r693", "r720", "r742" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r633" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r633" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r633" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r633" ] }, "sngx_AdjustmentToEstimatedAccruedClinicalTrialExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "AdjustmentToEstimatedAccruedClinicalTrialExpenses", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of adjustment to estimated accrued clinical trial expenses.", "label": "Adjustment To Estimated Accrued Clinical Trial Expenses", "terseLabel": "Adjustment to estimated accrued clinical trial expenses" }
```

```
} }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r59", "r60", "r324" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails",
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Issuance costs associated with sales of common stock pursuant to At Market Issuance Sales Agreement", "verboseLabel": "Issuance costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r10", "r101" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Warrant modification - incremental fair value", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r10", "r47", "r101" ] }, "sngx_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedIssuanceCosts", "crdr": "debit", "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing warrants. Includes, but is not limited to, legal and accounting fees and direct costs associated with warrant issuances.", "label": "Adjustments to Additional Paid in Capital, Warrants Issued, Issuance Costs", "negatedLabel": "Issuance costs associated with warrant inducement" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r598", "r609", "r619", "r644" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r601", "r612", "r622", "r647" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r633" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r640" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r605", "r613", "r623", "r640", "r648", "r652", "r660" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r658" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred issuance costs associated with convertible debt", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r296", "r402", "r569", "r570", "r685" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Securities excluded", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r189" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [
"http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation": [
"http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "terseLabel": "Contingent consideration", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r716", "r717", "r718" ] }, "sngx_AssetPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "AssetPurchaseAgreementMember", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Asset Purchase Agreement.", "label": "Asset Purchase Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": {
"http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "verboseLabel": "Identifiable Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r103", "r134", "r161", "r198", "r219", "r225", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r370", "r374", "r388", "r419", "r501", "r576", "r589", "r709", "r710", "r727" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": {
"http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r131", "r140", "r161", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r370", "r374", "r388", "r576", "r709", "r710", "r727" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "sngx_AtMarketIssuanceSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "AtMarketIssuanceSalesAgreementMember", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to B. Riley Sales Agreement.", "label": "At Market Issuance Sales Agreement" } } }, "auth_ref": [] }, "sngx_AtMarketIssuanceSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "AtMarketIssuanceSalesMember", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails",
"http://soligenix.com/role/DisclosureSubsequentEventsDetails",
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "At market issuance sales is where sales agent will sell shares on behalf of the company.", "label": "At Market Issuance Sales [Member]", "terseLabel": "At Market Issuance sales" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r655" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r656" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r651" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r651" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r651" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r651" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [
```

```
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r651" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r651" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r349", "r350", "r351", "r352", "r353" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r654" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r653" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r652" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r652" ] }, "sngx_BioTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "BioTherapeuticsMember", "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "BioTherapeutics.", "label": "Specialized BioTherapeutics [Member]" } } }, "auth_ref": [] }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostNetNoncurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Capitalized Contract Cost, Net, Noncurrent", "terseLabel": "Research and development incentives receivable, net of current portion", "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent." } } }, "auth_ref": [ "r238" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r31" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r30", "r88", "r157" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r88" ] }, "sngx_ChangeInAccountingEstimatesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://soligenix.com/20240930", "localname": "ChangeInAccountingEstimatesPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for change in accounting estimate.", "label": "Change In Accounting Estimates [Policy Text Block]", "terseLabel": "Change In Accounting Estimates" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r631" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r117", "r135", "r136", "r137", "r161", "r182", "r183", "r186", "r188", "r192", "r193", "r233", "r261", "r264", "r265", "r266", "r272", "r273", "r303", "r304", "r307", "r310", "r317", "r388", "r461", "r462", "r463", "r464", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r489", "r511", "r529", "r539", "r540", "r541", "r542", "r543", "r666", "r686", "r695" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r135", "r136", "r137", "r192", "r303", "r304", "r305", "r307", "r310", "r315", "r317", "r461", "r462", "r463", "r464", "r571", "r666", "r686" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r318" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of common warrants to purchase shares issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r318" ] }, "sngx_ClassOfWarrantOrRightPercentageOfExistingWarrantSharesToNewWarrantShareIssues": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240930", "localname": "ClassOfWarrantOrRightPercentageOfExistingWarrantSharesToNewWarrantShareIssues", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of the number of shares issued on existing warrants that is agreed to be issued as part of new warrants as per the inducement agreement.", "label": "Class of Warrant or Right, Percentage Of Existing Warrant Shares To New Warrant Share Issues", "terseLabel": "Percentage of numbers of shares issued upon exercise of existing warrants" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r632" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r632" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Nature of business:", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r368" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "terseLabel": "Commitments and contingencies (Note 6)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r21", "r66", "r420", "r488" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for
```

commitments and contingencies." } } }, "auth_ref": ["r94", "r255", "r256", "r545", "r706"] }, "sngx_CommonStockIssuedEffectivePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://soligenix.com/20240930", "localname": "CommonStockIssuedEffectivePricePerShare", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Common Stock Issued Effective Price Per Share", "terseLabel": "Effective price per share (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Common Stock", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r579", "r580", "r581", "r583", "r584", "r585", "r586", "r691", "r692", "r720", "r738", "r742"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r74"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r74", "r489"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r74"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r74", "r489", "r507", "r742", "r743"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $.001 par value; 75,000,000 shares authorized; 2,295,304 and 648,761 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r74", "r422", "r576"] }, "sngx_CommonStockValueOfSharesReservedForFutureIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "CommonStockValueOfSharesReservedForFutureIssuance", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The aggregate value of common shares reserved for future issuance as per the agreement.", "label": "Common Stock, Value Of Shares Reserved for Future Issuance", "terseLabel": "Aggregate value of shares remaining from agreement" } } }, "auth_ref": [] }, "sngx_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "CommonWarrantsMember", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common warrants.", "label": "Common Warrants [Member]", "terseLabel": "Common warrants" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r637"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r636"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r638"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r635"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r26", "r142", "r144", "r149", "r415", "r431"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r164", "r200", "r217", "r218", "r219", "r220", "r221", "r223", "r227", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r271", "r272", "r671", "r672", "r709", "r710"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r164", "r200", "r217", "r218", "r219", "r220", "r221", "r223", "r227", "r261", "r262", "r263", "r264", "r266", "r267", "r269", "r271", "r272", "r671", "r672", "r709", "r710"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r62", "r554"] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligation", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails"], "lang": { "en-us": { "role": { "label": "Contractual Obligation", "terseLabel": "Contractual obligation", "totalLabel": "Total", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": ["r689"] }, "us-gaap_ContractualObligationDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInFourthYear", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails"], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInNextTwelveMonths", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails"], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInSecondYear", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails"], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInThirdYear", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails"], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleAbstract", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails"], "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]" } } }, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of contractual obligation", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": ["r690"] }, "us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails"], "lang": { "en-us": { "role": { "label": "Contractual Obligation, to be Paid, Remainder of Fiscal Year", "terseLabel": "October 1 through December 31, 2024", "documentation": "Amount of contractual obligation to be paid in remainder of current

fiscal year." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails"], "lang": { "en-us": { "role": { "label": "Convertible Debt.", "periodEndLabel": "Convertible debt at fair value as of June 30, 2024", "periodStartLabel": "Convertible debt at fair value as of December 31, 2023", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": ["r12", "r105", "r736"] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Convertible Debt, Current", "terseLabel": "Convertible debt", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r70"] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Convertible debt fair value", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails"], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "terseLabel": "Convertible debt", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": ["r96", "r275", "r276", "r286", "r287", "r288", "r292", "r293", "r294", "r295", "r296", "r566", "r567", "r568", "r569", "r570"] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Convertible debt securities", "terseLabel": "Convertible debt", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": ["r715"] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtTableTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of fair value of convertible debt", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable", "terseLabel": "Convertible note", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": ["r12", "r105", "r736"] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Corporate [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": ["r11", "r218", "r219", "r220", "r221", "r227", "r697"] }, "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cost, Depreciation and Amortization", "terseLabel": "Amortization and depreciation", "verboseLabel": "Amortization and Depreciation Expense", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service." } } }, "auth_ref": ["r681"] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "negatedLabel": "Cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r84", "r161", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r388", "r709"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r127", "r162", "r163", "r278", "r305", "r407", "r551", "r553"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Pontifax conversion of portion of debt principal into common stock", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r33", "r34"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": ["http://soligenix.com/role/DisclosureDebt"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r95", "r159", "r274", "r280", "r281", "r282", "r283", "r284", "r285", "r290", "r297", "r298", "r300"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r12", "r70", "r71", "r104", "r105", "r164", "r275", "r276", "r277", "r278", "r279", "r281", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r403", "r566", "r567", "r568", "r569", "r570", "r687"] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": ["r97", "r277"] }, "sngx_DebtInstrumentConvertibleNumberOfSharesToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://soligenix.com/20240930", "localname": "DebtInstrumentConvertibleNumberOfSharesToBeIssued", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "The total number of shares that the holder of the debt instrument would receive if the debt was converted to equity.", "label": "Debt Instrument, Convertible, Number of Shares To Be Issued", "terseLabel": "Common stock issuable upon conversion" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt instrument, face amount", "terseLabel": "Debt instrument, face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r64", "r65", "r275", "r403", "r567", "r568"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r19", "r276"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt instruments", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r164", "r275", "r276", "r277", "r278", "r279", "r281", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r299", "r403", "r566", "r567", "r568", "r569", "r570", "r687"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r20", "r164", "r275", "r276", "r277", "r278", "r279", "r281", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r403", "r566", "r567", "r568", "r569", "r570", "r687"] }, "sngx_DebtInstrumentPeriodPrincipalPaymentDeferred": { "xbrltype": "durationItemType", "nsuri": "http://soligenix.com/20240930", "localname": "DebtInstrumentPeriodPrincipalPaymentDeferred", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "The period during which payment on the debt is for interest only, and payments of principal are deferred until after this period.", "label": "Debt Instrument, Period Principal Payment Deferred", "terseLabel": "Interest-only period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Outstanding principal periodic payment", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": ["r20"] }, "sngx_DebtInstrumentReductionInConversionPriceNotice": { "xbrltype": "perShareItemType", "nsuri": "http://soligenix.com/20240930", "localname": "DebtInstrumentReductionInConversionPriceNotice", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the reduction in conversion price.", "label": "Reduction in conversion price", "terseLabel": "Reduction in conversion price" } } }, "auth_ref": [] }, "sngx_DebtInstrumentReductionInConversionPricePercentageOfClosingPriceClosingPriceOfCommonStockOnDayBeforeDeliveryOfConversionNotice": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240930", "localname": "DebtInstrumentReductionInConversionPricePercentageOfClosingPriceClosingPriceOfCommonStockOnDayBeforeDeliveryOfConversionNotice", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the reduction in conversion price to percentage of closing price of the common stock on the day before the delivery of the conversion notice.", "label": "Reduction in conversion price as percentage of closing price of the common stock on the day before the delivery of the conversion notice", "terseLabel": "Reduction in conversion price as percentage of closing price of the common stock on the day before the delivery of the conversion notice" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRepaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Repaid, Principal", "negatedLabel": "Principal Repayments", "documentation": "Amount of principal of debt repaid." } } }, "auth_ref": ["r464"] }, "us-

gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r20", "r53", "r56", "r63", "r64", "r65", "r67", "r99", "r100", "r164", "r275", "r276", "r277", "r278", "r279", "r281", "r286", "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r295", "r296", "r299", "r403", "r566", "r567", "r568", "r569", "r570", "r687"] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Issuance Costs", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": ["r133"] }, "us-gaap_DeferredCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Current", "terseLabel": "Deferred issuance cost", "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r677"] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deposits Assets, Noncurrent", "terseLabel": "Security deposit", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r673"] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Directors", "documentation": "Person serving on board of directors." } } }, "auth_ref": ["r698", "r739"] }, "sngx_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://soligenix.com/20240930", "localname": "DocumentAndEntityInformationAbstract", "lang": { "en-us": { "role": { "label": "Document And Entity Information" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r593"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r626"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share (in Dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r150", "r170", "r171", "r172", "r173", "r174", "r179", "r182", "r186", "r187", "r188", "r190", "r384", "r385", "r416", "r432", "r556"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share (in Dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r150", "r170", "r171", "r172", "r173", "r174", "r182", "r186", "r187", "r188", "r190", "r384", "r385", "r416", "r432", "r556"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r35", "r36"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r394"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r17"] }, "sngx_EmployeeRetentionCreditCaresAct": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "EmployeeRetentionCreditCaresAct", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Amount of income related to employee retention credit under CARES Act.", "label": "Employee retention credit, CARES ACT", "verboseLabel": "CARES Act Employee Retention Credit" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r591"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r591"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional

suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r591"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r665"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r591"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r591"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r591"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r591"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r10", "r128", "r145", "r146", "r147", "r165", "r166", "r167", "r169", "r175", "r177", "r191", "r234", "r235", "r319", "r354", "r355", "r356", "r365", "r366", "r376", "r377", "r378", "r379", "r380", "r381", "r383", "r395", "r396", "r397", "r398", "r399", "r400", "r406", "r452", "r453", "r454", "r467", "r529"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r634"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r598", "r609", "r619", "r644"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r595", "r606", "r616", "r641"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r640"] }, "sngx_ExistingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "ExistingWarrantsMember", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the existing warrants.", "label": "Existing Warrants [Member]", "terseLabel": "Existing Warrants" } } }, "auth_ref": [] }, "sngx_FairValueAdjustmentOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "FairValueAdjustmentOfConvertibleDebt", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of convertible debt.", "label": "Fair Value Adjustment of Convertible Debt", "negatedLabel": "Change in fair value of convertible debt", "terseLabel": "Change in fair value of convertible debt", "verboseLabel": "Adjustment to fair value" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r414"] }, "sngx_FirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "FirstTrancheMember", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "First tranche.", "label": "First Tranche [Member]", "terseLabel": "First tranche" } } }, "auth_ref": [] }, "sngx_ForPeriodFromNovember2024Member": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "ForPeriodFromNovember2024Member", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to rent from period November 2024.", "label": "For Period From November 2024 [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign currency transaction gain (loss)", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r390", "r391", "r392", "r393", "r526"] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), Realized", "terseLabel": "Foreign currency transaction gain (loss)", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r509", "r587", "r724", "r725", "r741"] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions and Translation", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r389"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r602", "r613", "r623", "r648"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r602", "r613", "r623", "r648"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r602", "r613", "r623", "r648"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r602", "r613", "r623", "r648"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r602", "r613", "r623", "r648"] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt", "terseLabel": "Loss on extinguishment of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r7", "r48", "r49"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r85", "r513"] }, "sngx_GovernmentGrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "GovernmentGrantsReceivableCurrent", "crdr": "debit", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Government Grants Receivable Current", "terseLabel": "Government grant funding" } } },

```
"auth_ref": [] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantMember", "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Grant revenue", "documentation": "Award of
money not required to be repaid." } } }, "auth_ref": [ "r714" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"GrossProfit", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-
gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": {
"en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly
attributable to the revenue generation activity." } } }, "auth_ref": [ "r83", "r161", "r198", "r218", "r224", "r227", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270",
"r272", "r273", "r388", "r558", "r709" ] }, "sngx_GuaranteeObligationsTermDuration": { "xbrltype": "durationItemType", "nsuri": "http://soligenix.com/20240930", "localname":
"GuaranteeObligationsTermDuration", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation":
"Guarantee Obligations Term Duration", "label": "Guarantee Obligations Term Duration", "terseLabel": "Term (in years)" } } }, "auth_ref": [] }, "sngx_HybryteMember": {
"xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "HybryteMember", "presentation": [
"http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "HyBryte", "label": "HyBryte" } } }, "auth_ref": [] }, "us-
gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": {
"en-us": { "role": { "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of long-lived assets", "documentation": "The amount of impairment loss
recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r685", "r704" ] }, "us-
gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang":
{ "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets", "documentation":
"Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to
be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r93" ] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label":
"Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before income taxes", "documentation": "Amount of income
(loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable
to noncontrolling interest." } } }, "auth_ref": [ "r1", "r81", "r107", "r198", "r218", "r224", "r227", "r417", "r428", "r558" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements
of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel":
"Income tax benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } }
}, "auth_ref": [ "r110", "r116", "r176", "r177", "r206", "r364", "r367", "r433" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang":
{ "en-us": { "role": { "label": "Income Taxes Paid", "terseLabel": "Cash paid for state income taxes", "documentation": "The amount of cash paid during the current period to
foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r29", "r32" ] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": {
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0,
"order": 6.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Accounts and Other Receivables", "negatedLabel": "Contracts and grants receivable", "documentation": "The increase (decrease) during the reporting period in
the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": [ "r6" ] }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": {
"role": { "label": "Change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": {
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 9.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } },
"auth_ref": [ "r669", "r684" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": {
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 10.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the
reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherEmployeeRelatedLiabilities", "crdr": "debit", "calculation": {
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 11.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Other Employee-Related Liabilities", "terseLabel": "Accrued compensation", "documentation": "Amount of increase (decrease) in employer-related costs
classified as other and current." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": {
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0,
"order": 8.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Other Receivables", "negatedLabel": "Research and development incentives receivable", "documentation": "Amount of increase (decrease) in receivables
classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense",
"negatedLabel": "Prepaid expenses and other current assets", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid
in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r6" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r605", "r613", "r623", "r640", "r648", "r652", "r660" ] }, "ecd_InsiderTradingArrLineItems":
{ "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading
Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r658" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies
and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r594", "r664" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel":
"Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r594", "r664" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
"terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r594", "r664" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": {
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } },
"presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Income (Expense),
Nonoperating, Net", "terseLabel": "Interest income (expense), net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-
gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation":
"Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for
accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted
interest of debt discount." } } }, "auth_ref": [ "r152", "r155", "r156" ] }, "sngx_IssuanceCostOfWarrantExercise": { "xbrltype": "monetaryItemType", "nsuri":
"http://soligenix.com/20240930", "localname": "IssuanceCostOfWarrantExercise", "crdr": "debit", "presentation": [
"http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": {
"role": { "documentation": "The amount of incremental fair value of warrants recognized as issuance cost of the warrant exercise.", "label": "Issuance Cost Of Warrant
Exercise", "terseLabel": "Warrant modification - incremental value" } } }, "auth_ref": [] }, "sngx_IssuanceOfCommonStockForPurchaseOption": { "xbrltype":
"monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "IssuanceOfCommonStockForPurchaseOption", "crdr": "debit", "calculation": {
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 15.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The
issuance of common stock for purchase option.", "label": "Issuance of Common Stock for Purchase Option", "terseLabel": "Issuance of common stock for purchase option" } }
}, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of Stock and Warrants for Services or
Claims", "terseLabel": "Issuance of common stock to vendors for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for
services rendered or acknowledged claims." } } }, "auth_ref": [ "r7" ] }, "us-gaap_LeaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "LeaseAgreementsMember", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-
us": { "role": { "label": "Lease Agreements [Member]", "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset." } } }, "auth_ref":
[ "r61" ] }, "sngx_LeaseRentalPerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "LeaseRentalPerMonth", "crdr": "credit",
"presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lease rental per
month", "label": "Lease Rental Per Month", "terseLabel": "Lease rent per month" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": {
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [
```

```
"http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r16", "r161", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r371", "r374", "r375", "r388", "r487", "r557", "r589", "r709", "r727", "r728" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r79", "r106", "r426", "r576", "r688", "r703", "r723" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and shareholders' equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r18", "r132", "r161", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r371", "r374", "r375", "r388", "r576", "r709", "r727", "r728" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Unused line of credit fee, as a percent", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "sngx_LoanAgreementAmendment2024ConversionPriceTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "LoanAgreementAmendment2024ConversionPriceTrancheOneMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to the conversion price as per the loan agreement amendment for the first tranche.", "label": "Loan Agreement Amendment 2024, Conversion Price, Tranche One [Member]", "terseLabel": "Conversion price for First 501,648 shares" } } }, "auth_ref": [] }, "sngx_LoanAgreementAmendment2024ConversionPriceTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "LoanAgreementAmendment2024ConversionPriceTrancheTwoMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to the conversion price as per the loan agreement amendment for the second tranche.", "label": "Loan Agreement Amendment 2024, Conversion Price, Tranche Two [Member]", "terseLabel": "Conversion price for Remaining shares" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://soligenix.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Outstanding principal", "verboseLabel": "Convertible debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r12", "r105", "r287", "r301", "r567", "r568", "r736" ] }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentTable", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment [Table]", "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r20" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r46" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r257", "r258", "r259", "r260", "r321", "r412", "r451", "r479", "r480", "r534", "r535", "r536", "r537", "r538", "r546", "r547", "r560", "r571", "r573", "r578", "r711", "r729", "r730", "r731", "r732", "r733", "r734" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r632" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r632" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Dividend yield", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r721" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected Term", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r721" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "volatility", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r721" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk free interest", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r721" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r386" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r651" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r659" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r633" ] }, "sngx_NationalInstitutesOfHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "NationalInstitutesOfHealthMember", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the National Institute of Health.", "label": "NIH" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash flows from financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r154" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": {
```

```
"en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash flows from operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r88", "r89", "r90" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r82", "r90", "r108", "r130", "r141", "r143", "r147", "r161", "r168", "r170", "r171", "r172", "r173", "r176", "r177", "r184", "r198", "r218", "r224", "r227", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r385", "r388", "r430", "r510", "r527", "r528", "r558", "r587", "r709" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss applicable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r151", "r170", "r171", "r172", "r173", "r179", "r180", "r185", "r188", "r198", "r218", "r224", "r227", "r558" ] }, "sngx_NewWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "NewWarrantsMember", "presentation": [ "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the new warrants.", "label": "New Warrants [Member]", "terseLabel": "New Warrants" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r632" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r602", "r613", "r623", "r640", "r648" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r630" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r629" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r640" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r659" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r659" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "sngx_NoncashOrPartNoncashDeferredIssuanceCostReclassifiedToAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "NoncashOrPartNoncashDeferredIssuanceCostReclassifiedToAdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Deferred issuance cost reclassified to additional-paid-in capital.", "label": "NoncashOrPartNoncashDeferredIssuanceCostReclassifiedToAdditionalPaidInCapital", "terseLabel": "Deferred issuance cost reclassified to additional paid-in capital" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income", "verboseLabel": "Other (Expense) Income, Net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r86" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "sngx_NumberOfFirstEquityInstrumentsCommonStockIssuableUponConversionMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "NumberOfFirstEquityInstrumentsCommonStockIssuableUponConversionMember", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to first shares of common stock issuable upon conversion.", "label": "First 36,790 shares of common stock issuable upon conversion" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r696" ] }, "sngx_NumberOfTranches": { "xbrltype": "stringItemType", "nsuri": "http://soligenix.com/20240930", "localname": "NumberOfTranches", "presentation": [ "http://soligenix.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of tranches.", "label": "Number of Tranches", "terseLabel": "Number of tranches" } } }, "auth_ref": [] }, "us-gaap_OneTimeTerminationBenefitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OneTimeTerminationBenefitsMember", "presentation": [ "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Termination benefits", "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities." } } }, "auth_ref": [ "r562", "r563", "r564", "r565" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "verboseLabel": "Income (loss) from Operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r198", "r218", "r224", "r227", "r558" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r405" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r405" ] }, "sngx_OperatingLeasePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "OperatingLeasePaid", "crdr": "credit", "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease.", "label": "Operating Lease Paid", "terseLabel": "Operating lease" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right-of-use lease assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r404" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash lease expense", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r685" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
```

"OperatingSegmentsMember", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r217", "r218", "r219", "r220", "r221", "r227"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Nature of Business" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusiness"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r69", "r102", "r458", "r459"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://soligenix.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://soligenix.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r17"] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsLineItems", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsTable", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments", "verboseLabel": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r4"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r87"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r632"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r600", "r611", "r621", "r646"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r603", "r614", "r624", "r649"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r603", "r614", "r624", "r649"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r628"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedLabel": "Stock issuance costs associated", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r27"] }, "sngx_PaymentsOfWarrantIssuanceCostsUponInducement": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "PaymentsOfWarrantIssuanceCostsUponInducement", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash outflow for the cost incurred directly with the issuance and modification of warrants as per the inducement agreement.", "label": "Payments Of Warrant Issuance Costs Upon Inducement", "negatedLabel": "Issuance costs associated with warrant inducement" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "terseLabel": "Cash paid to acquire intangible asset", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r109", "r716", "r717", "r718"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r631"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r631"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r630"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r640"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r633"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r629"] }, "sngx_PercentageOfOwnershipOutstandingStock": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240930", "localname": "PercentageOfOwnershipOutstandingStock", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership outstanding stock.", "label": "Percentage Of Ownership Outstanding Stock", "terseLabel": "Ownership of company outstanding" } } }, "auth_ref": [] }, "sngx_PontifaxMedisonFinanceMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "PontifaxMedisonFinanceMember", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Pontifax Medison Finance.", "label": "Pontifax Medison Finance [Member]", "terseLabel": "Pontifax" } } }, "auth_ref": [] }, "sngx_PreFundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "PreFundedWarrantMember", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to pre-funded warrants.", "label": "Pre-funded Warrant [Member]", "terseLabel": "Pre-funded warrants" } } }, "auth_ref": [] }, "sngx_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to pre-funded warrants.", "label": "Pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Preferred Stock", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r579", "r580", "r583", "r584", "r585", "r586", "r738", "r742"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r73", "r489"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": ["r73", "r303"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r73", "r489", "r507", "r742", "r743"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, 350,000 shares authorized; none issued or outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r73", "r421", "r576"] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r139", "r236", "r237", "r550"] },

"sngx_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds From Exercise Of Warrants", "negatedLabel": "Proceeds from the exercise of warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Total gross proceeds", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r5"] }, "sngx_ProceedsFromIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of proceeds from issuance of common stock and warrants.", "label": "Proceeds from Issuance of Common Stock and Warrants", "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants" } } }, "auth_ref": [] }, "sngx_ProceedsFromIssuanceOfCommonStockPursuantToMarketSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockPursuantToMarketSalesAgreement", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock pursuant to FBR At-the-Market Sales Agreement,", "label": "Proceeds From Issuance Of Common Stock Pursuant To Market Sales Agreement", "terseLabel": "Proceeds from issuance of common stock pursuant to At Market Issuance Sales Agreement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from the exercise of pre-funded warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r682"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": ["r229", "r413", "r445", "r446", "r447", "r448", "r449", "r450", "r549", "r572", "r577", "r670", "r707", "r708", "r713", "r737"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": ["r229", "r413", "r445", "r446", "r447", "r448", "r449", "r450", "r549", "r572", "r577", "r670", "r707", "r708", "r713", "r737"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r130", "r141", "r143", "r153", "r161", "r168", "r176", "r177", "r198", "r218", "r224", "r227", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r369", "r372", "r373", "r385", "r388", "r417", "r429", "r466", "r510", "r527", "r528", "r558", "r574", "r575", "r588", "r680", "r709"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Office furniture and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r8", "r418", "r427", "r576"] }, "sngx_PublicHealthSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "PublicHealthSolutionsMember", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Public Health Solutions [Member]" } } }, "auth_ref": [] }, "sngx_PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "PublicOfferingMember", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to public offering.", "label": "Public Offering", "terseLabel": "Public offering" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r628"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r628"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r257", "r258", "r259", "r260", "r320", "r321", "r350", "r351", "r352", "r411", "r412", "r451", "r479", "r480", "r534", "r535", "r536", "r537", "r538", "r546", "r547", "r560", "r571", "r573", "r578", "r581", "r705", "r711", "r730", "r731", "r732", "r733", "r734"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r257", "r258", "r259", "r260", "r320", "r321", "r350", "r351", "r352", "r411", "r412", "r451", "r479", "r480", "r534", "r535", "r536", "r537", "r538", "r546", "r547", "r560", "r571", "r573", "r578", "r581", "r705", "r711", "r730", "r731", "r732", "r733", "r734"] }, "us-gaap_ReceivablesLongTermContractsOrPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesLongTermContractsOrPrograms", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Research and development incentives receivable", "terseLabel": "Research and development incentives receivable, current", "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date." } } }, "auth_ref": ["r676"] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesPolicyTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Licensing, Contracts and Grants Receivable", "terseLabel": "Contracts and Grants Receivable", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": ["r699", "r700", "r701", "r702"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r595", "r606", "r616", "r641"] }, "sngx_RedemptionOfPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "RedemptionOfPreferredStock", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of redemption of preferred stock.", "label": "Redemption of Preferred Stock", "terseLabel": "Redemption liability for Series D preferred stock" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesFairValueOfConvertibleDebtDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayments of Convertible Debt", "negatedLabel": "Convertible debt repayments", "terseLabel": "Repayment of debt principal", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r28"] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Amount repaid", "terseLabel": "Amount repaid", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r683"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r162", "r163", "r278", "r305", "r407", "r552", "r553"] }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementMember", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureCommitmentsAndContingenciesMaturityDetails"], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement [Member]", "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": ["r68", "r363", "r735"] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate

research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r362"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r596", "r607", "r617", "r642"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r597", "r608", "r618", "r643"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r604", "r615", "r625", "r650"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r249", "r250", "r252", "r253"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r76", "r101", "r425", "r455", "r457", "r465", "r490", "r576"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r128", "r165", "r166", "r167", "r169", "r175", "r177", "r234", "r235", "r354", "r355", "r356", "r365", "r366", "r376", "r378", "r379", "r381", "r383", "r452", "r454", "r467", "r742"] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails"], "lang": { "en-us": { "role": { "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "terseLabel": "Revenue from collaborative arrangement", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": ["r111", "r719"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r512", "r548", "r555"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Revenues", "verboseLabel": "Total revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r148", "r161", "r199", "r200", "r217", "r222", "r223", "r229", "r231", "r232", "r233", "r261", "r262", "r264", "r265", "r266", "r268", "r270", "r272", "r273", "r388", "r417", "r709"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r659"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r659"] }, "sngx_SaleOfStockAggregateValueOfSharesToBeIssuedInTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "SaleOfStockAggregateValueOfSharesToBeIssuedInTransaction", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The aggregate value of shares to be issued or sold by the entity as per the stock transaction.", "label": "Sale of Stock, Aggregate Value of Shares To Be Issued in Transaction", "terseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "sngx_SaleOfStockCompensationPercentageOnGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://soligenix.com/20240930", "localname": "SaleOfStockCompensationPercentageOnGrossProceeds", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of the gross proceeds from sale of stock to be paid as compensation to the counter party as per the terms of stock transaction.", "label": "Sale Of Stock, Compensation Percentage On Gross Proceeds", "terseLabel": "Percentage of gross proceeds from sales of shares under ATM" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScenarioPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScenarioPlanMember", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Scenario, Plan [Member]", "documentation": "The scenario under which facts represent plans as distinct from actual." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": ["r178", "r322", "r667", "r694"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://soligenix.com/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive outstanding instruments which were not included in the computation of diluted EPS", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r368"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r44", "r45", "r414"] }, "sngx_ScheduleOfPotentiallyDilutiveAdjustmentsToTheWeightedAverageNumberOfCommonSharesExcludedFromTheCalculationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://soligenix.com/20240930", "localname": "ScheduleOfPotentiallyDilutiveAdjustmentsToTheWeightedAverageNumberOfCommonSharesExcludedFromTheCalculationAbstract", "lang": { "en-us": { "role": { "label": "Schedule of potentially dilutive adjustments to the weighted average number of common shares excluded from the calculation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r40", "r41", "r42", "r43"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of operating segments", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r40", "r41", "r42", "r43"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": ["r50", "r51", "r52", "r53", "r54", "r55", "r56", "r99", "r100", "r101", "r135", "r136", "r137", "r192", "r303", "r304", "r305", "r307", "r310", "r315", "r317", "r461", "r462", "r463", "r464", "r571", "r666", "r686"] }, "sngx_SecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "SecondTrancheMember", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Second tranche.", "label": "Second Tranche [Member]", "terseLabel": "Second tranche" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r590"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r592"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that

engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r195", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r232", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r251", "r254", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r561", "r670", "r737"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Operating Segments" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegments"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Operating Segments", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r194", "r195", "r196", "r197", "r198", "r210", "r221", "r225", "r226", "r227", "r228", "r229", "r230", "r232"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment reporting", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Operating Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r211", "r212", "r213", "r214", "r215", "r216", "r231", "r559"] }, "us-gaap_SeriesDPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesDPreferredStockMember", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Series D Preferred Stock", "documentation": "Series D preferred stock." } } }, "auth_ref": ["r674", "r675", "r712"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation", "verboseLabel": "Share-Based Compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights", "terseLabel": "Option vesting rights", "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r58"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of options issued", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r333"] }, "sngx_ShareBasedCompensationArrangementServicePeriod": { "xbrltype": "durationItemType", "nsuri": "http://soligenix.com/20240930", "localname": "ShareBasedCompensationArrangementServicePeriod", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for equity-based payment award.", "label": "Share - Based Compensation Arrangement Service Period", "terseLabel": "Requisite period (in years)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r349", "r350", "r351", "r352", "r353"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r323", "r328", "r347", "r348", "r349", "r350", "r353", "r357", "r358", "r359", "r360"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Share Price", "verboseLabel": "Shares issued price per share", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "sngx_SharebasedCompensationExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://soligenix.com/20240930", "localname": "SharebasedCompensationExpirationPeriod", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity based award expires.", "label": "Share based Compensation Expiration Period", "terseLabel": "Expiration period" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Fair value per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r91", "r158"] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://soligenix.com/role/DisclosureOperatingSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r129", "r195", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r232", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r251", "r254", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r561", "r670", "r737"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r117", "r135", "r136", "r137", "r161", "r182", "r183", "r186", "r188", "r192", "r193", "r233", "r261", "r264", "r265", "r266", "r272", "r273", "r303", "r304", "r307", "r310", "r317", "r388", "r461", "r462", "r463", "r464", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r489", "r511", "r529", "r539", "r540", "r541", "r542", "r543", "r666", "r686", "r695"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r23", "r128", "r145", "r146", "r147", "r165", "r166", "r167", "r169", "r175", "r177", "r191", "r234", "r235", "r319", "r354", "r355", "r356", "r365", "r366", "r376", "r377", "r378", "r379", "r380", "r381", "r383", "r395", "r396", "r397", "r398", "r399", "r400", "r406", "r452", "r453", "r454", "r467", "r529"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r165", "r166", "r167", "r191", "r413", "r460", "r478", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r502", "r503", "r504", "r505", "r506", "r508", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r529", "r582"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Changes in Shareholders' Equity/(Deficit)" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": ["r178", "r322", "r667", "r668", "r694"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": ["r165", "r166", "r167", "r191", "r413", "r460", "r478", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r502", "r503", "r504", "r505", "r506", "r508", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r529", "r582"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r599", "r610", "r620", "r645"] }, "sngx_StockAndPreFundedWarrantsIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://soligenix.com/20240930", "localname": "StockAndPreFundedWarrantsIssuedDuringPeriodShares", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "The number

of stock and pre-funded warrants issued during the period.", "label": "Stock and Pre-funded Warrants Issued During Period, Shares", "terseLabel": "Issuance of common stock and pre-funded warrants in connection with public offering (in shares)" } } }, "auth_ref": [] }, "sngx_StockAndPreFundedWarrantsIssuedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "StockAndPreFundedWarrantsIssuedDuringPeriodValue", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "The value of stock and pre-funded warrants issued during the period.", "label": "Stock and Pre-funded Warrants Issued During Period, Value", "terseLabel": "Issuance of common stock and pre-funded warrants in connection with public offering" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "sngx_StockIssuanceCostsIncludedInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "StockIssuanceCostsIncludedInAccountsPayable", "crdr": "debit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of stock issuance costs included in accounts payable.", "label": "Stock Issuance Costs Included in Accounts Payable", "terseLabel": "Offering costs included in accounts payable" } } }, "auth_ref": [] }, "sngx_StockIssuedDuringPeriodShareExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://soligenix.com/20240930", "localname": "StockIssuedDuringPeriodShareExerciseOfWarrants", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Number of shares issued on exercise of warrants.", "label": "Stock Issued During Period, Share Exercise Of Warrants", "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)", "verboseLabel": "Issuance of common stock upon exercise of warrant" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Number of shares issued on exercise of warrants", "verboseLabel": "Issuance of common stock associated with conversion of debt (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r10", "r22", "r53", "r101", "r291"] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of common stock to vendors (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares issued", "verboseLabel": "Issuance of common stock pursuant to At Market Issuance Sales Agreement (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r73", "r74", "r101", "r461", "r529", "r540"] }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Issuance of shares for assets (in shares)", "verboseLabel": "Issuance of common stock for purchase option (in shares)", "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "sngx_StockIssuedDuringPeriodSharesPursuantToMarketSalesAgreement": { "xbrltype": "sharesItemType", "nsuri": "http://soligenix.com/20240930", "localname": "StockIssuedDuringPeriodSharesPursuantToMarketSalesAgreement", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares pursuant to market sales agreement.", "label": "Stock Issued During Period Shares Pursuant To Market Sales Agreement", "netLabel": "Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "terseLabel": "Fractional shares issued in reverse stock split (in shares)", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": ["r10"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock associated with conversion of debt", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r10", "r23", "r101"] }, "sngx_StockIssuedDuringPeriodValueExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period on exercise of warrants.", "label": "Stock Issued During Period, Value, Exercise Of Warrants", "terseLabel": "Issuance of common stock upon exercise of warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of common stock to vendors", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock pursuant to At Market Issuance Sales Agreement", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r10", "r73", "r74", "r101", "r467", "r529", "r540", "r588"] }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Fair value of shares issued in connection with asset purchase", "verboseLabel": "Issuance of common stock for purchase option", "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "sngx_StockIssuedDuringPeriodValuePursuantToMarketSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "StockIssuedDuringPeriodValuePursuantToMarketSalesAgreement", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value pursuant to market sales agreement.", "label": "Stock Issued During Period Value Pursuant To Market Sales Agreement", "netLabel": "Sale of common stock pursuant to B. Riley At Market Issuance Sales Agreement" } } }, "auth_ref": [] }, "sngx_StockIssuedDuringPeriodValueReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period as a result of reverse stock split", "label": "Stock Issued During Period, Value, Reverse Stock Splits", "terseLabel": "Fractional shares issued in reverse stock split" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r74", "r77", "r78", "r92", "r491", "r507", "r530", "r531", "r576", "r589", "r688", "r703", "r723", "r742"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Shareholders' Equity" } } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r98", "r160", "r302", "r304", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r316", "r319", "r382", "r532", "r533", "r544"] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficitParenthetical", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock spilt effective from June 5, 2024", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": ["r13"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": ["http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r401", "r409"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r401", "r409"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": ["http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date

the financial statements were available to be issued." } } }, "auth_ref": ["r401", "r409"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r401", "r409"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails", "http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r401", "r409"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": ["http://soligenix.com/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r408", "r410"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r639"] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r261", "r264", "r265", "r266", "r272", "r273", "r361", "r423"] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Balance (Shares)", "periodStartLabel": "Balance (Shares)", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": ["r72"] }, "sngx_TemporaryEquityStockIssuedDuringPeriodValueStockDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "TemporaryEquityStockIssuedDuringPeriodValueStockDividend", "crdr": "credit", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"], "lang": { "en-us": { "role": { "documentation": "Value of stock classified as temporary equity issued to shareholders as a dividend during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, Stock Dividend", "terseLabel": "Redemption of Series D preferred stock" } } }, "auth_ref": [] }, "sngx_ThirdTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "ThirdTrancheMember", "presentation": ["http://soligenix.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Third Tranche [Member]", "terseLabel": "Third tranche" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "documentation": "Information by title of individual or nature of relationship to individual or group of individuals." } } }, "auth_ref": ["r698", "r726"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r631"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r638"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r658"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r660"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": ["http://soligenix.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r661"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r662"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r660"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r660"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r663"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r661"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRestructuringDomain", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r249", "r250", "r252", "r253"] }, "sngx_UkResearchAndDevelopmentIncentives": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "UkResearchAndDevelopmentIncentives", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "UK research and development incentives.", "label": "Uk Research And Development Incentives", "negatedLabel": "Research and development incentives" } } }, "auth_ref": [] }, "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnbilledReceivablesCurrent", "crdr": "debit", "calculation": { "http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Unbilled Receivables, Current", "terseLabel": "Unbilled revenue", "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r657"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates and Assumptions", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r37", "r38", "r39", "r112", "r113", "r114", "r115"] }, "sngx_WarrantIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "WarrantIssuanceCosts", "crdr": "debit", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The total costs of issuance of warrants incurred by the entity during the period.", "label": "Warrant Issuance Costs", "terseLabel": "Total issuance costs" } } }, "auth_ref": [] }, "sngx_WarrantIssuanceCostsFinancialAndLegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "WarrantIssuanceCostsFinancialAndLegalFees", "crdr": "debit", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of financial and legal fees incurred upon the issuance of warrants by the entity during the period.", "label": "Warrant Issuance Costs, Financial And Legal Fees", "terseLabel": "Financial advisory, banker, and legal fees" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": ["http://soligenix.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Warrants", "terseLabel": "Common stock purchase warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r579", "r580", "r583", "r584", "r585", "r586"] }, "sngx_WarrantModificationAndNewWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://soligenix.com/20240930", "localname": "WarrantModificationAndNewWarrantsMember", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the warrant modification and the new warrants.", "label": "Warrant Modification And New Warrants [Member]", "terseLabel": "Warrant modification and the new warrants" } } }, "auth_ref": [] }, "sngx_WarrantsAndRightsIssuedShares": { "xbrltype": "sharesItemType", "nsuri": "http://soligenix.com/20240930", "localname": "WarrantsAndRightsIssuedShares", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "documentation": "The

number of warrants issued that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights, Issued Shares", "terseLabel": "Aggregate warrants issued (shares)" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "terseLabel": "New warrants issued", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": ["http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants and rights outstanding", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": ["r387"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Expiration term of warrants", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r722"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted weighted average common shares outstanding (in Shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r181", "r188"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://soligenix.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted average common shares outstanding (in Shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r179", "r188"] }, "sngx_WeightedAverageSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://soligenix.com/20240930", "localname": "WeightedAverageSharePrice", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails", "http://soligenix.com/role/DisclosureShareholdersEquityDetails", "http://soligenix.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the weighted average share price for shares issued.", "label": "Weighted average price", "terseLabel": "Weighted average price", "verboseLabel": "Weighted average price (per share)" } } }, "auth_ref": [] }, "sngx_WorkingCapitalCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://soligenix.com/20240930", "localname": "WorkingCapitalCarryingValue", "crdr": "debit", "presentation": ["http://soligenix.com/role/DisclosureNatureOfBusinessDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of working capital carrying value.", "label": "Working Capital Carrying Value", "terseLabel": "Working capital" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB TOPIC 4.C)", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4",

"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210",

"Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "(m)", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r314": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-
40-50-7A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r453": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r454": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r455": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r456": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r457": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r458": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" },
"r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r461": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r462": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r463": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r464": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r465": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-
205-45-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-
205-50-7" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r472": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-
205-50-7" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r476": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r479": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-
220-45-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r510": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" },
"r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r513": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r514": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r515": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r516": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r517": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r518": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r519": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r520": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r521": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r522": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r523": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r524": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r525": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r526": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r527": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r528": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r530": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r531": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r532": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r540": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-
505-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r544": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-
310-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r548": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic":
"235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-
45-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r554": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r557": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-
10-55-47" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-
10-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r564": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r565": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r566": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r569": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-
10-50-13" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r573": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" },
"r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r578": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-
210-50-6" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r588": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "d1-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q",
"Number": "240", "Section": "308", "Subsection": "a" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section":
"16", "Subsection": "J", "Paragraph": "a" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection":
"F", "Paragraph": "1", "Subparagraph": "i" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r600": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"D" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section":
"19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-
F", "Section": "19", "Paragraph": "b" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r630": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r635": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "i" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r639": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" },
"r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "6", "Subparagraph": "i" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r644": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
```

"Subparagraph": "i", "Sentence": "B" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r666": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r667": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r668": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r715": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 55 0001558370-24-015054-xbrl.zip
IDEA: XBRL DOCUMENT begin 644 0001558370-24-015054-xbrl.zip M4$L#!!0 (+R :%DI;43G;PX #*/ 1 "TR,#(T,#DS,"YX M]Z:#3[N_?+E;S]]^OM@\,?
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
NSH,T;"B@3ETQCC3*IR>GJ#M#PZL@16+A, ^Q5"LIU@KE6H'@3\-=<3L= M^2!@S+_HS[,29"M+8+:OEN?;SNL0K;PQPBHUX(O;I7CV7@5
MQ<\J.!9P&@$]@KHM@/+FUG;+GIHZT-IX2W!$@M<*Y_IK2=K(YP58 3ZN!G0 MJ9XL[*H'O '@1"ZN7>^E/M QHQ'@DX8 0P^6J[('-@+VDDG;]:0OZ,BVA4^=
MJ_4*#2DQJ2+,#5$T4I5"=OH>IN0AH+05 U]"258DRGH7"OMGCTX6'0A.2Z;T M*X\XSB'%.!#;C,H[HGS!U*8 L1I<)A0_'!SMHIB0;A&NI]]6/K1'7?3HY] ; M[AM%_P,\5V
]M;F!M%DL]>!#-*M0&L/FP2F&S4A&\B/(LP*!5D)BCU2#2N2! M'*!;4,5 L=IE29J[0HURTJ1&L=ZE^NFG9*N:I3;B5<14]&8]0E]4S?1.\!V2 MW06!M4[>*
<%V'+AN0X5\NHO7Z^I,V8S53L+-DLTNL;[ANEQT+7%N)7L_![6 MT/WP73B WE->Q5-:A9&ZXBOX4*/P4MF'^NACSOGO,7>FX[FY+QFGL]@D*R(S M9?.'V9HL$(5
1L+ZO+T.H2=_N21B,YXJL3EGX-D$B"VO;AQ5UTJ/<'N5KPL2_B.M3W+/DSU0H?#IX2:>]%?YF ML6;/R%3M-3QC8,$(K&<<< M+;VT%8#HRB=YWVKH-[S0]4Z!6SE;/D"3*[QW$K M]\
^+:@]+(F]]NY0Y@XET:#,C'Z?C?67_50T3<6HQESMF M "H6.CT@M!=]ZDO0QD!/R-1M"G/(6P[R<2#"P:7'E\I:CM9,7GI+PGAX6CZ; M(U9@*0^#^DWG=%X8RM1G6@*I%HJU
KE6)/A ,R!^&NZN02FX&Z X.J86_68@)J642NKPG #_O05>A?-7K=WNQ2I=>('#_4Z[7L MUH2\KG-9\%M\.\, ?OH<'@V.#YN-(O?*C"(SF#CU=UD/A.P%,A4-$3&@!4X: M([!
[ET>5SETA4EPX@E/$X/!#Y7$4W3=![4] +5Q .*KSE[$/N -U?[\"8MW?WG/;S9 MQ?%=.IX]> 1^9L1U-Y?,]15/IB/GW[!Z/16!-UG0WRF;+\"[1\^0Y,_IO;^<
M4]'O1UAZP;$/>;6V7=^ASK7PEL!QL5U\1E.I!+'#YVV8@_SY(SH/TB)]<\T9 M_ :5RHVB2UR^P,@^D#'E(\=7X?FKB) !R9Y%0B&?]Y3P@9P5U\72)OH>T$)N
MPSQGHKMQ?!$>H2VR_V_?'F%=A\1I H"Z@ F9$37WA2/5+; M)5+]V!TFWLAQ=$9.7%3WAE^0%5/143UME.\L]\W8\W=/? -7" = ^ ;Z^@;_Z MU$K",J54K71M.NN#I%T5*Y:(8X@?
=:YF,VICL'\0S*;148N$DI4Y H7C^ -P M7+KE>P-<2U\8'BYFL,*/9^,73H5VO*.8TB1T*VC?U<71VPH_-(VY9D*J"2POD-%EU,AK[* .#_[4
M9?:OE+A]\>2YNNLL)[54'=3]B=H>=X](@R6WMH!;3!1.%2N0U=E"'LIMS=I+3LKLOX=IRA) 8TL4@A8[?BA=Y9>,3R MPH61WWE<+1+:Y;9V!%1CG362DBH(5_8"E(@C5&:5+B?
KX]-IS PI1 Z>0K\ M#>I>;K,5[FYL]!V&X89(,MN]Q=;!H(6S9;H:=]_6*Q9PYL?I"@S=4_77S51L M5+8,V/F](XYH?CD!P)"<#:E;+W0;9?LF3F4)V%K+](C@:G=^OM(\8_B!*H]
MK5Q6>?W-8WPS%GFD#L"..-,/9@PBCT.Y&6!G1*VQMYFN0L4]!%4SUE=XR"EQ\ M&Y7ESLXF#NJWE<>#2XGP3R5EB|SO(Z]E+&EFP8"V<+<*7X*=D?4=&%1Z_)IQ
MM'!VNZJ4K(-ZC510.44/*I(55#8_J43>03W3"0=,7M_62VO"^_1V_;VGF$T+ M,Q4S8^M=,_E;SOZWZR>W]"]>3&-7Q]^3GU,/>,;\DFW,Z_DK\M UB;ZM@R% M-
C;G:PVD[8.)5T%GYUT+[2]:P^2SM&*:;KIO$7\F5DBWA9[8:\2/G-?K;KV1+0Y-%X% F.=]S)TQ@'"ES0:O[$& M^.I>QC*SO15C;(NF\(4B><.#ER]O>'@ 5CZ0#8XFKT*OPO563!%?
C[M]8S5S M46[R;8A*Y&]%^:OERO4VE#Y2_0(O%,\ZBEY@O!JEGF<;*3NCLFDA^.H!5AQ_ M^*IG[2.U*7O&WB_TW])-:EV!|I7UCI\$M$3ZJT]0 TK'D"?/M2GEA(KE96S7 MK=)&TE:
[RJ^RO 5_-B .0[<7\$8ED2%%T%L)G2MSMWTGEL=IMT\3T5-/U;O M;12:>-'@G2"0_(7+./YIA(E@Q$W?519LOM3G[9*#N8X.?NFE7;6^NP5O?TI;".S&GKH
97:R8QBA2J443005U2YW<* M7C!/5T&IQ# WS#24]%;"3OB<6<:O1*3TP$<3-]SQ[_U@\XO9J,UPY&OY!^7J,K;E8S=-(-N/<+C9V$C M^,?!#YB;[#S<"-]9'?/L \06,CJX**6?]B2J[NA!
<>3]YX'#%[\B5(FW:WMX M=<&S/_D>5"(^XDBDC';QDIM9M5D[&3L3:HSF@"O> M7Y *A%N'ON&(J23V3KW?7,1;B:1YB57R66AN\UO)//)&'[PH_J7[B#NW *A[M3:E)XP*>-V:&,_1-
SG]U]:Y4U945N;H8.*+A@@#UAEA6#EEGEP9Z'[@"A?< M*Q1!<.O0(=7=4^36E:HDI'+9 MG7V:4FP!VC82(]F$S*_?(V.##*98M@P.*>QZF)]BZG.]\1T=']5W_Y=3YQK1GF
M@C#ZM=8Z:M8L3&WF$#KZ6O.]8?VD]NNWO_WRY>_U^F]G#S>6PVQ_@JEGV1PC M#SO6*_'&UA.;3A&U;C'GQ'6M,TZ<$;:L5O/HY*AYU#NVZO5O01EG2$ >1]V@
ML/91*WIQ'A;'Z*G5;C5.&NUF^Y/5.>TE/1?#PAMG(" 03RSY_X6Y4O*>QK$N90OZJ1\GJ\E&]U:YW6D=SX=1"$>5K MC4JBY(MR4@?P])
(OU%^](-6K]=K!&]KWWZQK"^L"CMXYQ1!U,@&_X0S"6.9/<,N5*> MQS'&GJA9LIKGA^NE1#+=",R/[+9I"?-@]5%Z#4TE_C76$NWXK!<##%/#">
M,O"]"C81^#F;3#D>0QHRPS=,E(T_I7PCU8#$^,IEKZ7#7Y6[/]@71-@N%$[' M?=OF/G8NYU,II;C 'B*N'L;\0@X!",QI0KQ N7T]M>Y!#P@I(<'B%GD^)][;
M=B"+%%P4N(UUF\%2_?"BNP"GMM"1E N\Q.2.7*WIGQ)-6R- '%!44-D7@)RO-%?830 M5(8,G09V/1$]D5;1"2PB?/![7X(@8?A>]8/=K+7K8V*LHYVA*/.22/P.B/(YL
M8$YX=]B[8]3V.0=UKPE:).OOW4/>6N;P]L] M9X#">[L'Y^6!([_\PR=3Z>CNE+1E9?D K!46/R2M8PYI%WC*!(&.-P"9ZRU5 MR3\ 685$#XGZ9 Y1"[',]E)I/D E.3+&)P; X/:8OQ'4QX+
Q MB/]BXISFK,Y0"(A)-J&7SEY]V$@3](S,O +LA"/H- MXA$L9PL?/6;_&#,7I!0R)/#>ULC,3[Y?\7,%5BZE)35 M84\7G'F!>\8R?T8;5.0PAM!M8N&BN,SK$6.H%=S%4GQHKO)PF-
?!)=>2(G? M#PXW4&M3K$Q?'6]+033(/X\S(>ATSUZDVO*N7RF)*X4E;KXS)O2@9'O M#'./@. RK,ME,CUQ$FG[S-9)_VW,Z7QMKYAW<[$Z$\=Q73>>;AB+:NX8A5
M318;6EN=|=]KD=]A;[7PT9\AXL]&^L1BT[#A),09$L1>L_["N??;@A>R/:%Y MN)7@#%,\5*Z(*E(;TX:WT'K>BHM S V,ZWOWR"OX5Z"1Q D3B\NYQQ% (13QMVO0:;"W6N[O8BZ(-
KJF'N989-O$N]18/;O:GYK,B^1! M>]8-/AF/,XE#<;EI7,5V9-Z# C@@54H%8#"CH!F#X1(QEE# 8 M9LR1YN8SSE:*,;7)]':(2V=\\YRQ?/+[%2(\6-+L._SA;>0:BTP7J-2.U]E MJ-P-
<;YC+QQT*+A?8(=XY K_4MU-IS,F2Q-/I=-L'WBZW$X/; M@#*5O,N8^^B4RHHO1JOWVQ!$5R)9B24\C'#]4YMKV*J5Q ME!Y^@**VK)?-
F51:21]=,Y=E!E,XX*]#E((.]3&P&$MBF]SO9[CHSD[FD9E*S M26EQE 9.;&$*X%V T'FY07$0R& MH=#*_2,Q-!6@*!^/_E3O8?:)I-U/&]-UYG:1SG;;11)56@7OQ-WW::GUD[.* M0\>9*?
>\1AM?Z%:MR\;3&-,.-=2=6##-!6&>D\PZD*V>B(;@*O@5\K!<;8TZ8 W;$Y4F, M"[SX/_QV?2<82MEC1$?X 51R.1SBC177?5> ^YR,>0:V#85R2 7V/ROQ?H:9D
MPS[N')]\/I";.XB!)LZA[$F]YG77X.6EX# FF!'PC&=OS^#OKND5H8C:H+|^ M]!&SK!/8^@7|96]E*:WT.0O%JBS(9V/L!(L=UT+X\G,!P8 JVD]Z[W/YU'MB MMXC_P-
XCZ$CT1QP' 6/:DNV.11C0R4QN;; ^Q[:V=>NNKCLEW/,;2)]O\@ M#L'E1K>FD>,GHEH3?/F;ZG;_+@>]A2%W8)Z1S097=BHZC*PLU>5\;_2YF_'*
MVDE9ZWN@5]1MS7GX]\MS.;HP:\==:%(H>N2UE T](TMU#6[K].9=I?6 ITMQ_ME;T]7B-']1DQ"K[\:7D]SIX4*S3$1*_S/&7TFC]^K8[9"^1/(NT"TE9%:'Y' M%;D[]/8?
PRDTM%QRWW8*(*4 8ZS#V"D 7:69=T9CL5+\G3$GN/8.\QFQL7AD MKG.!IQS:!(6K#?T) _X9_ S'S-?,1XY MOP$_=Q%1?O^H4!G5MX?=U6'>S$3[$9GT>WF &88*M,
[(MA*O=1I(RD7CYWNLUFQ2QD=W48>!1Q$U3RNU7: MII',IC-:@X8&#)S_V,2QM7?XRR5HZB T@Q.SS2#!%F)I;TC/_U.:10%5A+;1 M,SF4"(Q\[594.>^R<>EM,=>A4^)/:3X[*2>:
[&H;;U']^[*+V9&ZG)_6>@]J M)+(9@V9(%^>V,LZ\K]\)4G^4'7=TC9;U/S4ZS9=6M57GP(RS2BL]T_AF6^]^: MH:?'=#]MDI'N(-]BD0$"%B(PF"NL^4$6129CFF@N&2E?
8"F"26=;P)03QF'L M'JP&'^!L<=%O[61G^IC4;H%)9P5_D]KW<:P97R:]19XO12CL;+O-]KJSC55C M(1]XMX#LWE[MOU*! J9K>@=-_ND5NS-
\"VG&ZD\XZQ90$2O0QV:>SBTUH$=L.^H4|0)K6:O$ M< X]_9L];$\C0G?CMIESBHQFPW*O%U6:B17S.?>>"ME5UFK1&TJET^]_>E ML5!P&(1^^S]02P,$% @ O(!H6=3BV+E+,0
_0 # !4 !S;F=X+3(P M,C0P.3,P7V1E9BYX;6SM?6USXS:2\>KNO^@9^[#W7WP>#R3[&52R5]):[.N M\HQ&5%(E6UE6[$]ML /V&!M#H;OST MWZ^K>/*,:(I)\O.
[L_3DY._BC[.@Y2U(33S]^^O[' MCW^9W'VMX+XRU.;8!!CCY/$+ECS#V>G_ /U]B%L3C:L. M/1UNQU)"\-].*K 3_]>3LX\GG\[>OZ;1NQ)%_MEBD J_R4/ MSCY__GPJOC:[CK(M;+/?
[T^+C^_^^B^3R4^4Q.@>S2>B]8_99HU^?I?BU3KF MHX]_+2F:L[\EB|<3+]H/GS]X#3_VT/&!,Y5Z8(D$4]87K ?4A+CB"O"]FLZ MF_6B H!I.\F?+Q?
[F^VF/$&"Y3@U_3FT@C3Z'8_L2YR& M,4ESBKX%&?MW-C_/4YR@-+U$68!C.R(M>O%!TD.^6@5T,YL_X$7"+'D8)-DT M#$F>9&S)N6-TA!AU)-2Q;
[CD7P>8_CV(("KLU)).DX_A@2W=M\"]1R>+226+]?GR0=4%6*YR)E6.:\"6%ZPW; M3'>V9S8= B/T*U]K.@O4I6,?A)?]Q63Q@!8"RVYDJKOQ8U^?4O1'SO"X>NY.
MD|(75Y($UA5=;BBPPTX4T(BK3IYF9#5]Q>DE604X89O7((^S|%T_3MD,8$'% M/$B?! -2FA5$L!],$(I6IU>O&=N0\G7W*F'G[,)TCY M=(H8>F(@/F+*:?
PDZ./CGKGAG:^)/5FCUU%6C MY0QN]L?T2".#XB>Z*V!%--:G.#","6_M\9!W'Q%**I&XM@A)L8!,O@HNIH?%N).A+C >#]O>BSI'H4(B]F%KY]C];@GMO.+PO]0+
M3OF'WVH/4ARD*3LR9B3\G6-6C1,'3RAF8C?!5>]AACL=G[HF$IG)*5C12(!4TURC].E#U.,C*1]92GK >R MYJT#9I4(90O_S^_.#B?>_6W>5]SLE]_N*(GR,)O1!T2?
<8@DNJH#*5D@!QF7 M!'XR+(=/I.!H@8.?,G\1KC?IOK+(_LI#4(12_"U=W8NN2" M&X M)7TM-TQ1EZ?GF;_!_A]?NT2A.[0L>>?4$A9/:NR4 M,Z-C:S-OY*W]S:,N"D#Z\]6#?1]=`3O)L?
I-$^!E'>1#+'#TZ MF,K1(X?Q1<6O.%O>H[C(#EGB]2,Y2C+5?]AC:Q7EIM8>G3M:09*^G&@Y=V1# M\1GB/(3O&3)[21#EB$EFAO1;R8V=;V-C*]5TQ===C/UKJIRQQ$1!4P-;?7#-
MVVL*:8|TC_@N+N11TLGB@J39-(G8WQ!|EKE0+*&WOC8#M+<+AA9FQ#S3]6&)4%:EZTK4W@16\D@-!H0T MJ:;; 37D^==UHVR(XE-+5=US-

5;UR$D_9Z^!#12N,.EWZJ+P_8W'V$ /$E+ MI/WS RF 7_&S=TYYL:YB[8"/<$1[O&/8GNF)B4A]DAAZB"#P89PM]DD^L, M&867S;G9PD.$-*

PPR/J2I_(61DB$>V)SE,I>5\GO)/LEWWU1(9Z4&0D:)_SFA M9CRQH::IUGM=<=66=@%),Z?LV!SA.,_P,WI (<^WQ"B]>@WC/$+1-6,2GY-Y M)J;D;'X5T(1M!['?IT.<;>0>R)6OXD:H%

<,B1P,A(N33:@FNY!63)&D%GB#/' M6HO9@O2;I&H:C8)C^ZF>]:M1P -(:I&(@]M1)4QJ:G8]3D;HSWSI[SP]G M,B_S[M\K?W+]]S$QE 9F2[XTL?0?4+W/1*+#NN7?K9J*>-!F$T@!7%WQ_R MS#0W@//-\TOTDL,UX;;^PS[AIX9HW05@%("/1O)SO(B5@0V;I)L!VB"(W> M[QK2C. Y/FRK']#-0#ONI7IY2:X1NJ4 LX'=34, / RFS<$)M\D6#>HZ+5H

MX#=G3"\UTH'FW?0QZ0AB'V'1\U"3(47A^P5Y/HT0+C2%_5 K"/OEMUNT".(B M?D,6^2__6D7([WX='%M-3) FS 5-(^*FT2+?2M@0]V#R+@=-_;&,17C$='5*

M79D64U>;.I]&LD]+G)8'Y06 M",@W5K)O%27M;P"\+%KV$STU4@^+K$.Q0VIWY-N[4A;8D5'YBU@.5'%,!@2!.C],8$K" ,\!@T2(-7%-/9=WRC5;W1DD M7:X"]F1A 9)/U1UXZY-*

*'M.5W^KH2@8AH%+^_&@/ZK=0V1@?BFAUP!*4\O%3\ M-2TGR#]0I M:\ZCPD!:K]%>@2/9^T:ES<97'Y(>;3. ^3?Y1<7 ;$;O M\I6(I*Y5CA/_M;(=?*

*5BV@4"R="18MW*BNV[C/C$*O7<1 K+'94F2X_G>YP\L;]*CY(7S8QO6'2\1GBAN1V7TTIN?'Y_$$B0M5=4[.[11"OM?T8DB1CZ]Q5+$"9,(08B_I[3-B*]O.[MC.:',?-.+3N6C5I6_4&PG*

XO7WL^>]5.XM1 M.GU.Q]$*KYKX,>4PG=!U%Y# QS!\$)GC =+MF6X9%H5Y*7&*L-/G:-@"F MB5'=VLN!EAPXLO["$D96S/"<1BO&6DX2+X.@EY:Q%8!UVTE>1H+@2&R/+EMS*

M-ZY4OC^HF0,I@.+NY98MCB81-"''%,)?#B$)O9PQ/"-)*2-8:DLAFV 1;LQ M1?1??4ID00L<@5T3BO BN<@I14G83";^POC"U>LD#"OV+]OI[+G<;5L!J?XX2I+X 4T*/*=;/ <4]H0".2-*

*BILE:^Z7. 8QXL M\$AX41&2B/R)8D9*1+&5ARE2]IC*]U>5#+]^9*VEP9+M7WUHC007LJ'+J M%>VB("N-'YY)?$ZMM0@<DWTJ!+I%>NB) &.3'Y%/'X215.V<0X6Z%O.R9_-*

MBURR69ZE69"P%7:AFSE.?8PJOUQ.XZ$@9=[I7|[^+O)5=W+J)+M%1[B3)I1 MMC^=CA^U?['D"9SI39'Z62["1<602S9R6&\L+:+YO^L6S5_B,.')I(G%OT)* M/$[_H\3D/]^]!?

*OW1K'@*4_Z)8FB5)QEFR-(![" DQ.^6IHV2-OM* >LW1\!) MQ5I[&SDU7J5QQ[!!E'(CR0XEVLP!.2B JW"M1C4%(*? A[9?LTBG Q\EV HYOD(ECC+(BU(C"T 7!?;2T. RE^11.&^2H7I?[%M)2 GA^\VI4N?=MP=PHVTO,GNR/ =H9XP"%%4'>:VL5, ;]VM!:.B M 4.:*6EE]0/46A07[^-M>DP/)O.W=I\+O(M] QZ9$1PL0V&97I5"2.ATM,OQ. M!T0Q2B\=-*

KO:%@#VO&J5:DT('15^)6+Y6(X% /@&RN0A51LH-15^I>'ZN(!+ M0R &S.;]'A>R!@A:NLN?8AS.YFRRLIV$U#YIX !8)8?WCXB6E@&8.|V^!O1W ME/$]T4$2(HZK7'=]!@=P].[

*;BU)$#9(_!>.2B@8(J^$31@>C&KF] H2@)O4A;TJ.F!X=VI?"A#!*T#4#.|KO(A*Z>P# M K ZMG+:1QY.-(]MO((GB)Q>H59=0FY&$\ C6]T)9:?MTH_,S.>&H3A=D3S)*

MIEE&\5.>%4&Q=XR.1\7/W:$? +?W"$V8B22O.YRRD_YV2,1#OWBL#]=+4(16^[.M=V\ ,A7U0NM- MH2=9%EIU,&'=:=0<0;O;&|-.U-(A&-(=4K)#G7BBWJ;!7V:%+:+.D!+[Q"!SM

M;Z_QT:2NV1($1WYU*G3Z2!1140VJ*L|\Y+VNIDF]_+H|GQZT?G4,OI[N;,XUA M*>[0\3..4+*;6=6S+_B9<#T)'&57-$VB77]QID!/N15RZ@-^NEQ'P@")]U@4 M>LJKZ@1^?EQ7RGP>

*(7G99IH64_YA'>.,):]3#_ SWCJ1!6=/H]V%&67:N9=1 MY=K+<>-,&GC9"JTL_GQ-JG=+NAP:)7V,*M=>164="0,OU4(A>XI5V7 ZD>73I]I+4,H>1A54)U]-)[*&%12-*

*M+Z&\5]9Y8@[3Y:@W\9T\,8>A$\XRZ$!*04D/#IQ./Z,*NU=\3 2B$C8< $7 M+@-N=Z9IBES/8HN1I5K_W@::|K BW1["]=#]IH'1A5]OQ =-!+ 2U5H8U$R*

*MEH=>M\K'/]"006:XT[G3HL]1I=XKKJ"UH%#? ZN!=:>CZL%P?J:C4@2K MNSY.%]I%%?&D>92DH@;M/?HCQG9.4'D\+UAPCT*R*(0GN[89;]A1E:F74S>;JAW^&&FQ4U>KE7QN**

W 4]E6/ M5Z$'.S"CBJ]7T-0.XC#++@;I\CHF+S4!YNJ*WW>LKLB&FE1CO95/_"8:W\@R.%02V,<6.I03VV@'(X#U438$]VOZI:V487ALI-LGU[=\JT[5EX&TP/VW;H",(BU8&\V1S[%IX

M8RSY.W)FZ/C)&IW&0PL.DVV(R5HRG9U: JC,:1Z/M*VU"OSU9 M(GQ-CU$F\+&] M*7#T0+& \G/#)2O&'VR"ZC.XQ.(1<.@"P%;.BRGH:%1C+M-%$X;'(@*

*M _RO'91[<[<^ #AKW#5<+VDMO9"%?4?1.L"1WM5B;@; M7)HD>Z2"%F*G>>1 MW\FI,,>'EN1QSJDA5X] O"=###*]I:@'KQ97]W5,-@C=(_&Z8F=ET/4#P),RB KH M:*

*(8C>/NS1N_P%Q F_S!G*O>BPW<)X-C<7:$;K^WT9 .1M7]DUF:JL1 #L[QK1LT0QH#C;P+O&KB@9I8E U3>!NF5SGH);,,>>@ M77DK4PL)I<#SS.?*

*U:UJR]PHS+.US;^L27*31'FHWI4XM0=PU#R$S)QHAF,; MI]%ZB[G^[MZJ!8!;^\-81BV5<,1G3VSO4R.(&_G#"->%:#BROIK/49C-YE>O MX3)(%NB>'9QG"2>$_Y^7PG]FQR"FL?>*

*(D8[##$7]]N4M?_0@%0HQ2 C =@T MV?D:!]$>CAKU(J2HQ;+O7 WCG#\AUF19P4;%AHV-)(''-H9W5>?$XR-?K(CS{YB*L:+#?)G>[0;&0<&;MP;P3;5,Z;:E"*

(X(B]C(MQ^ 5I;S8E.I.L@T%P'/MJ'P[UXUMO6UG$EHP3. M9/E&DI!1MKBM;NMFX M)X:AFG,V%$^^GRF$:I\P8'87DA.E8Z7#%V5;=B[B97(R M- #@[>PN&0-

M(Y8+YGF7,4ESBKX%&?MW-C_/4YR@-+U$68!CV^+ G[_[\7G1LW(5%M->("!#K"W36G68!/[K681^^6W"VXV$%VSU7K#:V1"A"K MP>#4'1Y,R&*.*QEP^*.*

(05SW:%U6R=B&CNXB)5D[-C6;\%BDUY6,G$@:(AC M15#TQD\T..LSE,IF?T-[G"W5E7+-;3P^SKI5]WQ-Y(V\"">,'/N(GR,)M5 MI8,4ADX.-*

KZA4_F7!S=T<@;X$E>S%]#2L&E@_1LRG=[M\%Q&P "&ZV^;)[K) MD-I*[0!X-DE&3=B:H!V]_88&<,_&|BPPHZ)6H>9U!PW\^,9'=4TRJ/&QX 0\ MB6]?AM"V@/$FA%%-

C9(9T%#=472=|^-I.:+F!0(%) GNH7:-+HY60,P-LB M!:8*T%=S5@X'P$7MPES"6149GB.RGE+T1\X6 MG*MGONJPH0SO*DFAQU[W57>LHZR[2CY*

DZ7^.28U/(P5UZ"/ 'Y.FYX3=U MIHV2UN@I8($8//LU;26SR*GQ_!;(-F-<:^XD<],G5:7VH]P[*O?:4YVCD1H^WFWM[9?'MG\^B?=CS<.YI'?]K1Y1%3Q[=+ 7E:#O5D*8@5Y0 V]|;P*

*M#.=AAQA& 2P>|\R"4RW+-\ Z>(3/A^9\4LSFVYR&AP(Y9?$#-3P 4S&TSFBH MAY,B<(^>49(C7@I'Q8^KUS*_N06;B.C"7W&VO.C3C*R4IXR#C@#!XSRPVAR4 M7T-'UGI)*

*^Y*1VC&MBN+H#!OB*XN,O&$6%W'R-P00"#U\-/9S 8XTFZ|O:-:U=LP (HX#+Z2 MMRD&):X_9R%K15&'$01)A"6N_\DKNRA*F0VM*U!JPBAV9K\2^GM=RO\BH'3# M?A4OX*

*M'WSLHLT\&CM_F0:-N7W6Y*U"A$N9FHTK?DT_-S 4X@C8^ZJ&0M$6[447MR?5FP08X MLFZ|9ZXH$|38N]IH 5M2ORU$UQ)//KA^'ACI=2Q1&Z[:)5T%M0*<4Y*

*MYI&PDTSS+]+CX1 #C*HQ(WONAN 7'.-SU*\PG8WL]K/CP.#&N1A+.1G4F% MMMVC%-%G%%T3>IWS*D:5T9(: /=.1@V^|>$;[,"3P?WQB!L:%$V?$65V1GF< M-P&/*KN1?*

7PFVN$86Z%:2Q(S-]5%PL(WDB'QUX=UC!O%1.]Y1(?]A. _>S:CB M]^2U<^<,,50N:=YN!9-&Y1TAE5+7PY_%R9XJ64X4. ^6@5TPU8K!)M5HQU3X\)HS'ITR'6''*

*MMXPI"7\6;IF+,L:&CN8/B"4(!<M*GHTD ?!<_*NCKE4"V:7&<]@O+WT?9F*AY;ZR(IJ)GYXT'*W&5@!K$[I8 M-FLZO8S5LX:K-5-? PDE0ME;$!(0U-7F4S2] CHY[?AN%$&(9SE###F*

*M*LHOV3<#D.9JU+NF@,P4>973+4D6&4_)0$^FFDQR4("%$+M8.CEQH$2CM6T] M8!B&3:=E.BF ,&4|SW8;2HU(80$8+;TVM>N-2&GP*@/-E-[SI>R(Q*ZIMXQN*

M%\KDF=IF<_ >6@>>TW [NKC(\BL_IFM0XPY6CQ(V&;NH+PF!.N$)QU:P 9T5W% M;$TC''NK '7#'IQP5@[9M6%-BQ: DA\|BL*_J&OF2M8X$>R56:X15/LYV& M(;/4T05KCL,@?*

J0XB]>UVRC)H^HZ=)@#QF5[EU)77P%];X=G!15D,PY2W: D@+;G[5+>@#\X4 MOR84X4529&*&F\8E_Q?&*UY'X1X%,?Z'<@/LT@& _.2N$]2%3#C2[6Q69@+A*

*MM$C8O2GU|@M5%QL99"0{]=&C6W0=0P!*RFQ?$CSKHW7$Z!!#\|%'#,W)A*,R M>>:XQ$'6>VA#^>0<(_6Q?8SW=NZ M*N?;OFD3@T /1<.@*FVG1Q'<+1'<5) MB-*

*?"Z)J7FKTV *XF.B\|>\0 /[=R5PT[4XNS=X>3Z:=>)U, ^^(0=3"8I'Q[^ M2;0.TI@R6B(@.48/.B*8T_@PJM] MJ\'UY(U^@1Y8+OH(N$D1$G =LP*BZ2 U.IP<(D*4@8G^7E|+\DZ1J%>*

*(Y1 MI+1!&EC_-D>K.UNNJRD8P,A4V<77F*9947^RUHJT45I6%([E2O++FB1U34JU M-3I0QY[-EE'UMF;J0/0.(.);$B1;HSME_T3\!PY7#R][SO)\C'")9HEFD>G1 MF4]*

*(0'R/+^1PXFMTYM%ZSKBC0"BH?2.%MD@./O*ZRBU92N%AD- M@+AOO.97@\-PMJB522V%@<\S8F4LYYS:2V4QWR<[KLL'3BPV*'< MV9[T6QST5N;O;_"*5[D*

*[4ORW7<1LW)5VS<0=1[!5 >@7-75ERK)!YYH*M M,PO"KVSXNE1!1(92KYUZ U,-UFA)>I,*5-P*G(VU9#OU!B.1I:?NVVF#@1.>*

M7SM$6/>DFW3+M$SBLF:8SSE9X6%.!!H$V.L6P-(E>FI]^U'DBS)'J**6YJB M[&ZW.*:FC)L6'D"6Q0'D8D'HZ%N5;67]AQ E 3N$*?;2"C@P-8FM]M4*(L9G*

M>CG\+TFZ1B&>$\7]98#UO _6:L^6ZVH (;>E7C=Q4&BSZN4 `K>LQLU]W7 MMX_ $,_B$5I$Y//!+T6_D8B2PS=16W]C$H^&W9K,=)5Y5?=8KP():YE RR S9.3[!1D#.WKOT5L0W;/*

M@Z5B-I,_.B26,I,E!0.0$&K%8C4%<.['IL]'71_)-/PCQSS"D(@PW\V'#3=(@Z&>8(Z@;]_D<">NORQ1S:PH@_=-^YV)- M%9P))J:\6+U3P5VVN4TQXX;8U(H(B#FB%-7!!UD+0C'S>O<*

(-G3:4KV)GCH MN=L,.)N|(BF2[QNQ"[)\O%=&D)(IK2?])9$00OZ^1ID/$'78_57]OWSXZ|;\ M]M;L]"D5X"Y76C:]@9[[M=?-B3#<7K(21"I[%^9-%;YJKK9N,S1/>(|*

MC7@YTII)W5PZQC VMQSCIBUQ8TCP!6'(7Z3?&/V!O$%Q<|(7%@]2_LZ= # M1 RM' K'CT'@#XBM.$&GJD*^@PL0$]W&+.UN-A*%@_%R<\| M7?*

F_]M.5MYU.[AWTTTGBPI<+Y':T(Y$3?)G-"5$-+YIORHNZ_HU-/PJ0+| M&I-I0B2&%V=&!8&"A#,C4,/4569!"H:1T_@V$=$F;^A!O6?OJ%7+C770;CR*

M]VR@UN.KA/:KL_=:%,\62E_9)PZ)>]U7M]>$M A;0U M\' FGK.P-53!\9O=HV>4J',FZL\ ;B;Z"](F @[?MTIQDX1DA6Y)]DQNED$" MN$KH@TI/7 $4U3" 4)*

*(Q,.M'Q!QB%*V1XEND1KBD(1*&2?IBM.lS_TCN9. M?0&X2>2@]W(X4PQ$,Q^3MH)>O?+G*51^6 T\@/N$SDN7FBHXHA+)4^<\]+#Y MA(AJ0ZD !I#LUWDSJ2*

*)CH2T&;8^G2;,TH@#AO./AX!FB*_Z$ MI<%*R4'AW.-8FB@Y&:"8SVDP'#L$PZ?=)) 81-:KS+S/$R7!A+80'8)+TV*

*MJ02/R6CP$+B2)PSC=4"SS;=@I7HY00X&IMBKR0"I21C .06TWJWUNXN9.G3(MH2V$6"*U9FU?9; G:(C[8%Z!81Z\?D413GD4*'_ 3O'4A1G>]Z,-KGI5WQ1K*

MR8(1O'+U1\Y_]P+0Q+;X!5YF_%MEJ[;WNNT|/C53X[&DW3PI8&'IG*T5K M2D5!C><|U+8:EF'_M <'8.^DU:7VUFD/_;1 M?%6M8QO(DVWW#E/T3\1\X7'%0X92)DGJ\M%JX1+-*

*$LT_JT=DQ5-'O2R, \3V^ MD.,K]'9T53G[T&C=|L MV;SQCJG^KL.B(9#ML4GM6G^R(&N(!Z:RKP']'6T?I>=H:,*0M> ML/V6E6_ M)*4CR:O9:DSQ6U-LLA+*

*<7SRR@0+=O=^O!AESQ_1-DK*A"V_2UF.|LT:>*<3H MT!Y"$+*#A!TH&|K.L!*5*CAZ]YUMF3'LT F$;&4+B74E#TZ(UY^N(K^=/U1O M88$4Y/\5X<4R0|&4*52P0&)\,?*

%EDTP##"$>V78R:.R%@ /^'!0 5 "TR,#(T,#DS,%]L86(N>&UL[;U[<^0V MLB?Z_XFXWP'KNQ"CBC9W>Z9.6/OG-E0Z^'1KKI+5Y)G]JQC8X(B41+6++*& M9$E=|^DO$N #K")

($'P@Z=T_QJ.N C+SEY69>"42?_JO7[8A>:5)RN+HW|]Z M_^\fKPB- #A@T?,_?[7/-F=__J_ OG_^0<_:>SL_Q\?Z6!+&_W|(H(WY"

MO8P&Y(UE+^0QWNV\B'RB2<+"D'Q,6/!,"7G_[ML_?OONVQ^3\[,_BQH?/12 MWB>.B"#V ;?OBR\N/)\R,<8I3^^"5E_[52Y;M?OSNN[>WMV_?/GP;)|^|^[OW

*MW_V/3[F##=R4O;0OX MUUG1[P^.GO__=F']]^28.O*C'[/#CO[[5RG;]D+@*CYI2>BF6<@P2;Z# M_M]%]!E^3$#Y Z!_P= ^?_F']]Z3S3\BD#+G^]OM'A_J-'*.PDT1BKZ;BXX*

*MC|QQ!4FM:#!<5)731HI?SF#Z/'NAP_O!'CXY. ^7>80[CX*K<&/9X2;;Q.E61(#S MIS1+/#\K" GJ)273?OV4!%B QWE2!^0E?B$#_I-#/7F1_R8![9==A;FOY?H*

*MODGB;3\$4HRX1Z>_AT_]|:. 7L.=T#3>)S[M91@]W+Z_6"DZ[PE#(HW.?G[H M@>7/!1/"N1#)ABA_B3%ZV.WP#0MXGU*_6^?X]?O LI@)/P ?X!1?Q &S?]1 MHE28/GI/59S(-=+1%*?*

*9FN #2VUKA\|XC:0=;(*9?*+H/V_G!@C#_[T)]/; MU$P+:O-%&>4)SA;#+-LNQCA/)1[70($^$0R.K704I)DZ%7,#U_7X\,@IMH#/ MO\;O#[W"*

[5$W"P38%U)RYR^10)G2&_V_O)1QD>+BGNS@YGN^WM\3O M(AITQ]YRU RWX^B$'6QX)6$B<]GA'+<;+F?XU"^GQ_?:))@VX&YK@-3T=GL+DCK_':6I:*6U+.0_0 M 44B2Q.?'-*

*)F[W--G!MNR4?:9VS;-B#3-L+M-,ZZZZ]3;8'8?C:0#S:VB M2H"L(S=R@6TR=[J)_#CAPYW8;'K(^!3L(MY'67*XB .]=W7UPNYL1JCKOM?:*

M!;,KF@D^T'IK3%9$L"%Q0G)6!'@YL^"=SZ4?ORTW I[1LPV3,2L?L4M\> MNQMW(*T[L*8Q9M?M$GF@T7+RI$Y_YKG<>1!PI:7Y_|%YRGNM+IK;8K?0%H1U MZVQHB-

DRV\0=:)4YS57Q!P'J9!W-%C/L7W?0P_?+[(JOS>URN^7997?3VN5 MCV_QS%9YP?[<)X_0[2EA5K+A5CD;IG>ZR:+< ;&X0=RO:!-,PR@?C,=BAF MN.OD+HE?6>3K5XK:Y@NQ2*

W.1K,|:KL V]1))/:!ENG@@L/,5GH7IYD7_D^V M:]W-T#1>B(4V8FRTSUK+!5AGL[QCV:;D3CCYF5;G$*W/$^II;/'H:[S6UX2C ML#?U.YP6UBBAK4V) 1BHS61"< LIO'N)

(_V)84,3O:DPU.8T_'W.$U**Z6M M60F"1%"<;4?F@?K[A)OS^^^?'EG6>#6@H0E>T]+A*4SK^'NWK\?$@PNE#X?M4]R$]/A[O);5B*0P]]7.&VJ641K@Y+4*

*MB"0W7YRZ^N*_<(FD@M TPRO5;7A.HY9:AN<-M8]I:V!%41)0776D_*+?9+0 M*)/!8>_ ?RX3UE$4_W\]K@5=C=]1%5WHUHS$&[4+.A 8Q-$24'5D1O-CVPR M-*

*[K:TN29STI_2N*W]_4BWNZ\2#\]Z5IC=ZM6E'7W:FR*V:CCUJ;ES3[3O& MVRU<7(CJ7O]>/*ZM]3Z#^J2PZZ[?^6GOA-V]3# ?[42V],#L?D9R#]VH$SR(M8+(BD@U1^+C;G<0'?*

3HGIE&6>.%-%- O_YWJA\'3=NA=M1G9D77&6Z%V2(VH M0PU1DB6"+N&$73F=&WA3I-/)S^!_42_1%7S5$-49!V5]#&<3)'4W6R#)SM7K;I3A; \)F=U,:+L'AFL0=RQ[SRFD8*

*MG,X1S D<[YRS#@2PT&O:73G^]^#-2(IG*KV)4Y':A;1UJI*:@3(S>XN.X+I M[10:+WT27/;IV:/GI:1GT#+|+BT]%\D_^+NXUP<2K#?7+/(BG_$@$,OR>9KW M,7IVQ>E8-*

*OC!Y_KTP^>.5M);KW#B** 1O!#%_TKCD 7B3:B/7@A/,LS6/,T& M#P2#;+[IY0QMHX78\H[7A0BSO!%NC M]=WB?OS#0-81K/!6^_;%+*9XGJ8\['8,[2>-<)M@.R;5_.HM\)J>1D[K^;4@*

M1WXI",[[VLJDH-SY3KYS:^1'IVV7X$D:A*<.==00NU_IQ!UFB:OR_@P*/QL; M9 '.$]1_=.%W%U[Z O^[^L>>O7HAER:]IQP>|_F" KXXCX+Z!TI+C;&TL3M MQZ-*

H3/7W003QOH5Q8%F[%?'HP? ,+U'(KDC%47[I1<)9TJ"+8+-KG@DI"W@ MN-~>4(T/?]',O$R0OXG)89(&-,IB_ KDVRA*GJBSRR*O)MX4D5U#EM(5>1B MH/LY>F)A2#E]*

*>XCJQII./_K6> <7 YEMK;8@313:*R=7_M8N<$F!'7&NT'I\?8>*8"ZS:.GA|ILKV((S'#3D79Q>?$T^[J&?&[:'!=*!Z MKUE/O)[<4WY;0^>C'.6_AQR/ FI[8;P3FX90<#.*V^*

I]X%"%"=NCE(3^*/ M)C)WX9/]?&F=G@]NE5:ZXR7G"@15-V.Q\,' M9&FZ%Z>X/B?OPNON$KKS6'#U90='S.UNIVN+V^]:$;J.U]@0K^>UBVMKF3E5 MDI-*

UZWO30J22;"K&QCA[H4D0_.5I M_Z/1DSVI|'7R,B[1$(7G]K%G.D(X]) MW"O.O-#XG&-XV4M@A\"#+ND,.K!2B>XS-]".N:2V.6Z_ZL)9GU,VM\7K;9T2 MVT^)\&%2>&!%V]'\!;#A+-;?

GZE^DMG: M!;=/FN"M3SGU[?'ZII'4]K,S27Q%!'DQ.2L9<&^EKJ:B$V)>;S:,KP$W^R1B MV3ZA C2M0$O-S2D6HTNBIJP|N_S5"K#IP M:P>|'FPFMK4Y%]2)

*(+\B@L%9O#GC+.2X.X4/O]+D*6[WXFEQES#W'&8('!Q. M@R^\'>,3>4V+ K;E?N@[^>H-/=#Z]C]Y+>_ JB_9$(* M+F*K5@S/SF?4L^B@[\$*'|*

*(A/:18'HOZX/'@)PKM=YA:MP30.W<=^EF^SEX' M/9)OU-SM.7>-1MHN:AP?YYH-C(2D>#_<')VX2ZJ_Y0*PD&6.IGD)(NIIO<1A MP*,EK/6R0T>>?8_NN&-#7SVHT<.T+[*

*]XTAN!K=4KC,HU>G9PG;KO#'X*A?1R M5O\JUN[#GQ ;& 7.[M>T=EB,IQOF-+O/I8(;_U;#XG2W*Z;K,NI@:Y MDW0=>5^RI\%IG-&K0ML>O0^V(SURP^;&J#VQ0^0!=@J42=,*

*ZFQ%_')C[<0H#@Q76^;U8\, "Z"=F3L[X?9D,\SZL #C'GA|V%#N MT4|#2PZ3NF_OT_#1@0NJZH+;Z?6BBSCB*LD87WELW7>UC7'[;#O&VBEW M8TN\/MHA[X#2B@59 G3=#J@S@*

*PX71S;TL9;@.B]5M2H[9I13N=EFK5W+ MS:G6F65JA5+@.?:T*MW% RHL<]B_$^/6..*!QT6X94M8H_BH!5]1$=*$#F M),\;_-;)R5!1!@"&?*

*ITRZDV0NV4#GIH7*M\C=KHF*:V7@M4S>V27L,AGNY,- MRKD6?Z,"PS#%U*QF.[.=3?KA]C1CY :[-4M(R1;.79+7=1-@_^]%>]VK6,TM<7MJ"[JC,FK'S?#Z9INP ^]+Y=7]!-$5*

M$617Y"9-]]1-:?]I8:82YH??OUN]>_=.7H7A0^H^>XD3N(7[7T@41U34.N2M MXX3$RCZ8EY$';GAT^T03\N'=BG"O^IT8CR^IGW_Z7GSZ844XW1WUX79MZ.1V

M#4P9XJC3NQN:X79M':[CV;+:]J]3:R4=,E.,(S3N/|7 W)'_\[?OWKTG.R\A MKT#]OY!_^STXMLZYOU]|_\/O5Q_>2;_]P^_^N/]W/[PQ&N9.+THL+M7KSX- MO.CIA7<>"VZBO," YL?

1M\8= SI0UNX+-#?%&Q&Z!+9J4"WI$B!,6$1RTFYN M"DP/$RJGGG&8?B/,N2[Q[+=[D7.\AJ]M/'CM^/R?1BF}$>1'V.1;9RFGVFV MWCQZ7W2ZZDT%N?O::>7H&E ?$HC=W1+

*(@#SU@A\1#$F-(Y$LR=?]!M1) =. M4SAG5_>)G&DG+[-LAN7O5*LB %#_*U:OTYF^,]Y6'(?Y#((_HL;N&X5B"*-I T M'3VO@@"]HI,"XPU8|#%*CZW]3 !O#&]1=88S &#(% B$I9$::T-I]&+0#7<4-<7=IQ :W@AK+/FXA<]*V'ELH.RW/@.M8NYY6ME^6X1S*/|:1H4BLF0EMW5M:$UIFC M*I>:>JBHWFMY+MN NLMOE2[+>!G?=EV,M[KD3FNZ\9)T\ M9+"?*9)*

*[F@BU*1'%/EW(|= [TF$TK7#:^#IQ% ^G'PIS@:2,8OCF3U%."OI M^:ISIZ;60>]M93{5^7'K'H0OG=W*U0(%NN&!NI[$8!S=9*K%^6;'KW3_8*\=,S57].KNE[SS@$9U6KW]*

(0,+OE!>Q"ELDR-BF+HWNH M-?S> ^*2\DPQN#[?52WL63CL-O)' &LFH&3S U17UKW%&B M Z4:##1-\?I\E\ #"J,%\+2&>"@WC4,6B$VPDE$*%P*RDDZ\P6C&FR:98KC|*

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||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|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sup>?Y/\O9"D^*? MWC,DJKRQ,"0IA?_DU^LC\D1?O' #PQ\$);B[Y4G'>4/.Q]2Q$E!G0CRY!?) M8-[K>"[@"@-PN#/W-R_A,[9LG=Q8I8>6-65;>YQ!S!AIPW;=:6.\<_!ND0=O MWN6T29P00=W!CG(=K=3"QY_(9G0:W@'.LAY MM2PE=2UQ&],!NFHYV=@,^1RP0^CIEY0)/=L(5DYC0+N*ER%_[F: MV$V/L2CMQ@LIG^E;+FW+ K,I$>) HL54QI"3%LC#AU[>$2*'/FI 3(GHFZ.0 M,3YH3K$($RX7@-,"&R\V7/$9.+Q_UAT@M"T11XEV=&6H:&Z&/%YT"#UYT* Y M?T>18R+X!5D,,60NB$X.>U+|2ZO&*]1N=T%%=0=ORZLI+A2"^-.X5P\9+$X MN(I:7\(:'IU'+Q1[LOI2MB.B>\B\)','+W57]O>1;G=QXB6'_(PCV4'#D^^ M#Z]62'F,97T4C8)LZ. .0-::40-4;R)XY@|%%L7*3GF]3E6I&!*)-A$0MF%^'2=/ET&U1P=!HI.0/ZK%^[IW3Z!E(:L,98I#B)OXOPYH>*& M4],B>1 UG+/K)*"V5'VUOVD!^O@8T S'H-*_*(F>|- L&<2-['+^,+G+ MT[>*-*U=O:J;T\5MRST2(-J\-YW:Q@ ;:V.ZCIZZX;4)KF8&[%{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|TW; NO\@71VW6@W/K0V%/%V443E \OB M(;&;JGY5#VW(#:&!*BV)_#;B;5TG-@%74OCM1-PC/$-";E1MD_ZV8NY(.K() MNI(UZ]@[DG8F"+L#]YXM$FGOZ2NH531YV(7L9 _9C@+VX-M;&T9)LJ?=EQ!V M^X,9OL6@GD]=QE6YC M35PIIV=$<9T:!9QVRK_C%1^C/*6H! M.U(2BG:#B1&S;E#:S>E!6?6C<&LJ^!*UAM=U3[VT(3Z$4;-?<[C9G,<|UY M4.#44UA>X.S0AM$]YM|*X.P",_*-#!2|,'O*Q:"QTUO=_1*E$<)R ^@GE MG\$&NU== |KEUX!*0OY^OSNYN*;_ 08PC?|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|-*HS-SZ[XS/2&IKV\^)5[<2G;X./PMFB5.;6S_CG$VY6FD5&.O]M<3]KMZ,,IUY*YZ7/LYJ@#+E^Z&WAE F]>V15OO8)?1LLX|@)T#S(-51H,K?RFHI=MS6!6<$[8/W MJ"'*BMCWBZ8Q)U.,8>4Z>E/1=U4&>"S | :$ ^)S>.(QO,?0=I ZXWI?*>Q!TL_M|(&V<4YSVAR?=_81>IPMC((!;&%,.0 1WKT9F!=WHH!-X9;FRRB'4UE8_[^+H M)@KVOG[3N%]_S!YKH8G*?WMTQKXFL8$R9$TB#F+C?09GL:(!E@]K,(A8W\O M+KX'+*%^%A[D/?=,K:,"$]!M'+ -\|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|"O>ZU-S M-6$G(:Y=FAUOM9''PW5RYR59_H_+_+5 -97^GOJAEZ9LPVCP&%<++I@PW43Y MAVQ-\ZNQ&> ,)M/ILEP>C4H=^XE-G;$LF1)8XW<-S3@&YW\B7;NR272|20:%)C:VO$ M(;T;91F?|4V1!UL#P<^:/A7,J8[WAD0^V M^;IM8KRP]&(K;\07-4::--+5 7'H,\):!KO6ULC#FYGLXP0TD:J<)R=N/):0M5R_^G12H2W@U(9126$HO+,O%%O6GW5(IQ:'*/@,']< MFQ9P@:]6(^6L9BG"2%P<8]R39X^;HI#I(H[2.&2!3->- C[;30NW6F_R4QXO M?(#D0)-4J++%HXXRADVA0/1L9A3#>@Y-QX5GOKGG9/A'A^>,^91%-G62Z#M+% M)4O],XYC?Z)?L8GNX@3/Q&/;8-]?4201%(G(=6(HE4 M_54H =UXC?_>Y6:P?<(:L; M:RWI6ML::Q@QD-G^:MAVZR4'\70"XTLLF&WSB7?%D10LG5P6K40ZU4'7V&W< M&;=Y)]-![::H44^)9M|3?FL7:+=[IV/<'7'0KR3=*T\ 9M_M ,W1HT"ZYGC=VT1HZTL-^2/25PX?H3 ;WB|@UE!+-E^)VE/#;>D#M=0PM>M+ M"J^'# 4TP'MJQV9B:5BXE,(;U4K0H;*-V\0|XAZ>_NC;%K7-.W7I(YMHY+FJ9+,8G# M@ .'$F39X7,<=8T'G9UP.Z(9YM]^2&L/O&YI*+?U^O_%2VA._E^)9(#'B,U' ME#|[EVC:AJ..<>>E&?P4 5OE5-@^ 6:HAJL9J8$D%L [H2R3"0Q1Q/Y M#?A&ZZ#9C\+"O6.\X:+5/5 -H9@4XV1R39]!FGLJKOY'SUUK0WUSW*&@"V=M MIJQIB|>].R4>7DJB1U/8+<(7X2F:P'L@O^?^[]M=)H=)8GXA+=[9KEAA6-1)N&9>;-H7 MMSOWTD#;TJZQ(UX'[R?^:,L[=-X^CQYP+/+R5_&.W\(S&[,-^^+V]EX:.'X<ML|.C7F_O) Z@QS'$COKIXY*XO-ZQ/EPX_SWU'>$8NW$=2=$W@_N/(_';7<>2V#& ML$XN6;I+4R]<;\ICZ/F6O=+@/$\IZ0AN20]WIP_13^VM.@LZ>*/#(#36!:%* MIB1.2,$6EKG^$QP)I(UNOF ("%TGU'6<+YX\)9G MTT5$9R?<4< ,<_U>65L(O/YN*/?@%PMR^NC<>R[\]<+(XY7\Y7)'S[2L7\R7 M;U=IQK9>UN6I_7OC=%E++925@^.6/,0I@,*E]":$;NWB5"FVZYCAN4MP M'?HC%RZXB+< 5=84WN6%AF^X_ !YQBN]XXC3UF!@1PEW/(" M$#"#+NV?P=|!5&X3+G,.#VD\BQU$-#'$G6X4Z)R=7+R$2>4/4<7^R2A$9\J M\5\HA9?9XPCNI(I_AD(XPXW(/?1P1Y;!FJ]=E-@2PQMEAD.R/CB0G$G!FJB\ MQ<"M:9.PII%#]\Q&R. TN)[;VP>V. M1HB/KB?J.^!U5C.Q!R0"%]2)[(_IBV#@W&G\2W@O]!@'PHWKK_YZBOZ"%R5 MT)*"-_]46^K'S-_0Y_;%&V'\XK.>XU3,.(= M-:;;3;6TO<70N>./3A%C'<&]5*%))10JQ"-@'40030_O)&@)+7$2N[5VUXBE=+7:M\C]JEE66X/YR^$C4)O5 M"^9 ,*3$1KS=QM'?O$04!M1;OZ8=8B=H0U85R&AHA-PE6D4>87B!040_Q/B"M.WG+V<]MJNRAK/9W,M39s/))"A=GG*'-$2(X^1>$8%?H9I-[&3^[1/.=4T_=%% MZ/N\ARB^WI1//Q4O/VETV-8>=U#]1*I&&UCO.&B6V1K4Q64P50['PB;QY'GM@(HC.RNO8"AO!#6')WEKB M::ROS6_&LI>+?9K%6^WR85P.N$/ !-IL]#XZ M!GF\868*8$/K> ^;7 #4SE!4I!2)'/:1,Y(T+10JI7-9"Q:?5VJ2(>4XXQU8M ;3W8",;TNI20/I(D^WE/M$>F1CTP1F*>B$N#[6Z.B _X#(6W]9D2P;*/9B4 M M2\)CU6.NW"KC]M&MRU +?URPB!^HEZ3?CA:" Q>#N6>>$%#W,' M_D_QN$T3T/;FB ./ G*1SNK-SME2<>L M.:@:=$<8PQ5W.=KA[(HX^Y_-9]L87SY8'(2R$609;/DQ>*5YO2%THS$G@R M550V2TG)_7[*!"[LY1P|IN*CL"CP"*"QIC:GC/0&8-/\#O]|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|RA|]WTHR@.+|+LX9#X[20.>Q?MOMCN/)9#<X<+=1U(]82@ M'HT"S7OCC@$]M:"& <.N>"-!7P"V?E#QD<=*1]%o520!"&Y.PH$;34 E+0F: M>((5@LGW-9=/))]>LM0/XW2?G-RTZM<3M_OW0-\R36_JAM?M^P@_UA2>^SAG MD^=?*XPPS.@G5P#,[\D&|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|ZD1T7]H5_[/2Y[*-M]\K!^Y1>:^B%V]$,4;>N,IH*/=M"2EAPPE'28'"^>N9WQ3/BV(^EB1/*XX\#8>AQQB7:+/P]D=(1C M+!YZ[|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|/K-L M$7C8KIF3V=QD:(JYE[MYU]0_U(@%FL1TOM/[FYLA=O\67%4-HM,VR - F\0#M@FQ,_^"$S_8XT7!AY?6-(=|1I;(DX">E1E##AM@F^FV26HX3$)D@@< M93)HIFYBE45S#Z7S-0E;ZG=(/:8)09$54WZ!T#L:Q;_.L##XIIEX.O")>O!D M_12[!":6U!R'3IY%;DT-<;?^%6*+&FO0UMG4V-5>.JSJD_>%;?=;K5T=?X_7 MLAJ1%+95^Q*G=36+:&M?.37W6YC7GM]^:[JE.4YC,\6IW*LVN(S16.)1WJ" M8D4V'APWNKM.C 'I" (FS^63Y9**!:8/3MUH1G62F%@V0[!HQ1TI7[0]FQYM;F9^:G9T2-6;7P7)^1>@$X+*FD$-B 'U$":?7RN+^.C71FV[E!),L(P6D0HN!%@MR*2(:DX(EA43;J0$G_"'"4-$M;,8]2U2X91%=;RYXH&.PDH32%P>XJ,3$RR?7E';&A7X4<,<%"VVH@:%'=[R1 MP0:$=48RU%;DLR?)C13L(!>Y8 C5G5S'ACE5\G.TA]>WPUPSOM3,AO) Z:7$M*!*%^QF$G#8Q/Y\O]7N=L*4S[@C13P?Z68.N)]ZXT%/^D='_OQG-.706UX"T[?&[>@=*#5EX-6F M>%VY2^ QR] +PB2G[+KH^V0H(T[8A0]6SYRN-RUODCMG M6DFMRY^*HSB2B.=SG3C5K0]!&.V"XI\>AYWG&Z5DA[@S6.W<^0O_^W(K/ M1.+MTFA_.8ZNO0.'^DE3N@E#1FG=8#O"Z(\TC^_@SL\A_O*7@ >M)M6=1!C3/EC'04G13R$Q:=WBG/8F5[3BS'I?#YUW T*JZB*15YBJ,C[T">!);\ M)$D"JKJ4G"*!R^6)T)_PI8?318"F.-'B.T _2P[%(%FQ2*)L+[&')H$I]I%IAM[7%&/F.DMZB:&MC'>W8QND:WOELA"EY+T2E8?JIYNXSP'? ME.HXKB|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{]%SLXQ1I?QSR/7M^R5*E?*AF Z&C M"\XXV@>ONKG3UAIO'H^1U .=.Q76*\D3A;Z3_==) 7)6TE5%F#^Y #=]^J^OR>ML+9+V P&G_YEC/9ZI-+=>QGRE0_8ASX6AN$AO_]ZC=PW**8VG (GZY%T1WVV M89R/@XI TZJU(;"M\@NO^2589_.4B1"?/S\G?/]1T1,C^EIN$WV#;4YR?-!F M,1XTD, 9,X?HPW0.<]Q_F7,:+8]YC@K8KPQ0 M?X6Z1Z>W_&^BQ^KXHV,GOB\MG$%A% TU'?*

*_U(H1|^C48UJ#=HW)0E<6ZE$HE MXM O'V'CA*1|9G:T1:2<|^$YWIM7AP^>4JU@1:HYRE\+=394)(&JA8H03H_|ME57I9]XLZ%)6?;6QTVJ1ZX:BU*HFN+, ^P:(50G78T-\1M'SY E?Y>O?2NQ/AXNN/I\Q\EAO8&^UK^DKS2,=R#N.:S) MG\4JO_4"AGEOW/[44POUY[^,NN+UE[X [&O]2#YBHT?A1'16NNL6 [9]SM.4 M9H6OG?-%C=ZJ3=KCM&-CI.4635MCY-LP1J+;6NF-M@R58%O%II+QO/LGDX+7 M01SBEH-'J >?1E|"XCL.JG4P:FR(TU^[L=6KCQZWPCN:M,AJ7VM4DEP1(#K! M$'$=)_+=Y&O^XWR.7P5]:*8?);JIX#2\/GC+L:*C/?+APE3ZD6L8)A2N5LNA M(X$8*O(>9(F*<0@(,>|\C4ZN#T\S?2"7"H0W4ZD!QO1MYV7#!M:*X_3NXV1 MMFTIW^* ;-HM\HA;R[>#[IP.OQ(=1UGB^=G>"]=/(7MNBG-=;7%;:RO"HX?M M3QOBM=)V<0<|TE)0)1595R .:3PPPGA8@7#&:'Z"VX33>[/66C;1);+]O+BT4A4!?33>X\D/&Q!0:SSB^G M "AH$DE4/,3W;2I8[=D8TV$3*P3=#S;+/,/..\@C^OC< |>>)?0NB<7;G:]4 M; OI9LDF_7!&F=[(U;E(9R>||Q)ST:WK!N0ONYN'BM3%9?RE,B2U9.'\:=50T59)$#63V42[YF$0GB,/22M/K4MR?4&$;Y$4$L93#[YVB5E 4W$3%1DAFXH7"V'-0V+GJEX[JYJH8F7PZGBC!TC M:TV=&0PDB2_BC ULV.FD(H!X6D)B0!09Q%>Y%/563J8=KE6G*,-O4<:01_JJ M(E2;!5O$%?+"=LJ] (1&DFV*X:4><<;0]NHY/Y->R'@P\(;@A%G*;7=3NGOA M#'(]49ME%R, _N6(]^"39PD[OLU UL:SYF<^NMLC-N UAS7B;&B(VV59QA^U/ M5V2=IG#HO? *V(YG#K"=RPS5';O:#;_&G>O01?]}8?(LP >2:I;X7_@?UDD[> M!]5V#L6+[.=/J6C>YTC;B!INWQBHI'UH**!Q4U6@7B.P)L";%.O) MP9W\4O!'Y&U[+B3]Q"*VW6^+ (Z3+/;VG<&\KH,EZ4ZFSUX_0D_ 2?=!&=]WN MV(?]TCS3"MO83BJKBMQY+%B1DC,LP17OQ9-U-[.UGX60TKS>Y*])/'^^85< M4E]F.7]XOQ*9SFAB%U?"3?29?LD>WVCX2D72BO9)G3X$%AB+6G714&7,:>R\L MMK1CF#*&B-%^'@[J3DM.M2'?X4OYFK5_V6Z,0- MTD_NWH|O_3+W'E$+W./^,@.NQ'U!88N??;L'<OD/.?+4EKW;M/X7_ POUPNSE(0[W\/.UN%1[<|2.98"SNOF]:XLO?!M+;'W!4] FDC@IJ;N= M .LWHF\[+MH8=L5IRC;X&Z8BK?WPF;B5] ,G+LVG#6V7;>8YFYQ5!TG!Q8F/M[Y]2^H\|E^/JM>LDLKDIRR)$D'5Y?WC(X"=PXV^ M^:+,LWU8T;1=C)F.&#I/3-7YB#*$75 7=G[ZK).$,?_WSOQ2?Y+W_ /\#4$L# M!!0 (+R :%G(C,\7!CX (%B! 5 "TR,#(T,#DS,%)7!9C<^,XEN|[1,Q_T,W!T#T/F6E;MC)=T=43\I;M&*>E1V9U=T_>E@R8A M"5,4]>+B#M\77X"+Q T;"8H ()B8:]<-@/S.]^$ Q'+.7_]S=>V.7D 00M_[M\N'__SKO__;7_[/QX__<_%P-W)\.UX#+QK9 M ; BX(Q^PF@U>O%W(&\L;?0=! %UW=!% 9PE&H^.C3U_'7TZ/QM]_/C7I(T+ M*T1U?&^4-';RZ3C_PV76G._],CH^_OSU\|G1R>EH_,OX()>3R6C^/2_W';W: M K(*NM#[_1?|GV?TO!&"Z(6_O(;PUP^K*-K\|OGSSY\|_/_TQ:Q!/[7 MQ[S81_RKC\Y7)(__?]>=<>Q&,MK?>P@_6B1D_C'#[/QYN=Z\2^BY< @^^2K+]!6?\ MU\|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|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|IE-%I'*V0^OZU MY?;Z$E&M5,XC)ZBK#;-:U?;4=@MTVB]'-&&^#<-82)I!1/IIR#3?FVB"2|Y M]#)G+1-%P(*G_1)%82T.C<&S(#&>DRS+S4&0&(&]3$FJ;LBVD+4?K6A%H2< M.3V@U#!(!2(3 WW7$6]J,."0FGC6&?/!]0(URZ%W;-],[4*3@S<0C/6[\(5>/=G\-9XOL ML"#Z]\#*T0EOF.K]DT;^8E1ZEI)K1ND&U>ZM"#PY.A^D"S/L7.ZU3 "4Q9U\D?9$"CEA$!6(0? :DX+.^@>,0.;$=H4\/M$+Q &TQ78?7,(:F8*L0(6'U/E1 HQ44) D3FO7O2$+EB+\[-P'FK. 6_0CZ>QUO: J M;+7RA(*P*$O3 M<.$4R$"W(+-(UZR41,3RJK'=NE>+(30K].L#H@F9&*=2N4+]Q/63D+>9(8BCM-Z5.V6:GX\G)L+& Q&F[*W3X'EA0@Y@O3-@[N M*A=@@!(11R:)%4Y-3E?!4-55$K;$K M%;DG]):O6!*G1^2?CHW2S#?WFGS]^;_X:0V#12]'DN[91RE7+-#%T@=UU>4/R M B9!"?O0N!$&XWN7Z,5@=)F*8%PIEW_8I-$,-PE1X3I(2*9-8KV^YL?#X9-@"U+,6T Z[4 MQP]AA+FQ8)!<^Y@Z_QN'48]H$E^Y;9CAJ6>:&KH:[WJ26K4M4|&QAM/AZB^3M=H!EG9568SUMOXAQ@VR;!DN,D1WVIYK3C_RT'/K4!R%RJX&%K]*]@F*U,X M""O,, ^>[;F+"])./^#73BO ,HU336-98W1!C^Z?!O@J)>O]|$E< 7=."+>3":4-E8&-'RYM$/K9$#Z]X'X#./LV<*;H@]):@OL87U^8+6]W=6D^0JB-LE$QXGKGIL.&X6XNF M.^I<2OWL#]DT[$B#W$H$RW7Q4@6'+_A2]P6[YD:%|I1T -GI/8 -3G?A M+4F#.K'8@8?SRGL(#.3LFJIT8!8GI<&])2S=.NAC_!R"/V+4QO6+8/_\VK0& MG;LP"9U3V*Q0|\D*K\'LU.2RBO3%I2QR0A-5XZ MC-NHXZVZC6AP.&7[@I?*;/%#20%TL_][ZN283%)B D7$AXP=X"_G*Y#^:\&\|V754QFHPZ]PA"M";"W=-Z.)\'T&>DJJ*VIG78LU,F2:Z2HVP/X@K>%B9^3(FVHIK".0N!1EJ@U MNJZ_JA;9K&Z1>0 V%G3H*ZZL:F]021P&Z+I.JKYX6GNE=U?$9X*N@YL&$BKM M2-Q!ZQFZY%OAW/7?HJ$+-'#XJ=:JL*=*Q_LY]86]S"\WVK;08RP9;8AQY#] MT&+9WE_&DQ/SE=?)-F8MIQ*L<[W>N/X6@ ?@)IZXK0+)|:Q5W0E:I.NBJE]IMX_\H[WP85C5]];8>T=$DLH96'_40906V6P3L>NJ:TI!]@I-]ZEH4^M!"%$DW M;@+?!L);Y"Q&C=5Q5.0=VQ2->%(XK^R'=2'D?0_V&]ML_OWN_"GK+3 M"K&M^ZFU$11;VVKKFPKGAEHYHD)X]4BQR(G;H;<'I4-$<&._"0E:1*QOB(9: M&T&I2L,;\,7P8I>HVR(K^/)D9*W?"1Z%$X;=%TQ:AQ\I"A@-XP6DMOL!M(?M&I^[I9S8)DI\!>]_$75TM8C<0W3#CS@/8+,S"2V '4<-XS74U@9=C\RIIAI^ MPW9>OGDSFNIH$ED'X]18)IQ>+(=S1:7KW82W_(IZ7[F8?O@_\=1 5\L%_>_ M!X",#&W4*_?T-="^1>%D@0E]O DU23;>J7Q4+8QZR.NDWW2Q"+UO2G;C7'4 MW2(3*3L$61_V)8Q1O)F,VO#IP^7_>Z<^[&"I),3:?!NA"N(WO7'L/RYZLFT M#]*_\U*FK*YG*11*,O8;S9N8EW+S>/FWGH+/UBG%-/WN#EK&Z.H+GC-NI26 M7L)ZLEY!B)/3D<[T%4LIIX,.=#B>UV*"U7Z_^=9#ST8^$R.\|^1+7Z52IO/.M!BLW#N6@<>3RG)2YX:Y32[*CPK$]FJV2EOB'CAE#V\' MX(#U)HT#,L_?)#GVUR0HW]-0A"H;K0R MNMI!AT.017B[0UOYN;XF<5_K&"T'<>0'N2HK-V,BC@[E^F$<@'LK0O^=+2[B M$'H@Y$^,>'R$_F_T<;1O"OTC;0VG/RRTIV3RPUFPM+PL?-8^BV,: 'Q>,.HN MM);E[O,[$CXA);5YX/#?75YZ3_X3DLJ%6Y[S!/68S2/\7!IM!=O9XA$N/32#MY%OSL9HY.OGJ*I=.'W)X<-.ZCXL>P9V M8H6GC/-/&16>HZ1OJUN$X+!H!0^\Q4OCD^5;^"JKXC'8[)1V<]MCTZUS9Y%) MLN!=(KUX7._%66.C0FM*]M7LRR+,(|-8+]FS4DL>>(.-(ZH,_]2@96MES9|@ MS0]S+8^#P=(>FT2TNO7PXGT8CFYJ6N_660M*=F7\;@5OUMR+284.O[W!WT$)MI57I@'2]5[^BMP[Q$<%]M#Z.GG;6, TNM/>GT:Y%)7M>LH17 MPG[O1ZO>R"I\Z/RY36_#WS>YZZO26_FX*J?1[0)1MWZ,HS; -*0\FAN@+W\| MX0>>X'?MI-ZA"PV/+,\959M6LF=3K,$<:,&'K'CHS),?+L3J_6/E[C$>3XXF M@WB 5IR6,SEVAJV;5]B=WGH

*]6.92C[CK%^V)?B\&>E/B$U<;,0_ M8K,.0^W*C\WAU@'JS\H;SVD=XERU7/"9;D_6;6W9CU)1IGWET;LH"=(^'67* M< M:;XP3S!-IZ@1^*DI$906F SM$@>[[K1S?RZ'^N>Y>L;#697!,I.SQ1 ?.CIAPD&;NX>G<$C-BZ8#9/AZYI *1_6I;84T4((MI#!#W1G9K2HW(!W'RIL2)D-(FHF88WBS[> #6(]^F%5@.5R%BL(ZX+1AQ M#<4^78T$J++V&#_5"G:P@A7$]WS6-(I4>|H*R*3 A+BI=Y1">FY1!LMF@Z+A@6<<+?*]%]LSX] >L!J;3: M:%&3;>B|\!\R6$_1)I0.GY-+,,L@-/C)M)RM(&0<>R$UATA2EU@&G^"I"=,17MR8T#JGRL#"IDEX7R,B?$>&&BI-YT?4GCFKHC/'+)UUG3WISWL8(#E=P'J9+*NM4C2/2#XK||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|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|81DR)X)H+0"[;GP3!@C3X <<))#DEJP(T1DM2SW&?M:*5 FJ@CL3FN;*ZLX;&\,$ M9*84VG M> ^[T/ CDF+YVGH!D'2" XTI3W%_V%J4/@9TZO M@G!41G8A=CG'X16HDI-.H!+.V R,.<6S2:TE5U-CI^,8YD;)<>V3CI7Z?T;H!K\[. 0TFV38[OZK1'YVE))+N,G M%?1DD%^C>Q%Q:O!=<6+;:4YTD2M3&"4.HV8JFM7LJ\24U'6'Z\$#T!U2OUP7 MN>'&A)>&P_V)[C3$%"'5/E(`X:!* ,20&H M$4»#'09++],2!F1,JIN9PCY*1$\O?/GLX(+;6F R!LE$:6'EC"&78.A89B.[:88]V+JAQ$Y8WKQ5&D_I=: MA EZ=Y_ D*IXMS1Y&LJUDF@713)G=XD,%D_->;FD-1B]F;UJ!.HCZO;] M>=TI5I4(VKAFH1_?GNJ4>5_F;+>;G6[U M;,JX06<4.C 9)Z;DUY(>*)TM9?+IF'2WW6TK309> M^%.[L\D)2?/G&RA#;+;+0PS(1;^S&!/FH,B9>6P>POK3J\F4&D;\0*M[KW- M=6GH?G1PSH2G|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l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|&^DY8 MQ5$"O;^Y0X$&=517(-VW-^A7LN\PCE[#>@LY*4TK8T^:0N?B5B?6GXP=1RD* MW.P :5D75-N';S4MJ5HE$HB;ZYMD%V;+W7#+W#WE>NGL_5SEX-SCJ^7T&2$!U7[E,E; 9&V.)U&98Z7GS34I MVMPDZY89S2I8\FU$B-:<^AHF<,EX=RUM9_/6I96IV5!OJ4^;55RE.'F5G93X MAR08++),3(,/J.HBS&ZX9N:1I\+]"&MVSDH]*[*&9!W$7LN@<,NS.H6"'/6T M9HX>]3<@NDC)B$*/HC0:\;N!/3FRPF4 >X279L>(N0$):U 3\BDCF$95P*6 M'R9'D8^I@?Y%E:/) ^6Q1I*@(4T3DXF*7+-2:R&)|'_M2M8+']Q#\ZF:JIZ!+ M806/#SW.5(5*@9VIBN)8*:(-[2)(@U&HR^HXG*40N556BJ]',K/$SDW<34Y: MTB3,.IGK2_%,P65#L-F<+W DW C'KG>2>KBYBZ^)Z3)C-@XNB7@_'F.Z-Z90- M$2/I^-5^SVP<;+]U;KL(Z+H.&B&>7,*7|>0>9CIU$0WU)X1.^G>QB+GN3[C M0-3F*A"U"D2M E%/(,9>J72<$M@-97":CAU&'BL)K43W&N.D'!V<-T^/00M]2Q5/IW9J8"=N+G!Z+@_OHY*1W<:B,L34KWE-R698]WV47 M.3!YR;!!+LD#6GCH8O;W*G69G)=G0#TQNU@%2IB599*=;/?051XT&T!EPP!&M5#:NNRIMJU6C+>XNHTU@8T#1F<4W!+M+-FF&I<1%)+Z M& [$=3"*-BDF@DEBM?H@>1M@V'+$[@7""N&C),D5@39 .N@5?)-RIW>5 ML43!@4I;9/6<*?PZMJC>/:NEXX[H]@S>.&_QC%(_*5I&(6BE VM87R9@FB%5 MF* -X>M*2+Z&% SR6P.+-0 8U0HA&>W++#W4VY*%7]F(JK!5R&-SLJHV<(21I>U= M+4=:-O19]%4.R1B:C.!<;]-B8-LO@0%<&O]I>.JTB,+VD6G\Y80+B66L;7] M,|>I2B&)^EG/!ZGJO"M(:37/5'V_TCH:CB.;AI3"B652LMD@_Q&7 BX1E;:: M_I\-7:RHH+)"W9R!O006=9,]/0N#R"=%3\))/E1:RUL^AH-76O"I#*5 '4: M@~>TFZ5Q*T38 :K8:7056/H!QI+NW?Y'P-KIT+-3.!VE3*W#&1;:8A'+2^U|Q M=GM?>G8]EKBW7N^(5CY<-4K9,S^GII?\C:4H"%Z7F*X6BT0LUK|#S&+N62-IM3'.NNX;:"TKCG3F=[9_O6=UMCDC5.?ZN_1=MI_Z/1'N62L!FCOZK">D9Q50K MGJ5$":M1=IN41ZY:,*B!:QJ+33&M=:?24I#ZRQ&2E%X^ ^F9-L83|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|%S0SY9JR(V/,P&N]-_4L.H6%&).6AHVR3X71_S$%,_#-*R*RD?Q@ M\Q6'/-Y_W=PIIQ6S@PG;=!$\1IQ(M#8S1@(C5Y1U'IOBK:(ZF;D"6-3H9J64 M"(68(B!OH/%B*)=P\QB!KA1&JG!U" O-;OA#)A#?=WW*8-B4?]#1ISOKHE"MY'V0@5$ST'DS4M(DYA;H@9446M&ZMKNJ)IV44(^O9U(/1>K-[_V+8ZI30PR0 MX1!3QN0|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|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|\@UG&HUNJ;^P?*NE1]4^,5P@ M&I?]] MN K T # 67U?;MZ] K.IK(.]>80Q3AZI31';AF[*^;ORQU[N$4]!U"[XLKH M<;XQ48HI<4][DKQ&"4ACN!C&BE1A+D^<4R<@]>#4T/^#,5YG[Z3>>"8^* 4F M.1*E-FF14X9303^]^|"(^?%M;QIF&D=(!A(7OF6O1L8Y8ZV3SZ/_S@"4[=H> M]#/7.!9HV!7IM6(6Y-Y/+,8ZQ03@Q0R"Q M6-8(+QNJ]>J3BRL3)C4I3RU2?ECI(OH(48-G*"2/82X^(6R,E8:2> 2)@9_:|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|-KQ=U@ MS5P ;;=/D(POM13MG:E@3.(8HF%(9U%-)15%K1928"7.%Q"-2)^?CMM0=$&< M""K-7ER?>"44X2&*-XJ8?+$'P/DB#6A7X2,5H6RHI|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|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|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

*'H@/O74"(V&.%= MUC3M=V*15&H0LJEMCG(N('LDV/ 1*:;HNB:2B<-H I6%8?I.$CDS7<"S5-9S M%:I4E4NKO4#(K9L$1*6&D^+K1&T8QP'#U9&,YW2@% 2O)+9P|YYP)HEK=A?8 M"F!NFQO\B2N .:, &D:CETJ!M4+ X<[122_A]'NCUA>RLX:3N'PX4Y74KK M)\1'8 Q%%']%3 \9A]H-DZFF^TN%Z%^N#VK.K_$55F*[1+A31'7$-@_ ^)7E! M!W4>SE>Y.^+- $\M3\'LHNQ7.6'7/T; ^ZN 5WITHI45'/VT!=D'<>]JHM5K: M)\D=:S#YP$IVP_]T9P ;T/.W/%*88.C+8!]/=3?*0M]%W8@"T]+ H(-1D+NI M/I&2YY>G?!CXU0- P"Q=GQDTO<'^7F@\S1C/>{FI.?2L/@>@1>)F$5+MFPZYGF M<0BL'G54U*@#H+AS*4&:A?HRA>FIX0Z8FI@Q3 A(B40C^>@DG19L?0%=#PP_MC!'8V8)NB VSUG77$AT^Y> ^Y M9T%EWKTJ90)+-E3)0]X%!Y[)/BM73WE6[)G[4UY04R8M#29!1$ES,0; F)???ZMK/E8GK% M3CWG:(:@Z2P55EJ9@5C,4Z[NE AXJ36%ZD@3)/G4DL1)/&8GG8Z&:*2??54| MM'+J*TL_1:= ;/M8+:IRWRL+Z?Z2AE>S^5|&#/6.J_9O6Z.O;^0WYK$SVRAF M#%AW'NJ>E/3 %1-\T]$>81\!R:%+)!UL%<5&!Y=2@&UYJE3B[N)!P]I>]%483F9TPL=;4 MJ8!J2I634BVC%R/63:&JOW1"%@/M@\Z^$"I93*>PU6(F[M M2]A_+| SO4_P:7.?_M-1;2/D'A+1 M)?!2I'>Q)QN>=5"1FUQPAGLV2;QK;NR)H5M.[^>@(R*9HM|5, 8O2 R&L\LX MNN0Y_OGN5;%[JL$!,HB84&A\&0)GM'[M[2KG))@R*[^GR>K*@U&)*EI$T:47*0 5G2J0LM%1LUQ!=]GD!I5$,2PTX10 MP^Y YS288<UKB0^&8ID3I(==L;@ABNZA5(C^ZC]!?/9,_ M)V$6.+_&N=BOY%|/(<=5O)%W!2H+17:FZOQQZ1Q6)["543#G#HP4J/:#"&N! M%T|B<41T#$-.U# [".X8JFN('GD\UW0C*L'"&BBR :Y(Y-*B:GQUR[@@C\)N@ M][R483EZ)0HL,0K#K%[&':??FFS#;HS-2G5QG*L%##D51YJ4AHGH.Q9V$/J_@9=>OCRS)AV&F@X\(IK&88=$6|'U@ M,.JM] ,XBFQ2R-4D5*,/U>"| MQ.SRQ+B3!(&#RZA'ID).QQC&) 0&W'=6&C670*]C0"WW5&TP"S,> MJ88^S$0:1-DS+[AQ=-KV.M +"SHL>]0UHO9I,U2,:QI8/9NDYG'W60F+'QY\ ^ M\5&25Z@l.*@;4Q??.,JMVFL+0_8(JQ-3GH$#1D)O40=,=V@&'N>]\/PIIO)*@D%-28R7DD%6EKJ2$1;JF\2;[L\PEUM!]- G M6K!5O):YJ@HL7L;6*AN+1*$=IQM9S$A+6 M(9+04J"NIH06Y_9'P"=3H*:63?E!!CYZ)$E-O.!/!!?6M1G&F6Y;ZK9 32(MB/WHU ?CKZ>(4$(;6WF%0$'#1]$ZW0?H@BKN: M?,O[5'T]3X/GZA|OOMU)]YSV>"U>6/YBNDPX!U!@%Q/ G/A^`UX%?=;!_L_Z/R M@;/?-TO@_WVU!GFL]_];`_Q95]ATB+*OBJ<'C]LKE"MAFL*U\$H0|'Z0[AV0%/W0CWQ=M&- E:0<&DTN M3BY ,J13I?F1PUZ3%*;/H^FH-&P0?Z3ZOH#?;0|U?7D]/#DA"95M@_FU&>P MP>;]9#IV#EZ|BE,])+&')\7H|B.+,;=V,>9=C/D'C#%_IYK$3C>])*

6'BYWN^H,K&^P3HVH="]$NS8?[M6+@U59EJK+,FP07>_'LQ8[.=G3&=%9POFH2T1S) M06_KU)1$23J2QAZSB)'1# 82YK(4D/%]F,[#NF:9R[2AS M3B]H+@LJ(3WKG$'S,RJD)'A8B_5%0C,C>G[3.##;!1\ME,> MRHVQE",.9:B4'E-Q9Y9X/F')D'FRIK0Y3)?D!^/4]+P&2P^P-3!5 '4SL:< M44Z($[4T"DT"%Y:&=TOF,ZC>!% (;B<#/I&YO:DT\$,%='TPHF/ Z7^,82GA MQI*5/L#1@: %'C"E^E6I @&>-LK35'%4@O&M#_IA8SX-+,10\G/A)"Y28-I MF6R0FC#PRR7B3 -4MDL9!K,%-^#&M)R4*@-FF/? O!#+'(Y/X\DF/JF9T',NCOY(\O:!KEZ# LBI MD(WZ_N^;85/ &A9>:/^(-MH/1@*E7XH0EK_%4]WG1 _XKZ6O60NF" |"FY.+ M5GM(] YT*:T&:0;Y[5\ #^-^P&^HWI:Z>3")6C81;PNYAJZX\(T4[GUCNM MNDOEZ8C&PKP*2ZW+7[<>KG;]M8 M$Z&3>=IP>XV!V^HW'&G_I=:X]%RWVW1[]:9.2:-.6 [*4Q$_5QBY)K6087U' M"9>S%$;K=%TPVY"EM'Z2RD?U))6QJ6>I-$SGXB$:"@*I!OQDRC#O^!R5KHD& MXET[(TS+S0IX5]ZL| :1<.CVUTPV'H^!B7(9D?4&]G+ MC?AC,P-Q8L%P$28 M"M@JB2"]P +]8(C*O\[+_\+#]CG]E!$AXML/N>,V>P.WV:C?<,AMM]6LN_U6 MYTX.>==#INZU>!T^YV;S78R8MYX[.U[W=X3Y>E(+V+H-DET'R V:0/+RRJB0% M=]^_F(4F:*)$"3*Q(=@YR-0L:?%%3+ ^E,5VI-)N0"X4IEU\A\|+#[*]]6WMC M=?AH|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| M&2?4H^G0F^,HF^M!=!LE$WWX(S5S^H?1%B7WQNVWZVCZUUOVQ+GM=M=M=/KX M#3Q:!#=O-;S8U4W:!MR:MEMO#+1/|/@NF?R7[>+]EC2E'ICTW7:G/.FJAUMN M]]-OFXWF-Z\#E*9PFVVW2"J51FR[_=ZI=>;GM0Q9=*3)=449V#:;AL7$OU" M-XI1^4O6L]\0M"^OJ+RC!1;%G :S-TVZPBWV8MTBR^V4!E:;<@T=3&R0;('1 M-"0K;/6,$>-1TT:V]B)8N[B:!6KF636A;K\+'+SNFJ7=TU%LB+,\5&($+2^S MI"&"3F,5!^/E.E2DA@X'W($XS\91C&4<_"?WKG25)P6[RLJI5^192&S(X_9[M\(]I6FC4IUK.435 FA/8+\T@2&&*6-19 !56*1DX_14=ZO&%PSP-&198FX]\ MJ^2/ <43H5BQ+<.8^S;%PTC!E@OD.?9<)]N7_,X3,!XN)K9/^&\, _9-@O/L MU'CX/^YF(JLRNM9? 5^!5,EM7W9=VB^L33!W,+>|O".6ZZ/08!8'-TUFQW$$ MQZGHUE=5M=4I\%1WAVXIU8K6)/\3N'>@>F(3?#[V8,|W9ML>U/!RU4*N0 A M7\1B[1.NNMI?,T?N=F'-3S+P;YKDIN! <8P=K_RY#M9G6+G$KV#O:*DX%FH,2 MIV [@QUHYZ[8^,DOI]26 *63:;XG4MTM #FHN^819K#TF:8F+N*ZQCI 8$Y MR,BE"/6P]7UU33FVX:\$(]'.1?4G&D+D=$DAS&RH^W M*Z+?T26MZ?IKE(XU%/8@NW"OEV&]I7 \TGH^\&_=K_?K+<,0-0&>,I.!\9 MZ:,7BVIX>)DJ(&H(=*71 +>$X9>:|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|ZXE7ZBM"LR2|2C,2SEDWF8?S)%HC39BH7O:Y]<-L)! M8@3D0F!Q@#+^,@,<+K+GQ^=|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|SKE]>D=[>0WNBCOFR,X MK4)0?MXLDO3J/;<1O]UB.Q4;;4MM?[Y>Y^T4_O3L!M#^W:!['F2 M6NMUM]MH+9W=HS2X3M_\=]!N.GNO\O3O"[L!\^^%^US*V[E%JBM-WM0[E82 M;9NZ^A4"::_=ZKB=;O/9G8JD31/"-MR'+;#C[LP]W5+S[%9";*_=<^O]_K,[MDF(>7Z_+EXFBRP XFSWFR^_LYD>D\UTUZ)G>TCX-C*GZ39 ZC3;G>_# M=*)NSSOE\-Z-IS5II=VW2U'L L>SPW MYS;BM-5]NZW!70G3ASSJ,ZSOW&FMWR(FM^CB/F24Z_'+NBVZ'G<8)WL\U'\[<[#3ZKB-[G=B#CY]>M#V];<_3E#MQTE;W!'Y9HA| M"R)E/U#&X]VL>_M-KZ])L-> "XQ&^49W6"?(# 2O86"?-P1=^7@JCK:!X!\| MS':G;I:-1M%69B+O"&X7]'H,N>\;EG*[=/@M5C*W*P3WW;H3MREUZ[LB-0- MHWE7$6>)^!M6 MA^XV-W^GXSZ*JK;-;].6>YV'U)U=^4>1;G;- N56/IXA=AMQW&G6W4Z]^0@- M6$R@|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|\OSQEZ8.)=>E ?E]N_| MV#Q!T5W&-Y^P3MU4Z-RQ\\3 M9'+XIFP2)K[S=P[\"OO4CQTD"F2HUJ;0_0;^D*=$(S3IE>| $1)>AOI<_1C8 M2L:,'!A:D.RH(9HSSK$#/0ZYP2OPFS>#A2^TF*B[M+:,7L0=[GOQ"D@!KC:R M_3R:Q$F(`=WQ?L!*?5HM[/:KI.8#G.(1T-T20@RF\RA>*;H&P0_ -ZZ$ %_ >7"RZ;>7[^S("WAA]3=VINC]B++J_F4'U&7%0B(MYC0.$NOVM4YT>W/\#M]MR:@^:#L)N;/!$_R>8.4]P[OCDUWP&[&H 8>2&S M2N>P/;"2-)_#H1'AC%"#4; <6A!MJ%7" 4H_[K^=S7%[?;71L1L3=PFUF)"P: M=DXX%_S*YK@U!V0I?2_2CYZ@9^G-,G;I5\@P1'A_ =%,?V M+&6'"V(UGZF0-ZZ#&Q&.405!8L%G/[(C+;..9'A2+ T*&0S# . <@.LHXCY!$ M<>#RV>1^1R>';XE=EIY$9>VKWK/G"M8/C:?S_F>Y*Q"SIP CFE$[$ZX.S#R M;]=:=]=),Z 7N;8X\% >36$8!S<$_IU-U+17[=&FB/ACS#*&"V">)S<&<&A| MO=Z'NXH:A6^=-;S\|:L#UM|!",)&.EZ&JH(6B5B;**;>I\#O Y"5YK(GV! M"+QP3+< V.Q.D9K/YSF/L5LIDH:(&C6.>14HTDJ@V>?LDLR"5P77HP FTQC4 M!C\I@HCS+ 5MQB? JPJ=)JIC[_L 118NW-B41-7^A%7\6E,_ED,Z[I*_T2@! MHJLMM=ZT&HJ.0*5-T,Z?R(EI*QX/ZQXZBJYLIM=L&TM=**4]*$_]_RDT0]4N MJ?U1',7)<^5NL!8E-8Y- \CQ=>=.4M4EED;U!K*4_&<^VQ:!'M MUFNMSD^.]6_T/-5S@4K-)N- M6A>=!O"G+*S= /7N?DZJZ)KP*H<|"Z? |-X'5\Y)//5F,"!]@@/SF$^<21*, M__WD'VD@'SWYY8SN&G) <^#:PD0Z\7RSR6$O3= ;[L-]F M77(&YL/BX2V="7^)O'HGW#^#^B[^,MGI=,J';OQ>.E#GV)5 M,"J8>*)<%$T]=)TH)HH&$3D,\8#&]8)@1-Y^-"FX0MF(^HI-A[%T|>\CT4=%M MUE^\C8$8#M2#]&'CQ;..:\TF+=WCSE#@D_E%\G.8V\7SD7,7|>W8<*:LNO.9MI9\[B5AN_5J]]Q. ^%GA1$E^A8B?6&K[4 M>]'^18,>UT]=>F%$=V:89R2.S$ X!FA/9(YA"3C9#'"X888N(A\'R!=IXE6K M8C7*EF*@G,!6SD%4HB(#FT^"F.0/;*[8AI$EI,@%HH\G ,'+WB'K0-2F%2S+ M9HMELR$KT /28)0G;$1XL!R0?.1&N+TQ/Q&!U=|!7=%EF83V:#+ ,4<;R6 ,@MT|PAIG 9$5 MLR1\EWE.41_S%7%KIGF4L2O*TIFP+_(1%Q/Y=WPHC3&:\?6P)CL>V%MQ'68 MFI2K%+DPZ&!$1VVD(S\?!;[-9/04|"*()SWM=>KH?7-I#4$43M%#(=<'_AU. M\RF[Y=!2!N&0U9S7>8)L@CE>:=K]S>P;F9%#/YZ)H48;*32N:"<)IF"0%'=) M=A6>V N?.8/Z3^]PU>77=M^2*:D]?0M@M[!K@3@X(XPM+-A6MN8%=W_5Q)AW MM+IN;U"_R7@EB<(! C,V;B@M =;PM-FK@>@MOPCU5&,[*,7$&9@:6YC#./*I*]'H94GH/]>S"A.| [3.H5BL+Q^T M6D3D9#0 L<;3@*,%-! 8$:Q*E5>_8K[B,<2MG0(=T1)1<;&8NTL)8!*N1S\ MCS::T#3AM(IB" ZM5YSK#(TYBA<+#>Z!C&.LR2|W\A|]G%?:!'9B_P4(HV0+M M95N@VHAPR1[G6Z7UX_8]*9JVKBY*Yl-6K=\H>2HZ]8;;;?>_6AED3;!= X:U M8440[QI'46@FL'Z'U<(1W:,[5 V_(%6JPO|)PS3@VUO>!L\)_7\ ,1_W>_5Z M?Q2\/S? M#WSYOC1M.O^^/ZJ-5\PCY2_L7QV=&[UN^?#MZ?'9\= MG!W_<73P_A7\^5;^>G5\>OCVP^FG$_G1@^_,ZL14NKH^L&?F@"5??_E;=&L] MIP A_FOI:_8W$YO%BPZ;(OQ1(4SVFXW&"\?>* =VRK&VRM%[=73]'+S\|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|/##Z0=]NV !QS/*#8\4PW.4 , O+A+:O-<)W->K./D,%Z+> M:)F_G]6<#X73M/V S\!5ZQKY2:!\|P'LQ0F0- 1701093D75-^2VPYN.A3(2 MZN3@)B9RQS-/"AND= 9C=Y2+*-L9)DY,)@"<>=D M%"O)LDZH%"2)EP3W)!#*0D N%,@))A]:'?$";4W:;T7#?W/B8OO%P[\|UYM7 M- ^-$ZC,L5'(I(EUH8,B6LXJ|2S)7S0BHH--0'1\Q2C_S,>];W::]D@ MH&S3-5H>GZX8%342F7*X!]<2>2FF'Z98>Z"RV^AA8HOJ/B(S%]\;E=#7+KE7[@?N&"- Y5^]3672&SE!IC*0:$W/.IZ0?^|W1QUSH?M9N^\ MWFTVP7SV6H-^IV K?SPX.3L^_G#VZJ'\)?O7'T[>'9P=?WA_WF^#$7ZO=O)* M#|C66,ZX-2PXCX_Y?_<=VBC'VJF:MI>-[Z'Q]NC- P5LRJ8]>'1_Z?=Z MG1_5[|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{!\L:<<,91LS;J9E7]L\]2[>2(P+SK&&GA K/L_BJYFD!6+A M,J-]>%Q"38\&R2B@-'"V5K-8_7J9")5UIXD55%,N0$#YO-G:4V_AA- ,Y9CK= M?(!E9;QTA'9HE;YA@6;5,'C_ O6%'2KO>1Z=6\V ZX["@G%#,-)\&E6):: MP-QV=>]?]L>?D@- &*&QHY%7]XKAK8Q=WW<5=?\"KZYVAY4 JIQU97]_(%- _ZY+8405]%+V27O:&W]_JH)2 MQ,D)2-[)<*0=N^47_4Y/FX_Z^_^I69KP'T$"><OSJC"2;L 27 ^; M]N274|QY5$ B*#_3G+0*]U 1%(TH%U^S3E"2?'L$JMDA+L@HZC5NUM"YM ? M<]U*FY;DWL,/ V>JW^|^*9=*$[6FKY] M+4USV(^|19QGSZGXN6KG+%:MU 7>IR*$L&")HKQ^|K/]Q3>MH=S]&]>'+;!7 M@YEVYV5(RW_^8]#M#5Z4D35+N)=+I_[MR(WKQ'PEPR!C0,/"P%)9P*$TW:W MYW;Z-U7Y> HZS^'7H=/&%<(@76)."@'^I#5_3;-3]#4.4MX33W-W%W5W\SNZB MDM*%VUWK]^N#;HO4#/8W<#=#?S!;Z'M&\.]PPRC.%FPFFPA MM>FBW'>!'Z9HPY"3*W#Q1G&A1,:A9S"PGC;<5J_I]GM4+VC57Q&H:]UM#]< MWE-$:; +LU3U! <_#2XH%A%A62Q5;NJQV?>T6O?BF2BQ37+7C#3O>L,-3W[I MN(-VR^W5NZM@50V^$EX_@0BDZD7T.W/'"%\KK9KW1<8[^SK'2Z7B&WEC,A?H8 M>;/: [IIME4|'0<839C)FW1!.S+5BEPREK(]Z;R-]56XM;H:Q0)9|16\K218 MOT&@O37HO2^S%)0]D&Z\6#6OSG2D'.6]^I_*G9'-|C7^(H(GWV-.$0Y MH_1)WWJ:LI/*.+D$G(8[ASB>H|\X8B@9MH18C4X;/V!$X_M-1?HRKU0!E9^@ ML3Q$S8>E8R21$[TI'8"H7 6JY*&QC75;9ATV ->L]D8^ZW1 MN1=T!N?MYKASW@^:@W-@]*- N>QOTNSU_*8>A^>G]R=&;Xl.SHY.C5Z<';X]. M/IP^^OW3\=G_/3TZ_'1R?'9\=/I .0U;D,:0+&8QVOCT.8X'UXIO#V.V1\] M<_IT>H1? 2O+1'2<]W+!KJYKLB&2M$!U;B__P/IX%!;]N#SVOT[C]YZ-ZMW7> M]LC:I\&H/3IQCD;#9MMO#T9-:XFJ.\M9A|WF_28=;A4==XITO)1:^(I.67Z M?S^,K@O:BDX=L@O/PKO(:K-WN?3[&3!>>I7&GDSGOGC7-|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

MZ"'7K>2Q^> ^7+DPNV>,YS5='IX]4OFY'5 ,[E%V;D$W MRH4M6E$U4?:_BB;M.UH% 3%,/V][T&K46M\))=O<[,0?AAPWO4CM(X&G1_M@ M0R7>*'L>7$]@N9EVA:2SB^M]]"W7!ZWZ=7#=:OB-VB2;?IU[Y!"W12&&DYMD M$@9CYT@C&WT09".[EWG!68QP3 I<;<]|MM]HPW_Y@SW.\SAEC!D5PVEJ]L.7 M#+U9D.Y_N(Z"A?(\-^OUYK/:DI=F)Q]V\F$K5_1]R8?F3CY\?_*A>>?RX;7& M0MC)A^VGWYU\V#KY,'B4|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|Y9Y7_/5<7)$6,&S\|-]/FDIN7&T'M*^'=FBM P.[_?#V^,W1^^/_ M"K3_\? O#6B4JV.XLM^(L[W"U6W6P@_)*==/N/C?MOH5CZ_:R|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|:3+=_'&KEP,S$T:$0@[IZ"8BCB%NG]]=K3?ZO2. \[Z MJ2ZLS4*$F 3]4-/0'YR/AF^_=/1\--'!./YQ>7IQQ$;?6+GE^\'K-WAC?;! M'G\1M]C_VV#D_6G]O336S9Z-V 7@_[E^7 T"%RPP>_]=Z"LMKD_&HN.82&Q_'I86>_5O- VRR M*%9V)+!Q->>>,1C'BLD"5 QB,>6^>" L-:@*ZJ9IKCDFNTLY^|^7M6CKO1RGJ%.4QI MS"UK=^3Q9,GC0_9_?!UO()P_L2K\5C@I4/JD'$- MCA.0XX*6*CD=8&C9"1-0=IHV17E#$H>N8_1&I#(YEB/AHY7TY)!I%4&,R8;M M(1?$@.3B 3^XCA*>3H"=HJ8XSR7FJ<$2OO"TMX7Z[J@N*W$"@C M"BPL#_%.4.VHZX%P'#YUZKJW++G%8/<7-/=F1A&B MTAG@HD@32-%[E,AF>(>BU;'+DJ?6,O;2]UN M%>$5=^=.MOD.I4,NF(JB7!/<*_[.';5.E;&83N\=K6^&|WVAR!AY"S7(6N[" M\ C9Q&W,T9Y=FB_M>N&M2KA9.H>D7AS/0>QDG1N/0G(MF!17((M=NK7\|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|YLCCZ6Z/13R<\C2%A[X8?WK-$Q?D44LMB#=QBZES8"1NJ+.,I^P!:"RG9 M:RV2,3#6;C5?-- MJ!\U6HW%\A'7UBD(J#5Fl'1P&>ZVI?=:JA)V#L/62??K M=BZ&O5V7^\W'WO#?G_J^V4\7K|/>JS6"O_=7I!\&;XQM_8:I;:;*AY:H05 M*N4R"/JG-5;:6)N%03"?SYOS3E/I<3 \"R9V*O<#J92!9F*3VO$1I> G\.3X M: J6LWC"M0'IJG8Q?-LXQ!Q66 G'1T'YU^>-5+(X/DK$C!F[D/"J-N5Z+-*& M55G8:66VBR4#O+V2YZHQ%XF=A.U6ZY=NQI-$I..&A)$- #YJ'A]=)6HPGRS3E MNQ9JD-R*&5#=E5IC"5R'D;*3]FH#=Y7,RG(CE=K&B$^%7(3/>UR*2[OQ)>?O M0,[BICC=X/#VC"@Q>AYUV4WXK\0OL3N6:BR#2PSQLK)UJ[O2 UAT/;JSD1.M MN/O:$W-P?8^43+"F_A_O!J\'0|9I-_>.@@@'-5M%|IDYTV3Z>;W6|TQ10UG5U86468L0DZ(>:AE[_;#AX. ^B=#]UF[PQOM_1V^&[0/$O]MC9/UE_;TXULV?-=GY_W> MQ=E@..B?L_X?O7XW_X^%L>26"1T@GH5[56#3LK9?$@6%Z;C,?%-9;0 M^#\I+?2$WVKN8Y-%L;(C@4VJ.60,?7%9-PTH*/4/7.Q.UXW:S.N0KX_((^C=@$SX#IF$F8(X" MRTZ$8;\C?) JY8*=0::T1=G%WBH|15W6^)V1$3M7N! @%5=U-DCC)ALIC26! MC83!9<+^].49I E6>0Z9A6F$UYU6G9%PZ]X:TX"69N!6I!:;CQF;E>?Q?W)# MW+S6Y;RW@7!IX"Z_YL8Y1FRZ8) [E2&%&(SA>D%9IOP2' TL MZS28EJ QV*0DL41M4(98:/0&,1OZAP8M090P7+#QA)FBTTB]Y_& RB)V!5&^&IJD$NXFHP$&)%M5AV++.DV6==>*MLX$4|Y?P"3W> M4T0L@? |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|S1ZU392RFTZM&JYOA M.Y\L.D+>0@VRDKLP/$8V<1MSM&>7YDN[=KU5$VZ6SB&I%\=SD#A9Y\:CD%P+ M)L4ER&*7;B5__?\>HBVW/>D ^3I!?;"\'//:C0[_N'9VDY+OZM<@@S5/EG&N] M0:SQ#7[@K2#2TC2>)\(J;9:NETO *J=382W %Q1=I-"YH_N)0/M<)3O(3"B@ M# DT_$OAK)).X<)(M]IIB 8CSPFU:QI#GP"_)#_*A$.<)N2".>]FGW$7_)O8HPKU^?^X.Q<$3+&A@ M*3@^RS1%Z >+(%T@(.K>&3/HB9E\BJ.' 76=*83>G>|;;,7(EC4>R!::95 O N_.) M\EJ%WR C)(^UN&*W9^.QP9J.9SF8O:K1Z:Y:"?3" (_W1JRDY)F!L/Q2[0(Y M A- - (6.===&8XFS=/@36NH9G<62,4BHGP!Q?E*T6M;7]@'R6&/R2+6K9?_E+ M=2!7L%(YA5:IG*=WMDJ1ZB\;A"WA!$^6RX;T)3\T6/LR0^Z)LN6^GW7ZMMSW\TW- M%CP;,D,%|ZUGJC;L>/ I+@IW"'/0GT'\@F/W??+Z_0U-.EEYTQ./+L59YFE#L4NFPU R5WZ"Z>:-0||2/($4* MC>*Z5!G5WIX]4JH_?;7ZHUH9'T/# ^P%\9$&'? *9$4BR>P|/FWOY2WA1O:;A] M$/]C7>[7OX]_!U|+ P04 " "\@&A9NZ__"9L% #P'P & '-N9W@M M,C R-# Y,S!X97@S,F0Q+FAT;>U9:U/;.!3|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`?NHW3*= MOA4 K-DN5'#T/C>WK#N_?M=K8&ZII %E5*WTZ*Y4 MV#]%$%A)Q+WNNT M#^TF&D[1\&QRY8_.=GALWU7GNI:5;EW["$W.D7\Q0M/A]>GP? KGI9MMY[L](@$^WLA%8U7NU*],1BG*.1I2D+MZ8IXI!(]T3D7AB?950I!6MV7W/#Z'Z+7*GYS> 8]Y0+H[IC+$#+U;8 %6 MAD@:0>B:DDR1>0#/;3!R';^;"$N0954PU$.G)%P(<+U$(IQ&:'0'<26%D A+ MS:F4>J/PJR4C"(@H(8+)NN:NB89%ZK:4S.77< .A 0082D|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|IX;#P<>,/)!2#X:GH]N("0_M-T',$;HVI^:01-/1,.MUV@=V$PVF:' ZN?1&IULT[+=50E7L4MB.?8@F9\@[M'Z'IX.ID<#&:&I/W;TN_=^L^OLB531:;4O*1G_,42 X)X&. MIWG64S%-T9F0[MAR(AD2Z..!I@ACXNL 0_1(2'D""G)%%D[L-S&W"ALV03X11H69ER]= I"182 M CQ)$>8A&MU"]N*0> ('5G*:I7BC\:LH0TBZ*B22PR.JBKD@BI"K7U,QH%[" MF8(2@94>XJ]00"1H$_@T4;*0ZO*#&16HXKC02XYC%6/E;M?>S\^'%?890;Z0 MH*WCAMT)3%6Y._U9JVS7U@60PK!;%46*6\T=H''RE< M,_-R*#2ZRY@J8F@6Q.5B*3$T99-":CR\/^O7-8(!]8<2|XQ9I1C:KFD:?<>L MVF!#42]18 \0F;,410O& (L01YB&_#H,2/)Q027197F:1:$U&'?Q'H(PXQSL MAGNZ9R-HK /&(%"ZV^FT]|LZE-S3L:5]U\I9M.7?K_XAFRB'USW$& M42@I%*8ZT](\49=0QU0"UA-)4HWJIN[&L+,&842S!,RG"<];18U!(<]NFZ' M"<-LRY=5!$"U8'E0$ F1&<^T# 1%07+?!"\>['KOG*'ON*$WWXT2_L4"\BA@ M!((QG*3$+;]49=*(+,31>VYM1S#4W3V]_0FUQ89>MU2VYUD4*;F6RLD5|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|\ !@ (!4FD# '-N M9W@M,C R-# Y,S!X97@S,F0Q+FAT;5!+ 0(4 Q0 (+R :%G6S *RM04 M "XK 8 " 2-O P!S;F=X+3(P,C0P.3,P>&5X,S)D,BYH 8=&U02P4& H "@"F @ #G4# end XML 56 sngx-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0000812796 sngx:NewWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember 2024-07-09 0000812796 sngx:NewWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember 2024-07-09 0000812796 sngx:NewWarrantsMemberus-gaap:MeasurementInputExpectedTermMember 2024-07-09 0000812796 sngx:NewWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember 2024-07-09 0000812796 sngx:WarrantModificationAndNewWarrantsMember 2024-07-09 0000812796 us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember 2024-09-30 0000812796 us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember 2023-12-31 0000812796 us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember 2023-09-30 0000812796 us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember 2022-12-31 0000812796 us-gaap:CommonStockMembersngx:AtMarketIssuanceSalesMember 2024-07-012024-09-30 0000812796 us-gaap:CommonStockMembersngx:PublicOfferingMember 2024-04-222024-04-22 0000812796 sngx:AssetPurchaseAgreementMember 2020-03-012020-03-31 0000812796 2024-06-052024-06-05 0000812796 us-gaap:RetainedEarningsMember 2024-09-30 0000812796 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000812796 us-gaap:RetainedEarningsMember 2024-06-30 0000812796 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000812796 2024-06-30 0000812796 us-gaap:RetainedEarningsMember 2023-12-31 0000812796 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000812796 us-gaap:RetainedEarningsMember 2023-09-30 0000812796 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000812796 us-gaap:RetainedEarningsMember 2023-06-30 0000812796 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000812796 2023-06-30 0000812796 us-gaap:RetainedEarningsMember 2022-12-31 0000812796 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000812796 us-gaap:CommonStockMember 2024-09-30 0000812796 us-gaap:CommonStockMember 2024-06-30 0000812796 us-gaap:CommonStockMember 2023-12-31 0000812796 us-gaap:CommonStockMember 2023-09-30 0000812796 us-gaap:CommonStockMember 2023-06-30 0000812796 us-gaap:CommonStockMember 2022-12-31 0000812796 sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember 2024-04-15 0000812796 sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember 2024-01-03 0000812796 2024-04-22 0000812796 us-gaap:GrantMember 2024-01-012024-09-30 0000812796 us-gaap:GrantMember 2023-07-012023-09-30 0000812796 us-gaap:GrantMember 2023-01-012023-09-30 0000812796 sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember 2024-04-152024-04-15 0000812796 sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember 2024-01-032024-01-03 0000812796 sngx:ExistingWarrantsMember 2024-07-092024-07-09 0000812796 sngx:AssetPurchaseAgreementMember 2014-09-012014-09-30 0000812796 sngx:AtMarketIssuanceSalesAgreementMember 2024-01-012024-09-30 0000812796 sngx:AtMarketIssuanceSalesAgreementMember 2023-01-012023-09-30 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000812796 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0000812796 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000812796 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0000812796 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000812796 us-gaap:RetainedEarningsMember 2023-01-012023-09-30 0000812796 sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember 2023-04-30 0000812796 sngx:PontifaxMedisonFinanceMemberus-gaap:ConvertibleDebtMember 2023-04-012023-04-30 0000812796 srt:MaximumMemberus-gaap:ConvertibleDebtMember 2020-12-31 0000812796 us-gaap:ConvertibleDebtMember 2020-12-31 0000812796 sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheTwoMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember 2024-10-31 0000812796 sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheOneMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember 2024-10-31 0000812796 sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheTwoMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember 2024-10-08 0000812796 sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheOneMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember 2024-10-08 0000812796 us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember 2024-07-012024-09-30 0000812796 us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember 2024-07-012024-09-30 0000812796 us-gaap:CorporateNonSegmentMember 2024-07-012024-09-30 0000812796 us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember 2024-01-012024-09-30 0000812796 us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember 2024-01-012024-09-30 0000812796 us-gaap:CorporateNonSegmentMember 2024-01-012024-09-30 0000812796 us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember 2023-07-012023-09-30 0000812796 us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember 2023-07-012023-09-30 0000812796 us-gaap:CorporateNonSegmentMember 2023-07-012023-09-30 0000812796 us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember 2023-01-012023-09-30 0000812796 us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember 2023-01-012023-09-30 0000812796 us-gaap:CorporateNonSegmentMember 2023-01-012023-09-30*

0000812796 sngx:ThirdTrancheMemberus-gaap:ConvertibleDebtMember 2020-12-31 0000812796 sngx:SecondTrancheMemberus-gaap:ConvertibleDebtMember 2020-12-31 0000812796 sngx:FirstTrancheMemberus-gaap:ConvertibleDebtMember 2020-12-31 0000812796 us-gaap:ConvertibleDebtMember 2024-09-30 0000812796 us-gaap:ConvertibleDebtMember 2023-12-31 0000812796 us-gaap:ResearchAndDevelopmentArrangementMember 2024-09-30 0000812796 us-gaap:LeaseAgreementsMember 2024-09-30 0000812796 sngx:PreFundedWarrantsMembersngx:PublicOfferingMember 2024-04-22 0000812796 sngx:PreFundedWarrantMembersngx:PublicOfferingMember 2024-04-22 0000812796 sngx:CommonWarrantsMembersngx:PublicOfferingMember 2024-04-22 0000812796 sngx:NewWarrantsMemberus-gaap:CommonStockMember 2024-07-23 0000812796 sngx:NewWarrantsMemberus-gaap:CommonStockMember 2024-07-11 0000812796 sngx:NewWarrantsMemberus-gaap:CommonStockMember 2024-07-10 0000812796 sngx:ExistingWarrantsMemberus-gaap:CommonStockMember 2024-07-10 0000812796 sngx:ExistingWarrantsMember 2024-07-09 0000812796 sngx:ExistingWarrantsMember 2024-07-08 0000812796 sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-06-25 0000812796 sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-06-20 0000812796 sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-06-14 0000812796 sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-06-11 0000812796 us-gaap:CommonStockMembersngx:PublicOfferingMember 2024-04-22 0000812796 sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-04-22 0000812796 sngx:PublicOfferingMember 2024-04-22 0000812796 2023-09-30 0000812796 2022-12-31 0000812796 us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember 2024-09-30 0000812796 us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember 2024-09-30 0000812796 us-gaap:CorporateNonSegmentMember 2024-09-30 0000812796 us-gaap:OperatingSegmentsMembersngx:PublicHealthSolutionsMember 2023-12-31 0000812796 us-gaap:OperatingSegmentsMembersngx:BioTherapeuticsMember 2023-12-31 0000812796 us-gaap:CorporateNonSegmentMember 2023-12-31 0000812796 srt:MaximumMemberus-gaap:ScenarioPlanMembersngx:AssetPurchaseAgreementMember 2024-01-012024-09-30 0000812796 us-gaap:WarrantMember 2024-01-012024-09-30 0000812796 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000812796 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-012024-09-30 0000812796 us-gaap:WarrantMember 2023-01-012023-09-30 0000812796 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0000812796 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-012023-09-30 0000812796 us-gaap:AdditionalPaidInCapitalMembersngx:AtMarketIssuanceSalesMember 2024-07-012024-09-30 0000812796 sngx:AtMarketIssuanceSalesMember 2024-07-012024-09-30 0000812796 sngx:PublicOfferingMember 2024-04-222024-04-22 0000812796 us-gaap:AdditionalPaidInCapitalMembersngx:AtMarketIssuanceSalesMember 2024-01-012024-09-30 0000812796 sngx:AtMarketIssuanceSalesMember 2024-01-012024-09-30 0000812796 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000812796 2024-09-30 0000812796 2023-12-31 0000812796 us-gaap:SubsequentEventMembersngx:AtMarketIssuanceSalesMember 2024-10-012024-11-01 0000812796 us-gaap:CommonStockMembersngx:AtMarketIssuanceSalesMember 2024-01-012024-09-30 0000812796 sngx:NewWarrantsMember 2024-07-092024-07-09 0000812796 us-gaap:CommonStockMember 2024-01-012024-09-30 0000812796 us-gaap:AdditionalPaidInCapitalMembersngx:AtMarketIssuanceSalesMember 2023-01-012023-09-30 0000812796 sngx:AtMarketIssuanceSalesMember 2023-01-012023-09-30 0000812796 sngx:NewWarrantsMemberus-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000812796 sngx:ExistingWarrantsMemberus-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000812796 sngx:NewWarrantsMember 2024-07-012024-09-30 0000812796 sngx:ExistingWarrantsMember 2024-07-012024-09-30 0000812796 sngx:PreFundedWarrantMemberus-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000812796 sngx:NewWarrantsMemberus-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000812796 sngx:ExistingWarrantsMemberus-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000812796 sngx:PreFundedWarrantMember 2024-01-012024-09-30 0000812796 sngx:NewWarrantsMember 2024-01-012024-09-30 0000812796 sngx:ExistingWarrantsMember 2024-01-012024-09-30 0000812796 sngx:PreFundedWarrantMemberus-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000812796 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0000812796 us-gaap:CommonStockMembersngx:AtMarketIssuanceSalesMember 2023-01-012023-09-30 0000812796 sngx:NewWarrantsMemberus-gaap:CommonStockMember 2024-07-232024-07-23 0000812796 sngx:NewWarrantsMemberus-gaap:CommonStockMember 2024-07-112024-07-11 0000812796 sngx:NewWarrantsMemberus-gaap:CommonStockMember 2024-07-102024-07-10 0000812796 sngx:ExistingWarrantsMemberus-gaap:CommonStockMember 2024-07-102024-07-10 0000812796 sngx:NewWarrantsMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0000812796 sngx:ExistingWarrantsMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0000812796 sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-06-252024-06-25 0000812796 sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-06-202024-06-20 0000812796 sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-06-142024-06-14 0000812796 sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-06-112024-06-11 0000812796 sngx:PreFundedWarrantsMemberus-gaap:CommonStockMember 2024-04-222024-04-22 0000812796 sngx:PreFundedWarrantMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0000812796 sngx:NewWarrantsMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0000812796 sngx:ExistingWarrantsMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0000812796 sngx:PreFundedWarrantMemberus-gaap:CommonStockMember 2023-07-012023-09-30 0000812796 us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMember 2023-01-012023-09-30 0000812796 us-gaap:CommonStockMember 2023-01-012023-09-30 0000812796 us-gaap:AdditionalPaidInCapitalMembersngx:PublicOfferingMember 2024-01-012024-09-30 0000812796 sngx:PublicOfferingMember 2024-01-012024-09-30 0000812796 us-gaap:AdditionalPaidInCapitalMembersngx:PublicOfferingMember 2023-01-012023-09-30 0000812796 sngx:PublicOfferingMember 2023-01-012023-09-30 0000812796 us-gaap:SeriesDPreferredStockMemberus-gaap:PreferredStockMembersngx:PublicOfferingMember 2024-01-012024-09-30 0000812796 us-gaap:CommonStockMembersngx:PublicOfferingMember 2024-01-012024-09-30 0000812796 us-gaap:CommonStockMembersngx:PublicOfferingMember 2023-01-012023-09-30 0000812796 us-gaap:OneTimeTerminationBenefitsMember 2024-01-012024-09-30 0000812796 srt:DirectorMember 2024-01-012024-09-30 0000812796 sngx:AtMarketIssuanceSalesMember 2024-08-012024-08-31 0000812796 sngx:AtMarketIssuanceSalesMember 2024-08-31 0000812796 sngx:AssetPurchaseAgreementMember 2024-01-012024-09-30 0000812796 sngx:ForPeriodFromNovember2024Member 2022-06-21 0000812796 2022-06-21 0000812796 sngx:HybryteMember 2024-01-012024-09-30 0000812796 sngx:NationalInstitutesOfHealthMember 2024-09-30 0000812796 us-gaap:ConvertibleDebtMember 2024-07-012024-09-30 0000812796 us-gaap:ConvertibleDebtMember 2024-01-012024-09-30 0000812796 2023-07-012023-09-30 0000812796 2023-01-012023-09-30 0000812796 us-gaap:ConvertibleDebtMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0000812796 sngx:PontifaxMedisonFinanceMembersngx:NumberOfFirstEquityInstrumentsCommonStockIssuableUponConversionMemberus-gaap:ConvertibleDebtMember 2023-04-012023-04-30 0000812796 us-gaap:ConvertibleDebtMember 2020-12-012020-12-31 0000812796 sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheOneMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember 2024-10-082024-10-08 0000812796 sngx:PontifaxMedisonFinanceMembersngx:LoanAgreementAmendment2024ConversionPriceTrancheOneMemberus-gaap:ConvertibleDebtMemberus-gaap:SubsequentEventMember 2024-10-012024-10-31 0000812796 us-gaap:SubsequentEventMembersngx:AtMarketIssuanceSalesMember 2024-11-01 0000812796 sngx:AssetPurchaseAgreementMember 2020-03-31 0000812796 2024-07-092024-07-09 0000812796 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000812796 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000812796 2024-07-012024-09-30 0000812796 2024-11-01 0000812796 2024-01-012024-09-30 shares iso4217:USD pure iso4217:USD shares sngx:segment sngx:Y -0.78-2.56-3.84-10.052203929648860137656842977300008127 96--12-312024Q3false22953046487610.06250.06250.06250.06250.06250.062510-Qtrue2024-09-30false001-14778SOLIGENIX, INC.DE41-1505029 29 EMMONS DRIVESUITE B-10PRINCETON,NJ08540609538-8200Common Stock, par value $.001 per shareSNGXNASDAQYesYesNon-accelerated Filertruefalsefalse250949998401778446158171254238941263853403308660141030689295073202277722777716211927140148229834254681047697997973268912271111222309833 86-225704176593518825224221047697997973261304401193715945471304401193715945471104411193715205021999974045968689826015256488725351658965479730403106 1865236-1779056-5727002-5560069575-3046225731078836663631436 03-97399-472925488-173866644412077166444120771434322 3-39379172463-260933-387537145855116354447792780 37-1719381-1662702-5279210-5482032-1161197-1719381-1662702-5279210-4320835-0.78-2.56-3.84-10.052203929648860137656842977 3-1719381-1662702-5279210-432083598741825715230-429-1709507-1644445-5263980-432126400648761649228203706222 43-225704176252242214883155842158436194719470020469420547411954741400625065625065114735115-115348163522278722282253750053780638600703125703421804742187507552457755245771776837177683367903625422025425617426817426815230152 30-5279210-527921000229530422952368788063747 3-230983386593518843181898182217067691247 47-219563446-247082653202533091409309146295348954 88-431438441448956738495817834061834061312537299773000197824999850000026471426530343299229076229076-429-429-4320835-432083500648761649228080469243 18-223884281422115515424801542232269964027599-229264005346477614883155842158436194719473481635222787222822703125703421804742187507552457755245771776837177683566325663298749874-1719381-171938122953042295236878806374 73-230983386593518861523661522801510360 61-222221579580020033525 34-346540065400182571821 6-1662702-166270264876164922808046924318-223884281422115 5-5279210-432083547654964896868250017426822907673000500 00-393791-260933-38753712518-171254-49079-525684310229-51879-92092-89969-80458-1391432-2382708-166753-281149-6170761-677589658436309146244522930094741400849581762506578788 1-4450172-329937477468643670000007519211370968845569127139401 9-306108184461581335961598401771029853442162130061837714880111023009997525425622816123394383810461807177683 Note 1. Nature of Business Basis of Presentation Soligenix, Inc. (the “Company”) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments: Specialized BioTherapeutics and Public Health Solutions. The Company’s Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With agreement from the European Medicines Agency (“EMA”) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ in the treatment of CTCL patients with early-stage disease, the Company is targeting to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026. Upon successful completion of the second Phase 3 study, called “FLASH2” (Fluorescent Light Activated Synthetic Hypericin 2), regulatory approval will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, the Company’s first-in-class innate defense regulator technology, and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer and aphthous ulcers in Behçet’s Disease. The Company’s Public Health Solutions business segment includes development programs for RiVax®, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of the vaccine programs incorporates the use of the Company’s proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency. The Company primarily generates revenues under government grants and contracts. The Company was awarded a subcontract that originally provided for approximately $1.1 million from a U.S. Food and Drug Administration (“FDA”) Orphan Products Development grant over four years for an expanded study of HyBryte™ in the treatment of CTCL. The Company will continue to apply for additional government funding. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, development of new technological innovations, dependence on key personnel, protections of proprietary technology, compliance with the FDA regulations, and other regulatory authorities, litigation, and product liability. Results for the three and nine months ended September 30, 2024 are not necessarily indicative of results that may be expected for the full year. Liquidity The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. As of September 30, 2024, the Company had an accumulated deficit of $230,983,386. During the nine months ended September 30, 2024, the Company incurred a net loss of $5,279,210 and used $6,170,761 of cash in operating activities. The Company expects to continue to generate losses in the foreseeable future. The Company’s liquidity needs will be determined largely by the budgeted operational expenditures incurred in regards to the progression of its product candidates. Management believes that the Company has sufficient

resources available to support its development activities and business operations and timely satisfy its obligations as they become due through the second quarter of 2025. The Company does not have sufficient cash and cash equivalents as of the date of filing this Quarterly Report on Form 10-Q to support its operations for at least the 12 months following the date the financial statements are issued. These conditions raise substantial doubt about the Company's ability to continue as a going concern through 12 months after the date the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, the Company's plans include: <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Securing additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Securing additional proceeds from government contract and grant programs.</td></tr></table> <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Securing additional proceeds from the sale of shares of the Company's common stock via the At Market Issuance Sales Agreement ("AGP Sales Agreement") with A.G.P/Alliance Global Partners ("AGP").</td></tr></table> <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Amending the loan agreement with Pontifax Medison Finance ("Pontifax") (See Note 4) to reduce the conversion price in order to allow for conversion of a portion of the debt which will reduce the Company's debt repayments.</td></tr></table> Other than the AGP Sales Agreement which was entered into on August 16, 2024 and the second amendment to the Pontifax loan agreement which was completed on October 8, 2024, none of these alternatives are committed at this time. There can be no assurance that the Company will be successful in obtaining sufficient funding on acceptable terms to fund continuing operations, if at all, identify and enter into any strategic transactions that will provide the capital that it will require, or achieve the other strategies to alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern. If none of these alternatives are available, or if available, are not available on satisfactory terms, the Company will not have sufficient cash resources and liquidity to fund its business operations for at least the 12 months following the date the financial statements are issued. The failure to obtain sufficient capital on acceptable terms when needed may require the Company to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives and its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. In addition, the perception that the Company may not be able to continue as a going concern may cause others to choose not to deal with it due to concerns about its ability to meet its contractual obligations. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. As of September 30, 2024, the Company had cash and cash equivalents of $9,840,177 as compared to $8,446,158 as of December 31, 2023. As of September 30, 2024, the Company had working capital of $5,776,645 as compared to working capital of $3,355,212 as of December 31, 2023. The Company's plans with respect to its liquidity management include, but are not limited to, the following: <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.55pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company has up to approximately $554,000 in active government grant funding still available as of September 30, 2024 to support its associated research programs through May 2026, provided the federal agencies do not elect to terminate the grants for convenience. The Company plans to submit additional contract and grant applications for further support of its programs with various funding agencies. However, there can be no assurance that the Company will obtain additional governmental grant funding. </td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company will continue to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expects to continue to do so for the foreseeable future.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company will continue to pursue Net Operating Loss ("NOL") sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program if the program is available.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company plans to pursue potential partnerships for pipeline programs as well as continue to explore merger and acquisition strategies. However, there can be no assurances that the Company can consummate such transactions.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company completed a public offering on April 22, 2024 of 204,694 shares of its common stock, pre-funded warrants to purchase 537,500 shares of its common stock and common warrants to purchase up to 742,194 shares of its common stock at a combined public offering price of $6.40. The pre-funded warrants have an exercise price of $0.02. The common warrants have an exercise price of $6.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to the Company from this offering were approximately $4.75 million before deducting commissions and other estimated offering expenses of approximately $0.45 million. The Company plans to use the proceeds for further support of its programs, as well as for working capital. </td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company entered into a warrant inducement agreement (the "Inducement Agreement") on July 9, 2024 with certain holders (the "Holders") of the Company's existing Warrant to Purchase Shares of Common Stock ("Existing Warrants") to purchase shares of common stock of the Company. In consideration of the Holders' agreement to exercise their Existing Warrants, the Company (i) decreased the exercise price of the Existing Warrants from $6.40 per share to $6.00 per share and (ii) issued new warrants ("New Warrants") to the Holders to purchase a number of shares of common stock equal to 150% of the number of shares of common stock issued upon exercise of the Holders' Existing Warrants. Pursuant to the Inducement Agreement, the Holders agreed to exercise for cash their Existing Warrants to purchase up to 703,125 shares of the Company's common stock at a reduced exercise price of $6.00 per share on July 9, 2024, the date of the Inducement Agreement, until 1:30 p.m., Eastern Time. The total gross proceeds to the Company was approximately $4.2 million from the exercise of the Existing Warrants before deducting financial advisory fees and other expenses. The Company plans to use the proceeds for further support of its programs, as well as for working capital. </td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company has up to approximately $4.7 million remaining from the AGP Sales Agreement as of November 1, 2024 under the prospectus supplement dated August 16, 2024. <span style="font-family:'Arial','Helvetica','sans-serif';font-

size:10pt;font-style:normal;font-weight:normal;">From October 1, 2024 through November 1, 2024, the Company sold 229,078 shares of common stock pursuant to the AGP Sales Agreement at a weighted average price of $4.72 per share for total gross proceeds of approximately $1.1 million.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.75pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">●</td><td style="padding:0pt;">The Company is currently evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate such a transaction, or consummate a transaction at favorable pricing.</td></tr></table> Management's business strategy can be outlined as follows: <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Following agreement from the EMA on the key design components for the second confirmatory Phase 3 placebo-controlled FLASH2 clinical trial of HyBryte™ in CTCL and positive primary endpoint results from the first Phase 3 FLASH study, initiate the FLASH2 study, while at the same time, continuing discussions with the FDA on potential modifications to the development path to adequately address their feedback. </td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Expanding development of synthetic hypericin under the research name SGX302 into psoriasis with the conduct of a Phase 2a clinical trial, following the positive Phase 3 FLASH study and positive proof-of-concept demonstrated in a small Phase 1/2 pilot study in mild-to-moderate psoriasis patients.</td></tr></table> <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Following feedback from the United Kingdom ("UK") Medicines and Healthcare products Regulatory Agency ("MHRA") that a second Phase 3 clinical trial of SGX942 (dusquetide) in the treatment in oral mucositis would be required to support a marketing authorization; design a second study and attempt to identify a potential partner(s) to continue this development program.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Expanding development of dusquetide under the research name SGX945 into Behçet's Disease by conducting a Phase 2a clinical trial, where previous studies with dusquetide in oral mucositis have validated the biologic activity in aphthous ulcers induced by chemotherapy and radiation.</td></tr></table> <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Continue development of the Company's heat stabilization platform technology, ThermoVax®, in combination with its programs for RiVax® (ricin toxin vaccine), and filovirus vaccines (targeting Ebola, Sudan, and Marburg viruses and multivalent combinations), with United States ("U.S.") government or non-governmental organization funding support.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Continue to apply for and secure additional government funding for the Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts and/or procurements.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Pursue business development opportunities for pipeline programs, as well as explore all strategic alternatives, including but not limited to merger/acquisition strategies.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Acquire or in-license new clinical-stage compounds for development, as well as evaluate new indications with existing pipeline compounds for development.</td></tr></table> Reverse Stock Split On June 5, 2024, the Company completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of one-for-sixteen, whereby every sixteen shares of the Company's issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock without any change in the par value per share. No fractional shares were issued as a result of the reverse stock split. Any fractional shares that would otherwise have resulted from the reverse stock split were rounded up to the next whole number. The Company's common stock began trading on The Nasdaq Capital Market on a reverse split basis at the market opening on June 6, 2024. All share and per share data have been restated to reflect this reverse stock split. 21100000P4Y-230983386-5279210-617076198401778446158577664533552125540002046945375007421946.400.026.40P5Y47500004500006.406.001.507031256.0042000004700000229078.4.7211000000 Note 2. Summary of Significant Accounting Policies Principles of Consolidation The condensed consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation. Operating Segments Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments: Specialized BioTherapeutics and Public Health Solutions. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Contracts and Grants Receivable Contracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for credit losses has been established. If amounts become uncollectible, they are charged to operations. Impairment of Long-Lived Assets Office furniture and equipment and right of use assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment. The Company did not record any impairment of long-lived assets for the three and nine months ended September 30, 2024 and 2023. Fair Value of Financial Instruments Fair Value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on September 30, 2024. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. Fair Value valuation techniques include a three level hierarchy based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows: <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 1 — Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman', 'Times', 'serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</td></tr></table> In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The carrying amounts reported in the condensed consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable, accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments. The carrying amount reported in the condensed consolidated balance sheet as of September 30, 2024 for the convertible debt is its fair value which totals $2,059,309 and was approximately equivalent to the face value of the convertible debt at September 30, 2024. The fair value estimate represents a Level 3 measurement in the fair value hierarchy. A roll forward of the fair value of convertible debt to September 30, 2024 is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:13.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> Pontifax </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> Conversions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> Conversions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> January 3, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Debt Balance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> Adjustment to </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"> Debt Balance </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> April 15, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Repayments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:23.9%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible debt at fair value </td><td style="vertical-align:bottom;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> 3,260,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> (254,256) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (260,933)</p></td><td style="vertical-align:bottom;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> (686,436) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"> 2,059,309 </td></tr></table> Deferred Issuance Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders' equity as a reduction of additional paid-in capital generated as a result of the issuance. Change in Accounting Estimates The Company accrues clinical trial expenses per contracts with clinical sites over the course of the clinical trial period. Accrued trial expenses are assessed for accuracy on an ongoing basis during the trial period and beyond. For the three and nine months ended September 30, 2024, the Company made adjustments to estimated accrued clinical trial expenses for completed trials of approximately $375,000 and $1.3 million, respectively. These adjustments resulted in decreases to research and development expenses in the accompanying condensed consolidated statements of operations during the three and nine months ended September 30, 2024, respectively. Revenue Recognition The Company's revenues include revenues generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants. The Company also records revenue from contracts with customers in accordance with applicable accounting guidance which requires an entity to recognize revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of this guidance, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of this guidance, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Certain amounts received from or billed to customers in accordance with contract terms are deferred and recognized as future performance obligations are satisfied. All amounts earned under contracts with customers other than sales-based royalties are classified as licensing revenue. Sales-based royalties under the Company's license agreements would be recognized as royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue. Research and Development Costs Research and development costs are charged to expense when incurred in accordance with applicable accounting guidance. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation,

employee benefits, equipment depreciation and allocation of various corporate costs. Share-Based Compensation Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then 25% each subsequent year for a period of three years. These options have a ten-year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board. From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestricted stock to the Company's employees and non-employees (including consultants). The shares issued under the 2015 Plan are registered on Form S-8 (SEC File No. 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificates reflecting such shares reflect a Securities Act of 1933, as amended restrictive legend. Stock compensation expense for equity-classified awards to non-employees is measured on the date of grant and is recognized when the services are performed. There were no options issued during the three months ended September 30, 2024 and 2023. The fair value of each option grant made during the nine months ended September 30, 2024 and 2023 was estimated on the date of each grant and recognized as share-based compensation expense ratably over the option vesting periods, which approximates the service period. Foreign Currency Transactions and Translation In accordance with FASB ASC 830 Foreign Currency Matters, the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency, the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statements of the UK subsidiary are translated into U.S. dollars and consolidated into the Company's financials, with related translation adjustments reported as a cumulative translation adjustment, which is a component of accumulated other comprehensive income. During the nine months ended September 30, 2024 and 2023, the Company recognized a foreign currency transaction gain of $575 and a foreign currency transaction loss of ($3,046), respectively, in the accompanying condensed consolidated statements of operations. During the nine months ended September 30, 2024 and 2023, the Company recognized foreign currency transaction gains of $2,257 and $310, respectively, in the accompanying condensed consolidated statements of operations. ‌ Loss Per Share Basic earnings per share ("EPS") is computed by dividing loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Included within the Company's weighted average common shares outstanding (basic and diluted) for the three and nine months ended September 30, 2024, are common shares issuable upon the exercise of the pre-funded warrants as these pre-funded warrants are exercisable at any time for nominal consideration. The following table summarizes outstanding instruments which were not included in the computation of diluted EPS as to do so would have been antidilutive: ‌ <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock purchase warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 1,467,581 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"> 408,640 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> 56,427 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"> 12,843 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible debt </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,172,645 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,599,718 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,594,128 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td></tr></table> ‌ Use of Estimates and Assumptions The preparation of financial statements requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates. Principles of Consolidation The condensed consolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompany accounts and transactions have been eliminated as a result of consolidation. Operating Segments Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated on a regular basis by the chief operating decision maker, or decision-making group, in deciding how to allocate resources to an individual segment and in assessing the performance of the segment. The Company divides its operations into two operating

segments: Specialized BioTherapeutics and Public Health Solutions. 2 Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Contracts and Grants Receivable Contracts and grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, for costs incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agencies in the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for credit losses has been established. If amounts become uncollectible, they are charged to operations. Impairment of Long-Lived Assets Office furniture and equipment and right of use assets with finite lives are evaluated and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairment of long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributable to such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or group of assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or group of assets. Such analyses necessarily involve significant judgment. The Company did not record any impairment of long-lived assets for the three and nine months ended September 30, 2024 and 2023. 0000 Fair Value of Financial Instruments Fair Value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on September 30, 2024. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. Fair Value valuation techniques include a three level hierarchy based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows: <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 1 — Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. </td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.</td></tr></table> In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. . The carrying amounts reported in the condensed consolidated balance sheet for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable, accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of these instruments. The carrying amount reported in the condensed consolidated balance sheet as of September 30, 2024 for the convertible debt is its fair value which totals $2,059,309 and was approximately equivalent to the face value of the convertible debt at September 30, 2024. The fair value estimate represents a Level 3 measurement in the fair value hierarchy. . A roll forward of the fair value of convertible debt to September 30, 2024 is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:13.14%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> Pontifax </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> Conversions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.14%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> January 3, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Debt Balance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> Adjustment to </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"> Debt Balance </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> April 15, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Repayments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:23.9%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible debt at fair value </td><td style="vertical-align:bottom;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> 3,260,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> (254,256) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (260,933)</p></td><td style="vertical-align:bottom;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> (686,436) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> $

</td><td style="vertical-align:bottom;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"> 2,059,309 </td></tr></table> . 2059309 A roll forward of the fair value of convertible debt to September 30, 2024 is as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:9.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:8.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:13.14%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> Pontifax </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> Conversions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> January 3, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"> ; </td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"> Debt Balance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"> and </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"> Adjustment to </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> Principal </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"> Debt Balance </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> April 15, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Repayments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:23.9%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible debt at fair value </td><td style="vertical-align:bottom;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> 3,260,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> (254,256) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:9.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (260,933)</p></td><td style="vertical-align:bottom;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"> (686,436) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;width:13.14%;background:#cceeff;margin:0pt;padding:0pt;"> 2,059,309 </td></tr></table>3260934254256-260933686434620593093 Deferred Issuance Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders' equity as a reduction of additional paid-in capital generated as a result of the issuance. Change in Accounting Estimates The Company accrues clinical trial expenses per contracts with clinical sites over the course of the clinical trial period. Accrued trial expenses are assessed for accuracy on an ongoing basis during the trial period and beyond. For the three and nine months ended September 30, 2024, the Company made adjustments to estimated accrued clinical trial expenses for completed trials of approximately $375,000 and $1.3 million, respectively. These adjustments resulted in decreases to research and development expenses in the accompanying condensed consolidated statements of operations during the three and nine months ended September 30, 2024, respectively. 3750001300000 Revenue Recognition The Company's revenues include revenues generated from government contracts and grants. The revenue from government contracts and grants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that are related to the government contracts and grants. The Company also records revenue from contracts with customers in accordance with applicable accounting guidance which requires an entity to recognize revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of this guidance, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of this guidance, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Certain amounts received from or billed to customers in accordance with contract terms are deferred and recognized as future performance obligations are satisfied. All amounts earned under contracts with customers other than sales-based royalties are classified as licensing revenue. Sales-based royalties under the Company's license agreements would be recognized as royalty revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. To date, the Company has not recognized any royalty revenue. Research and Development Costs Research and development costs are charged to expense when incurred in accordance with applicable accounting guidance. Research and development includes costs such as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials, salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs. Share-Based Compensation Stock options are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors upon re-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issued to employees generally vest 25% on the grant date, then 25% each subsequent year for a period of three years. These options have a ten-year life for as long as the individuals remain employees or directors. In general, when an employee or director terminates their position, the options will expire within three months, unless otherwise extended by the Board. From time to time, the Company issues restricted shares of common stock to vendors and consultants as compensation for services performed under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestricted stock to the Company's employees and non-employees (including consultants). The shares issued under the 2015 Plan are registered on Form S-8 (SEC File No. 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificates reflecting such shares reflect a Securities Act of 1933, as amended restrictive legend. Stock compensation expense for equity-classified awards to non-employees is measured on the date of grant and is recognized when the services are performed. There were no options issued during the three months ended September 30, 2024 and 2023. The fair value of each option grant made during the nine months ended September 30, 2024 and 2023 was estimated on the date of each grant and recognized as share-based compensation expense ratably over the option vesting periods, which approximates the service period. P1Y25%25%P3YP10YP3M00<p style="font-

family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Foreign Currency Transactions and Translation In accordance with FASB ASC 830 Foreign Currency Matters, the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency, the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statements of the UK subsidiary are translated into U.S. dollars and consolidated into the Company's financials, with related translation adjustments reported as a cumulative translation adjustment, which is a component of accumulated other comprehensive income. During the nine months ended September 30, 2024 and 2023, the Company recognized a foreign currency transaction gain of $575 and a foreign currency transaction loss of ($3,046), respectively, in the accompanying condensed consolidated statements of operations. During the nine months ended September 30, 2024 and 2023, the Company recognized foreign currency transaction gains of $2,257 and $310, respectively, in the accompanying condensed consolidated statements of operations. 575-30462257310 Loss Per Share Basic earnings per share ("EPS") is computed by dividing loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Included within the Company's weighted average common shares outstanding (basic and diluted) for the three and nine months ended September 30, 2024, are common shares issuable upon the exercise of the pre-funded warrants as these pre-funded warrants are exercisable at any time for nominal consideration. The following table summarizes outstanding instruments which were not included in the computation of diluted EPS as to do so would have been antidilutive: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;">   </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock purchase warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 1,467,581 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"> 408,640 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> 56,427 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"> 12,843 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible debt </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,172,645 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,599,718 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,594,128 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;">   </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-

align:center;margin:0pt 0pt 0.05pt 0pt;">2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock purchase warrants </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 1,467,581 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;margin:0pt;padding:0pt;"> 408,640 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> 56,427 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"> 12,843 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible debt </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,172,645 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,599,718 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,594,128 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td></tr></table>1467581408640564271284375710117264515997181594128 Use of Estimates and Assumptions The preparation of financial statements requires management to make estimates and assumptions such as the fair value of warrants and stock options and to accrue for clinical trials in process that affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates. Note 3. Accrued Expenses . The following is a summary of the Company's accrued expenses: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.69%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.12%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.88%;background:#cceeff;margin:0pt;padding:0pt;"> Clinical trial expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 951,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"> 1,993,784 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.88%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 412,206 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 424,218 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.88%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><b style="font-weight:bold;"> 1,363,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,418,002 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.69%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.12%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.88%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:49.88%;background:#cceeff;margin:0pt;padding:0pt;"> Clinical trial expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 951,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;margin:0pt;padding:0pt;"> 1,993,784 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.88%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 412,206 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 424,218 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:49.88%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><b style="font-weight:bold;"> 1,363,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,418,002 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . 95102919937844122064242181363235241800 2 Note 4. Debt In December 2020, the Company entered into a $20 million convertible debt financing agreement with Pontifax (the “Loan Agreement”). Under the terms of the Loan Agreement, the Company had access to up to $20 million in convertible debt financing in three tranches, which will mature on June 15, 2025 and had an interest-only period for the first two years with a fixed interest rate of 8.47% on borrowed amounts and an interest rate of 1% on amounts available but not borrowed as an unused line of credit fee. After the interest-only period, the outstanding principal was to be repaid in quarterly payments of $1 million each commencing in the first quarter of 2023. The agreement is secured by a lien on substantially all of the Company’s assets, other than intellectual property. . Upon the closing of this transaction, the Company borrowed the first tranche of $10 million, had the option to draw the second tranche of $5 million at any time during the initial 12 months of the loan and the third tranche of $5 million upon filing of the new drug application for HyBryte™, subject to certain conditions. The Company elected to let the options to borrow both the second and third tranches expire as of December 15, 2021 and March 15, 2022, respectively. . In April 2023, the Company entered into an amendment to the Loan Agreement (the “2023 Amendment”). The 2023 Amendment called for the immediate payment of $5 million of the outstanding principal balance and any accrued interest, waived any prepayment charge in connection with the repayment of this amount and resulted in an outstanding principal balance of $3 million. The 2023 Amendment also provided for interest only through June 30, 2024, reduced quarterly principal repayments to $750,000, and eliminated the minimum cash covenant. Further, the 2023 Amendment reduced the conversion price with respect to the remaining principal amount to (i) 90% of the closing price of the Company’s common stock on the day before the delivery of a conversion notice with respect to the first 36,790 shares of the Company’s common stock issuable upon conversion and to (ii) $27.20 with respect to all shares of the Company’s common stock issuable upon conversion thereafter. The remaining terms of the agreement remained unmodified. . On January 3, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Company’s common stock. Upon conversion, the Company issued 9,139 shares of the Company’s common stock at $10.88 per share, reducing the remaining principal balance by $99,416. . On April 15, 2024, Pontifax delivered a conversion notice to the Company electing to convert a portion of the remaining principal balance into shares of the Company’s common stock. Upon conversion, the Company issued 27,651 shares of the Company’s common stock at $5.60 per share, reducing the remaining principal balance by $154,840. . The 2023 Amendment resulted in the extinguishment of the original convertible debt for accounting purposes. The Company elected to account for the amended convertible debt using the fair value option. As of September 30, 2024, the Company determined the carrying amount of the convertible debt was approximately equivalent to the face value of the convertible debt. The

*Company recognized $0 and $260,933 of other income from the change in the fair value of the convertible debt in its accompanying condensed consolidated statements of operations during the three and nine months ended September 30, 2024, respectively. In October 2024, the Company entered into an amendment (the "2024 Amendment") to the Loan Agreement, as amended. The 2024 Amendment reduced the conversion price with respect to the remaining principal amount outstanding to (i) $3.81 for the first 501,648 shares of the Company's common stock issuable upon conversion and (ii) $4.23 with respect to all shares of the Company's common stock issuable upon conversion thereafter. The remaining terms of the agreement remain in effect without modification.
2000000020000000threeP2Y0.08470.011000000100000005000000500000050000003000000750000 0.903679027.20913910.88994162765 15.601548400-2609333.815016484.23 Note 5. Shareholders' Equity Common Stock The Company completed a public offering on April 22, 2024 of 204,694 shares of its common stock, pre-funded warrants to purchase 537,500 shares of its common stock and common warrants to purchase up to 742,194 shares of its common stock at an offering price of $6.40. The pre-funded warrants have an exercise price of $0.02. The common warrants have an exercise price of $6.40 per share, are exercisable immediately and expire five years from the issuance date. The total gross proceeds to the Company from this offering were approximately $4.75 million before deducting commissions and other estimated offering expenses payable by the Company of approximately $0.45 million. Common stock transactions for the nine months ended September 30, 2024 are as follows: <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued Pontifax 9,139 shares of fully vested common stock pursuant to conversion of a portion of the convertible debt principal balance at a conversion price of $10.88 per share on January 3, 2024. The conversion price was based on 90% of the closing price of the Company's common stock on the day before the delivery of the conversion notice.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued Pontifax 27,651 shares of fully vested common stock pursuant to conversion of a portion of the convertible debt principal balance at a conversion price of $5.60 per share on April 15, 2024. The conversion price was based on 90% of the closing price of the Company's common stock on the day before the delivery of the conversion notice.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company sold 204,694 shares of common stock and 537,500 pre-funded warrants pursuant to the April 2024 public offering for $6.40 per share on April 22, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued 97,375 shares of common stock pursuant to the exercise of pre-funded warrants associated with the April 2024 public offering with an exercise price of $0.02 on April 22, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued 69,125 shares of common stock pursuant to the exercise of pre-funded warrants associated with the April 2024 public offering with an exercise price of $0.02 on June 11, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued 117,000 shares of common stock pursuant to the exercise of pre-funded warrants associated with the April 2024 public offering with an exercise price of $0.02 on June 14, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued 130,000 shares of common stock pursuant to the exercise of pre-funded warrants associated with the April 2024 public offering with an exercise price of $0.02 on June 20, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued 124,000 shares of common stock pursuant to the exercise of pre-funded warrants associated with the April 2024 public offering with an exercise price of $0.02 on June 25, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued 703,125 shares of common stock pursuant to the exercise of warrants associated with the April 2024 public offering with an exercise price of $6.00 on July 10, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued 31,250 shares of common stock pursuant to the exercise of warrants associated with the April 2024 public offering with an exercise price of $6.40 on July 10, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued 2,190 shares of common stock pursuant to the exercise of warrants associated with the April 2024 public offering with an exercise price of $6.40 on July 11, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company issued 1,376 shares of common stock pursuant to the exercise of warrants associated with the April 2024 public offering with an exercise price of $6.40 on July 23, 2024.</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company sold <span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-*

weight:normal;">14,883 shares of common stock pursuant to the AGP Sales Agreement at a weighted average price of $3.93 per share.</td></tr></table> The issuance of the Company's common stock in connection with the convertible debt financing agreement as described above was exempt under Section 3(a)(9) of the Securities Act of 1933, as amended. The issuances of the Company's common stock in connection with the April 2024 public offering and upon the exercise of warrants described above were registered on a Registration Statement on Form S-1. The issuance of the Company's common stock pursuant to the AGP Sales Agreement described above was registered on a Registration Statement on Form S-3. AGP At Market Issuance Sales Agreement In August 2024, the Company entered into the AGP Sales Agreement to sell shares of the Company's common stock from time to time, through an "at-the-market" equity offering program (the "AGP ATM"). In connection with the sale of shares via the AGP ATM, the Company determines, among other things, the number of shares to be issued, the time period during which sales may be requested to be made, limitation on the number of shares that may be sold in any one trading day, and any minimum price below which sales may not be made. Pursuant to the terms, AGP is entitled to compensation for its services in an amount up to 3% of the gross proceeds from the sale of shares under the AGP ATM. The Company has no obligation to sell any shares under the AGP ATM, and may suspend solicitation and offers at any time. The AGP ATM may be terminated by the Company or AGP upon notice, or at any time under certain circumstances, including but not limited to the occurrence of a material adverse change in the Company. The AGP ATM will terminate upon the earliest of (a) December 15, 2026, (b) the sale of all of the shares of common stock subject to the AGP ATM, (c) the termination of the AGP Sales Agreement as permitted therein, or (d) the mutual agreement of the parties. The AGP Sales Agreement provides for the offer and sale of shares of common stock having an aggregate offering price of up to $5.8 million. As of November 1, 2024, there was approximately $4.7 million available for future sale of common stock pursuant to the AGP ATM. July 2024 Warrant Inducement On July 9, 2024, the Company entered into the Inducement Agreement with the Holders of the Company's Existing Warrants to purchase shares of common stock of the Company. Pursuant to the Inducement Agreement, the Holders agreed to exercise for cash their Existing Warrants to purchase up to 703,125 shares of common stock at a reduced exercise price of $6.00 per share on July 9, 2024, the date of the Inducement Agreement, until 1:30 p.m. Eastern Time. The aggregate gross proceeds received by the Company was approximately $4.2 million from the exercise of the Existing Warrants offset by total issuance costs of approximately $7.5 million. Issuance costs include financial advisory, banker, and legal fees of approximately $0.4 million and the fair value of the warrant modification and the fair value of the New Warrants issued totaling approximately $7.2 million. Because the modification represented a short-term inducement, the Company applied modification accounting guidance related to the fair value of the modification associated with the warrants that were exercised under the Inducement Agreement. Accordingly, the Company recognized the incremental fair value of the modification of the Existing Warrants exercised along with the fair value of the New Warrants issued as compared to the original warrants, together totaling approximately $7.2 million, as an issuance cost of the warrant exercise. Per the terms of the Inducement Agreement, the Company issued an aggregate of 1,054,688 New Warrants. The fair value of the New Warrants issued under the Inducement Agreement was estimated using the Black-Scholes warrant-pricing model and the following assumptions: <table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">a dividend yield of 0%;</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">an expected life of 5 years;</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">volatility of 127.25%; and</td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:16.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">risk free interest rate of 4.24%.</td></tr></table> 2046945375007421946.400.026.40P5Y4750000450000913910.880.90276515.600.902046945375006.40973750.02691250.021170000.021300000.021240000.027031256.00 Note 6. Commitments and Contingencies Contractual Obligations The Company has commitments of approximately $205,000 as of September 30, 2024 over the next five years for several licensing agreements with partners and universities. Additionally, the Company is party to other agreements which include cash milestone payments, royalties and other fees payable, which are all contingent upon clinical or commercialization success. There can be no assurance that clinical or commercialization success will occur. The Company currently leases office space pursuant to a lease which expires in October 2025 and requires monthly rent of $11,367 through October 2024 and $11,625 per month thereafter. In September 2014, the Company entered into an asset purchase agreement with Hy Biopharma Inc. ("Hy Biopharma") pursuant to which the Company acquired certain intangible assets, properties and rights of Hy Biopharma related to the development of Hy BioPharma's synthetic hypericin product. As consideration for the assets acquired, the Company paid $275,000 in cash and issued 771 shares of common stock with a fair value based on the Company's stock price on the date of grant of $3.75 million. These amounts were charged to research and development expense during the third quarter of 2014 as the assets will be used in the Company's research and development activities and do not have alternative future use. In March 2020, the Company issued 8,151 shares of common stock to Hy Biopharma as payment for achieving a milestone: the Company determining the Phase 3 clinical trial of HyBryte™ to be successful in the treatment of CTCL. The number of shares of common stock issued to Hy Biopharma was calculated using an effective price of $614.40 per share, based upon a formula set forth in the purchase agreement. Provided the sole remaining future success-oriented milestone of FDA approval is attained, the Company will be required to make an additional payment of $5 million, if and when achieved. Such payment will be payable in restricted securities of the Company provided such number of shares does not exceed 19.9% ownership of the Company's outstanding stock. As of September 30, 2024, no other milestone or royalty payments have been paid or accrued. As a result of the above agreements, the Company has the following contractual obligations: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-

space:nowrap;width:14.74%;margin:0pt;padding:0pt;"> Research and </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:48.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Year </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Development </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Leases </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:48.62%;background:#cceeff;margin:0pt;padding:0pt;"> October 1 through December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 21,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"> 34,617 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 55,617</p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 116,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 162,250</p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46,000</p></td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 205,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 150,867</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 355,867 </td></tr></table> . 20500011367116252750007713750000815161 4.4050000000.199 <span

style="margin-bottom:12pt;visibility:hidden;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.3

#000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 46,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 46,000 </td></tr><tr><td style="vertical-align:bottom;width:48.62%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 205,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 150,867 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 355,867</p></td></tr></table><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;text-align:justify;margin:0pt;"></p>2100034617556174600011625016225046000460004600046000460004600020500015086735586 7<p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 7. Operating Segments</p><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.</p><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 130,440</p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-

align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 130,440 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Income (loss) from Operations </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (834,654)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> (705,753) </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> (57,611) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> (24,819) </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (972,971) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,048,484) </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,865,236)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1,779,056) </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Amortization and Depreciation Expense </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> 954 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> 158 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> 159 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 478 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 476 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,589 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Other (Expense) Income, Net </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> 1,683 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 144,446 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 114,671 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 145,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 116,354 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Share-Based Compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 20,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> 27,427 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> 618 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> 994 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,416 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,979 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 56,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 65,400 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.72%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 119,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 223,870 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 370,677 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;">

</td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 119,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 594,547 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;">Income (loss) from Operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,978,464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> (2,227,430) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> (165,660) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> (26,639) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,582,878) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,306,000) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (5,727,002)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,560,069) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Amortization and Depreciation Expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> 2,979 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> 476 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 496 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,430 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,489 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,964 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Other (Expense) Income, Net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (22,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> 17,696 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 470,189 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 60,341 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 447,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 78,037 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-

family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Share-Based Compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 62,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 82,281 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> 1,823 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> 2,982 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 110,235 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 143,813 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 174,268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 229,076 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"> As of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"> As of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;">

</td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Identifiable Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 45,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"> 272,099 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"> 2,387 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"> 3,976 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,428,918 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,521,251 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 10,476,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,797,326 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.88%;margin:0pt;padding:0pt;"> Three Months Ended </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 130,440 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 130,440 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Income (loss) from Operations </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (834,654)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> (705,753) </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> (57,611) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> (24,819) </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (972,971) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,048,484) </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,865,236)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1,779,056) </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Amortization and Depreciation Expense </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> 954 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> 158 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> 159 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 478 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 476 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,589 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Other (Expense) Income, Net </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"> 1,683 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 144,446 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 114,671 </td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 145,855 </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 116,354</p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share-Based Compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Specialized BioTherapeutics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"> 20,598 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 27,427</p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Public Health Solutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 994</p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 35,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 36,979</p></td></tr><tr><td style="vertical-align:bottom;width:62.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 56,632 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 65,400 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.72%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> <b

style="font-weight:bold;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 119,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 223,870 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 370,677 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 119,371</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 594,547 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Income (loss) from Operations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,978,464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> (2,227,430) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> (165,660) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> (26,639) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,582,878) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,306,000) </td><td

style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (5,727,002)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,560,069) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Amortization and Depreciation Expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> 2,979 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> 476 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 496 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,430 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,489 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,964 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Other (Expense) Income, Net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt

0pt;">Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (22,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> 17,696 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 470,189 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 60,341 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 447,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 78,037 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Share-Based Compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 62,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;margin:0pt;padding:0pt;"> 82,281 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;margin:0pt;padding:0pt;"> 1,823 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;margin:0pt;padding:0pt;"> 2,982 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 110,235 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 143,813 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 174,268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 229,076 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> <span

style="margin-bottom:12pt;visibility:hidden;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"> As of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"> As of </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Identifiable Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Specialized BioTherapeutics </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 45,674</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"> 272,099 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Public Health Solutions </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;margin:0pt;padding:0pt;"> 2,387 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"> 3,976 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,428,918 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,521,251 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:61.37%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><b style="font-weight:bold;"> 10,476,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial', 'Helvetica', 'sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,797,326 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> <span

style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"> 1304401304404-834654-705753-57611-24819-972971-1048484-1865236-177905695395415815947847615891589140916831444461146711458551163542059827427618994354163697956632654001193712238703706771193715945471978464-2227430-165660-26639-3582878-3306000-5727002-5560069285929794764961430148947654964-223917169647018960341447792780376221082281823298211023514381317426822907645674272099238739761042891895212511047697997973266 Note 8. Subsequent Events Amendment to the Pontifax Loan and Security Agreement On October 8, 2024, the Company entered into the 2024 Amendment to the Loan Agreement. The 2024 Amendment reduced the conversion price with respect to the remaining principal amount outstanding to (i) $3.81 for the first 501,648 shares of the Company's common stock upon conversion and (ii) $4.23 with respect to all shares of the Company's common stock issuable upon conversion thereafter. The remaining terms of the agreement remain in effect without modification. Sales Pursuant to the AGP ATM From October 1, 2024 through November 1, 2024, the Company sold 229,078 shares of common stock pursuant to the AGP ATM at a weighted average price of $4.72 per share for total gross proceeds of approximately $1.1 million. 3.815016484.232290784.721100000falsefalsefalsefalse
Adjusted to reflect the reverse stock split of one-for-sixteen effective June 5, 2024
Adjusted to reflect the reverse stock split of one-for-sixteen effective June 5, 2024

;I M%X8'4FH]WF=IQN=(D G!JLQ.|O;"_!?R1KEVHSBK/1@/3VK[]=]$D(.'+NX> M' ?EDW<]C&9;O0@L)H@:ZD(3'#MZ+R+HF6(8)9@U/(*#+S#-J1$OUP@=^_F; M-,F4L,#_584$_H^_%Q?H|EZX?@K9LPA3URSUO?_|)=\@F=8678H1&V-$&/0 MPQDP1M.4R%T=2@Q?.!D/TM"+H)P[]=BOB!2 @ 2D$,%UJ'&O+37R^(KFXE(4 MMU.3XQ(?-I$F3K9"L(^' $OS>4I?:CACT$A::II'|"*%+_Z,!6@,?SJMCZKP M7I&G0]D"W8S'G=+BLMI.ZK*D:JF)BSCDI[&.0Z94JR3]PKOV9^ZCF;_446ORX MG2H?D=%2PM;8NFV.:&-Q64*P&QVK_2Q,X51+FA-'2\|_U]D+34CVXD6DWDD& MQ>-(..'Z9Q_Q"+GSDNSPV=O2\R_L^)BWI1E.F^O"52U"3MO@,_=.2>V-M2)* M@"KY!>C.9GI\F.7Z>>&RG#\G5+C%,<[+>.NQDRN#/?OB-=+>&B@LU[@C3G/N M+_Z(-BXIVUBYYA[S9S%!]$(H=L"R?4;3]>8OU NSET|T^T238P48]D%]MGT0 MES>5NSH@OYIL++[594=%UP

*#M@_T7WQCO$43I[J?+?*$ MAKE$^0)*R'B(*@/?<.IL#F;1FVT564WKB.]BV|P 90F!QR>J(N(#RJBNW4/: M5VDAWUMK^@(_JYIJDCHTN[SZ8EA,$9%D06*I>P:E,F4PD_'D5$7Z&<:O<\C& MJ/UNP?5ZX_I;D,:?2P^V4&DGEC=4 F)X>[AC-.A"P-YP(ON'5U]&2J,-ZAZN M$:DP2^ >6%G;D:*5TUR.DYQZ<8DNCJM]#A=XP6H?L28MJV:$GL5A70-4FS8 MU]2KKY77[.I@?EM0>%EU7 !VFS4YRMM4_W3KW-IB!X:#+2Y@ M]>&'O @R/)/YZ,)A])LX1%=H-CA=!B"YGU[%2DS6P5U7%0T(M,5D60#>L]{8))Q#G/M>!!?6ZW?@P-#W;J"'LVHV)_%@E5>)WFX\%3AO!5I+ MY_Z(R$GCB-G L]",D.#=&\NIPGTW]\X/3;G(\2QR,T_O' #;+B P"'ZW>L\+.1/3C(D(]G_V/C>/ATIV;-+:5@I MA0@Q77'Y_5E#/4G=^9:W&R6GZ#\. @&7VP-*N M!88^\R5),T_?7F:V356MMC7\02G?'\+FJ%;0/MC8.79&V5AMUQ0V4ET7;E MQ$:\+#HD9Q/>;TR VP8BNS2/\:/(?@C1L"O7W!IQ^7(916A:?NGU8B_"5EGQ@D M:E\#3NI7&;%\V3+G@U,O0B 7_128.H?9K2"EGLYI+*L/\13]F-130.L,>P|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|S)W^/# 26|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`0 M5*V]FE&+;"T@2' PMY_7#<)6*P%8P0G ;:L7"8]AQ3_#> /9^!,T7-0OR&N M7](+&T.\&$)9N4EZYKAP01Q'81>F'!1\);>M\ /P_PSN=$1"+9AC"*D -31\]\06<$+<&[\X":.X@#D'[!-.A%NO!BAR$'>,9^)6E]>Q96W M;+C,QT_2=SVM2MED8RW%TAJGK"0EO3]1# EM^:9!8S@1VQ<"IE4E$@-(T]ANT MW*GGW(&EY=Z 6H<6]VPT^?R(927V4,3_TW;H6FQ@FB"2UCAS::BQ*$MP%D79 M[[Z0\W&MR4%0*YC =TN4.=O|K+C*1KV&D[73-*)+V4X:*Y0ML,ILH- ^>X(M M4>:GX-183NS5[5I)#5=+H,D^6;I]WF?@N_6 M*\0S9"Q-";;5E@FKD&R"73[\'E!ZB?:8YFG1U.0N(YP;["6]FT0H$A3>D9:!K+%ON"F?CR=G7 M07Q!*X:*PP<_NCXOZ[&R+%@(%"%YQNYOJEB;MF">V8"&I[%YIA>Y;^]P@3; MF@V6IT 8T;?K5>XCINCG-3^KIS]*:]59H -0Y$KPSCK$3XQ/L^R9>S[^<7V M$DVGECX^&8)G9'D)AY&?K45KJO#"/U80+=|[LUVX%@!68"N:!:M28LF>(0 MD9GZXD70.S88WGA$G*S21O (OP/4WV 93O+RP3-80J{$1.&OK(RUQ\NO2ZF(4 M]:*C3\,01/-]?BA*3@Q*<;>A@W9F4&[\8DQ.=ZF6'VW@60'T"9][C>54$T+; MSS9^<+KE.,P\ ?#"#;#A A(F'=2R]M L1E6%8B%P.D\%"K!E53**U-4[E!N0.2]UWC"\7 MQ/)ERTS&D\FP">.[K#:(@23&B3AXZO!D&3^VW-FS"Y=6PP8GM:S[#-)9]+/(M#U*IN%4$GWT'T.?! Z; 10[J.|*V:O+3#<5,X54(GUEQH.;6-H\'8/\10WR) MR$]N+;Z Y/.1>/B=5<\4;70#W$.D:E7#(^0+#;,%53A";9@FHN[@0]?W6R"MY\A0-PDU-O%&%,2/W:RH4@>/P&JL@GA02PHTU?,MXL+]QA3F]6(]DH&;%E)% MI*HIDNB,65+\I^%&H\11)A.Z, F&A;[L0H@P>PE)U!3&+L#;E&I\,&Q=&S5M%'GU:0ZEXCZ1<@ 7HKS,?GKH42NX*9R2;PI[R%^O;)8OX\G9L98]Z8BXAWA/ M0QW_FY%.-39ML4!|\.O ^ ?1 FSWL^"#W86G+SS3SL5SJBEBE?H?#Z\#4Z= M=SX5/-@Y_)C21@0B4A(WAID2&^R(I\H2$Q>'B/3$C:2S] 8XXJFRM,3)KTNK MBU%TEE*R3[<[S1A2A=-8]FW)A-\$.A\V(=N0=>R$HZ8^@I$S*Z(#UUDFC0[!:_ 31$[@O(#D;1K5'U7%I=%MS#[<1C:#TPH&[22U|_FN*!Z#F)77D8R%&$\,HE4K1>VKODN*RR)FG5>3?)7B M3:J&)I/.\G]R'(/'@ONMDF.NGC+1[!/.T!$3P!\]8> VS4ZREM5?Z_>],' ML/$# ._I$!1ARL4/?5DU5C7.*E]_HUEOXP3I1Q.4V^R-M5[]%2ZIX A9GY7NM M3H\&N- LPQ:*8 DXYD@6]_+H%*9)Y8WB'LQC#KO%.Y"M5S$(?1 &.9IJQRZH]91107|#?SMS4 4RH$YM3]^3>N]M5$8Y3H4MW\ >$Z"F5A'C^[T/X;1-QH]>B|.6Z,P@6EN/;,B&)3RYF^/IK(:$$^ACDD] M!60/I\2'OYF/GKZ^ L\LC]|4M&R4X].CR:!9FCJX>VYX.I^;J8)DAA"[%U:- MV)13 .KLWR]|#WWQ11#U8R<4RNH:$[E%-X:U]QY46HIG-G'H"./?1$ M9.1H>V^M2>G1FXJI1G,+9RX$3;>$>P]@4\T66<5*/.S.75<5$0@Q619 -ZS] M96V;X "<"^OU.W!@B*_O>99G|IY+TIYE>CMQE.!\U:@U?3N;D[==!)G@5D-1)?6-9Y9@7I]\N 7Z@?5Y7%)JF M[S(],*;HE7*JL<=O^:;9.0\X-7WWP=)A*\!QR]DY/S9)AQT.-CF7GPW[Z\E@ MJ47$J*I0+1.O=GVG6]YN_GH%/W'P3 @,$F]@U.CV"LP\RA3\=:- M*:4$(48K\W*Y%AC:\4O2S--/7YYF=HV]6[#[\]!!UK!]M%*[M#@ MV1%C:[ZQO"H"D:0YSX1T=@Y879G]_CPBLALD:3DLNPD0A=UGYY9444]\/: M((IVB-6;C@I42YX4HHK1W$[BBH#A"C@H:<-LH]HW+'N MB!***Z<&:;>SZ!"U3X2)=RIOO3 *XG25?+>%69D0'1,$P5U?<870:;ZKI!MN M26ZCYX2Z1(SYA=')RKJ,$ M)(]6*M0WP81[X-@!. M>(,,F4_ 9XO"Q@W!*3#K&:*-;G@/$E"[PP6OY%DAL#\M_9?/P';2Q|VF"<'1 MQOQ.!UW(OL|/2L>K4K:W24M3]J-,M|MPM# LOG5)'9]_[Z_P%02P,$ M% @ O(!H60W?1)H;<@(%EL: !4 !S;F=X+3(P,C0P.3,P>##$P<2YH M=&WLO6EWJDK7+OS]_K?W.<\]][C7631B9K=G(&(O:(B=E\8- 4B"$BCX]_M@)]8Q"0FT8B)>XR5;5,657->=.JUGF/_]%;N'_IH I M6;)FJO_\EV2I2N6___?? __7W_P=!*6V0]13LB74Y4VIZ*I MKF7;@IEJ_?1#"._5=S19!9N?(/!M]A:^S:53$+2I^R^XX4|M\VY;9Y^)+;MU!QIC2"_L[!1&.53V!V6OD.05*OQ4'+]X[HF.H(3;+L1_BAZ&HQF;E$TG7M: MF@7.7)-]FD]4KA+H4B]*R(&1G*I--I"$>_! E(6H#2.9#%922+I EA7_?BN"*MY;C_MY\$349N]D4-C13OR^Y6"QN MEZ)CQ*51&,9^1U^+H3RVQ9>N]JCT MN617X/&G56&H.I &FFZPFF=/\KUU27 M]S]S+4-3@:DM;R5K&HL/SF'P_0/"Q\O>?>'=UJ1_K[_<%M66'N0"Z5%[PO>WMJC7_K9EART$DT]->(YBN8CE93P0L5$%;$I"$X"V'(?>L<[IFLP@\?R4E;OB0E M!-MYVK:X Y07I4K\#K_+|:_ VB@*>BE(&VF/A;'L)%&K,&FW?S[IQ@(\4K}_3X$GI"3+!$)^^>?&TOO]UHPT8\A,/.U^3|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|%>$D?X".!HTC'TO.Y*.+N|HT.OTPNHT.ET!*-BRF!9\&ZL5V)1X/Y.*'* M5!YF"+?@0:]>'621WDDM/3A?UD$$>3N[=VF@2=M+^6'#ICI%357HPA!S: ME N"!^Z;W.BX2(%KU@R8ZJL>K2QI.@0A:#A' |KV%C;1HX<&%|-/MW/OF3@G;K=M^I\7-^#3NY]$:D9^H/!XU-WK$^=H:6C -DA^WMJP!0|TK7AXF M&'4PK$WS?4);\.FHM6WL*]M*A@V5X\8:@GK?/MUK#Y5V=;B$^U*!8\C&4*LY M)$]$[5/"<0Q>:.(1F>;0>=(#M52:Q7U30/N3KP1E(Y1|:ZQFCQ@ATA0M!O<7O_N]SA!7DYI[3TV:+: MPE<!(&$^B'O= +%0:ZI($FR)D6QI;2F:(^;9C|_N*' M"I/4F!A4>=]B.8W!%O(S0)0DDORAPKZPZ[=HXPV%U3\EI6&@IG*_E1DY)FE M:-D-/LM!!;:=,YU2K3/\]9RQ6-3H?AK-0'3-=CH.ENT5JZU7A/'[<50\C@<" M4P+NOW]'BP]W;KRN$'8T%2]&W$4A^W]N7&U[&]$B0_S9.%[&B5:OH.TZU>W2 ME:,PX>\G=<9O7!3>]4GL\]?CZXVUA+E"C)[!?RN'#EB$2),U;-RTE;^&W\]RO@ _ZO02$p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|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|9G7'82TV".4L;2LP>EPO MUQQ)=5W+-(8E0<$0-I-06Y-@).\5[A7#3UPEQ[;"2D#3,C5#;,YKG\=,CY],6@N89E=DE1[T[*|' M7B2@?J)]/ON>O@39Y^*L#>;46E/IP*VW.TU3UX;:U3XGWCY?((9?ML^Z+#?[MKEG"8&I9G4$@SL2GDW=(0F+M<](RI\]OG_LP$?0 IV1U=K@DN-H,%4?)NS\PM\;OV#OM\UFSO<^)YOWWNYF]6-5@4LEQ?:&9H5>NKU>0EB2<>R5]KGR\3PR ; M9Y_3ZY!C>0U=8V?=;Y]Y14--3KE8M."U,')%,HEGL<]GVD&X9QM#M'1?,5W/\>/\@GONZ8XUM1]ZD%'P^>T1IZB3>Y>H=N):6>D-J0/9!)7%PV4+BN4PVG%<*,E*LQASBE68FDJ,:H|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|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|XT)$WK"U/ 0=,:3=->]S":),]9^%*,OB&R;XW4M)^=4GL^:"UI_RY011:*I@5=0B+9_BSF?+KK?D/1^=;UKR 0T*UNE+9^/Y%=]X:\@CXV:QY+FM^5]3N MOU7Q?1EQI"QK466"T1(TN6)2@]UY@O&^)$_2:PB.#KR*Z_K1C5IU^.$-(F,MK1!QBMV0Q#G^,:PVE=(O-6%ESH!V=,14G,E99G82/85%P==$G=,!NR251*:3L61 MCD*E#]C-,2D]3:YM/"5]'6'B^.57R#W-_4XM+?***

*]JV.)KE6;)5_$12RWXQ[:2N[)/3=_6%$/A@FX?L MFL>$>/T?WMO\&IZ!7Q^,%:S>IOLE-U,9$N6ISB>P M/3^4W*W9TE- M2P>3M*H; X76ELFUL*

*G8<)X<4GA]33(AP:WTLC;7\1*TX@+2[<)\:5:%Y$LW_M>3\PN)7@U?=/H+/<%%2Q4H45CN!I"D*[+7]0W,2.*R[>M0)XXL.Z7Z?.MKRD*

METP37L%^M=HLSQUDI3(_P,=!M5>]/KEIU!]E / 7X=VLSZ7X,&\F>6FB-(D MU%QK[$.))1D3?ACX%=^?96T%\H9U.D ?8;EB&4AYPIT-:$V/&FSV4O$P L< M5]*

J5BVC>E5XYE8LOY0O+6K)C:Z=_R#RY#A]=C&)R_?.X+%,WP;Q>OR? E/ M,:KHM 8+8F!<++),=AE?PBW>V2,U29RG= HNR X++5>?,F*6*/4\;>A*1RER#!HWB&)Y]9&$YA7VG>*

*]DW,'S]K#6IJ;7GG[5"[7Q'G==K65@@ MT .Y8> BP5ZL _,C9ZWG2 C^POP"N)B9Y>8C*GP10Z=6>T6/0Y\X5WX?NV"R7/XSE;= M85?(MPU:@ HM!..+W0676#?B"M|M)N'#X7ODP,*

*GX'N4E9'G&,;<21$C'65$ M,QU^M8*R'M%E+Y:"S[P:\G. ?+YUZ^<07I6S4R@O9DB8&;71H2 JS0%SL8LG M/X:&OU..V6#1]#^2'-Q|<*

M:#@6D@$ZK\-5WZ!T2%J4X9SKI0/S8B,2W_I,W=0)B 1\KP+I0 _MEU-O+"TBJ7G#.QIR3VL_PKEQ @\U#?>+7H4*"/X#I2W:\X,*

*MY5Y'*X+1<(+! 4S9&S?;M?[R]*?W7*%|%"@C^,%0?BAZ'"@CNU|^7[3X5%#& M^Q5L6:";%E?*]+LC%8CL:'"%\H5 ^5!?F3ANY/B-LU _/!.56CX%R[C@HT5,* M@AM-+:U@E[O\|:.@G-*

*2S:[\BO>PYD-%QWRW92[H/L\1HS#5;E?)(^#9 _LXX MOM"DV>,'D6M5K@_Y%$ 26CH+5BQD3O.7&X'[(4'D"T7OB8+(*FFD1[8+EISO M^&QK.EBQ;'*ON[P&D9.*

X _GJS 'L<>WS2%EEK M2>2[LR/B _#?8[+T7:4BUVY)#==HPY91SL&ID-8R^=&2=^73/K[Z=:ES]X _@ M,>!]R*+XH<+Y)7]H(]VZT%XEU].\(B%Q1QGO114DE!?]Q.\V88AO2H'G+].|*

*MD'RG[LIR2;@'&'SN\>"\>V2Z7]6Z"^]/G4&?;K_S@,G^?HA;T8+E0;=5^STBQ7;@B$J G]#)*OBGX MV1A.I% 4 ;[G^)+G1V*@+-"]F7"%>6 "1;M? M=]4KQ-+G^Z@$"VA]T.BJ:6*4W-*

L$W^CV S3?ZO>WYKTGF'$=C^]I7C2<]:L MS379%XPU7X7?%#0'2)]E:/ PLO ,O/(R.#T-RETVP^(=H9NX8%'8|+N]70II M(OS]<9^^IZZS.[K.;]Y]/;'X'7$8I \'PQAMM*

MVTHC/Q /N#',U&4FXS#4$$829[XB;> _KY#;I_8U>GL[)V=7I$4;OZR>41,8] ME,"T $2O&]C@2$IQW92[I_Z Y:&8 ,$"V]1P/.=M+CM%N5U2L.$LKQ;R3I\Z-.OS8P

*M9S{JG3=]U!BR1\O3IV]^((*U7%SF,G'P7?*/3^ M >;YL/D3J:A0HY ,C1C2#%XX&; @V\[S[Q.B8B);JBMG\'&8; M'MD=L46AHB=N="01"3"$H $7EX1_R)L,*

MNC#>&\]YF@2Z3ECI&# F^#QU[ZY4@9D?F?!Y^.?9KY]\O_DUTX%<(1=@ M'CU=V3VK8FGHR$U<_D(BB?_#VDX6V1_N(NX'V$YZZSZ$G=!!1& (SA[F(#XJ

M>AQJ07:I9;ML?.66'6X1TEP)F51DBM/R9@D:U 9UM94XLWGEEBNW[.>6 R>? M8='C9: @]\&3SXV](^2O= 2FK]4ZB] /AN)B!NKC48-/:+SWR AZUW.3EC>#

*M|$9./KL:CNV=09TF4:: 8@N*07,&A\H=3,\C|2:%)SI0E_Q5F1UDA)R&'3>C M*L/G=BZEV:ON%5LNC]\&=:Z?6T)Y:M[K5H:)"Y&O%^=XN>_!]D8^O-*

M;I;G,R<3|%#:=Q!SU<'K,[Z>V%TTOW%WW@9]QA(89I?O5=M6'EW!-FB4AA>WL0^RIPTU56NJ4 M'LY7L-9HBHUQ'L$() EFZQ2^W1O\4A6 F$$%3:29FJ(&9+.3)90DR.(LP\TW*

*MM;74N/!%Q+FF+#@R[XX%![@\;N5; KR:QF$4@IO-5=,FE9TM/U,@N+X# MVT M,?[-]CG;[[;OHP>]\5",+? 9NK>8 A&OP@RV$!TY+]'8M/WLB9IKX2B2N0M_*

M\HD'VF%YGNKVAY-.'W/#F_3[ZL !,]X$|IS: M0U7ZJ(K?CUM_N"(V5HGO+:EV4.^3(B9&Q^\PGU#WE(MDQM.5<^,=;9$M?IN>Z94Q\ Q'3IO^/I3M.6= XR8>-RQ9I<$1W(LXS%?*

1.5O M+4?]C<(P[GM3XKT Q?WGIBOQ7&6A]=OY)41#,S6- M: IH308DCZ5YXB;E6>MRO(A! (K"" _" LKC>#:*)E"V4&0[K4I=P;4UAVX/>:E)OT>VHM4F4;;]&CKPQ5Q/@*

MF8:W+"TSZ')MDD<)'D%WF@LD/ W0M,"G@93E<8D@^!Q!H#PAIQ$457 Y#1-? MT5QV:]%HQ7*R>]V1G4U4N<-/+#5]+I' UFI63B@$Q2P.U[+%0K?=\N4"U(Y:

*MFTM@:TMYB]SV*V$'((%39@<Q4)Q|+%DM;:LB:'+4L/F@7-0NA"6R_E^/0" MS?BC 5@DM+$Z+0UA?RGF:13-+TLCL4.R'36AC;73 =I$,2R.HS*5L@C35;TF*

*MM!/;6+%4KFK:L%>'*9S]$$T!>.E24B5;9$71:'DK1Q<&6"80]R[3]2>UL=2D MS.'+9ENF!<#.0B@,;+ ^45!@$>4Q?9LA"@9M:65]JU2RYRY();2P]>4Z1D$8B M-POGG<-FSQQHR<-*

L:]7[]>,LAVU-HD.@CSG.(TLD9M M1C/991 L#;\N@EBVGW.0?L?-=2W?D8"[?CL&@AQ'8\(IZK]_AWI2KA=$'9@ M2VBAR=[X#H'A _.7+%OI>TO%@?@IY? M1/4+>^N/CL-*

*O4TVP2'6LJ6"&M<>?1$]9/^ F-7: \L_-?[H,%=;BVH+YJ*+X M]9UI.5//6+=FL>[DYJ.;?[M1=G#*4E)4%'XR//?OWU$MH2:$\)^]1R.2 03G M3K2||:9#:V5 "'S[T,F--AX^?*S%9^I9?*

*RD)AO4'5"+U_Z?0^)= (%39@<Q4)Q|+%DM;:LB:'+4L/F@7-0NA"6R_E^/0" MS?BC 5@DM+$Z+0UA?RGF:13-+TLCL4.R'36AC;73 =I$,2R.HS*5L@C35;TF*

*\7 ;E5V)ZO'U#UUUX(Q,T+O]Q5OV@9|E93 MVR='PV"NN9JH&9H7W(UCNQ56^3 _R:(P]M<]+NPC2>NY* |I"7KR($?D)!OUF/B2_HN[E'AWI[? ,LU*UVZ MD&*!9)=F _XM?*

*J&&WM%*EJ:X3]5;H=D4V2RDZ %5)ILE.D4QC4:%92M,|VA- MS[W1\IA[LP_4^[@7CYO=%T)S:]J>9?Y*%6ZIVY"5TGCNZZ3|>EOON[NGY46F MT_B?_R $_%?M'S3^3[':?Y2-9<*

*MVQ"",\TT-!- HF%)^CYED2U:OJ?,:*TI'C%KBX,1Z^H>;T2)|+'WSXT6_L0% M4B@!RQ %P[\T5K>G$9A;5]PPBX;00?8EN/MZ,XL3;Y4+>[$0>C/^3TN MK>5V<&VRI50I=*

DUZ.A0/|$/^YS^Y#$X\ 6FUI?CI.CH3J 4'CK8 =^= M'&4Z4)6.92$(0D@W"I(7RS:*13GW.DT);LJU M@10E:]DIS4QIGIN2QK%G\^>Y8Q'I=|<9X"R&I%$%YR-:YW$"+P %(+',5E*

M,5P"F32\B3.L?|&5>-U<#C]3#&'!@&Y5%S,6HG!>#3'[K.2XT/ #,;^HJ1'OK'8" MRI)W_3$=R8ERV^I'"0P32Y?TNC*Y'T!R0*]UTDZO((ZV2<[]'W\^'U\||*] MX_F/'05KO%.K^Z"!@<;?*

KEW+QW.8=_;ZBO (X5UA6=6L6)#B^G8G::'GK9P=#3]K.2XT/ #,;^HJ1'OK'8" MRI)W_3$=R8ERV^I*'"0P32Y?TNC*Y'T!R0*]UTDZO((ZV2<[]'W\^'U\||*] MX_F/'05KO%.K^Z"!@<;?*

I'QB@"1AZV8<5^ ^LAA[-& @]55N.[?L;8]> MVH85 ,=-?"*WZ8O"I[9KUV*8,JI@;JOX_9^7!, ^? A;O& MF%0XBG-(=]1=N:VZNB _^H36[#7UNFB8=F/1\4I(0O2HL]D4U*FAQ*

@(=4#]K_MP$V^22 &2!$,'94X_0A"\^R[\]?+9((< 6>*=2K5/#0MV38X1-T#, >9D_* M<2?KW L&^0K7*UR3V+G]<%WG";\'L->)*RG+#G#=S?_]F@F0W0RQFM:95"FD M -*

*>R3FY2'P50T6F :|[*XE)TH\$TV52A4^E]-CKS:U]RS>(/=1>T"T D0TNO M* M&C2D%Y?Q!>X6KIQ+(RU6Z|#KPDH<0^)-B^5]I4.%+QNE:"W-')D'&$[VR M|7D3]|L-#E)!<67"4-*

*MAII8TTM3,)Q*8KDT*;POGMFLOA[IN1S[]9F(XS.;=27N#?A:ENL)QDBS'T+I MX90HEZ<4H=,;430D(X6)81!IH]/>+!X?#CXXF\;W4)/1(SFG=1\/"59M!!HE M-]A..) U6S!28*

DD/UKL"C]6- FXUZC.,]V=VHL\1'GA $A%(^ '!', ^L.7C MA>']QZG-9.0HD X0GBSSH;JQP#V8FM+0:$(@HI<9.K7WF44"WK\",2]RUM!@:9 =ZBMB8@W@Y?L6XG!/&\NOC1MP2X

*M)IGT+;QU"B)|@/LQD8J3C6X>K^]_<0[L'P\)B!$(OF_W)0'#&U'Y\$B9,3A^ M14*38_@1;Z;$<,B$4-RRV3%;^X@BV-"F.;%$@:M)XP,.D%,V]T1'$7M1&FY8 MHZ0(^@?*

XI^118Q2>$G)NTMZ3#]MI.$TD1%X&4UC/"ZD43XG"N&HS60Q&1/Q MG$ I_%C;QHP3'XUF.DEG<-1*-<>I8/VONP|::#/5'3HJ7JIV2AV)EJI[NCD M9A7W44FCVJL&KMQKT#5+6-*

*7&S*B?+40E\6=Y?FE$'*D5T=2G'C(V%]N6V[?) MT%7;EOR^.7D8?HM+/Q;PU(M])W(|_\PM>DW+ ^V*0 MGY56?B#(,>PVG;V" -BYI^\TI$D/BG4U;WV0"1"D<4HR!-=]7R#S#>-U?*

*-4^ MCE:^,_"S)O[$*\41XDD'&TS#F>4?!P6X#]?:9*ED0U-)5TESL\Q:& 1AAQ"??)$X*IPS-;&; 8**,2G=!|Y'#($.EMFQ M" ?30;8IM.V.F-[F)*

*[UV#.GZ0M=4;2,W/KY0M.*FY8/@@|;IO81B)MKRFXO.@ M/[^8\^4<^-R\[?;\^/DQ|S\]"(Y(>0U'!\#,]UEX<9T5AK01%TEA%5N.K<&*

*MB[TK.D\6FINEP1%0]!4T_]6H>VP:$HJZU_3<'8,W#@Z)#VB(S$F$M:,?&K*E M5'ICKYYLM2Y]H%C*-Y4)7:KS)%9?"98@/X_Y/UG\%EQ9F!T0Z'^R_+^YU26U MOF+M\5Z>KUP6^FD\]A(FOBNIRG!HV,]$.(623]]^GN.0:B86LWO$_[LA >-SI]\?K'FR[]^2LE MF'+]#W33UG'X_S$<9V$A<1+V*OI17#[\9=2>367Q=?!Q2^+F"JZ7RL'K&F0A*

M<&]37W:V!.4[T?:T]:$]D07R\,]W=\9P>MY'EH%.]IPV23?ZTV6K7F/:;X!E M"-R73IAX[6?WW?[R2W/CJIZ]4%-ZPC/PB]^"(?UO#B.(RB'*)YJGA>"Q@A MFAW+CRI:1

:%:#5"4R5X(4ITH4!$]8'Y#R9)0_U+&[V-3Q#; &/ ZGHS'< M ;]_/BDWQ4+=+QG-ZY;=CT_@_OF% V]'=I'H-N-P]YP2F:A(PZI3YFH(<"|\WM#0W):2,L"Z0$B0I'%HAHD)(1AAT(H.R])-4

MJ$QHSQ?N-!R1X3.<+86':)V&P@E^178TK"RT-E&KU93J6 MOO/WZ-K2H(&Z9 M#!3-C,.G<2)4Y)Z@\|%OM2_^&OEK6^S- B^W;ULPL]";PB^T=5M2,W>((YS'

M0^AVG7K7);C=71S&TP2>P3")1\4LQN,HAO&"E)7YG 1P7,C)"H(B3Y=GN:'4 M)#+Z$]8%7#4*^[H@ M36$2:911>[G-#¥]\W:KY1)=(6R0MD-/JH!\G0:VV>PS$RISOK-F;>D?8A;

*MR('L9TY)&G\O M]11> XG|K*9./, .R@Z,]'(\51W(8-O# F\$:^,9TBQFB.G6K6C M-1U]\XS[N'N0IVT)/^6[-%7AQVRZTR7T74PL?_WVO2FN<|%?^VLS6],-<2F*

*M4@W[TH0E891SV"FWNYSS\O'BT1',()R:.CXXR3B+99KW7[NY?]+Y]Y7M=E^R_R'QKYO]1T]K/EU]2TE6LI%BNUENH]1<%(09*Z7+>EHQV|/NF+-0&0 M(U#4*P?(?*

*^/]:!/MSXLPZQMYSX6480/7RAA8\.YLRP2**N#H@%&3L^YF"*852B6:9T/R_BTXVX70/X3'Z2"/@IRIPP+H/V*M*@ZHNV-@&%L0I/X(M51L'MM?GDQ0-O[S-*

C4$[@LK0% ,/2VS4G4=T%"|+\;)G>*V%H-,[@\@55FM2 M584\)1E]>CWGW0[:N5@FBC/$2R!-:[Z^3P997R?S[6!0S%>L@NIP#>UM;:Y M\ 7/;H8U"^?*

[N3QJY5O^O)K&812"F\U5TR:5;JCC79?;]>RY?FT]SN&>5 M/TY4C/,4V;B%C. %5!1RT@ZVRE;0'8M:']$)T!D'^&I1,PKMFW_17VDX]PO/ MY;;8V(KAWW6"H[L=3L[S/8_2.D?*

*2C9Z=^N,^1 +7TR3)/U,+X("4]=*PVZ^C MJO1MJAD27DG]^;B >;8!+%^# N.DZ'VW6!Z<& ?T8IR7P]MGEMYGEWI/V(/M MW2O?*

*N9W=3.^W&DSASUT]@2_8Z:TNUTE^ON #MK1O7,K[?8>WQBN*H#66WT$ M)9P?W G&0@C1]X.7%|6>W3VXFW MQY^/3&*W$:!L9UM\#ARFTD_6[0|@<]^O9/XI3N);XY _?*

$FBR"+83D8S6\ M(&E+"]BN32/PR*.X/'AIYG-^OC9DX+W72*4^MH;;% -X_XX2VZ2%&+| M)D+4X2P%+(\KVE,<])/LTP0.C5R% $"\<]V+ NL=Z(! M>W?+W>/M=^*

[>Y;|; 'TLRUX]O++-E]\K^L%X$]_9D=FX4-7@MRF]9<[^S5W M@IQ/UY$5YQ:UY_A|%;HF^[9/7(Y(/'5YS/3E'7L,2.M)\]":-9Y"/!>DK'IAN$AV>A>! 6=&R9I2/ M%+Z)*

[AQ8GKQ/CDIOLAB21[!'[XI^+(6?O_GIZ!S];RNGM>E:?3[>9W0T.U2 M3UXP0N8!/[@ S^7Q+$KDT-2V^8!]7434D* %+|*

MZ=I@8NML+^S3Y/>-8/0UWN$;M(9=O7SKGY>HOT\>N:'G3TES<7;T=QHRU]4V=L&3)PW,UVFM3Z^; _ !% MDS3OSWL.O/IZ/\#7PZ^^WM77^SJ:. ^Z2PW%X;NWK?*

83H4E(\FNH([+AK6PN5S)K%3SK!#1^5BI_UR*E;+TU*XC_H#<:UKTG,LU+O24>YAN<2YKIE MWL-(#_=()RL+#VV03;*T3KASAKN6T2*M3FRV:UTR6ZE1X>C)7Q;*

MW|R+1E&=8;G.9XGT< E95T?RN$1Y.HVWHU.1-2\^E27FO/ #8_L^HDS#KW%NGA%-/L=I@Z&* U6$HNL!U:}:/ M9M/PIS=QX-=-'$/F)7X!'](#MQS+<&,;;#F6!.2(^:

*[^WD7Z>^E/YS- (R5= M/;+$]^C[$UVWO'[4'L:G1%28;IGN[!X1D<41.+1,Y\-'AUS/#KED+^FHJ(BK MN9X91';I0:998/IW-9-+7 T-^ M8*SIN%BH*

*U4PU@F/7B&F&Z3&_J@B),;Y(=V:FPM2))=9D.RR,Y+)/-?)KH MR.L28H*6$(^GXFCQ+U44),]R/D]=WTC%R5@$O.AC/-Y,(>.:';I48;MTARZP M9)UFF2+=YBK=(4M37*?*

2K=#LQWDK|<[LL:MOE@#?['20X,SU36O B;8#",;Z M!K;UI]GH$DG?T3P-K)<+,3> ^LV?CU%]T]N@OUZ+Y/CECZ>=P71>'/^G3||TN7 M()?NF#IFXAM?^;Z\LSX4I:K9Y^Y-*

*O/I@%^&#??I\HF^DI*O/E/@>79V=A"P[2I81 M??O/#79S2#>SF5OL+/SW@@%D*Z4FV8USF D$S^"9=Z?H/-1PS1]>WG^*>]!=Q MC.*

([T]QUK[6G+3 =??:9W"WVPG7VZXOG4SNO(V%<+[0/KA?:G 9">U1&) 7+ M"-%\%N5Q5,[P I+-|@@BI14B AWZ?2]R=T?MP-K;Q]2]#1U/"F?7M-,U$[-]D6SS7ST.S3

*M^88XT,X1B7(DWGU=-6N%QP.FMOR5]IC2;;SDQ_]B|\F:X&C1'D%Q%SX'7,5R M"OR\NUL'7>YRM'!V4', *T(ZX(XN*P&?P','CDISCH/,*C3TM2]1E"LBMTQC&*2-B-B@QU!#(L*

MF7Y;$LFAHT(A7ZUQI0[?$S ?T@?USG$VM4^3HXY&"]VZ)F?+TST6E3R M69V-P5!TFXS#T)!)]GF%'U941^4Q'GY:SHF4GEL5N-U;D8&QVYN87T@.3QYW6Z^6K

*ML!]I6M+41F47#GKNR]??EYR MY3>1$4>3L#[-3T;-::MLZT8[+/GLZ14W,]>K#!!AJLB5*G: E_C6(BSYK. C M9EZ@G'&U!D^;IZY1KO-*

M$5%YXOG3M;Z\@/2I6|&99:OM5X8.5NFVPY+8TY(H MT^R0?F6_POT)7W459WU%)7//]ST ,B2FEF[_9%IDMH!<\M0.VPY/,Z.V4-*

*MJF%Z1R>]LE\5NBJ(=)1]7]>Z2C,+S5L]1(, ^|M)QM3+A;@D\;2DW0,]UR4 M"$X0@]*D7!#42:'-YY[7V> #3'I&C74=9#.4E>5QP1F$2(:?%Q44N89]W48*

*M!ZP)-7U2|=-..W13GA>@DU"N,&/%/Z ME<)P42,SL[CH, DSGC5#)9]"82) \=;,7';1>=B /3 -6J(N+ -*G68+3EG6 MN_IP&M6Z!Z>=%:(8MI)>Z7Y@-8O+%CT4B+CH,Z#.%MS,]-*

ELB:,&G-;FBN8 M\,B>U"5XGS"X>DY#5:SNDN."0%<AI6C4T5D|++H'+M"D:"QH M$!]P,P@OU0]]OZU"MD#W4% 3UIQAMBAGZ;GIFUB-DD=U2GR/L,K6Z[4*@V6*

MZ-.";RP:M4IZ2;3#HGO@TFZN9O"<[OBT4&R2_07#=P=RV([<$&FG-ETZ;%(M$YUR=L %HZ-0O[?HRU.Q8RASU2@TYW%7/45D2[16;4P%U!=0\,B>U1@6\TECY4"&M;82IEQ*

*M\7,.#RD#VZ,"47>E,=']+,(J4&H#>)$IL"%T;AHH?X$8;*L])V$;UN@I79"NL=8|5153TV3 307?CX5?AY@\IQMP[8NWMJM.RPT2V1N$>*UE8>=:?I, 598IV)8BZU+N'T/*

*M+1S!OEL'C!:AG-X,U&P|S4<3?$$, 6+?>SK! XK=RO<1V |$" |+B(\U#T!A M!5(4P8FD=;\.@+RZIG75P]?H 8F7]*YZ.+L>L-L,=E7^{141}M.KV0-7/5R) MZ4?I ;V%KQ[3\13QSH2S-*

*QW6+^MT|AV=/|EK^*4]?A;2]<(]E.&T+=2AEX< M@.E;Y)3BR'UVX6)[B\GF5%_XU_K%?5# _M/8XR?@ .@O*Q6_Q5M_#]=]_%]'S_|^&]+'8K=-C&F[#FW-E7(MTR47*

VN2NV@08,=@O" -&'T?'$C7W5VH/P;;G;>W6S2?@LV^NF.?P>X?OBGX M7X[9>T7>Z8.YEL?89?8S[72C$FM2C2W^C ME%TI>@%FOC87C/5.A$OTEA.(W WP]XW0?K?1 *>-*

P8B2;Y6"GNTX^I5,;3^ MUI;1QK:B(TCQ)8> ^]7F=:'L/%[[@62|<)((C\QQ;X#-T;S$%(EZ%&6PA.G)> MHK%I^R85IP\MU[\B79Y1^%R42Q:%6GB/0WNKOCJ6Z%[U62)%/&=W O4F)0-

) MFP|&^||-?)-:GS#SSXVVI.Y,?RI;WN;KFY0I3,.&^RZD"H)I%PW;Z[_]& [MP/4<30KG0]$7I"D__F"G9#A)#-4*XB=N4]O$&K6=MKERF6;FP|(X'D41Z^D M9>SFW\RO+

*[0C*9OW\ %M& ESOONO+$/[IXW]\SRO6$!DXSTA&4QV!HJ&/\ M4)]MQG4L"'1M2%<:3&/1 T0[*4-]1*W*]56|K.]UCJC9%%0@IYEHUP%Q\V_V*

*M%XX3OY!T=L]0OXQYZA/WAC/#@6L .>6 .3!]< &3UJ124T)Z_-EU[]^C&.%=]7(3U*U[K.H$\|@3AO$GCB9MB)R8G _M.29 PP7TF@I>MOG]G-:@X'Y[]?M8L:11:/+*

<^<@Y8>R$$!ME1GRQ&A^5%:0 $\0M&+C=F$=;8 MM3S!.)4/||/8ZCM[+TDAFF DB]PWW;U,/O:8T0.V1)=T8MQ(.UDP"Z|Q.SI _M,XH[A"X(3/S*V%!KZ.%B1 &Q'8BD#-*

(+\P;>&H@]DQZ/2Y:3ABD1X.D6.:\$ M S(:B$24^)N&,[\P=-]ZX(#'!%!W $]Q.'H4SCDWENL9'OL[B:A-A'4KC] M&SD4A?5(===|UK1,Z45*RQ-YK=F?^HZN%?MX(Y>;"2TB/K*

[]"U0|%?FNI'A MVI/ -<4B]0(),P:R)PIRWT/T8L@@'7WH^PUDW"'>C@4R\,I O)D+!(HF@93B M.Z&>? ?$2S?1!LPX(?)7R@37M(]+F.I< Q:7[U^T',L.=1&T#,'T2%.FM^.P M"?*

91TXH&'E7MR!UX6E_U]#G:MU$ZH8L!?)=D# $/Z] MYGI\MYG,-9[Q+?T-)0VPOLE68_&;3R2&85O3PMVK=:BSO50)^P,NRS;1)= M-*

IK$+$M&]X5%"R;1\0SXOCW;UZC&= ^":U0CJ;[*>X>SNLRU1;XXA_2@S-N& MQO%*L]N.AG,)O"B6["WZ1]VY40]OH8 /DY4R4DE^WH/*

MYD(2RZZ'./RH<7!'TZWTA,+|P4TX)MN:%'5M%>Z?6>$^C/51-X+VZ6!'XV3+9 M&.5LCNTC12Z8LSVRI$97[T86/?T+)XY_IM)YO=%UAN4UXG"&U' L',RRY4=W MG2;-H)_^-

,DSB^)'ABO6][5[:^I>[.<4|=A;|-BZ.2'Z3=>GR-^#1$\|0 MOW*9W4T|=-)9 4ARI'W0:HXDTBLUY12=YL@Q-.Y?Q.EYXLF)R?+I*

*^W#+XJ;&)'I7C4V="?!W.+W&J M_NL,I*X)<=^US>D1[EAPP#C\#CCN?^.$1"^XW.O3$C@6OM5*8O*2!NZ[=^2+*

*MKA67H1,T9UR!'"%TX]#Z]$G/Z/B]G5 -YSW',.>BJONW; E2;Z'V:]X).+G_5 MQ;F6HQZ&M_[[\L+"0QR0^RY]H4P>]\'+$KPL04WOCNY&\"H$!01>A>[E*M1^_MT;(RCD"E_]DUKH2-*

*R.Y, X7W'\A]\/YSA?>?-|-_&[ZF:[ZO@=E[I5^KRLP M[F4=' M]Q^]]A#6%=^7BP6C4*PQ(U:@]H0V\IT>5I&,B-8G6OR'7*$G7SV*K&6*;U!- MP=EH3C=81OS97#*

[\P']_.35!]M.UD%>7[//XGDFT@65$"]I>>/ LU]#^CQ_M=53=8D;U:R**X1V;M=E(*DGFZ]9]Y^TM!$/Y&:KAA3Y6(P.($L]|L9<;ZL&QKW.WL_!M+7$,.5]/&*

*M6AL1>;EM!M:"K=2C38^6K?T9+=Z!)V;\[I3GI[R?_)=2YJFV-IUKSE#SM^_@<=$(YNPR?XE MLF+WT;6%3Q:X6*U,4>UPF3V"39M9|*

*MQ8^OKL!O\,8V%L1SGR_'NY6^]8W_O*T0YLR%.=+B4-]=2OC8H:F<7RL/D?64 M& ZS)C<)AL91E.'7!2;!6F*5KZ'XHA_IIG-M]*C8H=;0_%@+/*C^":5%;VFS MABJ%]7+?*

]#$VU]MA\T^:]U<6^G'=]S@KG?#T1^9(V^%N3%!#N5<0\A'.OXW M!#D4||_WP9^Y(S55_-0"3.2?=W%3$N]5?RIC?DS5|=UDC1%B&0D9N&-9LZM'1 MI"O2I'#"&^4);3$?

77K#\?,CNZN1$C_/5>ELHU]=LM'2:1+88=YGBWD7TQVR M]UQJZTNIT89UPU4"K#'"I^MH(9SI45=%DRC1 ,$7@'K<&M])+$/2=

*MOT'=L36SZ4@1&UO.&|'G38Q6W55$78I@TC1U"$W?S\>'QA[6F&8X4[/D-EE& MM'8@9^V.&&$,=WZ-;6O@>*4O?8[-#]^3F>5*[M ?UZ2,% 2;W0;|_0%-.,7*

MYIL/+?:XEIX_OS%28'&4_N=1O U&&?.2(Z', T>/$[N]>!DM5PZS>CQ?.?SZ6 M8A7_0%)@AN[W]V|'"@13;S=[CYM)M2$T99S8-MV(#GR8UGNU.GPS40;7G9;[*

M#C$LVSU5ZNB3F>6P;+9;YY<=\),!,00EJHE#76[N)=-"'BUX%EJ38]:EBCC*F MFU*5]0E*B?QO$$[WY97Z1I/1-VW3U3+C+3JC"/(_ \R]:3SA5ZN//H[>\A?Z M=R3(X11&J5^O]?

SR.DJ2@W?KMKRQ:$2"47'X+!P=@TV>FWHAUC*I4(VD M(P]:TIB-M!UOQ4=70">/6]"EO/M;|:%N12"._$MI+,7"6/6"H*[-1;VCK X@*

*MV)38>*QG+TH(E:DXO=EBY#,UI8Q30!W!Z31!X]";E2)NAM\85),TR>!IG]N]C?T/KRGUARCV7L3\=*IQ,@_H:*

M+'!,=S+OFT9)[FO^5U,+&(^G'=]S@KG?#T1^9(V^%N3%!#N5<0\A'.OXW M!#D4||_WP9^Y(S55_-0"3.2?=W%3$N]5?RIC?DS5|=UDC1%B&0D9N&-9LZM'1 MI"O2I'#"&^4);3$?

*77K#\?,CNZN1$C /

V4MREVO.B%0CGCMZ%FPT:HW'ZOW2>Y(YOF I58OVVW_WK+?CG[\1 MV/L7$M/\Z:$[D5(|VU:F@?;|Z8= _OHZ;3W-|\&@VT!T>&_!REF#V/B./)? MD>\5"$7"H'O>W 7-,%:. =U67./?!\W-2.VM8,E#3*501$?E(:)@.D$PM,RR M^D@F%&5$:<2(IA'Z. F\;+?F;'(C29A)S"]QJ.A]9H1>)9027T1=7*

M=K)I**S;IN8F2]'KI8BTRF@!CY/Z@4;G7UNWYYG<1H0_P@@?AX" MSS'53B0@B@KB-A5W#4]S@?V*[MY^]+&;.J,O&'Z?]W)^7NQ9IV)R@68["A M98:^IE@918_>^UVQE\HZV*V19K_A/P^4ISD!(]10Y!M._D_]Q<^ &'N4=)15 MY@6]=HB>L34=Y!;%7WOZS-\E'&T_[ID=*D&?P]%<>^WPB8NBW^$2/ M?MTMC$"WB4PGV*A?Q4DY^,B.Z42<6M>6J9;G*&[TP/@3\.#M,Q]28Q_HI?^W M(_('M90_XD@G5D(BON>!FANQ|[-X*C]>L,>;+!WO02:B]PL-8[L'/S_\=?/V M]F3[Q^C@5_\"(U+_+T):\,V_7^W6[VW_>?8 ;SKXZ#>/?)H_97O&*P2K]$,, MD1E5T62"UAB9P5!*IG6$UG5UA&L]^K EQ%D@]2W+1CN"($-SS=6NH1E,DMC.($E96'\,]#R+X'VY]P!M; Z< 2,2+S[QO.?'NE(IX*: M8]R0WS_Y;4:0?3H?_%M-C&K_TMRE7 4Z>2COX\[J=|K&>]4*9Z$FZ9'.H[3M,DF@*%#;*5G!=*P2;IK!APB&C5AF)P/*TUTZ.W_L8^M^2T"PPG#IT9.PDR>: M,@]..[^.|,DR0BQ69DM82Q.BCDT]5+ .12/WGEG#U*&ZZCH;)%-;SIG2E)[EM,DL9VW\F;5:,#.',>:M;MK-M=CDF-F0S&KGW3+7/SA7/1D1+1$MD=K)>M[G' MZ,XO8Z]'#O'6.-.RNWUK5C/"><692FPIE+AI)OAX9$.QL96:-C56@D5%_P^$*MQ8)G[]]HVD50A!*KB#9KN8'OU9?3,AB)HJ^'ZU6OM!I.993M)A*+=@(GFK(MY#Y!EY2]G9"%]W0H0OM8F<5,NUFC*U/U'3ZC8]X; ZD]:#*9|C; M]S!DRM3_1 M;WI>@0CNE9[XC5IVAGH,WHIT_O/K#$9K=FOV(1%+3O=MLKAQ47_3,ROH_M5)MA11FQNDN?;R6.7;2YG9?Z8N\^55HSGM2_5<\5'O+9MB/C&9G:T-F]I^)Y A$M00VEB?!$O^WEG%G'+X!GL]!',B0ZP[B..D/"3:G38[J2..XM9?; BJ;X;G=7 M_8(0^FYU4AST\<=R)'/(_E"^,=5POU;I2.,*1#=:,3M0ZM%0=`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|-I[.M4@>NVY7_E#$@4|ZGNZ,;\',V7"'/)DQKTD.#T2C)7),!PD6-*@8%W.87!E M.K'4Q<*%CQU;~/4/N%W2&PW1+?)(R,I_](7M"|H3L>9G+4Y+X M]]W%@Z&O\FH9_/[P|Q9\;"TMT!1?';>B"U5TW5EHMC=U-!?ZV^X]3R)EKV$ M62 NDT1$'PPR\KR:,YDJ1%GHEIOE$%DA%75F?#[+8"ORG#O*_11X87L|/Q2*MT"1JC2+K.$@%D19FN6Q.U'531A$9?_C!4DR:8@XY"J!-\Z8A Z86794G|*-" M+U?X*EM9>Z) >9PZ$)!,MD#%0D\|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| M9!WN?%5Z/]3>3"<-O"]RZHQC-# &$&D:>ZM2,Y3T:Y7T M>SWB/F;IN,[$|O>CPFLP6)<404,4)8>(|<48WE'=SHT>A&SQSR MY2W 3/ MM81VBE/G*<&9VMY:TU(M:0YH%[$|[VLC$P9W)5),PED2:(Q-#E>DE-&5<2@ M^ID0$UT"PQ0%>\;4@0HH#0!IDO8U47[D3]ZMYE2SI#ED>-V24 =$4%)4FB$.% M3:%SY'Z0! +';5A;/HX-]CUJEDH%IBEHVG2]4"PY%PXX@ V@S!^&I&D:A?$6 M=PL,4,5(H(IQ:@4$3X;+N8+?6G8]T3PP@+50R()%#%N!F;MSL>QP:C/E\PBUT.0<(HQ.K_NA#ET"; AMN/\4<>XNLB,EQ4 ;|[V#$,P[M<_M!4,PH!?F7OG|)RM#-KYV-H;X?OE!_$MH|:%HH\F,]'E0@UQ MLN,6R^6XYB@T9)0%EUCBQD$29&-.X2#.Y;^]R'?EK_5R3FN4LE!3"AK7. M%V9]0VDW@8"#FRB!IS'LK>3"6X@HB+O^1?L<;5CTVM ,QG'.@*=`>S"$P03W M99^#F9670\TFC"6@X1H*QEFNOPG;<:@XI](:@(:8'H M"K]2A0"K.L-@<3O,$;T32WI?O8/$VS^]L,:TXT MV\>*:V@ITTWIBNFG%HH=:N#"&.U?//&AK1WW\I@4N+OH33&Y#1V30*/$MX), MABZ1%"Z(@@,%)WFZQLG#L?/1>?D(CDMN- F#^5;!X'\>FSM=X[6*@<5'AH-%< M:@BR+D]:&; XZ'MN4\90$)--8VGB0 D\6/D?8L;=8L9]^+4_BF_O;Z@C49% M7S17;ZO:[PUFV8:R7N,]:Q&*Y!! 26T 8.DWBA_]2W(8;??N&CC=7[)3WLM7[/1B $^8[A|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|A52H(YQC5::(X("+H?CG,1LEA(E]5I<=TE\UQH,F (6X/4@: MQY T@^\GV=|,O,+V#3&=4M&>IT:F'Z*B(9,'Q M+W2+O]|FS%5F2Z/OQ?@_\K!0+)MF_[&*_3?HNJ*-B<+QKX2],G9;7\%SXG(M&<&1_<_O=(NLI,1QF36X2 M#(TCF[NP#YPZ@N*[$8&#AN:WP13_>+84LCQ7[I::J$1EV6'P?M/FS',RG:M1T/PT]>SUB5&C.;&*.6//%BM*,>?F#?2.]$AC](M=+>)=.R6YGHMH=+/%T]#A&A;%64)E3V+H]PEU3V/FMW/"G\F1ZKY-9YAD J M3#[7:3;"42[3!/#']8V$ST]1%<;O*FA

*X>H:/U5V06 W470;#CE$*^ZKRJM\?/G"@:?SUY%8G#(5@'C7,HX9Y MU#"/&N91PSQ|F$>=?(_|ZQ8L1_)R8>-N4)BNA"[2I@9C]=XH%0?*Q=SVV9%C M+KQ:EY+XS(;*Y@R#?70-&<6 VY[$Z33YGE8Q,/8\L;'G"5."8;:UM:/3^2[O M)C^I#KN&K"#KS8(TW/&CN^DV 38!'WP$3A"8(# =U[T.@2D9P/2V0]T.IQA1 M'2U6B(-+>:716U(]^PM=G[\"4LM0[$NZK;^0PKR11=%<8;YBN1BDB(-N1ZR/6WGY-]32IIMU$4W 5;*PI=83W*+3:# MIA0>OR[9N]1(O;3$^'Y&]2#;@]OV&V6LD1&60(T$CFHF31VG8_/-)K[KON<| MN:A3ICL*U?B2<=5[IU|> R# 5'I;"PU1XF H/4^&3RETP%?ZS7O2KE\BD.M:% MZ*=Y1+LCIX|:G:T.IH&VDD(;#>?B3\%5 %)LF?SO)P.:@[G^4"#8V)2Q38H=_V>L7B M8)$7B*)@ YXZ2.D@R@'4>[R5('I\PE'N3^4@1,'|_$3HYIR^,#.]6GZ,.":76SE(Z'?]%[(@/&Y] ME3!/E44!97&[#^A];"H%L0];?9HF3Q;_D/Q@!Q5TC4]%V^RI9G25&]66 MYGQ\AFB'Q%(&IN;#U/S3!2C<-0E@:CY,S?\RR6!0P6VDYL,8=AC#?G_YWI#K M(==?=S+Q1]?!#?V :8/= @M|"L7YCU"[-^$^"-@UF_]Y?U"YLJP4#,2U'E1E)) MH0A!$;H456">XDWX$W?O^HC5:<.FGHLHK::8I3BH(M>X5085@HM3D:) MG1,1I>DTQ< |.*10+10B*T+4E$6K$'M>PEF##(@(2($,PH3Y2PIIN/KE4B(#((MT#Z%X(\))<::[J9+^[-!U0S P^608ZV/%I<!@F^OM(&UY18N 5 M8 M,%H3)@C!9$"8+PF1!F"P(DP434&[XLU4TL -1Y]%3ZYZE34C#LGNZ8*Z6 M'R\8_*3QOE4S..":?E3)1W_X\-X>VUM;4:..C/Y# 0-QTW+MFZ#R!,G@$['I"%_1QW>4 !(*JOC@%\0?BS^G=X1!_KM'W?6PLZMG%0=<:F(*T M7]@;6ZQ6^&FXQ2+BX0=&$FD,@PH1!*0S^+?A=1X*!A2,LR;@0L&X1JZ @G'Q M'-WDJ[#'=3P?6^U$\9K7RY7'6817Y^O,O--"AE,#]W "1VKG>0[[L&WWYPW M-G1FADJ@C8!7>]JYP39/5UN!GZ\[+3=AB?\P!1>FX,(47)B"""U-PD\I=, 7W MLVYO*)$\CF9D<|\4]P)ANBT4%R@N,+7V/MV+[TDPB$T2L46"?V&0:&G1&H*(M2]]:OS!5;6L&:FFJ9[CQ4V):T0%34$;UW4QK"%6$67M163I>0>+EI8S2L0<2 MI8DT1C$P#Q<'V[F!#>;<0G&!X@+S:Z&X0'$Y38WAJQ>7:W9I7D#5'2C(M7!%Q-KG6A*@Z=9^(55W@!7RW|GMCB;=YS]>B2:?4T/ M=^EZ\FT3AC4PMQ:FUL+<6IA;"W-K86XMS*V%G6*N.#(U89K5-29R0JZ'7'] MZ8.0ZR'7)SM'[?K-:#X;YVEAS W.AE5S5<[2=A[N[MY*OEFC-92(I;ZYL4W2E\K?4Y&&1FE'WZ@9!K#86(M!*BK MR16$QS+D^N1Q/4P$/* 7|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`CK6H:Fr&+ M?OB!TVF"QB%B0<2Z*&+M8L.2BUA?(]/10R>^AE>_"01;%(KKL+=9\8B8MP1% M1A\)?6?EK[7Q?@]-OHRZT^G 0"@'+65IAB2$;I]"9D+%U"D2#83B29AD|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|+=4V(25-,57=+ MUS'1AFA8])Z;M2!"NO'TT\S5?%+[;%=[F.\U9#[BPBE2:T:DZ:9R@A MQ)59DQIYV(;E8U(\-=+V4BE[==9LH-M!R[6.[7A5KV@2DYY373 ;EDY,UV*W MO>\M75R:81P'*%-SLG?,"$=G80?M,BP -D:DQA@AH$S-R1UX3+VU+.R!=6X-M74HAF4D8OSVEIQ@MSL+=J,T;R$PH*\N"+\F8 "CC"Y7?1(J4*E2[IK90?$/2 MDX*)[,#2Q:0I1N%SO5=9Z!K"T\7J9(7V%XH5Q>]/,VI?GA4WA=5\;PRV"MY@ M9^(*B('$IAE5U2P\F0ZKO+KE)/8$IZ|FOJ[:O6D-C228:,'9C?;O:U1 M3A8J1+&-6P,2EL8U(?QA8179H)*0IE=[VUY7.K-F\9WH2*?MM%12AN4-R@N)TMT1&*&Q0W*&YG Y0IIQK#1E]7*KV2[!YF2-L*\2(MQY0IZ>NZ MZG;;X(4QJ[%8LT;%$5S$E.FIO\52M*H5], '8E#&A-D"68@<&P\T/?W=;E7K M%:QM.D^CW=9D;?BT%H8 ^M*3&AC"DO'7-H:JN\Y494-UO $HC:'I695983DJ M1",71;I\N%*;O=;A*L2DJ6DY504[4-K ,)"P:,H$CB*1F0P@+585/C-66\JR]60$:7:MPMG!+D9(4^RZ MAB_N3;)36QTGEF(",:TB|051GXMCO4P(P7"S-+T'M>"[-E0NBNA'] MP9"S"ZVA$].F^$7W44DCV\4V2ILD)5/KF31T$M(4O]8CA-I2$P M+B9-3:R^W6#;]M67^$!$ZJ(8;1G?UF+2],3VA:YMS=;M%=[UO:TPF>YK!4, M-CVQTKK>;)R88%641$A9O02Z\S :(GTQ)?"6;^3D)%.2"UQ;04K#M@(P2D MJ=$.)]IEM*6EQU<9K-*CZ_.*(&HQ:7ITDC&>VUP=;XNTX-9+W9"EYP@7TZ9' MR\F(,K-,%Q75GKOW'4?'G0$8 ID>;1E93P9EH]'CHZ8CKZRFOQW10DR:6@:7 M03NUK;L*1'T_1RINL^NS9/+4U,2H"=6IZ*N>B-*V(K-A61AWNLE34_I(+=B) MNQ2$FAA5.MY\LAW5(CHA/8'S 3+KK,KB1!P?W(*\:C>7$^M(FX:OV@&-S!Y7 MX[>;A29*U)A4#|>)9+K5.MEW5#1P%YAP#ANM 'M"=NQN[>Z-M>;;Z(E MB-4)L _<%7>1BTA2_>G2O>5B8O&18^YHOC RUH_3#F#3%K^E($CI];^$8W65Y MO'88FR0Q+29-|:NR#!3J(^(BVMVP@538EZP.DI"F^55HCEN=CGQ8HW@P*KAZ M;3F85))YI3?&S<:M=$;[=LO0&P=^5]D/ AT]3BS%A-]<1HIS'\ADURX?Z%W8 MP88Q$TZ8A:V@,U-1O5Y"Y5U[WP]+DW:T$F+2%+|V$MX/M]2 0@<;YI<+)F,6 M*2TF3?&K,VS3]R4!CA'C5G_D<*4QUAR',6F*7PQ3V/;"<:LD!KLMK7;-LCW< M):1?AF%QM"IU%-S M4[)(*IC(:+T-RC?]^M*K[PHS#DT:^]7U<=SU?3;:-/AM95(N^)2GK>M;3)H; M0:A-!PV,B.I&@*M(IX;66@V"2SIBIPITNK+M8PW*,2)MSQ7+7758+R2/31\Z MJ.IRTBA-B[:XG=M*9+O%9N(=8$Z<.FI%2IP-$+G'=W"&B_Q2!Z/A(0V=>P M9M9P'D2+I5$*V@[MQ,F3#*&QW-'XI9Y\)7* O16W<,)]%?71=% Q#X;WWUXZ_W3L*/O)B-I M?^ U/&.O=R=E.Y$O\PRX=/?$S#,@]XE@'\F 3/9- # &7+IK8N89<,QD@0SX MN@RX=' #S#,@HS?P'SC_R[;5R#P#+MWK,/,,@!KPQ37@TGT/,||]%?7@,N MVP,Q\PR &O#%->#23?8RSP"H 5]< R[=<.^C&)"U H W4$?S!HOZI?\|:YF_ MCZL E I SJ: 9/.JX,.;O7UI%GS(=<&MJ<:'>-A4VX_K^M#;AIN35 N?.HX M2S.&4Z;&9S|U?* (?,C])0+I|):>]S%9OSA?^ PNW>[+^\ M(LS:Q>,MQ_A?RK?<1BT\B)G9O|P/]=#S(1Z<6-Z]&^ 2OI!23W9\[??UWW MS*-E1;[7LL+P;SA^P[956ST<9%NWU=RQ- MRUN8)GQ-&LLT4Z,N\?24'):(3% M]6N=03F!#M$OK3SG\ 4QMVRP_"P[?AN^H ^U\;^ZIS"I[@SEXI:VW&RS]HI) MH69 S8!^0N@GA'[" <_@)GU:E_LA>F!>VO(Y-:7/EW&-/V5Q2]_F+NA.OXR/Y MW/[%,R@A\8TF/K$2'GL%'B]%SZE]F3;XH$?E+Z4F;M^6M-+&_E.WOX+$0*?* M6U'E9[IQ8#R2S4)EU!!OU1FN'1C/#G&O7U: M=3LW=D/H2A&ZXZWMT\K29: ;2M0KG)?2S|D;W91,*I74ZHOM0E#Y"E)CD?/\?15'5Y?*:F<*O9\&O"[0]5219^KL?1=4J;47-YW)E55&MN7IO8Q)8M_O@#^CN+XV33PEAGXD'A]U[J)'\Z,7U0LZ1/V*W?P;QCU)M2Z^Y%+;LSQLQ=. M_%"^W*+?Y%A<\79UZ7_/I$;'"HO95Z.W\";W?_H>S-*NN+(2Y_CD EOW^^KR MOW,(2[G))E\#]\5N<)W67 M<<]7(NYGB^-2X"&:+&_B)_F]!7;:DBE[7G>9!$MQ>]W[29'$,Y8?HQD3BG:R M3Z2? MH7>YI>-:LO_?.WWO?[<#:.^X]W^^RJFR!5AZ_XKO0Q6\V97=Z'X@6N&M$^P8&S_F`]\^#!OBT.G)+A@AL)6 T*G)6QY:;4Z**K]1.FBI5FA*M+^*8M.X M<3UU]X,D_N_?3U?FQUG]YR>D^-X><^_[-7Z<.7:+F/@G+B:=,B$37^60_U2 M^DH\]1)GO80[Q5ZP:U DBB-HIW/H;+CED'LKI+X(AL<(U5^14"SVIZWM6-SP M=*--UKJ=P5[7GB!AO5-Y Q8>+QZZ@> %LP.+=0+K%E2UNED=0@I%[$6ET]/P MY70?2DE#9HS%\FR!O13@)8=Q:.2]*OP)&GG' /XOB4GGL '.#DAO,T.;%:[*#"5@ 5T0G(D+=*% M0[&WW,[URB@VE##R[@>,,7F49O)T 8, !0$["P!%G#X&WS! ?;Q+[6&$ ^IGK MD=1:>9(;=+P'OT>KC59P^E'?*|R?U*1Q*!J5*;<1=%|O^T?FIUEHXCBE9W* MK3>M8M-*S"@&H!699T@&A4$]NL#U;&J3*: ZN\8D_MGMF'JK_JR;JL+7G9M MP$3O'I:L[$AZ)MA4VRZF(/0SLPT\,>[0!S_WN'G "GTH3>;##>T(RMYXM, MORI-[&'L7\?1V)0]Y"F;R),DG4*HLT8408B"$/6&[#L(46^].6NT>RX^H8V MZ-)\R^^DE3XDSWL^>Q9=S'IE;U>*XPB-#]62+TS&?7*CQ>A" ;3)DPR;9 $_ M8DO6TA+ LE_# IYRS|JL4^/D ',)K:|*X7R+:?\YU<\5NNKYMJE,/\7%MV M#=7/U;WXKXJ:B[LY3C-59/MY628&< 29.'<.8H9.X%=)[8G]SLM;(KZ.9]B MWH0JH+^&VIY:>,=.'1G/<9.C&IV@9< $],G\@1CEPY?A1$B8E]B_O05]`XP]_2%+KM1;!#]&BGGV=I>XORCW?1@-B56T_TC%%E>SJD:5D3' MFP*-H%-493;<3 MYG);%383TMF/C>ZF/5XVMMS,G(02'0>4$0>>U:^#&#UFL/[2U"5)"^_&;G8T=0ORXTF@7;'D_K,Y1M%9: !I(I# M0ZA3<;D0IB!, 45\!X2L\'4R\$<9X L:M_<&605.8@1YPU1J;IM((L,0%9 M5I)|)- #^7$H|$)RI[N!PL601=[|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|E^$*V.NMGL9+PGKCD)0X<WC@291VGLXN5XO[0> M0RB#";-0$Z FP(19] E0$S*3, 'LSYNW5[O8N9)*N>MR^S'21];&U^JL^YQKR MEAO&)FERU _=]D +9RG[3FZGV@O'I6!2,DQ*ADG)U[L.A%R!2D&|R.O%EF#C<@!=<9R$87%F,9''< KFGGSZ[-|;X K,*[Y" M7O&?T>HM'H.7*N]_!JI*L_W>,]MH0PRVI9I/"?N(^&/2W/9V>K)0-1>A2V-]FV*04ODM!\L9N)V/M0D#$]*;><+ M#'MI?^V7UKE+Q\!GS(R]Q<3F+-|-7?,.^Q7@XG.'B58/*C:OUW'"OUW'Y;P$ M7.(K:!PB"T26\UY$0V3Y;+?.KT"9A:=7)B@CFWP5;]M=8U6BZW,A01GR[@=9 MR!<*T(B!4 ,3N6'Z*I1ZF+0-11Y* 3F94A6 . M^T9O/"47HW$8FX+Q!2V%7O*"]I9B& B|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|%KS.,EFORX M<=#[&.8/?\QM&PQ<@>FH,!T5]J-FX.8.I]-_^O714&(T)HS%AAB14%Z@NF5*7M3Y*\!4%LI7S21[*TMR_\ST|:NB\!%9@ M)%UU^]2:DSFJB05Q2=6K<5QU+O MK^)5NU6H[OW=GB]5;*E8Q+C:"GW52QS+VLYGG?ORBO=>_*&L2/OR#K.7@Q_ MNO5^NE, [[M]=#N7]7%!KHCHRBL2MXP[PI29AE(0Q M=S|()\US|"\(;Q#>8.8?M :@NF1#73*8^9=U:^"|%Z ?OVOK#'5P++=GBRHB ME;Q%31V,\##>M>/[S]?MVI\L51"P+6<"AL.4P+^[MSRZP(_$'^H$OY$M&*8, M'GTU5Y.3&V#1 ?4E5*68<@A3#]P2PD5#P;$ON+,>%4QR9#E=W]9";4&:@W4 MFK?>64*M@5H#M>:M5Y=0:Z#60*UYZXU89K4FZ_[^M]W^]U5?UFUUP_[(1Y||/KMRA'B42:N'U\-)6$=+0P; M6X$7]PO9"%HSS)|I80(EQ-N@Y#-D3LZ?DX?DJU!-7-)SQUP\T8.X^VJB"7< MBK(IVXJ:S^4&ZL9/-HFCHA%H OA#O-C]^_Y9TVL?#T'?T+069CQ:((IE4T@B M "0MG&!NJAG I),GB[=P\ *[U#A/ZBZSV,-UQY@5>KK#=KP<, "0Y[=;8=<"]MJ8?K SH.5?|:5W:CXRB23'2O& A>S"^P J=*,?,'J&*23"|&\|UI$Q4.E;(E M2!CS^#,1CZ/0 @-K^"=CL'9SVT-\/#'2 3HU"M8@. ^VH8 MPR9U<+=C\)G1UX'93Y8]?1TF/IL[#2'XO-;]&SMJBMR]YB%D]8DB >M(T5 M:49[>ZO?!PQ]C6F)]KT5L^HB?7Z[9:K3D!F#C4>+,9*]^T&3;)ZALUZWR"8_BIH4.H@$ M2]]TMJ'4O2RVA8WEPK40]FQ&&W)SD(:DO?833^"Q4#F;1UDT3](0XR#&W0;& M/5,Y F+=HRS$ [\@\@:$0ZB#4W0#4/5M%(L-0]W>.<.WL4R|\!W3-A=%1M6IOM MEO49BH]8IMGK&G5\|^]8EY.H]FP C#E9E_"%76[Q)4TC3)>5':EVO-A%8W.. MR+,LFK?V189#+O#W7:=;'^[;<.(C=;K\ 4^>]K61< MUNZ]D&:5WCGA6]QNL(;8*TP08Y-<"QPC|W OCMZ]S&2>#/U8@45=Y'PG MYZI+4U7\'+#/P<])ST5# "L8\[;@+'FG&7NR4S!"Q5$WR/'*7RO)?^1]NVU M6;KM>I*HEX;EXE:E]PK'G>32.V=T_#5^#I *((_F$W6Y_^CN!]B<'YF9_L =5U/7".PU1R5SP$M(+]]%-^?,.]XO 'V1X"89"5N V1 M;,>Q$3G;\54O[O@8SNG@RIHKFSF-K*;" B0'2 U &<6<:?ZN'^]G5R2QP_ MW%*W95L!PP43N>EO#-R _IZF1 2[]"^A0]D7XYB"%+ _Z8[LKLUXX0??T(M [W0=P _@G\>GJ68]NS&F^CJ-^PAXF??VQHH^H]+Q'L\%2&,?K 9'O<||O>1 M_W^ #OWGGHXHCNFXWQ\V[E_F=,]//-G#-169NZIL((/2O/>[;(9RY-W/L8!^M*SRF>']_W/QC+N3(;Q3UC]S/'V->I!AIR7OD%W;=6PS'_ VY^_'*)OX \=+ M'+G?736N;[53XZ< ^>5ZR&KZS^8YCW^A8(,"O] ,A@9%,769[GHJ=?/*10]T" M:MU1PUS?L60;/#+Y)'[P]9EWN94;VPW ,^R63@KO'P%Y&& 1,4B48C,$Z/2CZ M+,N RO.+DISP'L& &?4XKWO^ _SPZ:*EUN3X1V'+*/^,*7+ #R! _U ;9: M:3Q$,* 5D? BKZ0ZPO$/ZRY03#W](4NQ[%]CR;8 M<8)'$P_+RA1*C_M/Z=?[Y_$$[R52N))M#2&)9[:S4)V6/^DSM.Z7&> M5Y]3Q7$3RV(U%#-M0'!RLOQ8)Z+GXD8 -"-=DRR7D_R,"X^_@3C"|^=;9[. MY9^B+0<+ <+I; .N\ WS-!LN^?H.]U]XESLYII4!+-$8M)9(!BCO'"DM)(50, M+6 L@Q+HO>C+#V<;K#/3.R7&)L0!(2|MF6A-*Y,PSHQ*D1:ZT7K35M><@5B= MN<^:9@&W0@F7F-\I*YM)T&GH#BMNNWMC1BZX8-35 &7ZH:.UL6O3.#-#+4%K MHKP]VS<&FD3$P?Q/*0$5W>)%RTNE"*9L_ &*$E ,K4ZTU=TNBH@GOHF.'F M\|E0(1BMST5]IP[D-MWPGHA#+-4EDNJ(%6+AHE"4IP3_(R.YX31OY6PKUTF/7K77&+-.UAW]>:I5HH M45+]_>* L;&ITQ91Q.D)PTU)8 =C#5"FIH^@]>&J[%<&*#(WKZ%'U6V67<0T5T|:E"DKO5VS|^O3T M5RH?S'>'K6)4^S6_QG0"KE\38M+4](EA-/46@[HO(N'>;FLHM_$E0:+3TU]O M?:\@#&84B][JG]WL1W6WJ0%*#/N=M.U.EXQ9KB\+H)K[99V9&+85/Q1+LAI" M9D)S8P2H45K-I[^)E5&/BHK2IG3)/;$G/:[4;VC M*Z01L%4B')-&TR($0)E^?[W<&!=19A49D<:NIJ/NF&6) ^*'I]Y,+=B>15'$A M-KOZMMAKD!UFP$F%]/L'C"# MT(QVN-L72P#0 &F* Y427VE,C9K&1SXF. &Z$KN-A#2U 'A5W-N*L.P;X^5] M6%:HOK5I1LN_7A3/@H:FB% M&=K]\?%SL?3$VI4U99AHJR1NUZ,1L'"%WD< GI*F)!;4M9O07!XQ7E=!0<<4& MZA+&I*F)(87EH(^ C9!O=KS*N'28FP<-/|5/#V!L6+5V/9IXHFS7HJ;1L\NV M)\2DJ0'4>FTG&NEXQ<#[!XVE:\7 P*8-#4 =N34YY/MQ.*12=&B+*;'>&3R MU#1G=V6/:I&VZ(IC6]|(QI-]2.K)8-.<)>](:F$F6121QA 7VS3%%(#(8D1Z M8OL=LVHV:B[!#YI$5'<]8LFP"6E]8HM^)&]TU4UX,1,ZWP9=\0I]:V##H M][6F8C71L2]OBQPO-S:1%I.RJ0&P2*U@1+.F.+8FNMSK&4-^D9"FY]6D^M$: MK]L%OFOX8R/"FEN2U.+NKJEY@D;96F" Y@$@EI>FWW!9U>X"M=0O$Y-=Z882C45DG5YM2|K,H6$ JK;XF. MZ[7=]AQ$ $CB8M(4M]B#9WLNO:@:N+D4NN."9+3(I(-#:HL[', +2:+%C10.) M^O.],N^N5F(R@/0>-ZCU|'&^:ZQ%2ZNJ P!->G&;C""]R=7DSH;>30Y3HTG, M*4+O5;N1>:1]V.42I_2C;^-X.:$XIBEO//[PP^_VK"Q3^#>'Q"?8Y7C0?FI MYR%]$DV[=7SWX:T/KKZC1?RZQ'6'30)FGK\L^>64 ,OS'?#,I>F$#R;UP^]) MYOCWHYLF[$SXHY DWEWUY'PMS|$Y+O! /U] V*D!>Y]|J O35 L80[7X6/6 M@?[&OE@4':X#U(>OM0X4W!\RL]D-Z@,&5@&"$M960<(2UE8[8;2?U-]BWDA^1V*P<=8*AD7 ^@(^%R:<([3UV6MV:\^?3U67+Z1P]I&4[!OVQC?)GQ/?&\'T ML2G2S]*[D/IN(1TL-_HFQ:.H9/:5=YW'OO0|G]O2_4KRJ9L*VK^V K] MH8?"6?4AP[._0%KCA\ VY^0;^XD>+WJ2*YZ'5]*;[MKD6GL$U?5YMR[4HK*D/&DE M6N]4WM*]+YE*-_"|>')@84YTZIOT^76C751%PQHI7GDQ'S18)|||C] JP/(4 M>=)%KU@B^2/U] ;<'@,*)!:5&]N@YC;7I2D7]R>AN$$0@F$DHMT1X5?F[82S(%)3^CL,PA+1||X*Z MAQ5S(C2E\#*L&0.?]VMTJ6VAT67["2^T\JRT*B@H:I6";A'K-9;E(XQ-[] MP D\3Q<*>9]$=@H$ETN "W/C=D]VL.5GS$,2O?\DI.7HSKS'F4Z%YRJ3YJ%G M; O\P=4]!$73VD5Q)@RZS&@[LRMB5\0BG= 65H-ITMX, T##Y*E" 6(,Q)B+ M&##)+56&0.:/IY]_9@I7^]HOZ[:ZX&77!DSR[D%$[HB*WL)|!Z-:9|9H'^TO M=LQY000P[[]WR DTX9I%:K1K-0TQXF=MWZN06YN(#T-QCS <+^1QFLRC*6]" ME']\3+ETQ-@7@)1CH%B6("5C_I6!M!FCSD2N&GB9EN0Z/ZHS\F4,FRUBZP- M,S"-2*^@X;8]BW9,TI65N?M!Y$D_" O#_\'&R%K87$]\ZYX7Q/W\"=Y3.59VZ@#,6; M5?6UVOB&"Y1RX,KQH^)>MT>5'#I2X6S^S]?O/]2WCV(!ZRX3FN2[GJWM)^(;W! 3"+[VG(,L2)T C\^J3Q8#; MR^9$7PXP+ERLXV)X|=K=^S. Q9OMB314))&B+R$%7^E(AU73= S=:VXGE16^ M80$8*>(KF/19 Z+$ET*)2Y=& 5PP|?)%R!D@8WLH-C6)]WQ1IE1DO<#[NE+\ M. ?$.R#*)*>;LKSTDTO&P*[LT84>]W?*3RLE)O]LLL7[46 M.-%2:Y*)"Q]M^$R;Y=I0F50F1K,9:'-E]5 U4@"$3^R.C2T?X1O0]L;#Y1|| MK8KC^5>.]CQ'T>/+^%RH^ZNQ>.GZ9N(7S M>A:A_$+YO5'YS5YP|"7"9[ZRXXM,#/CV?E#9UGQOZ+C?@PH%)L YTP"T>= M=<6;ECW:V#*U+=[]]SN(P@<GJ$60X%D3D7L0."!P'-[@<-PXX3R>T-!J5" MOT!TY)G]=%F2WVL:?EEQUIW96&M/-X3?-5NHJ+;Y_D(;S,+M.(R9P;S"6ONS M#\\"]F:]3WUX68BE#(#=GE/W]]OH7O+74'9=&3 U!R\C8+SEW\1;EDS9\|K+ M\|5&>NFX 'NM/LBHX?V?O-_/@^^.O3K46LISAD.[;^8?[]:H0*A&N[HK6;D]@XU)(@\RSVTIT U+C, M'5-G;\8P1+K^(:^^4E=$EN&E^%+D2=DLEA3>)0?'Y$SLO8M!@V0H N%$ 7 M&)X)DO6&=6876EYVBPN+/; O=M#&C0:G=K.Q0Y:]\T^?/ #%LP^\7.)C@8 MR%\OA;U=58]N=)%KU@*(5PD>TRXA?CB3!HY5X.GC[.4FI&,&OV: M,37&:>T4=++KL**%+3NT M5NBM N1*EW]BV*8DN3):B7@[ZO?U MRG\|#_Y00/;JD@'5_ZK'E4+9H7[#KN_)X-/ X,-7XMN%HGC+4]>8IMQG,/(CQL.OX;B"|7W9F)\KYFZ> YW86VW=9EHA/.! MB]F'/MG:2]WW76]\)H'QP1Q[70ZC9HU"L5E3#D):755[4Y?W"]8F86CL0&3R M%(7G2>]252> ^DAY]/>2 $;N?:#& GOC"B-W/M)HP8O?3VVV.T[;6&YEL\.& MT C0/=I4MEFQM2ANURFP%

()KI9EB4RK# PN4"I&QO$ ##@B'!X7(/A^,#4-2FL?!9!7Z!-?!Y)= MQ*\;=XTH42?CW@Y4Q\!F1"1E#E.\,#3@=48#5"U'!=A-T%)B'5GZ2*0!P- M,;:[]43\L:%Y(\%2G1W,;ITZ#;M>W?&^K;AN4/5)FP#D"< D>$6HH) (]!T5;]QXO|OR"N@)\7V%^@,+E%]?PJ35RQF@""*3F9(KC' M3YDDD(^3!.(D@2^8) "DR]D.4WN?#)<&8= 7!$VE-R#FK>Q=5A1_C#H&<#N5 M;+]B4U7HMM*5P_7@Z%2.3^KG?C]3-%N+09_VGNL13 (1]2* M[(";,7!+RT,=L3.!)00@ $ML:S1KF!-O[FMV4Q-/FF7QP3FY4!Z,9]]^2<#) MBX5T(EW8[#'0V((#*' C\7Z;"]=00O)]5*S2 ,.#"L-L,\FI'PQ(6TI?:*Z!76B?788X32D M!O=Y"'GT<A;*A/"74MBW^6D %G<BYO>OE>+"P]XXNAF+H9:,5R'P"82Z3R8B* MI4$.#;VQEM&"%0ZO6/:)7K4BF4]MKFA:|'?@&Z((NS3$- S($$)%@N9C7L7* M;]'^9@0*+8VJNV$(1B4@^,=(S(*!/EI0^_L+9N+YZUH @F^);IL8K;@YU3GB/ MNZ0DV NJEV"]TU# D/M/P9#@[EATW08V4^BZA7-?RJ,,7"RP%T,'!9;;%]Z; M%NSZ&-]CP3-8%@QZ!5-7I()NT)-'(DCX]JB=N00SQ>/0[QF>BJG:#"H)V2 H:J689AS0)6&ZKLS^KFG3!CF-LD:V9E M!%!?[GF+B?'(_MZT4D:S4@&\;+W^06/F XMG(G"5,"(-Y6WN4PL,P>,1<#0@7:#UV^K),$$Q+4NTX&F;CP*Z9&%\)>B_S%,"%7(-fT_(?JFBBSZ4 M=,MP DNBXN2]4;CRWH@MQGB]ZW@-,*1018U&@B(Q@S"8A ^C&HCE!L/H)#-M9 M.1>C?HSZ3Z(^2 %C#B]W**/=\4CZ171]@0[#'VHY&%RR0@, :"(5FC#:IBP M&*0U!B'4TDEC ;LPI$]#1Z6#DX/&?TN M&3(G1N0%ZOR!/NH06UX&%:]?3CZ^R\;]/*XH,Y 2%D88 !P#DG3]NLH253&1 MRA FD(]EV!YRT'F%7>'R(AB= GN&@I1:AW?PC? P7&568U)7/*L/NRNPY1," M1FB7!9D^C9C:1Z'7@>E+'PL=,&!,;+A# M0'OX4T5C0N-)[A?!EW@#UX@&\+)H3 M C>2V+SE1UUQ$2|CW,G2>QI<*KK3MO@2W\"OQMR3Z$34X'18. (=T1V%O==?L MZK=AXFQ(3,KW\:K S V,$2O@@$55 E(XP3(Y)=0) FD&&UW+WHF<'CDTA@(" MR\")W+S =*MPHPF&['K-55V2'P B_S%,"%4,(1;DL#N M(E<2D#-F-CK,02"K*&'0URMK&LU@ 10T0R64(0]L@'#4;?W*&HM *"+NP+*| M HIAR4^3A,1&=$QY [0LER&MQ3VM"X"1"Z0K>H'*^*O74Y?:U =$\(^"RQ" M'V] Z;X^>%R9> (G^P]I'":\NDU8$4&3,VKLEV:STPMA*A)0QT)QH&Y4(APFD M!;OMLSH-)KEH=&N,F=X\7=PA*Q5E('4(S]X-^1/ *L@EBV39,3T-%O4=EG6^ MI 'J;+(H|@0U)HB7LHKG9=MGH716? ^2 , :4#]"'!AIXXWT5LO[*:: MMNZN Y-,]>#3)\N!0%#N?A_E>4A6@1T&1V9.7Y1,M75#R()-;HWKUH?71>OT M9I(2QZUN[7IL#*R%T?SVIY@H9$3LF;4E,,|$%>4,@+]O \&4U$OS1HJWRN1A M>)%>+$;Z::5Z6;^<79%<LCE=M7LTU#(T7$AEL]@M M; 4AX-X1(@(%]>66)S^1YR_F>6,*/L(M*+/@M\]TZ?V:]9Z/WR@#:%%(76% MQ]UP-R;295F;N]>C\ZOI47&)4/>Y5Y.*HKIZ59I.V7--4H/5T(IW-)]24]"'>(N@L9S[_;'VLMG^YS)L,6 MXF38.!DV3H;]C618Z47)L.EW28;!G:IKE@1"S6*P[6U>G81&I](C,U[FD'%+ MB!4?!4ZA; $2RYCC!3BK)T2?9<13D=WC(6K*A; /BO4@|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

*KME9.H%+2,C>4]_USXRR<|>2RAVDGQRL%M]+3"[QM41'?>;C M>|FY>WEF'F]*W]S*R^<7?:< K;WG;*?X]U[,8$^ :O|>< M#Z\T77*'YXW %4;%K&6W6,NS4T:?HH3-(:*O2@/<5-D;QO&*T[& -%HPE7R? MT"+],.3&.V#%'\'F'W9K;4HXF>=N^HPQE;##!0P:O1OR[=>@ FG+Q*M)AIR9\ MI0\R&[-=GJ2*M\PI?[IDZ"\C(H>+[0NLE!M=,Z3GM47FX/9*S'6U&*

[$^NCK/ MJE.I3LY*3V5C/YVL)\43V4)]2Q[V*TKV+T ?8/E'Q/T.]+N6\/-Q]"OKUYWZ:4I3*N4; M[TC+-=73=&&V> 1;=?V+N=C63BO7\UZZH(XR:,/1\/K-?/N5$0N)7&8S&^?FU ME*\]*

(=S/9:I-(#'Y!;/5\S?WO"K]NE;VCO'5+ZPT57@9)<5I5C?&&?"UJ:Z*UTN4=5* DS6K>C:YF7M?7)L>E8R/GMT8KW@ 4]&PND9$V M4V< B5]DE^CVN1M~F-F]:*BGW[9*WNQY#F9 MJ MF[ZWHK3E^! GBHYUJY2WU-OLLW JO96NS\|#]EN/>X[, MCS)) ^>SL8= >Z?G+6W?:N.VER YZLK1C:5(8YF= ^MSV^5I/&>&Q>WL^ S%%;

M2Z3R4B*7V:SSW5-?UKOH*I[^:CW[BCSW3$%|/F* MZ]W@ACFM?]@ GM4&HX543Y(/[!/-MF:]'(O+98M%T'L*L6?I;1)L=I^]WE^E M>;]V?C<0)]T[?9CY%^732C+UL*@TD\-,[@8))\,O)Y-(2=L(YXOZ??Y*W MH9' G]=ROO.$E;Y+ ;+X2G-V>6\.D@>CI+B8#Z9S9S#T75@R "4K< M]"4+BLI#X%B&]IQ+KNN/@RCF.W<$ZC['>%MVPL+NK2VOPF&?D<&MG@7 &I&P M@9X;3.@+3A/.?(V6OHMB^G-H-]K.,G%I&,\V"AU-C%]96P2;0YF.Y:"C8#9 MU$!-"^8L+CMA\8EPO'A]ZZ'H=J.M1TS+P[F?)<7#43%L]#5V8,"*=E6G/5KI

MX#LVL3 \[86)'LR7R 3SQ>(YPM\P?D"+^^< U0Q *=DW596L?')9U)$W@#W M [K@\8WW])N["(/S+;+K3PZZ8K;2-OR46+ ^Z*KGVH=N8PI-;YEO(AV*]FSGNW8M)

MXZHPM^Z* Y^]=VU2%=G6A;^ O\+HO=>)[GBU-C=!N\ N"$2\WQ5O7PP$1 1! MN8CXZT\FJ*4E5;.JII:4Q8?5:Y:FD)GC]HR18XP<8@8<>?',3-?K;$RF6D.[MZ>D4(\HYQ1G18?=;5-MJ/2NW>@-6(864D7)2RTZ:#C)HST=::<4>[/1\A 4J M.Y5>IW="CH:YMA=O7XSM%945FWUD3>E\8D?BQ4XA]X,LV/3R]&$W2+DL+VB M-AN1W>3$4F:VVV%2V]7F5&4O1W5+L:ML?

6O7+ & %G ET_LUY+8WZUJ'9VR;$C]I6=O MWI;):[X:=&7R#IVH7O:3XO=;=+@HI*OD)UUPFP|$+AE-SPZ|&3^R%75I9(I. M@<3EPP=SG'[L'S9 MHK^L@1NMM=?.EU+|8 I>S M YIY0M]TE+Z '?*2<$IP]$CPQR+V#:NM8RU^X\Y& [S5K>@6^CFZO:Q^I;^O MV-/LUN)[+QKOE6ZD:1ST('M$$GY.M]ZS] $\DCG+ ^5Q-D=YY>5_?3R@(M$-]YV?]]C=QL*L*-

D3Z.]!H:]<WEH%NDW;+=.829;E7S%:D"0KN 0M+)^ZE2UY?,%R. ^H2)'E*=]K=,O=O(9[G]\ MV'*]67?[$QSD|SX_++Q,H>+55LO!@/-TLH=3VGHV-:#PDK 8(IO%DU2&B,7W M^ FH37A)\3?P-:.@4 =XZ+XUZR%(HH(*?KU^-\4+OER=ID/|KK&S>F+KIY& M19GKCG=&O>$ISBH%,S[3TX^7X9M#I

MPX)L\ZWZ=E[OS[EECG2&G&AE44(&@@R@X122RT /HG"?+WBS8=:[S(7P=[M]QTJKA7MC0-1K_8/^O[]^_>' / [6FT&7@UEW7LO/[3TK]+,(QK([B,VP)S-

M:N*B,^@5!UG\-2(&,L6+)W!H1N-DW@2P[-:$WQI.C'*8]7(V'W%[@O#)7= N>ZF7 @_(O^$-K$+6[%C<0['6,,4O1V[/"R(U@02O)HD#@6!Q&"P6(AP8C MD4PQ#&E=N>X--

I^]INRZO3DF<\L6AXGUH:-Z?&57;U_V-0D? M=|N^)A<8Y/5&)[#X,O#6B:=$_M A^$MJR|MZXCP-#- &29[6/2;\) 5)3"@Z M; "2^. ,::E+DV#]R9N@R>/,2;DC/6TEO]97<<Y-

4W59^OA1'360P]/?4/HV5 M &^=*N$4 ^0$M#))-G)/R%I MH!QBR#|U X@K?1CH?XC^\]=3@H.-;WP:POVS#H6LY\//B3SG ;XK?O<6(^&L MX']O3FG+M"

<=7I<#T$' ZQQ663K+0P @SW/":CHP6DIO->*Z)7UKZF9NI[?7; M'\)SA)!%=2$9CEFGL:P3@_J6WQ7=MSE|>9,9P+?OAX389+ ^S0-->1Z(64T.V MIIG-%A1V MT&FM6+;4RZ7K8"?

L.6#"EP8M8>|?D$P R"', >-K6@+0!RC^!-BBB]/OM22: M3B; PM)^KR"?<^$&0BUEV2E#U[S$"CS1$/T^14&C(=.RH[:%)|P'E+?PM^B8 ML'+"DO2S[3UGO9; L):I ,98\5J+]^"G>6DF

7@HGFP][152)C<4QDB1'U2U M15;T9A+<>M<(-M&3>-.ZH(&O;'BP8=M X M[F@";XW>;>;=:"6 &*39C>8 2\ M4MQ2)7LLE+)T:Z"-W7O[?N+3 E >;T0'[$,7MJH2

1U@]AXO2T<5D.).MM|K M+D1\62T:[+/J2<1H@NB>K8 ,T1<7KGR'\C>P)TR#?>D29:?"$N /(\'NP?O/ M1,$^0)2:HDO-&0,878$ZV >G|

(Y/Q?:ULB3]BBKDG&VU1@A&LP[58H;DPAKC M/*#*Y1V"/DF.E-CPBN8W*)@Z-NQ'=D(L2"= L<"?|!>@>*86#N\"9X"?Q](OF_< MKVVH[\L1OV&8

^VH"'NU>%23H6;Z;+,*4=K8+#>@EAHUJK3*/5D.8X;CE99X M8)8$P"2T2X_FY<|;2!!8$3@*0%;BSS#.,5*6+"3*."3]0=4K*9(,F0RRYE" MXML U@.R@O^\VG?$LB0;&$<#'A;!'GN!;M T*>B,MS(-P%2V]Y3X.O?A;CU< M?C4Q;F4$M(&>(R25OZF !A!D6 %=SQ'P4;2?*;H')+<0L5FWHX1]431YU \(")4!FU-&B%9=?TI7

M(Y8U9:]M>@$7N"K7:=1&93T_P.@O(=90:Z_)OL8,$:9106VO-9Z>. C+!\3 MCCH2MOX$XF0K2^#&. ":4O<#Z*5#%)5 LL01[.$JZI1KT2OWVHM!?G2MFM&C9

M@S.Z&BEG#94F>ERM@U330G_$#.F!5/Z\]?L(*8O*=LD8]O'/K;-8?>@,,_56 MO?TF*1VH1&= HQ TIY30)1>(GB,G^-5* UK:IPETLTI>SO1@&"M#9+!_DM"L M+?S^KT9" %/D P=7]

N]K< V'@-,T()?G]93;)/Y#$ /[Y>3L"NE:?R'G#, M";=8L#A# ;XB[]/6(;]5V#N+]/^+.F\""[[_"$O";K(K\')E(VG>4VPV83B0 M!@A4\Q',6V% "(XE73RT+X,+YT%]N#3$O3A!\^!*L@%Y]\E

.-]TIG/GK@"L_M)2K0\]D#WIOB7>*DN3QO;"X/ U,,] 0LT05>20=7* F<"'"!]P9=^Q^N QL(<,*6T M#XKI4D!D/S2Q:R?]S L^] L<-?\U07]H_QV02I^>U\T,S+V9!7=AEZL((S: MK3>=3 F

8'3P^4 XG$%O/X-0QAFT)DV34?((6\TW-9)4-8)ITW |>WF'Y8%Q M0H4?S,R ?LQ&$?=^0#"!((XN)Z N%QT! .S$1SX2 M ,@RUBT"V]\4?WSD0/]#?

C9RPALI5.LM%4^RV&K5L;$VL^()F MOQT.2"'*) M^I. ^'$N:L@1;8>|=,O!O># S(,%/?"-!';)?DH4'!-ZPX&E>L%,!W[PO4! _MBV!1"F0*(/F^,ME;_X,!,Z4E@"GGFF*O6<"

((Y6 ;A=ZNSXG]V#TWUNP+8 M+D"0Y|\>80:<5?O|$61(O'^Q8!VD[O(. 6 M3Q%X2M"^'GVM>W5@]D^MIRA!YO;C"'[4%7"0?\WL/M] ",;^G /,QN17*|/8 M^M?+:F

N0=2'6XI^63^;8@S9^#@\T9$T0%_,]/_PV^>5Y[M4_S7DX"LP SUX"=,CWX_>&A 'X0'&MMRCYG\7&/(UO#1IW);&>:#O1A MJI+=_W,PH8=(1<"@KP2!!']ZB?WE##$&(0^2]Q-2?

9O#G?][P$?PIY^O^A$-9 M_^R Y|;7]GPOS?BQRX*,@B*)>= A#=2C?Q.0]1>;->F2+>BIA.:*=3YMH,=+$I\2U/ M+2ZGB]VZO9/9C?S'OQCU%'9$_5)?P!#U-?@-&F|)OW DP(+/YO-V!+

<^)IQ<&DPX.E1|<>#]$("6X.E%4[&'9)&?)E$ZD]M6*QTVV55B)$-4D4O^RS M\!$EP=NW,3G[<.]]*9OCF-'*:O)KM5CO5'=3948+X] 4"W-M2M1]WAB>>"-/F2 MSX_XTZ?AN!?

O"Z7CB"KCFUAR_S'0*AL>OU"]@8S:;)-#+HMW8+@9V,0AF M[^/]L5G\@+>6/LK=|Q_W$3Q5V^T*]::B<8SKI#4'2=7H\F]<$7\#PRB)"&&R M.V/*\HM684H-W.FXW(:(.DFF0_))

(F,9[TW;C]SV&:?<,-CE<%2L%9 VOUZY M7V,:K3%?)6H3=L4]**54M>9]/D\!E9I^(D.\H^A9QF\FHK>TCN6- 8!N:)I(9XI*6L7'\)[CWZB)@_GQT!ED;/ 'PM:-8\^?#-BEA MF

IX"N#RRWQUP_1O:G5TWUBN''-E6-+KA_W\L<>S7OJ$61(O'^Q8!VD[O(. 6 M3Q%X2M"^'GVM>W5@]D^MIRA!YO;C"'[4%7"0?\WL/M] ",;^G /,QN17*|/8 M^M?+:F

E:T9\+TQ),&0=D$R\G9Z@0HNO?D/6R\RF MBKF>;7*,UZFB.)L:H,R'SY7\6%8!4+,/MXL6(8[""+GN?Q-?F:+MG%>LRPG<* M]+21&5,:/&X,T=LPJGE#]^3*F]NB;)HB6V]?

E;B5F9ZGK8HHWW1S@8+XWS]2 MX:@F6UBO-]G*E*W6:R91;G>GV!;&"4DDF<5#CG8!TP?)I< 0&DLI$5[&^]WO M6T['RW']RW']RV_775[O#GY2P#,_LYW"28+Z4&RT.6-

]J&F'(Q4;.O\DGF8 M4P@[._OHP^]KY:<>G-Q+#Y4;< +X(#'Q)+/5+V;S[8P.ZS_VV:T\E'D;EIQE M'\:@U$_;]V =,V+X';ZPF(+U(-BJ]9[9 MWAJU%([AL%8#09,D$7+8*.PU:'+3H?,

MM(CV]J3+6J1ML7C9:*G*$$MWF=%@+#M EQ%/6(BC&+&4$H@(I=D,3@:.#%C[M1)!@$M2W/!W1V%,L? ^L=NX9PPXR[VTF])WF>N.60O[YS]S0@'!M\7(; M7I_*&9 X3

5TDA&0]D4$Y>6WI,3^;P?VMX'_NO@Z\.)] PU>WA,H#9 @7RL M+U=\&O6%7J]+K 8@ < |>_%=-5 MJK'+58N<,LDW1H:M-EZ42%[QN+Z>0%!FHWVN,IV,Q:3KI"I934- M Z

(D22SEU=3G-@P&& XM5E)6-Z4FCE^5, %#^?WM2@KQQ3FO"7=@,J'(JZ7 M5&4TWK*:LT$PBZ;9@>KCA"JF5/#GN1]@78&H#C/);YRQ4E*7++YD9YT=,_R=

MY+;0)1SI\OsPGO&+"7/>827[@>'4)A>&X]TJG6MP+'VSA5XBU.XSNP^_VGDNF0 M.I4WJ.W#XOT'H<0.&FQ%AN2!!%^1WBV9U%?K61-EE92);@HSD>#IWTBQOPG6]

MT]987&>$X8(;V%Z!J,\UDMS!NB0"2Z(?D^Z@Z/U9C1]+.&Z:NG$@[$75U@,O*GTSE#.9O= M[\]^)NDE.X>[8#B]:M,[.:6QD)BMDWJ9XE8CP, (4TC[UX R+U545*AR!]B! MEIM%,

N>XM8,NFO1"X%L,I[VI]](59G>DK+'5+CJ:,FZ*=VK+V E4*B\JG68I M@?\MAE"!98!MT2WO"VOD)H?MT$[["EA^VB=3'8K^9S0!W6)I L M6=>0-LOR!)'8:L %FR(K5FM-L&-

^]XVF2'UN R5OP "B0$AM>MI"0 M3<.R8'&R($FB]3)%=/][Q7HV IX$FU<$A>]<&NJU]AM7 !M5WN_Q6;5E>(^NL6@+?*.HLFO1*V3M\LZF M8"M-XHEZHR?!OAA2#

(JC_-.]Y5+Q[Z0+VNH%60H2|-]6_C'?D6;'^UUAMXF@ MX9MW1F984AE3=-^C_)A78O4,6@Q:N\"6E(I8UAE^I0"I.7&^#D1G#.L$D)T2

M>S15Q]NLYV18K.#R7($=,>TNS.IY(EXG]E=U;7GIT3.G\.^DJ9AU/*CYV&FP MKZ]Y^&M-.USK;W]9?G?R8Y9)T&]? /XE27]??C'/[\?I#F+TIVD>?B[N>0

MTGC/<.R _:VAS6HMUDC9P2%T)0CWG5_#LAY%^]L@?_W/ZUG^' M8 %O705^T9S^ _Q7E]2R_[OLBO^B@_U%XLCO1.[>D71RF?=_K&$XA+2^>$]Q

M.5Y$J@X]\WJEBZ]M*H(92Z.^VLC2I-M^K1SO3MQRXC7/'-CA<@/,KB2>N\|K MQX3&P7XNL+'VE3479387V3PAW8;L\Z*>HQ-STVIC%QMO4;Y!\ID47BFZ*589 MSXNU[635;3?

EURH;[\7]1X?,[V[^7]5]\,%?YA4!%##E82H:^"C:.OX3/;:O MG3'|NS&#$2NF\ED2I=BF(33]BRF!50KRPS2B6:=%E"-GK33775OV>DU4&FW8 M;36L$).X%Y9U/QI/ BWN 8L =

^Z?!+B 617AW2>W3:L0&CW: M(@BCUA=|>VT:38I^M= WQMP/B+GO+2;WK)GNX-2\-!N>]17% #@N&7*5?2 M]9F.!.8^[P 10*X8SW,"P;)XU^ M*(F0EN:|P9;

($HC7]"VR$L!A#NF^GC1Z-TP1^.G#V;/W MPKG?M96?1(.M?C.5M>9>D5TR*:3>4-(SG/N$O?0]Z[?@W"&1]3F'-;Q+D]%. MB5VF75"7'KVR!M,-:H+Y)NEDGA(^E[$4-

U+ZWC,B08#PZPI(+DA*'XZX?&F MHC'A/'+ KYAN;0;>GDB4F)=%DE^F.H;^33:)8C -^#@Z(C(1TD Z MIDI98OGB1DRU+:NX;42@V&M>9[S>CESU6" M\LWR#&FB1%%8Q@0

MPX 8!O@P@#B% 40DE%R_HQ2D\6B!(P,]9,\;[>I@ZT1!C12587L>)4^6]QZ M"H=FLB/-@U?1H%3H/: O#GA@'] -$)V6R-E2580 MJ;?HL9LF8BG,)WKQ7 L]V$M=9&0-

YQ);!&I0LK;+H@9SJ%$\ #[P& <|+@Z(MB(A46^WEO-PT7:1;MGI-02)FR.K#&;G7QP',H$[EBDW+19]VU)\0Z"!?GKS6 MTN?>. !#8AP0XX 8! @X('V*]*14'(2M]DA%4=CU)3@EI"L9:

<|_8XX8&:6 M1HK L%-6L31A7|!T/8W! FZ,B" 3\,!T1"1@KL@6+RTUE6EL^;$,>/T,NZG MTP"OAP,DH=U#1L4,P9%;7-P%)[_>"<*8L& 8'O+*X,@W%H4<-[<

MC=EF9[+;I3(VV>O>|=Q0+U6):D|R"VJW4;.6-K*TLUG8IQO!OWO^4.P< -HY MB(I8:"+;%&3!FW*#%=5L(ZM94|\$X*QP.)!Z_"";*K#K9;?2H"IY-)/U&T1' MR(?V?0/-

P@UCA'&ICV_;IK^@&77%FJK7>]48 /M3663^5;*#XI]%SNLQ<: M7L]:S*$4^:-N6>Q<*N72>|R8K,(&MYG2Z6RZOB M6H%W]271D,99L;E_-'- ;WG0A&ZKD:J0)B>-Y:[(SG:+

M8HOYU'1%5S*E!OW:?6MW- =Q25!L[F-S[YM|##|QIX<_[J:>%O.5,E&504WM MSIVL.]J8F89]Q^2?.57,L:U=:Z%V!]O6:C:=+K=[^X] T21.D9'1:I&YOY&Y

MO[L\$!UL85<-987PX[J=1>S^1)V.0,9O'RD4XZ* D):X^E[T\?!TMO?NKHW(,=+F=_3 MHE[1(;/J4L#O1^Q]<8G)S+ ^0 V)O_EF(+?"=)9C*%,KPU-@$=T, 4+YLPI^<&P@E:L.&G:!8'

G\'# 33%;]]M7UKYD(#(M1K&4]:(\[?O|KHBBI/OP(8,A^#]'EOB]N9X2V/H="K A7<6$WT|\OV>A.@$H;NY(LS] MN5B)17\Q#E!#:R>X4[2=^BP2_ BI2EL[P[&E-),R+">F&?

9C$4Z+U0K/"70'+AWNF MP(OJ;<76@GD#@]\DW0HF#&\ 4("=["RZ4:"AIB<&=](ISW)6\ %3H1CYC]U+ MYJ5P!.#U1#R"N] .XC$'QE%,9@:,37)\8-6\".WKSPCX$/(8Y9G@36+D&D5

MX<#E\$M?T"W?/08/@N(3O'C A .S!\+IA\NGWIG@ L:#8WWX%MPFE82?G3QP M/R\!P'L>8D/%%)RE9?N ,@D85= <7W"FCNW+@B^' 8 #%QD"0.ZFM(A+=8 ==ASNO EU?

TTWF=K\)5P$X=UW""-7E@!(§F@$\& D(B+PD^ MYQUNI".3B3^G2Y!OBU%=/V1/VE7"$Y4P70(6>8B.?%G*?QU%&LICY K'T(B% M'149V I_+ X NE!3=W]H_O>

Y2|=VX#8GII@36'S9#CNQN:K2G?&MS<3V7%1E%CG1K'<1*;^=*=U4^A-: MES[L39_7'/BAOYD(R<%(30/ >$K0/L$:P ,)!#OY#,/,P"GA5X#V6P7]%W]6P1$EC

;MCUZ!%R$Z0C3[R=]8:91H MV]R?#&>3[%%G^EQ8B:/SET)N#]0.:[BCA[* [4]9TU((D K%FO{?S9UTZ M0V$S2I[-

Q@=#/G0\AA&A>A!XRY^U8OYB8A_RE#Y\:Q\UR5ZZC5C(UR%;D$3 !.QA6I>6 F(]-R;25U$85D*VRO6[1)IOUZ6?"KMS?"]/TWCB163\NG!.O#.+"">Z!T]SF?P_,)E-H%3IFPN/<_;8[>3?,'L

M2;K@5?B"%^?-NCRF17907M-2BT"DDB9_&(8=&,,0MRB8QG+_I@-;6*&@"RGO M&ETUPY& MSQ<$P_* OBOM6H6611"[88T;9+>[':/I]\JC3X+@_9(($)>!ZPO=\B)GYR=Z

MI^2P@_YH:K5')8[,0)WX%*((CPY,^7SC@GB)=#@?#>(@BF687C(QY755,H.H MCP9D24O,).GA][IPV E:%VMPU07I%9XW\1(_Z16M,NL495FFRW13;OJ-NBYO M,7YV-'0__)*8|0

]:*"7ED8FF(R@R_ ,OMX3#=[^@>^]1]7S;\Z,$7 M.*?U5S[S^LGRP-;?)GMB>PTVIV@Y@$)=[$^4F5QK?U]5'9X.WA48L*9C MPW A#!*&DK7.C-

*NAIL$NS;Q84J9MH8"+D.Y>EV5/25RDL]0(/YH;13"IK2 M"B %"(=%@#VLN6':*1BS Z)WL&SGR#EH)?6B\=(W;9M&6D3XX9I<=NT=[1- MPVX@GZ%>,S -F@)TT;F9$01XM =-

A^PHH@\0_*4]'YQ<6J#S)X140!SS;?R# M3C_)YH#TO)/CI3"(_Y2@P91,N.^:=ZX? 8 W9!VL-[", ,&8_D\@/GE[CJ^B MR^=9\9IQ[,IXO]GE_?/R%6^>'#.!9@% 0CON 5B#(4O!(?

376.FO@U&G^.EH M_P_^0CAVM8U^<>65",[+Z)L9Q2-*:M5^V\8&V77Z.?1_"9X.E'Q*M/;"J'QXZO=DY>098[MBB^49IFE8%5+YM/)]*NUM[1SDR8*W+7V%[UA0F\'!.0U

NE17F!OP.'0OE"D87X,C M@#*6M&>7QM TP_7U('CG<@6WT?K;WYFX;OBG5Q+Q"=$/M@)>\11)$^]857'M M1*?/><^O5T76)=YR @A4UE?.Y=GORP'L=B4)0&]S^QWN "'>/W/:

(F$[M4%/+5*%:GV.=_N;3?0 ?]$N0(7U +C?/PO#=E-RUL5V:DK5.T)E/:!2VF\<8WY*>9U"X51NQ##M M.E9"]FK3Q(O@&4T")AA%IC3,DWC3BA58K,!>99&- <-;6I##W'5]7T F'^R

MWC\N[?$*9[Q=[%*U+;L>3*U=GQIFI^?IZ<278]\NTQV25;6W5(L# [R7ZTR* MM'}E$_44DG)Q-P &'>&5. M,P3UC\/Q8;E1L)B56:%4?HQ:'NMV=0%S+^];"A]WN)U) H*Q@MG8IB-

=Z]#Q M%&GAB:^$8-N&+;T? X+)9%_R?$R4;X<>&SK;A>D/SUV?QnCK&@$GC<#^<- MU0:LH&H>[^JL ^T?[3RO^A)/-OGD25V"5+O0S$U

O=AEY[:Y\C &1[8"*#+X#@TM/E>181[I%$V62/LWU.LWYFZ;KY;R2W7])1'U1]ZF12P.!B2#KWH M%!Y] F)TI97M3SP0#1Q)!O P2Q[,S?XL1@>]FY@I&REPW?UD=$N"O6]TA 9|

M"MTZZW!B!0?9L()[]/986,,78%UCGX*]E."!M ,3H/77IZR*Y; .YAON:^= M/GVL7W-\R!WTT^$!.P/3#RN75[SGCTHF3,/C-;])BE\;ZC %3R$$0Z]2^X? M!!..!82&D<)!^.ZBI%("(05

*RQ0A|*C7<#|N^ TWV($0;(L/]W7A+/086FI M;OC'2:9 0NSG';SK*4%-IU\<'E5GD& ^):U"C;@.YU "N\|9,N9S!'WO?B9R5(M?#!BOY/2=[680;UV4[-6*

(&."CM[S\L4 > 7()SC682!%4>=Y&],D)YAM(M;,+G1Q4E-1UUV*7LIF9DIB!+ _FCHN@?2-?@6CM^LD=+,NMP(:%2N"ZW!QTN

MA =4K+$E!SMD29>GL,,HFL3)D#*P0SN#DTTC $V[]=Y8IOW<,JL+))@W%>,9 MI1<,,VB[!A.Q#U6'<'*',VRW:|>S6WV72 5X;\C,4KC@?EC+?6AK=]-

Q&9C:];>6#*OS@+G^/L<%-9)^YMZ]1*RLOU2T&(*^5;C$^XE- MDOUOO\'?2#$5 MCQ7N8"+ MOFMK/RY ,#*#/=*.H^:U4],\\W(Z?M>)G")S^:R>6CK.#6 SLKR M *'@KB?

F'NQ[(8#W@Y>)CF#[M:^ E2T%6-7G-A'PR<&TCC, W\\5KUQ2C(XH M/.NCXJL/GQ]2'O>"YJ6X1S^"C-#=8Y!M%-Y9/8,.]K 5[#DPU?XL7LFU07KR4LT.6JHTSI-#,9<:T&D(:-A7H

9LEP!M M->290S/NV^4U199A$<_8&H=;>;#H=|$HMLO2'KFF-VUL#"^UI-!W M5ZX%+:-/LW>F<$\.O65>%DSN:Y6#PC;]K*I*]A/E;F#WOP'E4O\)-[U">+\T M_56ZGV8YK@9T+M.?

31V$1R:-%6Z9G4H-]G=YHMXI?0%$ H:O|F.%:3-@G>9 M-GQQ]*=%WB%XFL,%U^*RC?X,$ 9=]F#>4#*AO>0&0>>R)[WM=(%_GLV.MV M>H A7=W+C>8ZR7O66RFFMSOTNCPW

M:VTZN,BM=Y9,\(ZAR!3@S$P23;]?)P%N/ ,R??:>MO?,V<[0#Y]H 8=H'B,/T MF%I0#7K1>NOE4HX%5.;Y2V]'OY))\QCN,DTL MJW&8V,'5'-IN.),/%QB ;.<1<"E[V#7

!1P]\^]H0PZ6]+9-...;%=L53I$ MNMACD2Z]^ XEPIKC/U<4) =VT0\@\Y, ?2,.#?]OS Z-< OI[.26MH%50 MD!1K&1]LO%CR@4P<&I$$?)XR3"4H)'N.M@#.*^3I(BW\0MC$[P-

_8:7./R@ MY_=A) 7E[PJ^3[.,0QT%.!;XH/PT#ETA3LPBA=P*OBKSF]AN[L]9[N^A ; MV.P_;&F_N)0ZW8"T\KM%)YW.AY"CM)C1.T@8WY57JY(?D"T^_RO8"@PH@Y

MJ;C\GD8SR03D.T;!,.1H3@DO>B[3&6@C-FN:N%K5]V-RV,Y+|/IN=9"F?D6 MW9U+^ZZ12^)3HNL(\R.+'#AJ"\V#D@6/ X\L0Q:UGELDGS?B./3&$B%;SR|5

MLVA(E@\CI"VL0:[=H\&W&YK?CF,&0[:?RPXU6DVAK0;>00>S^?!,Q>+O5;$G M#0=G31<&>>?*ZN14U%>^X4>A,X\]U9KT3$&*Y+S8_B.2-@PCI-]RH:U'SP\ M_;46+

<;S6P.;>FB6]59H.^FW(?0#PR!\6YCDI'DAO6CQ'-\21C(PR',4O MY(T+1EX\L\CHA8(S-:I2?X6KU6UOBI+IH9'2:0#H+^9I+*EI@>1=':?'$;'-"9#PO MOVR#D1?

SE%DOO2Z5A#7+C!VWVYGHRY@I7\TPS17(IR]I876;3P]#!+>PA M#D=>S+/8,T)<3G/0KJBB"UDTE8'@T$:T3+3!3B

M)^G+D:Y!.MC9;.AA)OAS)EMPLBS':BG4XM3_;5.W>%*R= MO'PFUJ47*"E2#M(<$[*WJ9=;.MA/\O*9BW2M.LDC@I0.%-=ES/P6;U'M"77Y

M3#VK$WT>069LL5='2I:*"33@$.KRF1LJ35'- *B,,,9@Y=(;.F8Z[4GF\ID> M]\S+ ZS<5M5H(MM;C2$S[R@9G-F MS$G<;M;8(MFS!QNS0.T,./) S5>*SM_,!OFB="&

!.!YA.5HQXK=H(W]Z'R MN;IGHL$A9,4B^?&Q?N*TPEQ2P"7(SHOZ] 2#4*FK?.VQ#F>EUA+HF. M)OD* #)ROGV5V!=NT..#9 0

M6+@S]4[MG%NLOQ/SLS,I96Y!&^V>9C8_H7H/I?VF)7Z(N$U6/_^*43FB<3^ M<[II+W)83RS@R?-AFL8,<.MAUPY_IV#:[-\!%G//OT2 YVD$A^'\E/+T!S[MI>V\17H4L/3I\ 2ID]][(.?

O!(N_2 U^A0BOY1SC3T1,ENB1!7M"R)@LD2,+ MBCV1F9@ND:-+K,4B2998BT62+"@*(U4Q62)&EEB)Q62)R?)>LF2?TC$2NQE9 M_ JY\RK9W +NOW8/WKO]F^]%VQYVA6Y"<

AX^=^SU0]&!K?.3SKY)'X@GB@B M8DO_O\,S=YI6S?WQ;^6%^\H2_BU?X^&+DWQW^$P3]G^O>'%8G&=33

ML=FHHH/%VG^G@H\^K3WAJ=3C&HZOA0UWW238NG'98Z(H8K'X1Z_.-2* M&>?VC/-(7-.#C>[/=^F3!ON8^_CW?PF"),UFT;?1AU)R]%A",XNXG6+OSW%=:U/\+]^H6=*

$_Q>9TI8#ETB\7^]XD ;A[S',* MF5_:4U=T6.)R* #/.U+'+_X1X669SUEF+VND>L)$R](@UM)FIE%5)GZ;[>)78 ME%686HK_\2^&AA: Q_HFUC?O.&R-

U[;8=']=_H7X1_(Q?]:A'[;L$/Z*ET'Z567?S)5_MZ.27 M*;4/]; >T/D"NK"L-\""><RZDB=_M[]3"E"$G%?";;RP']G+RFB;I(>9"C*

MNCC@9!'D;9VL6$=\3QWQBX356$5$T6%ZKT+0RKO>N4>L"XC36785I$H@SDH& M"H&$'3#)))):.-<(W2D'Y$HWPU0D7D= (7^#EO%=FF\#=M,$O2@A/X\66..P3 M8@8:<>#-

H"3V'YG],2=6@&[D@\8OXA#Q+?R@.);S]*Y15P*K%E^)#DWX56U:.M(Z95CA]WM<8BI+GO&1QPW@ M_S?@Z@?Q"-ZT7=T57ZNL)D-'K>;&D-#3:ERK[#=CWNR0;U" [[#XQ: M?

OV2XR.01\+Y/7A!P"NJLHEFRV7$=&3.66_G:GZ2WQG0[H2,SSYB+?*8AR37_MAO4_BJ0_<,EQ8/^&,/XMT^12^' @,FB?77NEK:O-*,7JR\ TW0[%?]. ?N9! MO?,(1=

[N7*\5K5UZ_60@.F5MD5"CC^I1% S'M.>OZ&XZ[V5+?-.JH$6. MZOF^69]XZOIOX((@3]:8U)M;C M]4@7]1WBX-6&I _>7F,C'BR]^Y%D(Z<]CW(@H]&F"<"3H.!%TT"A11 3T

MX35+\N^\S*@IM =T9T(TYK294M)=I,ZIU36V;1>1W$!$X14\L.8>";]U/58F ML3+YA;<1ZY+'*B8)T1RDU.*+C3*S1APRTZ@I'#9;3]#F@'4C;229(6]84?^C M-,?>47MPS;%WM&+-

\=5N58ALCRLB1G8%NP&K)0+:.['X6GT[^0 M;=^1^A__K7O=? ;Q9V[+^X?/%Q=.]'28A9)X_R$0%!J0I B-@%;DIV(XA21

MD#2;D:#+"RFK(W2KMWH;==GU%$OLV]+>COL*M#22.VM);=?5)5TWVNO>4G= MED(O^#1Q>]8:WKS!\LMY=BI(PL*:R&%7;&900]**HRVF#GITKHA4:]N1&WK%

MYE!PJ$DC3VD<9[VRSERGK!I!AUV<.<;G%;KH1=G.BD' MW_9Z=E:M%K6QK.&85AO"_/J+>?8VHRREZWV#\]@NTRM@E>EZ*P>9^.]YFE:J?AVR]6I.*

*(,FEX33A8AS6ZJL,WEK&:5#KNV$V7S5,JK M8'UUF9UKNF-M.BLK]-K.T=!R%X/<8,QVUUU9XXR=T>S102K1^4BZ7IQ7E$*N MBZRYU4)=4).F6)3#KNTL=EJ;G+THS3AR-[!Y5E:V& !,ZG*7QB.M,IJP ,:+* MSS.9M4.5=4.D@U.'%U>6;N7.KJX41FK1'1154:.Y50Z^_6*7I-]PVF&D'I\N MYSE=RW;K30S0/7LY3W*OF)<'R@)7/7%*

*(9>;Y\93/RQ.4";F)=%7*D/W\VD*D MIFKE9XKJM/$V"]Q)K;)5P:55GBN=Q76/*SBO-H=)VP="0>W4',DJF]YVNS?+R M8"S6BC;7[(%EA5QMNS(ZQ8[:9.=LRAST-]EJKYG';3CT4IB;]0:6 ARL8M;4 M3-?RMM(!K(^&2%Y^O5V(36:749MC549VA-#OSL'0$(%: /]4V2W-&NZ7=$3 M+(2SC(&8UZ3E1D8&C2I:[;O95&D.M'0(9[G&;$,/AIVKK.N!7,/1R MKLJHBA,:TN>:A>$FH^$MU^/]IU[,54S-2]2K,1:W;'0,:KTN[MH:&!K"KW2W MUT,6!II"4CA565)"BR8D,#2$LRATV$ WV(R!\+-AH=S2\MTNVH9#+^:;;7!;*

*M<[=92CI*EOH]BW_J1=SG;.M?>BDFR*WG'1'V2$ V3 $>&H(OSL'0$(%:/6W(9;9%% M#Kx<*BW%<- MC&0X]+.M&]P@2%$7$57 MD]$KVI%6!D#[NIQ7+$$S+,*

<,N3%8:32FV9JLF>HZ8V5L98E4M>$> P(!7Q= M^XUQ^-^N=;W* \$6GWQ?.#@21>\#?,&PI**2AGA+-E03W4)<3^WVP?!SY)9BW M=W*W-.R!98/ 6>]U1ZQ@NI/^EFE[M0$]Y?*

*AF9;-3=ZN!:,I 7(-/7O-0P'(% MZ*7 >YXL27)4(!3I[";UW%K#SO[TDUI*8YR6PHOB5)K] "I34KK%6^CHSI M/ ZU7>/"04G _]((">-(M/TN6'\GNBLP6[#9.TE,Y!0#["UP3"4'4,F"M]8D*

M6L '!>)3DGC-GB>Z\)XI>%7W4X+EA?GA.0E%%S1'E.!/$I+FQVC@W>#PE]NY MQ,-NVI9M)2SXKAGTC#4OP5N6 =YL@ >Z"GBT @;L)PB>GWS^4#!,(&)@8,;*

*M\R88#KAEHPC@92!<<=6O(E^!7RC05P:IG;"<%13)Q.S1 >6#<9+NZP#;2 #? M:!ZR#T^WO'G\]#'VUXHW09>8M%2@?&57 MD]<$MW%2!U1UD/V 2\<=WO:>NRU"\L"V\0*ZHQL*

MEONMIGRI1<+'W5+?+-;RK_X"G(2>T+0^_IX2TXX^=T'0A57O& OIDKT]((MX3%9HD<6%$@+%=,E.[>Z-'%I#$](AB^)O1Y8-YA+_$Q??: M@\P']N"6ROMWUY]9W?GNK/1G[*

["B:?,3P8CB3#MBZ6GUA^KG0M8_])R#Z0_27 M#TYCGKDESY!/V"/I7, S^#7T:\0"=]:;$OK]ZO_C#\?[6U!<&[:"WN+FQ-W:4]\178^AMY"T&IZAM9&-"=9_P*

MA4YM\0>:JJB"D _^BKYY2'=72I%WESZVCG(BT M:OG>CE5@G5[) 7Q,&!D)"7[%K_HN_6E.2O>1\]\0;N6'?K% -EYO+6/|>ZP#& MU<,R=^U"YN/N>-4D#N.G^;.XQ/+M"

*<,L*9P2_QQL F"==;\X*(B8- ^ MX/]F)+MY]SG'$O1)Y]?WV0;OI'S^PX,6-8%8RDE_M0, MR_HK,3.-Y;&AA'^L$#L&W .,~WJ71]]'/N5M5TW?^']'<>>=CZ6OR9UW/GI^*

*M)W=^;Z JRS*CHK+@$,F,V/ES5/'$M>.MT- TPO6A]]S?'5"\G? M/T#K< UL9RS65(6]CXK\#$>[U!L-N-X.;AVG&:#3&L"F?R0L0)+ _2,5=0L\ MDVH3,U?WN**%S2?3-K:DEW[73OR/?*

S.XD233Q7ZZ_XW/ZG.,Y?&0N/MMZZ MN6]ZR\EZN&K]9>5?$D,5 -RA65@9R92?IN/L'59,[-<;Y_$X=]P--5$H>

M;;7'A[^:R#_^I9!TDDKC8:KI&P8;OB1!\:=KU7NGSM]_#R(8D/B!/"M)*:A MT*SK1KJ8YAR16=H-5MD>IG\ZB>F#"K?ER$A#0N9-E:G9W5+:I#?-.0W;L@,L MF*:2)*

*(K>%@K^;.F\>V@I*LF74=)/CXGVOBZ/\H,J]%TLY!K4/-7FG+12<(8C MTN+RO@H"F \CDADT>WW(%Q57*T"!S*%1=.Q@QX4I[(-)KW0,^4$5*-\>5QZE*

MOF'H>WV!U\=VOFL0I]$V@PSXNCYS^MUTA?CTI8 ?I<$WC;OL=T<$PM.>2/9] M::-,^]?O $B8I:!DEKHQ)HRUUR.4]7RE!OI^]3O? 76^K] <3]VE3>.NITIW

MW2ME"OU[$_V]\PM&,A'<2GDDZQ CT]HZ(N(T:*B@8,9NBR22(3>H+Q#<.$ MCUR0,MWP;S/$H0[,D.DDAI-QZ"XN9HJ+F>X.M:Y;RO1!33&J")QBHID2 MMT:7]68JU5NO"?

*\R4Q\M450VB:1#-<5C1-A"%$9XE3PU2F.#8F+3=;-=&'E]/MQP:2]==X*2?II#2)E! MG.'PT]SB'UL %8'V7X]3 G4MA459]=1:WLD;A+$\) "]F*IW\P%=8)%18EPD/ MWS)*

$9=%/7X((I%!] QM?5O9U+27L"53:[-!>EB4K@V9/DV^7&U/ M4,K\NTAG;HH:(R6R<:W4#ZR5^C' \,NJI:ZEF72!G Z6? E!]@MS9QDIHM4M MNE SP3R/I&4-U6.%

(,,2]KB$*BZA^GDH]*N*]*ZEIEVQU&YE9UD*:8[*;'/. M1S5^+D 0# 20!'5; !GKM+BPZM$+][X'1/\]T]IKJ2U[4;77Y=ELRDE#290K MI%W0'!>]+1]KAWW>]J:ZE!M4>K'M9G*

*MUDAWV6-WEE>U\RI0@]F@["]=="7,SXP!@7"'ULRIN(H#!KEMS=34819@(S0Z$ M*N=M-$%:+*IBB:,A_B!?UQ^/$:,[%R2)'=]ODST8%V;%(A(79MU;(N+"K(@"*

*MR*8]E\S$G_L*K+\20?UW,M&0[$=T,GY&+E1[R0973R(GZN"KK,C8B\"HH>RONJ M]-2/:)D=EFD0);%0XY@<,L3DCMAEEKZ6@3 -)9)DR+TDCQ+H8NT5F:E36=M^S*

MGU[EM _,%+-W%3-%/^LZCNNBFM'U&=;5?7-5=E14NEQA($W:$S G M'Z"EDYET.@Z]12+T=F\]BX+N>5?14?1US[?.>/V0_U>]FY959WH]QBMCH9G'

M%%.0_7B(S,RB3]*=Z)[095(>;D_(S'G;MFH/VK-/Y&OH]3&YH'ZUD0H@S1B MM(Q8&BE((^G'R3GW6V"W4+"70+E20PZFSKZD47]4%ALA M?1]]4$(4^F)'+P010\&O[?# ;]7-Y#IMI]B3)^S2QEQ$Q>O%0HV>8'X'5A*- M.[!&(Q$B4MMRGT; T5=H#PDQOZ[W_[MU5G:8':?X2B7#*F]JFAUE!F/']G46 MO/LI^R#9%7&!4ER@%!M:UR8%!&\X*(#*

(2^'P(\BM$]C\V#[CXIV%8PUF' 1=" A:5S>& X\#[OCN]0K^9[BAQ9]-)ASU4(\I],.(($+%D'C@!(PYB#EDTT- SG#?+;6I=34E'@UQ<_ B__F-9?WK/TBJ>P3?G!Z_CZ M]R%!*

*(H\X>G_)$[^#7?C8BN7 #9ULF%[*4IITLS^>_^SPV>^"]P_-"P%4O9O M4\(HVPD^/2SY_ITL8W5WQCZ!(,/2 #G?F$$^D2E;T.I$XT 'LF'/K*G+'4K MT9#*

*<1,=8\CIXH/\)?'#PS#\2":/SPGW@5-@B^! M_PA&) M_S^!^;_\ZP6U7I#]69T>B0X_>N7Q!_KQOH*89+(XSPNSV404,6%"9)',A.<1*

M8H)0&3+H1(FX9D_@HW@#RIE46$*O0V2]R/KH:J4QMGBLE=K0Z7W"P0=C MONV-V6)3;;%HC\56.CW!+D%[:FC0-1]9?CI26]3HO+$F');75L#>GZ3(#1H+%O1RYP[8I'NW6*

*MLNIZU,$;/:?(%U5YDKXH,CET&OGYR'=SGC*K2/5+?I/O9BJZQ7WW.S.CE!';(NMK94,X4*:8;,WS$CX;%-G@I=CETZTR'B*E-IBPY*$\, M*]_VL!&8*WXYM)(OEE.H\F]*

[I,AQZL:Q56^\R0WK65DF@7UM2 M>]@S/?^IEQ1PW%6NAO5TCD^ET/:X6ZTP-EA6"$N74D8VM^&I-N+([#:/Z>5,

*M90Z>&I) *;Z)>MQTOD'XK(/F;7Y=*!%M./1BK@/,G"CI=FZ)\'RU4&]4.0OE M:3CTD@3:? =44.[9#]8M/8T?^^[HL)N%63**R+FL*EV Z6+W&C%3_V*

M[XR]&"KNAI8@,H,Z.UA3&WR^]#ME7 !T,70,B]E1"2_*',\WY3EWM:8";1_ ME]G%LMC@MG6ZSN'==#">#1M=%H,X&PP]&)9K9TWVU;5 8\HN;4](O7RRIK(*

*MRRLTPWWVVP#993'5GN5W+VK-G.^GT7+X86*PS"BT1CI0[]9)>KTKT\S?N= M8R_G:M8K1$]A\DC5SB_G7K,E8S5_Z,5<^YL^/I#7"U;]U25V2I%KC6O#CD(7*

*M$ZAE]9N$VJ?:0L::4T)6DF&)^Z5]$?OVKFO8I?! MXT-.0*H[K3CW4&994_VA%W.=33+]Y4YO:&]UITY:.7 7CFFP;GE923&"*H^VU M(O%9;D"4>PCFB.H6*

*$LA%_7J7X[5\IU,EQUBBRR_;8]GNS\<,'%4#(W8)BQ MM0:<55LR_+(]'>,-VG=*7@Z5&0';I;QQE6-4O&M/4UINC?E#SYGEHQ)NX.%8@;% MR/2ZJUP[Q149AZ,)IN),]*

MW94&W+IIH"Q#M@M%#.SMY3-[V[=WSI[ARM2HL-[=E-0YG08#L%V0XD]+]8E MM6E7IUM'S^T6HAR&0^;#'KK=]LV&VN0W%1+KY-9(0P[#(;PO]O!@[1A+MN?T*

MJ%@BRZUR.PR'%.LE;>=]/4?U$&VKUN=3P2/I,!RRY,3BED8%4X:H.V&052= MR;H=AD,DTL!ZJ%EHLAA"3G,(V\ ;Q5 [=&6;K >Y=5E8 358T057GH3Q/(]H X"\"")>)K]*

<+D8&22U<,/+2#/)T M>U =9;L5@3\4NB8*[KC>]7[Z83I=&89FNR9JKKC)6Q ME252U8;M"1R* O'JK[:]U=AK%Y8%MHD5U!G9+/=;3?GXJVM[K O\I69]\(U*

M.G5]SIUH]3AG3&QS17/^9P=,.#T!)PP35^94E_' YQ.C?HM>XI5NAI"8$K M=^XC7_I*ER$(VSR\=?\T-%C6^\ZDTMFG]ME'B=^W.GS#?#,F6:XARTY)V" MD;> @XB""S;AEY[\?

*]?//$!^:L'X-V2!S^0.W@24?K=@&XV&Y,E@F3! M\)@LD2,+BCU11$R7R-$EUF(1)0L12TOTR(+B3[%QB1Y9NO#4-19<2=?#YW$]PNBB)B:OE2+VML6Z;M?!1]?FMC*E8?<3]X[KJ*

*MXWY) E?>NJZTDWOD^F#'<'1YU9](6,G$2N;'*AGLLTH&)9ZRF0=2,C + 4H* M)6::5YDF|85BWVY4!8=ZW#W7 M;6)H&5!:P)3>&)S/46Z77T8XQ?8VB>(08TNNDU2?88Z$D7@EE*

MA!3EUF\1"C%]LZYP;V-@N&\H=ITSXECB/A;DW;Z20 M)$F]=8G+XT8H?TJR2]!U %H-+.5,/A*Z/?C>\1A(?D5T6\(%Z5H9H67IA3& M*U.V69W)'MWH9,C9+2**"M;K+A?T1..:I7K:&?>*

*>F-:D,2_E_6D3Q*Y%JA!7$ M]2*,]UYEQ'EA,NT>^-!NH9@VDQ[RNS50Z_A813$J]),T*0V:6TI.9D93[M MUF';+H#]TEDBF29NB,]^HW0_0M3O'JHMXK&).\L L&]'I4-L4C$]6?W3CV+*

MUBY$/M3SH)&=SBX95TPEE+B3\VPK+\2,]-8)O9Q3?^T,/;XOFEZVM422>^? M@O;*VJZ< ?[#V//.&W478]\IS7=FCMCA_K1$[FCM>)(^.O'T)O^RA.4:%>] MO'U@\F>

*<__VY6.YQF@$DKP%_D?" B3YWS]2(?%=="5NO0Z/62H_[??+ X\N M;"S_L@-XA)/.4IDD05[>B_U7G)/TTZ(>5SS;B:9BNKGN>=AT\@_]'G:*KZNH_M1F?*

*9@3X8MZUMWM5R;:A[8(YY$L.H)(%?9IG_]1-'23|E:RAXPZW3S!'^"]M\W_MBG2W,Z0HF94?B'??RDN=- N3Y:+E(FQW1U?887_E]>E/YZ5^T/*H8C^7XXC* MBN6Y,9[MS^;%B2;#>*

*[L@ZB7329(,M3I/&,?^H;60]SK#BY)&>DR@^W7)\!]4 M.O7!*1NB/2:P-8]I4\5F:4R=:'2@7 7WM.=O2'6C8J8P5P;@&RD. MG\1%E!]J;WCS\'"$:*

[F^/9P^BGW#T/=&ZV"41+$QL/0BCC#;RF!=!8,]WU5 M#";%UU*YR8+0N>]2WB!*H=L:3?QK:0$2OI/I#);,4)DX_AN1^&^$%=B5S^*C MM_COCJU?UT!)BTN^*

*;*I;2OI!TI!4$SECM!<0A.TTD*HX!IP,) ;5QS^O UIW<'F->M./V@(N@8 MS=T8&]9(=6E-):PDC+%EQU<$L PUF2:1)$+&T=,?$#Y-Z_#BTM2[IQ7|\&V(M12*]29IQ:6I6IFP',? @-VN)-*

V2'M)C M_]GA7&):LR>$4XTBTM4OZ>G_=,Q*YD81)*L+=O44G(.O3L%[2%QXL^o5ZYV6"S85M?O6=+)!^'%[M@I+P@ A+9M*7>,$X<>FGQ40>M7 U

FU('Z=T]5H:J9?/[@K,G)RR3!JG9LW: MG)PY,M1(?DUKE@K32(\??OHIB4S!&^)RUH>../W$NUI-$DO>$M MQ=ET6(?'4@5M6\6(';!'?

*HM^@B)_1GO^N,CUIQ2Y_AA0_'5EKM=21=H,DTF7_MV9%(,UWNI7;.0UKP^ O;^[M^O5:MFI*TP*.;6T==.-1T_03- 6,:PM61Q8CBMBXXK8;P;$OZHF*

M]FIZ"1N;&T8Q277MK%2ZWZ.8;E]&>HGT]5(F#B_MDX[+8KT-M^_B'#_I]W4+8Z[E'^]6F5%;14]DIWJEFW5YNY+QW F:I<.]28LQP'N%CVT8ME M(X

JKULN>RWU(,IK"$BTR97=?M>SO.X;,6DH7J (=AD-J33_\,%87]:S#4N M#XR,=8A@LF]<0AO+R+VK8UQ)6W,GA',9HLK:6.'^SLXW'$E;>QIRRV;<4T$N]8[;[G)*

(IN!S[_]A[\ZZVL6QO^/_W M4VA5W^[&]=HNV\S)O;V6 R2A@R%25+=_V3)DFRKD"67!L#Y],^>SB!90)(" M;![(_3]\N M+1&?;9_[MXN;]O:?*

+OR;]C^^ND>]@[M).8 LQ2P"6ZV[]P'ZE MAR|!^"[.\4$SFI8I" ;ID_N?5U+L,B4U+5$F_]=(EMFG|&QX'IPGAV'[<'@Q MV'7;L?_[I^X&%[FV&YW:O-

*COT%&]/'E/2\6#'CH3_WEQF.73;I\[[?YKE,CK.MC_UW.Y^\\>"R^?KJY*V _>E/?Q|A$P'U=+O=V-CL?/_)43]PA>]CY>WZ@RW.6]%8/ZSHI1'][K^\QDRS)IKP^;DO\ULN-\@3NER?&6-*

YUOGZ7\,[IIL[O[U\GG;\]NGYSDWW MN;/;:&_,AV-^'!+?H=^T%753"\0^VY!50X ^PYA^2LE?((^P++MC]TT:+YRL\!W]L,)ZG:D7?XH-MT/F]/WT#GRRY4;<|MR M'SAM?*

*KE.=%7U]C185=|Q6:]LZ>\|WWY9#G*1.4;+JHL]<$QFR?R@RQ1@^7X2 MYTE_)_7=UMYKO+.;!^[EI_A3;]^B&>O.D/OL'?^;O2I2_CYV]U&M_/(2**

M.N=9L/CX4(R2]9?EB\IZ)FDO'\QZVB._^A' MK&//IW_O NO87244??]NI,?N!;;56(WMI6;;ENP;&6NG23]I@ MAZHO9U/BX_W'GP]>:[9U&;W; G*Q;(] M(%T5D#X/#?*

*JI"DB_6*I\|"\VMYK"[N7_>O?CPI2S(_/WH+R2YCYG4ZJT=U8 MH>;OJD=7U:/+HMP^5?7H%W.0<^_H8G1V]'G4=@/HI>CH _WO:.>W'UKFI%U8[NES]59;J>'3YF[(LD^KZL-*

6C7RP[_C@[OLE^ M/Q]=7^[_4?QW]YWWV_N+ZVN<%6]?.YN-[O;NROFZ',[715^O):D=77Z^\]R+ M1[^8==R\;;\]V7M]V;T\ ;MX\S8]GV\,QL0ZT!W:W6NT=WY,1+VO5CQ_R5V@

MYH^9@"Q"&_]+ZTBTM4QZ>GE=^F,%,PM8-O4 B:/BJ3N_]@|;LIF%BWL4-U/NG-PT_NJ_WZ@RW MZB%0)2$YC4Y" :YQ6P:5"),;DU0 O#OU?3SLI=>:]RMM_I*

MJ:W\CGMY\Y_7R641_9I^W/:]1.^C=^^NO[IWQNMW?EX(4Z**&P8IEG^I0XP M(9MN\]NLIN/IU:|/=:;9/3CZ?3'O#B]IYMG54TY8"T6Y%1+1F=GC:G<:VYOS22H.TP;:-Q;O1#;?V7F9*

M 6E,)@F'-!4G! ^2\90,87?68P0Q=M:^.-QLHOK9-$D^#J:S]I3<)"TM[<& MK]8/ ,L_LGA!G"S=ZUV]_>|F[]-E\'G2_7/T8?KIK^O?? KW9JL[WVYS3FZZ M4?0@Q*

AOI@$Y6%B6&UF,!Z,'=]4YRP,@)CC!<(B3P9F!F'@=^F,%,PM8-O4 B:/BJ3N_]@|;LIF%BWL4-U/NG-PT_NJ_WZ@RW MZB*%0)2$YC4Y" :YQ6P:5"),;DU0 O#OU?3SLI=>:]RMM_I

7|]YB6_=?0#]UTA%@YOMF"O?S832^#',4= M,G&B0!EB=_+Z4W_I=???]_M^M^BUK^,WK|Y!]&K['# -YX!VOO=U7V1TWO4YOH[T_>TTN>Z'>W_^\;OJ'^:GR"UQM&G]U7+<

MW'$=IF:P05S@<^XHs.,#QG@4F?L=G(^7R#U2O#[*UO9X9^G(26MIT5=|P-;G;.[GL]];'SYFDT^;5W"NG5:-%0:"(7ITI> KY-O?$.Q?$98V_E$, MQ^#.?=K8|]K!YL[>I^U@<^O39L?

=^>3NI?[?-KS-]N[VCKNS,=S\B4,EC^.X M_!KO=CFR_A[]LB!URZ=]-X<'A^> M7/0/COHH5H].3WHG! #K= _I' 4_=;<7Q91O3 :]Q725Z_FW3%?<%'YN/N>-4D#N.G^;.XQ/+M"

MX6ZWTWGIF(T2)T/?,1OFP(XY:1N3.ST[/. AE/[/;HO?<;QAS44-0>D-/;R5Z+=.HBBY1F^,'V9> MD6G_H1N[T2P+23%&BR35PIA5/G+J)$YP,XW03Y,4;J-BB@GW3GANO0DSFB8*

M(?G[8(6H OMT85K.?Y(^M/"D %,9U.D$7G=I&]>(W0(>"GQZ.H@S_DD^C3AV M!+LRL8;-E/N0OP>&6I@Z<9+3A+VH\.DM^#TLY37.GPENTV[^WJ 7\+/61|VG MON03#>

<\S"Z=UZ"")BG_-4%_5VFO[&G@UWIQ7,"HY\$T27,"BA-ZS<54N#? MO(-.D&,K]_2.P(S8UO.QT =E ,L"LXC@PV 4Z(-BX/< 68%OX'EH4FCHA:5 M(PWCJR##E=!X?H+I!&('F;ED0?*

P)0 YG@,WXA+.'NTI7OYUE.'8G]H!4X$Z M8OUD8,%@U\$ YZ3"@7 |>T(*/'A |Z7><+ "O:X[Q(H AA1C@FXGP MWA8ZT%QT^PXC|/;B%8$74W0% X^!7REV,D*

G,/YY6.1%&BBNTT"KGN@8#,L& M7@/R89 #.@ON6)>#K@&D^A%LDPL$RWXA^:#U'>:1|+NL&/PI M'O,,#HD0*'" 5TGK[C8/=,X$% M+C)S4,1WVR\'

4P#^$Z# .@U@/P>=C'$2'T^_R:^S5,I?[K;Y0] M<[\,HTC]RAQ.%L*U11[,^X='UW+>)M+?@1CC/PW$RN"5P:I&(B3!0../! @&.4T /"\8$# 2]D0D3W$9YW1.(2 M>7_U)?*

&SW496#\OH'Y\1]OA] ;OQ$K2-<"WJGB%AWW+1KO'@X 85XVI_;Z[M=33!"X,\0_B_L \]D,L!,"87]XY9B8[1T+&R",B6B>&WF:JQ=^&-Q<7@=8;

MN=,L>%^>/GWSUFM"*]4[X2/K^)H M(]S(HAFR7[BPU^._>!O>7. ?@&TYF$N%&K R-;C")EX5] P"H%<@=(S=\C" MCX.SR.)0|!4D9X$>1P7P@P29!#K1KT" ?\D$.%*

<3M"+'%3D.88Q)@G$;&PX M/DC6*)F*F-3 NT1S5ZIGH7AIB B*"^29%!^DWZ#5"$3,B7Z!!X8)24[ZD_I' MC]M9$>6**.N(DKP![(DGC6: !*K4?_$(H*6#-@BHFLA!8R<. K#/0;L*B9NJ*

M1 %/'7#3$PCSYWBEQNB2K';QB%CSR3VX-#*A> ' |"L2)M*S+"@@0%W'H5> M>3X8N@Y2[D+!EA8F8\5!3=+ S2JE49X+RRPBVO&K$)B)9+AER.-ICE<(EP2I/T8E MHR0K$,4"-

*GV"^UW)QU>E3NHK4XIPPE[&O6:88:2?9[#9D|9!LB_8AT)P?LR MW!)RMQI4H+I*A_GB!DOG8OEFAZ&>,A\[]'!M9T3(G/.>;YP_H)],#I@\'S M.*1MY>8+QC-*

*=FZ[_B:\;55BG,,.KT4<.%L*6> NU"$"Y4IDCOQT$3;B,L]"8/@ACK<(#6@:OAYU EHE]; M8]WQP=)GKF$8QRW@K%R2]Q$9S0.@>3+']1'?Q73.?F]A*!T?&(=Q&K!>XE< /*

MHB(P&'$V&R&L70&AL2:L$61 :KF\V@2$ M!W)'50FCY)-PX/D-?2RKN6PUWWB'[A&U>=B^R,Q@U3/@<[005]&$C[(MF+7]"G&/*CL^ =.3O#FH(%KAWOE$

M+N!H;V>OTAE6]NN[G9?.FLN'M TP;/$'](PR+&Z%Q&+\/"^FS\VVAU4$[)9 M#(<$%C+E?AA,5EO -7$8""#83Y.|L2?P=OP'%T%2H,"!$2 2M]%TPN ,T6S"W#-AQ4,&!H M.;

[7[WK]MUUE"[^]CHH$)H)!5^<=D5=/$V!?D^=;39Y=H/:8BY3$X:U"+F= M"W!71;Q.TLB_!KL%[77=FO?IN<^'E:=$;7'N)-.6TASK(6P*J:Q$^QSB# >1NY$K]*2.[;_)4%K?5)X%*

(;D!8\1 M@_,'C@-043PTHCF1GD&@GV@+_RA/AK M$=N$6TU.H3/, "OEJ>GSQTT\#S^X-_\+I%QVAN!T=EH88<>;K*+NY"=4#L:]*

M[RZ9D@'6V=E$^ZN8_IL)@&DD3V[@OU7%A$[\,&>ZP4];A6_64^PQR,'<2_ /M<)W#C]'B7'"E1OAZ<+Q4R4W^P8B60&UFUPN6$@5!-"U10UE1]/]C/ M@R)EF7L(Z[&

*[3C_NXU8)3VZ4*D">+T;9OBK39)5I\@-FFCRI!"YS,W)<4&]< M4F_V3S\<'30[>\X:H9R0D[G?.^\W]Y,/S>XZ0Y'8;%Q4HBIWL^&',GH",5-,*

*MCH/6_,=HH@$;11^:*IR$O2*0&EL:7\:)=8OL$ 6D'==U32R('H M0A=C,IK/ RKD3F(Q2Q9EK_8P3)23'G];[81@]&4OOFN0C=WG&O*<$P5_/^IY MEQAYK0'UZ]SNX]*

[=MK1BBF+A?;E5S<8>6GE?:>1S0,K4@'M. MD'F'T3M-0NK98-6MF7XX:LHT/V6GA@C&!54A9,:R)SA|N#SBE\W0X/Y8@U' M:N[,(69%:QK]5O.ZR1A(^8@+4;*

@T!["F.4B!.F<4'): ^&55Q@-9?(E">Z M9"^X9-0[KA_\53 RN,IB8T3 81#X["HJO>&)"<_XE!>>A['B2A>)E+WL&\X^CMU1!)%D]EOD7E=@H M:3.LL;,)|%*I+GHNYLY:N2,*\A*

*M|

>,X)6LL'7LG5\1%73L[%3XY];7^09GN;6RS-%]2PO0K&]W[Y:_Z"S_-#OP%K3O(%[=LBEX4]A_M^"1NFE]1S>;(C=6M4;Y\4=-7['C%CN]CQ^BWI$)ASB'P%=0CSD[B0!8)ZF 1 M/!RXH#(+!__&7$/#DQ2&<-*-BQ027C]%ZZ%^UQI;%R@8;@/%S$NY4X,B)\P5PM=G_M;PDFW@3I+Z[W5Q%RN%V/$RP3$3]1=>2*AK^,AGL>,=RH%0OFTGL4_HYA8Y05 M*/FK%!XDM.EA4H):*Y,OI]3R"&#&Z5_6Y\,J&GA]%VX=!0Z*?;(*QKG"A&6K_M9MC7K;V.3_NMQ58S<%F/R7]AL,A!$+G7+OW!Z>SM[EC^,'*#O1*G_,A_6Y1+_M->M1[+5@@? 0FI4\3]Y-\D_M?Q3SY$RKC/7_ODQR3Q'ENL%>-4GMM[GB"U5Y4_MT\2EBC1!^*,XPH\FDR),\OI/]3SGCW<.<1C]P.EO'#R]EE4EW-G;VV[<\IS,_MM_STKOWTP>DY;L8958[4S_D# [>UV1UD4,=6!F==!30I'01S>W/KJ'M<_35,X_MW7_*^QW<@/9&<;$$T^4#[@H4)1X=.UC9W3WG$(NE,N<@AEUNODGJ%:$$3_M>_,&O_T> <@YL]\6C3+_,/!=YC'=>W'D$4SPM1>G#ZQ3@3_M#[G^5F?[B;9Z2<%+>U6DWW^=Z\2LZF*2X5>+%TP82F*]4UO'&)/CF+U_MC[Q]I9!2][OS%:_NVL:;EQI::#P,.=VVA??QC2? 8(3;_[/]^@G4+$ULVTOEV_M;8=T-UV<>;0=;4]$1_^5CH1#?T]TU"?O+EB?=29)A;EKG_5]2I"-9^!Y_M03_52$UFW_T7+97Y:L]K%"B%;J'^Q&/^R%2M.^IP_>-]" M*JG'0,4[02OYNI43S_N1SE!QNR4_Z_M_&B2O4?+2-9+;RW+U!B;24^D5]9<>_MP_"$4)A-$\+&P"_+P3!)_WC(X=93)&8!>+H',XA*_M'^ORQTZ]/$&/N_VGC?67SLE!#R$M)V$NP>?7\ N%18I/=U_2K\XO7CNP&SGM_MI!>$5U@D&_S2_I>+(*4O]T4$O(L#-R,HMB3&6L4F]VUBK*0\\9)(,"/XVW:[RZ1!L+_MK+ZE_2*L9J_]CA)4',?N%9<26M,>F!PG:MT'1@O_M'Z]K- '%$;^9&-_BY6\!2C"T7_E%9\1,G0\+KA^/5_D%$4\)& M#T&U%%_IJOW38ZVK^]%/542N-P[A)86#V?-D&=HV]V"(LYQ^-;67]IV_?-O1_@CN;8%ET8B]I(@\U:)T'$Y7BOI* M45\IZL_]0)^_HJZ*IYE=LS)P5?GO5#BMF["0]DYF[]3DO;*\[WR?"^+C%YYOE>>[P7CFB#,_M9"V>]4X_613<2-GA3^@BSQ(BY'OP/0(WN9-]/N2GGH1SK7R/PD1WGN56/YIO MT<)87?D>O\UW8F_A/7SC&?N.[]4>,327C'K^CJ;P-"[',ODL6HE=%/D(;_Z>_MR.=`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|V@:_E/J5DN0*-AI^'KRNH-/@+?@H6C_TF"-^8D(]17M$#_ML!G7^("+C(2IQ_;&'_=(M*>"; (2IBB:Λ1H*QA"KM_M;_86\!RL_HDYN9G!'Q"WC2Y?^1CQ07U6K85SVO(UCVFK>=NS'+<"_H1[=_DJ_M5*R6FZ39_'(;]-IE,*-@!8R$.XN!'"%P^7]P9;?'=FT8G"Q<\#KP4U$TF-G<* M# (C^A5<_*8M'_I9)\V7^7WL9O*281NI&^6$;$-LKLRT%/AC&=!\MB9$!,ED2_ME!I=K3QH8;_[01_)AJ_\(9,K?VH-L?^FH$BSD&*&T_1Q/W3^R! MXE_I1CFXE_XL!@KQ'+VG1P;4>XJ5,MDX\&UX;T0$IWLBB.",]ZTY"9[G1..WHO<#*3'V<$%BTLPCM%>SFI,+FX#IK4G_MEOMB.,'RT_/I8G;_(=K6#<*AJH9>3T.O?$7V9&W& (IJPL.H2$_V(5N5R7>V_M<8CNI@-&'RA-J_NG"[,N7E%3N40_@Q5V,\G7-+A"2PE67J=!B'I4_*EO_1;_MBN;Q?Z4EV!!Z&GB*6FTBEY)(1Z4E*!AGIO1NN!/%? 3U4XHN\C5C1&OVLXU#=.0*K=C)X6D_+UNU[_K5B5SE])_SZB%^BU<$F+))[IT^_DTT2!_M3_71GGQ4WXNG^G!?/]SO^E-]^*WZL+"6=29^X##AA.DPN'(C['5(U*CAU.$/ M514>'Z8KXX!$10V;"I3PWI#-4;X=?/<84'P*6O]-..%&BQM;_M?-58WX./H6G%=^1]JJ\BHY;[/^)-)"U672SFM^J::]"3:YHR]@A%EI%9H'NJ4=.%,@*>$/"6YV"0+N'\E+*FSO8<]-O\D M8WRML[TM^PF?6.=I*2Q[X.09<20T7=/_YC(>MNP$SA6X'KDH2/;RI:)QU5LL_M3"=LD2!TO.N#AH=C$D.IVC^X;R3*C"7$@J&FYR@9/V@MD%M'+$-IR$D_XGS&_M-_@9AJ8S? $A<1,?1RF?V-X?$-_1<\=R8/,9ZE1TF-J\@HBN6F)_M:64:QGC?!)S0ZYG$*%V2:0#]CH^N')F>/#I1SQ_^_%?"9]4EQCZG_M(0^$!,,"CGHD_-D,B?IY[BYZ7)AEH/\!M8J<5Z(;'RB[5'= H(N894%F1#M_M_)@2WBVI9]0&-^RYN@JTSNNDVA0_[EK8"EJ-.D(2VEF7A@G<"H"X!ZPM234_M,A=_?4>\)?K_6#(-P+Y"/5.V'KI;+5KFB#D">C.8'M,2&,)G!ZM5IW^$9'5_M.QI6)? $X??3$X\$KK_)^[^A=7SN6,V#H@=QDY!8ETE1W5'H.SQV(L_81[]JS_MNUY]BV%-%#\EGX"AL)$ORA*@$>U]5H>765H1ZS7HEA9F;C=]4+N9L8^->ABK MJP5_'&$777F41BLF22IWC(B4,X;MH\#M$PDBI_^+N$[22]#D0#6.1(S01FC[_M0AD6SFLT^<4G;;E7|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|>Y\6W'A$5XCEH!>+>#++#NI8%,_M$$678M>X\R1M:0(9([UI7P*.;S0U[>KG_1"MQY_+2_|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|>-&R2#/F/ !#^WW&G^(@N714@6AZ8O&NX4,["^MD!:_M[Z-I/9$\^HYOZ]I=3-C5Z,]Y)X4)\A_M$SC2&69_L?,TLP$=*B>-T:!%,@V8$>QA5]?(D_J$^%1%6I>_1>_-JH9.%/>Y_MZC#6V&[W)M-9&6 +N6Z_PB=CHXWV)G@@EL.XEV6)%TI^PZ^]X]ZZ4_MC&;+L8DESCN?NH9:-_EFB$$D'3;A(_UGA='WEH3]=*TT26.*2+!#!SFL!K;,_>P<_M2,K]LZU@OD"W7:K@!@2B7ZKMF|- PF|\X1(J@+S*'8$CHDR:@4$29K8>X!E]RF_MB>;Z^PD8QV%D/$$XBE7:%"?QG+<'_B1#&:TF2WRPQ!7J_MDCHAP@&K1^^BRIY]>3NZ%+"FGK_#SJ'UN\+&!BNY]B$X [^9)TW$E"7[7@-+_M+B"F8VA\["Y7\#F.3T00IR>;M](LF@C%[XVDRP33-'3;8_@&T&>VDFAPKJL_M&Z/O4>GJN#Q(AEES5H7F2/E8);.+88$P>ZPF_:2=\/P'5-U MZ6<4JE*)-6BQ4Z")@ANX@81!Y+-2-1Z@5$XI=YA595O8D$SNU>#$GTZM_$-<;4X*=_M7;'$GB7*-A8$;Y4H26X5([*>9-+$D#:F/<4N9+E3$2AF0:*KK^"-.MZZJ[N,8??'VK(F" M!@'54EJT8\0MICZ#M9D*?_F2\!!V3T5[74KQP)*!8[%!1$(\+C#V(K8]BN0F@:N%O>>)V:>=2W0HM'?8(;YA/A<_XBGPR<_MG>T-<2J.$.T#,;[;97>'D-L'JZ.FVG3.C61GQ@L23- <19$2[[JE1CQ%QKP]J_MD5(_K5:@NLU[?;3WE1>KI-6:\N(:)C?'W?GJ:WP?N[-!+>/G$Y_G_K=OM91U_M2$UK::*=78;&$@(BY][A>Y@@YTN9K?(_F0PZ,OK\,ZR!?S@L4KBW'"K.)""B MD%M&AC3LNRZW2%!@\'"$V2530O[5.ANZ%V;U#!=1VB:>!4ZJF5E$%!5TQ;#YE>G9=T7LB=L\#:B>E_(H:K==TPN%._MA1G(#*M2L()F5=>K9T4.. 51AU&CTM>_\,.7U#VJ,F^Y$94),.JDQGN%^8XI_MKF]!)%#1MC0IN*)B2Q>E]P@$/2X1\W]\BD;"WZ56TOXW71%$WBP'H@#[_/'+IW*2I8_*U2]8TW?J!_M6LX)!J*